ICPE 2022

Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community

August 24-28 // Copenhagen, Denmark

icpe2022.org
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>BOARD OF DIRECTORS 2022-2023</td>
<td>3</td>
</tr>
<tr>
<td>CHAIRS &amp; LIAISONS</td>
<td>5</td>
</tr>
<tr>
<td>STUDENT CHAPTERS</td>
<td>7</td>
</tr>
<tr>
<td>ORGANIZATIONAL &amp; INSTITUTIONAL MEMBERS</td>
<td>8</td>
</tr>
<tr>
<td>2022 ICPE SCIENTIFIC PROGRAM COMMITTEE</td>
<td>9</td>
</tr>
<tr>
<td>ISPE DEVELOPMENT COMMITTEE</td>
<td>9</td>
</tr>
<tr>
<td>ABSTRACT REVIEWERS</td>
<td>10</td>
</tr>
<tr>
<td>NEW ISPE FELLOWS 2022</td>
<td>14</td>
</tr>
<tr>
<td>ICPE SPONSORS &amp; EXHIBITORS</td>
<td>15</td>
</tr>
<tr>
<td>2022 ISPE AWARDS</td>
<td>16</td>
</tr>
<tr>
<td>SCHEDULE AT-A-GLANCE</td>
<td>19</td>
</tr>
<tr>
<td>PROGRAM SCHEDULE</td>
<td></td>
</tr>
<tr>
<td><strong>TUESDAY, AUGUST 23</strong></td>
<td>24</td>
</tr>
<tr>
<td><strong>WEDNESDAY, AUGUST 24</strong></td>
<td>25</td>
</tr>
<tr>
<td><strong>THURSDAY, AUGUST 25</strong></td>
<td>27</td>
</tr>
<tr>
<td><strong>FRIDAY, AUGUST 26</strong></td>
<td>29</td>
</tr>
<tr>
<td><strong>SATURDAY, AUGUST 27</strong></td>
<td>39</td>
</tr>
<tr>
<td><strong>SUNDAY, AUGUST 28</strong></td>
<td>51</td>
</tr>
<tr>
<td>POSTERS</td>
<td>61</td>
</tr>
<tr>
<td><strong>SESSIONS A</strong></td>
<td>62</td>
</tr>
<tr>
<td><strong>SESSIONS B</strong></td>
<td>89</td>
</tr>
<tr>
<td><strong>SESSIONS C</strong></td>
<td>117</td>
</tr>
<tr>
<td>FLOOR PLAN</td>
<td>146</td>
</tr>
</tbody>
</table>
Board of Directors
2022-2023

EXECUTIVE COMMITTEE

Vincent Lo Re, FISPE
President

Caitlin Knox
Vice President/Finance-Elect

Tobias Gerhard, FISPE
President-Elect

Olaf Klungel, FISPE
Immediate Past President

Wei Zhou, FISPE
Vice President/Finance

James Vrac
Executive Secretary

DIRECTORS

Ursula Kirchmayer, FISPE
Government/Regulator (Europe/Africa)

Stine Hasling Mogensen
Government/Regulator (Europe/Africa)

Lisa Pont, FISPE
Academic (Asia/Pacific)

Tomoko Kobayashi
Industry/Service Provider (Asia Pacific)

Mette Nørgaard
Academic (Europe/Africa)

Daniel Prieto-Alhambra, FISPE
Academic (Europe/Africa)

Jennifer Lund, FISPE
Academic (Americas)

Fredrik Nyberg, FISPE
Industry/Service Provider (Europe/Africa)

Jeremy Rassen, FISPE
Industry/Service Prov (Americas)
Board of Directors 2022-2023

Elected Representatives 2022-2023

Jennita Reefhuis
Government/Regulator (Americas)

Lisa Pont, FISPE
President-Elect

Efe Eworuke
Government/Regulator (Americas)

Mary Beth Ritchey, FISPE
Industry/Service Provider (Americas)

Ursula Kirchmayer, FISPE
Government/Regulator (Europe/Africa)

Jessica Franklin
Industry/Service Provider (Americas)

Montserrat Soriano Gabarro, FISPE
Industry/Service Provider (Europe/Africa)

Gillian Caughey
Academic (Asia/Pacific)

Directors Cont’d

Jennita Reefhuis
Government/Regulator (Americas)

Mary Beth Ritchey, FISPE
Industry/Service Provider (Americas)

Montserrat Soriano Gabarro, FISPE
Industry/Service Provider (Europe/Africa)

Yoshiaki Uyama
Government/Regulator (Asia/Pacific)

Shirley Wang, FISPE
Academic (Americas)

Hongbo Yuan
Government/Regulator (Americas)

Stanley Edlavitch, FISPE
Executive Director, emeritus

Staff

James Vrac
Executive Secretary

Katie Geraghty
Deputy Executive Secretary

Melissa Castan
Director of Meetings

Jennifer Tarr
Head of Membership, Registration, and Data Management

Christine Morgan
Society Manager

Holly Riester
Society Manager

Amy Winter
Society Manager

Lisa Pont, FISPE
President-Elect

Efe Eworuke
Government/Regulator (Americas)

Ursula Kirchmayer, FISPE
Government/Regulator (Europe/Africa)

Jessica Franklin
Industry/Service Provider (Americas)

Gillian Caughey
Academic (Asia/Pacific)
Chairs & Liaisons

COMMITTEES
ACPE International Steering
Soko Setoguchi, FISPE

Archives & History
Eileen Ming, FISPE
Hugh Tilson, FISPE

Bylaws, Policies & Procedures
Stella Blackburn, FISPE
Frank May, FISPE

Development
Taichi Ochi
Leah Sansbury, FISPE

Education
Debbie Layton, FISPE
Judith Maro

Fellowship & Awards
Olaf Klungel, FISPE

Finance
Wei Zhou, FISPE

Global Development
K. Arnold Chan, FISPE
Maribel Salas, FISPE

Management Oversight
Olaf Klungel, FISPE

Membership
Emily Brouwer, FISPE
Rohini Mathur

Nominating
Olaf Klungel, FISPE

Public Policy
Susan dosReis, FISPE
Meredith Smith, FISPE

Publications & Communications
Juan Hincapie-Castillo
Joan Largent

COUNCILS

Academic
Soha Elmorsy
Amie Goodin

Government/Regulatory
Thamir Alshammari
Ann McMahon, FISPE

Industry/Service Provider
Jaclyn Bosco, FISPE
Solomon Iyasu, FISPE

Student
Miyuki Hsing-Chun Hsieh
Sebastian Jugl

SPECIAL INTEREST GROUPS (SIGs)

Adherence
Julie Lauffenburger
Sarah-Jo Sinnott

Asian Pharmacoepidemiology Network (AsPEN)
Nam-Kyong Choi

Benefit, Risk Assessment, Communication & Evaluation (BRACE)
Priya Bahri
Brett Hauber
Elaine Morrato

Biologics
Seoyoung Kim
Nicole Pratt, FISPE

Cancer
Armen Ghazarian
Maribel Salas, FISPE

Comparative Effectiveness Research
Grammati Sarri
Richard Wyss

Databases
Rosa Gini
Vinay Mehta

Digital Epidemiology
Dana Teltsch
Lisa Weiss

Drug Utilization/Health Services Research
Mina Tadrous

Drug-Drug Interaction
Katsiaryna Bykov
Thanh Phuong Pham Nguyen
Environmental Pharmacoepidemiology
Charlie Leonard, FISPE
Soko Setoguchi, FISPE

Genomics & Precision Medicine
Gillian Bartlett-Esquiland, FISPE
Leah Sansbury, FISPE

Geriatric Pharmacoepidemiology
Danijela Gnjidic
Daniela Moga

Health Equity
Eileen Ming, FISPE
Leo Russo

Medical Devices
Mary Beth Ritchey, FISPE

Medicines in Pregnancy & Lactation (MiPal)
Susan Sinclair, FISPE
Marleen Van Gelder

Pediatrics
Greta Bushnell
Francesca Kolitsopoulos

Rare Disease
Emily Bratton
Janet Sultana

Vaccines
Jennifer Gerber
Bradley Layton, FISPE

REGIONAL INTEREST GROUPS (RIGs)

Africa
Kwame Appenteng
Irene Murimi-Worstell

Brazil
Claudia Garcia Serpa
Osorio de Castro
Lisiane Leal
Luciane Lopes

Gulf Region
Yasser Albogami
Turki Althunian

Latin America
Yesenia Rodriguez
Yared Santa-Ana-Téllez

TASK FORCES
Real-World Evidence (RWE)
Helga Gardarsdottir, Co-Chair
Donna Rivera, FISPE; Co-Chair

LIAISONS
Council for International Organizations of Medical Sciences (CIOMS)
Stella Blackburn, FISPE

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
K. Arnold Chan, FISPE

International Network for Epidemiology in Policy (INEP)
Meredith Smith, FISPE
Susan dosReis, FISPE
Student Chapters

Basel Pharmacoepidemiology Unit
University of Basel, Switzerland & the Boston Collaborative Drug Surveillance Program, Boston University, USA

Brown University School of Public Health
USA

Center for Drug Safety & Effectiveness
Department of Epidemiology, Johns Hopkins School of Public Health, USA

Center for Drug Safety & Pharmaceutical Health Services
Research Graduate Program
University of Maryland School of Pharmacy, USA

Center for Pharmacoepidemiology and Treatment Science (PETS)
Rutgers University, USA

Clinical and Population Health Research Program
Department of Quantitative Health Sciences, University of Massachusetts Medical School, USA

College of Pharmacy & Pharmaceutical Sciences
Washington State University, USA

College of Pharmacy
Rady Faculty of Health Sciences, University of Manitoba, Canada

College of Pharmacy
University of Cincinnati, USA

Department of Epidemiology, Biostatistics, and Occupational Health & Department of Family Medicine
McGill University, Canada

Department of Pharmaceutical Outcomes and Policy
College of Pharmacy, University of Florida, USA

Department of Pharmacy Practice
KMCH College of Pharmacy, Coimbatore, India

Department of Pharmacy Systems, Outcomes and Policy
University of Illinois at Chicago, USA

Dutch ISPE Student Chapter
Faculty of Pharmacy
JSS University, Mysore, India

Graduate Course in Pharmaceutical Sciences
University of Sorocaba, São Paulo

Graduate Department of Pharmaceutical Sciences
Leslie Dan Faculty of Pharmacy, University of Toronto, Canada

Harvard University School of Public Health
USA

Health Outcomes and Pharmacy Practice
The University of Texas at Austin, USA

International Society of Pharmacoepidemiology
China Pharmaceutical University Student Chapter (ISPE CPU Student Chapter), China

ISPE Brazilian Student Chapter
Grupo Brasileiro de Estudantes da Sociedade Internacional de Farmacoepidemiologia - GBE-ISPE, Brazil

PENN-CPeRT
Center for Pharmacoepidemiology Research and Training, University of Pennsylvania, USA

Pharmacoepidemiology and Pharmacoconomics
University of Rhode Island, USA

Pharmacoepidemiology Program
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA

Program for Clinical Pharmacy and Pharmaceutical Sciences
National Chen-Kung University, Taiwan

Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus, USA

Talla Padmavathi College of Pharmacy
Warangal, Telangana, India

Touro College of Pharmacy
New York City, USA

University of Bordeaux
France
Organizational & Institutional Members

PHARMACEUTICALS
Gilead Sciences
GlaxoSmithKline
Merck
Regeneron
Sanofi
UCB BioSciences

SERVICE PROVIDERS
OM1
RTI Health Solutions

GOVERNMENT/REGULATORY AGENCY
Department of Epidemiology
Lazio Regional Health Service, Italy

ACADEMIC PROGRAMS
Center for Drug Safety & Effectiveness
Department of Epidemiology
Johns Hopkins School of Public Health

Center for Pharmacoepidemiology Research and Training (CPeRT)
Pereleman School of Medicine at the University of Pennsylvania

College of Pharmacy
University of South Carolina
Harvard School of Public Health
McGill Pharmacoepidemiology Research Unit
McGill University

Pharmacoepidemiology Program
Department of Epidemiology
Gillings School of Global Public Health, University of North Carolina at Chapel Hill

Rutgers Center for Pharmacoepidemiology and Treatment Science
University of Massachusetts Medical School - Clinical and Population Health Research
University of Utrecht

Complex Issues, Rigorous Advice

The world of pharmacoepidemiology is experiencing dynamic transformations powered by data science, genomics, and digital health. Exponent is your valued partner to help your organization traverse the continuously shifting landscape of clinical trials, regulatory approvals, post-marketing studies, and risk-benefit and value evaluations.

www.exponent.com | 888.656.EXPO
2022 ICPE Scientific Program Committee

Anton Pottegård, Chair
Jesper Hallas, FISPE; Co-Chair
Frank Andersohn
Kwame Appenteng
Wendy Camelo-Castillo
Ian Douglas
Sascha Dublin
Tobias Gerhard, FISPE
Rosa Gini

Christian Hampp, FISPE
Juan Hincapie-Castillo
Daniel Horton
Krista Huybrechts, FISPE
Sebastian Jugl
Caitlin Knox
J Bradley Layton, FISPE
Charles Leonard, FISPE
Vincent Lo Re, FISPE

Jennifer Lund, FISPE
Kenneth Mann
Judy Maro
Elaine Morrato
Susana Perez-Gutthann, FISPE
Syd Phillips
Robert Platt
Mary Beth Ritchey, FISPE

Yesina Rodriguez
Tania Schink
Soko Setoguchi, FISPE
Rachel Sobel, FISPE
Alexandra Sosinsky
Mina Tadrous
Shirley Wang, FISPE
Lisa Weiss
Jessica Young

ISPE Development Committee

Leah Sansbury, Chair
Taichi Ochi, Vice Chair
Amanda Anderson
Eirini Apostolidou
Dimitri Bennett
Elliott Bosco
Tirza Boyle
Andrzej Czarnecki
Daina Esposito
Nicholas Everage
Joshua Gagne, FISPE

Nydjie Grimes
Sai Krishna Gudi
Veena Hoffman
Linda Kalilani
Danica Marinac-Dabic
Payam Peymani
Surasak Saokaew
Xuerong Wen
Hongbo Yuan
Yanmin Zhu
Abstract Reviewers

Mia Aakjaer
Victoria Abbing-Karahagopian
Abdullah Abdelaziz
Devin Abrahimi
Shahab Abtahi
John Acquavella, FISPE
Waheed Adeedeji
Michael Adena
Motohiko Adomi
Fariba Ahmadizar
Adebola Ajao
Oras Alabas
Abdullah Alalwan
Omar Albalawi
Mohammed Amin
Yasser Almobagi
Khalidah Alenzi
Alijoharah Algbabani
Eman Alghamdi
Waad Alghamdi
Saja Al-Habardi
Ayad Ali
Ououh Almadani
Mon Almaghrabi
Sara Almishari
Meshael Alrasheed
Fares Alruabaib
Adel Alwisan
Thamar Alsahmari
Amal Alshati Almotiry
Dana Alsugeir
Mohammed Alsultan
Turki Althinian
Carlos Alves
Hassan Alwafi
Abdulaziz Azareza
Frank Andersohn
Amanda Anderson
Daniel Ankrah
Mary Anthony

Ippazio Cosimo
Antonazzo
Jummai Apatata
Eirini Apostolidou
Kwame Appenteng
Priya Aradhya
Alejandro Arana, FISPE
Alexi Archambault
Janet Arrowsmith
Keiko Asao
Mustafa Ascha
Gulce Askin
Quazi Atafer
Shilpa Awarebile
Lade Ayodele
Md Azharuddin
Nicole Baker
Mohammad Bakhri
Sulayman Balogun
Gretchen Bandol
Sojja Banga
Dipika Bansal
Clare Barnett
Claudia Bartolini
Benjamin Bates
Vincent Bauchau
Sungho Bea
Daniel Beachler
Claudia Becker
Aja Bedene
Sigrid Behr
Elizabeth Bell
Ariel Berger
Ramesh Bhandari
Anto Amith Biju
Mette Bliddal
Lourens Bloem
Michael Blum
William Blumentals
Marco Boeri
Justin Bohn
John Booth

Jaclyn Bosco, FISPE
Alexa Bowie
Marie Bradley
Joanne Brady
Emily Braden
Benjamin Bray
Alexander Breskin
Kimberly Brodovicz
Emily Brouwer
Jeffrey Brown
Vanessa Brunetti
Claudia Bruno
Camelia Bucsa
Katharina Buesch
Mehmet Burcu
Johanita Burger
Dustin Burns
Greta Bushnell
Anne Butler
Katsiaryna Bykov
Claudia Cabrera
Moksnes
Guy Cafri
Bin Cai
Gregory Calip
Wendy Camelo Castillo
Ulka Campbell
Raiasss Candido
Bruce Carleton, FISPE
David Carrell
Deborah Casso
Caroline Castro
Gillian Caughey
Carolyn Cesta
Christina Chambers
Vivien Chan
Yen Lin Chang
Zheng Chang
Chao Chen
Li-Ju Chen
Lu Chen
Nai-Yu Chen

Wei-Han Chen
Danni Cheng
Hong Cheng
Charmi Chhatrala
Pudi Chiranjeevi
Kate Chitty
Yohann Chiu
Ahhyung Choi
Eun-Young Choi
Andrea Chomistek
Te-Yuan Chyou
Javier Cid Ruzafe
Jacqueline Cohen
Karen Cohen
Catherine Cohet
Irma Convertino
Paul Coplan, FISPE
Nicole Cosrow
Deborah Covington, FISPE
Marianne Cunnington
Jeffrey Curtis
Benjamin Daniels
Mukhtar Dar
Monica D’arcy
Nabarun Dasgupta
Chintan Dave
Kourtney Davis, FISPE
Ghadeer Dawwas
Airam de Burgos Gonzalez
Cynthia De Luise
Siesta De Vries
Eir Delker
Huiwen Deng
Petra Denig, FISPE
Anouk Deruaz Luyet
Neil Dhopheshwarkar
Julia Dibello
Harryt Dickinson
Paul Dillon
Bethany Diprete

Rachael
Disantostefano
Djeneba Audrey Djibo
Caillinn Dowd
Michael Donnamong
David Dore
Colin Dormuth
Susan Dosreis, FISPE
Ian Douglas
Antonios Douros
Brian Dreyfus
Cecile Droz-Perron
Wei Du
Sascha Dublin
Emilie Duchesneau
Elena Dudukina
Ma Duong
Katherine Duszynski
Stanley Edlavitch, FISPE
Dr. Egwuenu
Giraud Ekanmani
Emad Elkholy
Alan Ellis
Soha Elmosry
Sherif Eltsony
Efe Ewuruke
Michael Falster
Ahmed Fatheerahman
Guillaume Favre
Muhammed Shaffi
Fazaludeen Koya
Tim Feeney
Nermina Ferizovic
Milene Fernandes
Dr. Egwuenu
Nadine Foskett
Matthew Francis
Candace Fuller
ISPE is very grateful to the 760 volunteers who gave generously of their time to review abstracts submitted for ICPE 2022.
### Abstract Reviewers

- Angela Lupattelli
- Jennifer Lyons
- Theodore Lystig
- Christina Mack, FISPE
- Eswaran Maheswari
- Marina Malikova
- Jowanna Malone
- Kenneth Man
- Kenneth Mann
- Omar Mansour
- Zachary Marcum
- Andrea Marcus
- Andrea Margulis, FISPE
- Morgan Marks
- Judy Maro
- Ashley Martinez
- Maria Martineczonzalez
- Nancy Maserejian
- Amar Maske
- Prithpal Mateja
- Shinichi Matsuda
- Geric Maura
- Sophie Mayer
- Giampiero Mazzaglia
- Leah Mcgrath
- Wilhelmine Meeraus
- Hemalkumar Mehta
- Rosanne Meijboom
- Cristiane Menezes
- Mikhail Menis
- Davide Messina
- Nkuchia Mikanatha
- Daniel Mines
- Barbara Mintzes
- Dustin Miracle
- Sonal Sekhar Miraj
- Fariba Mirzaei
- Garima Mishra
- Garima Mittal
- Jingping Mo
- Daniela Moga
- Sorouth Mohammadi Jouabadi
- Marta Monreal
- Francois Montastrict
- Daniel Morales
- Elaine Morrato
- Earl Morris
- Andrew Mosholder
- Cristiano Moura
- Mohammad Movahedi
- Tanja Mueller
- Zaietuni Mulaa
- Dana Murdock
- Nivantha Naidoo
- Gouri Nair
- Sreedharan Nair
- Aya Nakitanda
- Young Hee Nam
- Abdallah Naser
- Mitra Nekouei Shahrahki
- G. Nethravathi
- Huah Shin Ng
- Chi Nguyen
- Carrie Nielson
- Prasad Nishtala
- Yunha Noh
- Hedvig Nordeng, FISPE
- Niklas Noren
- Mette Norgaard
- Pandji Winata Nurikwan
- Fredrik Nyberg, FISPE
- Adam Nygren
- Emily Obrien
- Ingvid Odsbu
- Gyeon Oh
- Bruno Ohana
- Hemliata Qha
- Charles Okafor
- Monika Oktora
- Denise Oleske
- Timothy Oluwasola
- Oluwadamiola
- Onasanya
- Sylvia Ompanga
- Ibrahim Oregba
- Merete Osler
- Anna Ostropelets
- Marianne Otto
- Jetty Overbeek
- Julie Paik
- Shilpa Palaksha
- Karine Palin
- Kristin Palmsten
- Menglan Pang
- Sewon Park
- So-Hee Park
- Lauren Parlett
- Nalcy Parodi Lopez
- Ami Patel
- Kaushal Patel
- Jessica Paulus
- Alma Pedersen
- Imelda Pena
- Susana Perez-Gutthann
- Silvia Perez-Vilar
- Rebecca Persson
- Dyah Perwitasari
- Paul Petraz
- Payam Peymani
- Thanh Phuong Pham Nguyen
- Syd Phillips
- Syd Phillips
- Bora Plaku
- Robert Platt
- Katharina Platzbecker
- Lisa Pont, FISPE
- Anton Pottegard
- Lisa Prach
- Anjali Pradhan
- Daniel Prieto-Alhambra, FISPE
- Rajeshwari Punekar
- Dima Qato
- Jingjing Qian
- Adrian Paul Rabe
- Ashish Rai
- Asha Rajan
- Adepu Ramesh
- Muhammed Rashid
- Nuvan Rathnayaka
- Ravina Ravi
- Jennita Reefhuis
- Adriano Reis
- Christopher Rentsch
- Simon Reuter
- Carlen Reyes
- Jinnie Rhee
- Munaza Riaz
- Tatiane Ribeiro
- Kathryn Richardson
- Mary Beth Ritchey
- Mary Ritchey, FISPE
- Donna Rivera
- Elena Rivero-Ferrr, FISPE
- Giuseppe Roberto
- Yesenia Rodriguez
- Catherine Rogers
- Murray
- Vered Rosenberg
- Dominique Rosillon
- Rachael Ross
- Kathryn Rough
- Elizabeth Roughhead, FISPE
- Debrabrata Roy
- George Sabbhah
- Patricia Saddier
- Sujit Sah
- Nuria Saigi-Morgui
- Laura Saint-Lary
- Manbel Salas, FISPE
- Hager Saleh
- Catherine Saltus
- Savitha Sanathan
- Gabriel Sanfelix-Gimeno
- Leah Sansbury
- Djanilson Santos
- Amir Sarayani
- Jyotirmoy Sarker
- Grammati Sarri
- Wiebke Schaefer
- Andrea Schaffer
- Darren Scheer
- Tania Schink
- Maria Schneeweiss
- Oliver Scholle
- Suzie Seabroke
- Ryan Seals
- Juny Sebastian
- John Seeger, FISPE
- Jodi Segal, FISPE
- Harry Seifert, FISPE
- Maurizio Sessa
- Soko Setoguchi, FISPE
- Sha Sha
- Syed Mohsin
- Mahmood Shah
- Shahrzad Shahbazi
- Shana Khamsi
- Aina Shaju
- Jessica Shami
- Meijia Shao
- Shih-Chieh Shao
- Atiquilla Shariff
- Manvi Sharma
- Syed Ilyas Shehnaz
- Chin-Yao Shen
- Eric Cheng-Chan Shih
- Hojin Shin
- Adithya Shivakumar
- Shahar Shmuel
- Irene Shui
- Srikanth Siddalingegowda
- Ana Silva
- Ruth Sim
- Jason Simeone
- Susan Sinclair
- Ambrish Singh
Congratulations to Our New Fellows

Edward Bortnichak  Emily Brouwer  J. Bradley Layton  Nicole Pratt
Donna Rivera  Leah Sansbury  Susan Sinclair  Jonathan Slaughter

HealthCore Safety & Epidemiology Research

Uncover vital real-world evidence on the utilization, safety, and effectiveness of biopharmaceuticals and devices in large patient populations with accuracy and efficiency.

Safety & Epidemiology Services

- Post-Marketing Requirements & Post-Authorization Safety Studies
- Scientific Coordinating Center & Data Analytics for Multi-Database Studies
- Pregnancy Outcomes Studies
- Algorithm Development & Validation Studies
- Risk Evaluation & Mitigation Studies
- Medical Record Abstraction & Adjudication
- Patient-Centered Research
- External Control Arms for Clinical Trials
- Machine Learning & Diagnostic Models

Visit us at ICPE Booth #401.
For a full list of HealthCore ICPE presentations, go to HealthCore.com/conferences/icpe-2022.
ICPE 2022
Sponsors & Exhibitors

ISPE gratefully acknowledges the generous support of the following organizations, institutions, and programs. Their contributions helped the Society advance the scientific program content and increase attendance at ISPE’s 38th annual meeting (ICPE).

### PLATINUM
- AstraZeneca

### GOLD
- Aetion
- Amgen Inc
- Boehringer Ingelheim
- Clark Davis Associates
- Eli Lilly
- Epi Excellence
- Evidera | PPD
- Exponent
- Healthcore
- IBM Watson Health
- IQVIA
- Johnson & Johnson
- OM1
- Optum
- P-95
- Panalgo
- RTI Health Solutions

### SILVER
- Analysis Group
- CorEvitas
- Genesis Research
- Regeneron

### BRONZE
- Bristol Myers Squibb
- Target RWE
- WorldWide Patient Safety Epidemiology/BMS

### EXHIBITORS
- Aarhus University
- Certara
- DeSC Healthcare
- Drug Safety Research Unit
- Eu2P + Am P2 Programme
- IHME Client Services
- JMDC Inc
- Oxon Epidemiology
- PHARMO Institute
- VAC4EU
EMERGING LEADER AWARD
Kaley Hayes

SUSTAINED SERVICE AWARD
Alison Bourke, FISPE
Byung Joo Park, FISPE

SPECIAL AWARD FOR PUBLIC HEALTH PROMOTION THROUGH PHARMACOEPIDEMIOLOGY
Dame June Raine

JUDITH K. JONES AWARD FOR IMPACT ON PUBLIC HEALTH THROUGH PHARMACOEPIDEMIOLOGY
Luciane Lopes
Ilse Truter, FISPE

RONALD D. MANN BEST PAPER AWARDS FOR MANUSCRIPTS PUBLISHED IN PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (PDS), 2021

WINNER
Association Between Inhaled Corticosteroid Use and COVID-19 Outcomes
Anders Husby | Anton Pottegård | Anders Hviid

HONORABLE MENTION
Statins and Risk of Diverticular Disease: Nested Case-Control Study
Nils Skajaa | Frederikke Schönfeldt Troelsen | Lars Pedersen
Ola Ekholm | Lisa Strate | Rune Erichsen | Henrik Toft Sørensen

SPECIAL ISPE AWARD FOR CONTRIBUTIONS TO PUBLIC HEALTH ASSOCIATED WITH THE COVID-19 PANDEMIC
A special award for 2022 to recognize how ISPE members have made and, in some cases, continue to make a demonstrable impact on public health related to the COVID-19 pandemic. From a strong field of candidates nominated by ISPE members, the following were selected by the Fellowship & Awards Committee and endorsed by the ISPE Board of Directors:

Robert Chen, FISPE
Nicolle Gatto, FISPE
Carlos Grijalva

Daniel Horton
Michele Jonsson Funk, FISPE
Vincent Lo Re, FISPE

Daniel Prieto-Alhambra, FISPE
Christopher Rentsch

Reimar Thomsen
Almut Winterstein, FISPE
ANDREW McAFFEE AWARD FOR BEST ABSTRACT FROM A DEVELOPING COUNTRY

Gouri Nair
Target Fishing and Drug Repurposing for Pancreatic Ductal Adenocarcinoma: An Integrated Bioinformatic and Computational Approach

JOHN SNOW AWARD FOR BEST ABSTRACT BY A RESEARCHER/STUDENT LIVING IN A DEVELOPING COUNTRY

Pudi Chiranjeevi
Association of Sacubitril/Valsartan with Hypoacusis Unveiled Through Disproportionality Analysis in US FDA Adverse Event Reporting System (FAERS)

STANLEY A. EDLAVITCH AWARD FOR MOST HIGHLY RATED STUDENT ABSTRACTS

FIRST PLACE
Junqing Xie
Genetic Risk and Incident Venous Thromboembolism in Middle-Aged and Older Adults Following COVID-19 Vaccination

SECOND PLACE
Syed Mohsin Mahmood Shah
Association Between Very High PD-L1 Expression Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-small Cell Lung Cancer

THIRD PLACE
Seonkyeong Yang
Trajectories of Concurrent Opioid and Benzodiazepine Use and Associated Opioid Overdose Risk Among Arizona Medicaid Beneficiaries

MOST HIGHLY RATED METHODS ABSTRACT SUBMITTED BY A STUDENT
Lars Christian Lund
Adjusting for Calendar Time in Analyses of COVID-19 Vaccine Safety and Effectiveness: A Simulation Study

MOST HIGHLY RATED ABSTRACT SUBMITTED BY A STUDENT IN THE DRUG UTILIZATION RESEARCH CATEGORY
Widya Norma Insani
Statin-Related Adverse Drug Reactions in UK Primary Care Consultations: A Retrospective Cohort Study to Evaluate the Risk of Cardiovascular Events and All-Cause Mortality
2. Login to the App

Tap **Login** and enter your **ISPE email address** and **password**.

3. App Tips

**Download** the app before you go! Wi-Fi connection on-site can affect the functionality of the app.

**Browse** the event information and create a personal schedule by tapping on the star next to presentations titles.
## TUESDAY, AUGUST 23

<table>
<thead>
<tr>
<th>Time</th>
<th>7 AM</th>
<th>8 AM</th>
<th>9 AM</th>
<th>10 AM</th>
<th>11 AM</th>
<th>12 PM</th>
<th>1 PM</th>
<th>2 PM</th>
<th>3 PM</th>
<th>4 PM</th>
<th>5 PM</th>
<th>6 PM</th>
<th>7 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 PM</td>
<td>6 PM</td>
<td>Speaker Ready Room – Room 21</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4 PM</td>
<td>6 PM</td>
<td>Registration – Hall F6-F7 Lobby</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## WEDNESDAY, AUGUST 24

<table>
<thead>
<tr>
<th>Time</th>
<th>7 AM</th>
<th>8 AM</th>
<th>9 AM</th>
<th>10 AM</th>
<th>11 AM</th>
<th>12 PM</th>
<th>1 PM</th>
<th>2 PM</th>
<th>3 PM</th>
<th>4 PM</th>
<th>5 PM</th>
<th>6 PM</th>
<th>7 PM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7:30 AM - 6 PM</td>
<td>Speaker Ready Room – Meeting Room 21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7:30 AM - 6 PM</td>
<td>Registration – Hall F6 - F7 Lobby</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7:30 AM - 6 PM</td>
<td>Lactation Room – Meeting Room 28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>8:30 AM - 12:30 PM</td>
<td>PRE-CONFERENCE COURSES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmacoepidemiologist’s Toolbox for Professional Empowerment – Room C1M5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Principles of Pharmacoepidemiology – Room C1M0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk Minimization and Communication: Science-based Approaches and Case Studies for Designing and Evaluating Effective Interventions for the Safe Use of Medicinal Products – Room C1M2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:30 PM - 2 PM</td>
<td>Lunch on Your Own</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2:00 PM - 6 PM</td>
<td>PRE-CONFERENCE COURSES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adherence to Medication – Room C1M0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foundations in Causal Inference – Room C1M4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Practical Skills in Protocol Writing and Statistical Analytic Programming Relevant to Pharmacoepidemiology – Congress Hall D2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pragmatic Trials: Design, Methods, and Implementation – Room C1M2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Using Field Studies to Value-add in Pharmacoepidemiology – Meeting Room 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Using Pharmacoepidemiology Database Resources to Address Drug Safety Research – Congress Hall D5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Introduction to Machine Learning for Pharmacoepidemiologists – Room C1M5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 PM - 5 PM</td>
<td>ISPE Board of Directors’ Meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meeting Room 18 &amp; 19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Schedule-at-a-Glance

### Thursday, August 25

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM</td>
<td>Speaker Ready Room – Meeting Room 21</td>
</tr>
<tr>
<td>7:30 AM</td>
<td>Registration – Hall F6 – F7 Lobby</td>
</tr>
<tr>
<td>7:30 AM</td>
<td>Lactation Room – Meeting Room 28</td>
</tr>
</tbody>
</table>

### 8:30 AM - 12:30 PM
**PRE-CONFERENCE COURSES**
- Intermediate/Advanced Topics in Vaccine Epidemiology – Room C1M2
- Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounders – Room C1M5
- Introduction to Drug Utilization Research and the Conduction of Real-World Drug Utilization Studies: Describe and Compare – Meeting Room 20
- Modern Pregnancy Pharmacoepidemiology: Emulating Target Trials – Congress Hall D2
- Pharmacoepidemiology and Signal Detection – Room C1M0
- Propensity Scores in Pharmacoepidemiology – Congress Hall D5
- New Frontiers for Pharmacoepidemiology: Using New and Mixed Methods for Data Collection – Room C1M4

### 12:30 PM - 2 PM
**Lunch on Your Own**

### 12:45 PM - 2 PM
**New Member & Early Stage Investigator Lunch – Room C1M5**
By invitation only; registration required.

### 2:00 PM - 6 PM
**PRE-CONFERENCE COURSES**
- Advanced Drug Utilization Research – Room C1M2
- Advanced Pharmacoepidemiology Methods: Mitigating Missing Data Concerns with External or Internal Subset Validation Populations – Room C1M1
- Applied Sensitivity Analyses in Pharmacoepidemiology Database Studies – Congress Hall D5
- Medical Device Epidemiology – Meeting Room 20
- Real-World Evidence (RWE) Generation for Rare Disease Drug Development and Orphan Drug Approvals – Room C1M4
- Weighing the Benefits & Risks: The Science and Methods of Benefit-Risk Assessment in Drug Development – Room C1M0

### 6:00 PM - 7:30 PM
**Welcome Reception**
Hall E-South
## Schedule-at-a-Glance

### Friday, August 26

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM</td>
<td>Coffee with Exhibitors</td>
<td>Hall C</td>
</tr>
<tr>
<td>7 - 8 AM</td>
<td>Poster Session A Set-Up</td>
<td>Hall C</td>
</tr>
<tr>
<td>8 - 10 AM</td>
<td>Welcome and Keynote Session</td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>10:30 AM - 12 PM</td>
<td>SYMPOSIA &amp; WORKSHOPS</td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>12 - 1:30 PM</td>
<td>Lunch/Poster Session A/Exhibits</td>
<td>Hall C</td>
</tr>
<tr>
<td>12 - 1:30 PM</td>
<td>COMMITTEE MEETINGS</td>
<td>Meeting Room 20</td>
</tr>
<tr>
<td>1:30 - 3 PM</td>
<td>ORAL PRESENTATIONS</td>
<td>Congress Hall D5</td>
</tr>
<tr>
<td>3:30 - 5 PM</td>
<td>SYMPOSIA &amp; WORKSHOPS</td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>5:15 - 6:45 PM</td>
<td>ORAL PRESENTATIONS</td>
<td>Congress Hall D5</td>
</tr>
<tr>
<td>7 AM - 6 PM</td>
<td>Speaker Ready Room – Meeting Room 21</td>
<td></td>
</tr>
<tr>
<td>7 AM - 6 PM</td>
<td>Registration – Hall F6 - F7 Lobby</td>
<td></td>
</tr>
<tr>
<td>7 AM - 6 PM</td>
<td>Lactation Room – Meeting Room 28</td>
<td></td>
</tr>
<tr>
<td>8 AM - 6 PM</td>
<td>Exhibits/Poster Session A – Hall C</td>
<td></td>
</tr>
<tr>
<td>7 - 8 AM</td>
<td>Coffee with Exhibitors</td>
<td>Hall C</td>
</tr>
<tr>
<td>8 - 10 AM</td>
<td>Welcome and Keynote Session</td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>10:30 AM - 12 PM</td>
<td>SYMPOSIA &amp; WORKSHOPS</td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>12 - 1:30 PM</td>
<td>Lunch/Poster Session A/Exhibits</td>
<td>Hall C</td>
</tr>
<tr>
<td>12 - 1:30 PM</td>
<td>COMMITTEE MEETINGS</td>
<td>Meeting Room 20</td>
</tr>
<tr>
<td>1:30 - 3 PM</td>
<td>ORAL PRESENTATIONS</td>
<td>Congress Hall D5</td>
</tr>
<tr>
<td>3:30 - 5 PM</td>
<td>SYMPOSIA &amp; WORKSHOPS</td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>5:15 - 6:45 PM</td>
<td>ORAL PRESENTATIONS</td>
<td>Congress Hall D5</td>
</tr>
<tr>
<td>8 AM - 6 PM</td>
<td>Exhibits/Poster Session A – Hall C</td>
<td></td>
</tr>
</tbody>
</table>

### Activities
- **8 PM**: PDS Editorial Board
  - Bella Sky Room 181
  - By invitation.
- **8 - 10 PM**: Students/Early Career Professionals Meet & Greet
  - Midsommar - Biergarten og Rooftop bar
## Schedule-at-a-Glance

### S A T U R D A Y, A U G U S T  2 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM - 6 PM</td>
<td>Speaker Ready Room – Room 21</td>
</tr>
<tr>
<td>7 AM - 6 PM</td>
<td>Registration – Hall F6 - F7 Lobby</td>
</tr>
<tr>
<td>8 AM - 6 PM</td>
<td>Lactation Room – Meeting Room 28</td>
</tr>
<tr>
<td>8 AM - 6 PM</td>
<td>Exhibits/Posters Session B – Hall C</td>
</tr>
<tr>
<td>7 - 8 AM</td>
<td>Coffee with Exhibitors Hall C</td>
</tr>
<tr>
<td>7 - 8 AM</td>
<td>ORAL PRESENTATIONS Across the Globe: Injury and Neurologic</td>
</tr>
<tr>
<td></td>
<td>Pharmacopoenidemiology – C1M0</td>
</tr>
<tr>
<td>7 - 8 AM</td>
<td>Africa Regional Interest Group Meeting Room 20</td>
</tr>
<tr>
<td></td>
<td>Open to all participants.</td>
</tr>
<tr>
<td>7 - 8 AM</td>
<td>Latin America Regional Interest Group Meeting Room 18</td>
</tr>
<tr>
<td></td>
<td>Open to all participants.</td>
</tr>
<tr>
<td>7 - 8 AM</td>
<td>ORAL PRESENTATIONS</td>
</tr>
<tr>
<td>8 - 9:30 AM</td>
<td>Lunch/Poster Session B/Exhibits – Hall C</td>
</tr>
<tr>
<td>10 - 11:30 AM</td>
<td>PLENARY SESSION</td>
</tr>
<tr>
<td></td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>11:30 AM - 1 PM</td>
<td>COMMITTEE MEETINGS</td>
</tr>
<tr>
<td></td>
<td>Finance Meeting Room 18</td>
</tr>
<tr>
<td></td>
<td>Membership Meeting Room 19</td>
</tr>
<tr>
<td></td>
<td>Open to all participants, lunch available</td>
</tr>
<tr>
<td>1 - 2:30 PM</td>
<td>ORAL PRESENTATIONS Psychotropic Use</td>
</tr>
<tr>
<td></td>
<td>Around the World C1M0</td>
</tr>
<tr>
<td>2:40 - 3:50 PM</td>
<td>ANNUAL MEETING</td>
</tr>
<tr>
<td></td>
<td>of ISPE Members &amp; Awards Ceremony</td>
</tr>
<tr>
<td></td>
<td>Congress Hall D4</td>
</tr>
<tr>
<td>4:15 - 5:45 PM</td>
<td>SYMPOSIA &amp; WORKSHOPS</td>
</tr>
<tr>
<td></td>
<td>Drug Safety on the Cutting Edge: What are the Implications of EMA’s</td>
</tr>
<tr>
<td></td>
<td>To-Be-Released Risk Minimisation Guidance on Pharmacopoenidemological</td>
</tr>
<tr>
<td></td>
<td>Methods and Practice in Developed and Developing Countries? C1M0</td>
</tr>
<tr>
<td>6 - 7 PM</td>
<td>COUNCIL MEETINGS</td>
</tr>
<tr>
<td></td>
<td>Academic Conference Room C1M0</td>
</tr>
<tr>
<td></td>
<td>Student Conference Room C1M1</td>
</tr>
<tr>
<td></td>
<td>Open to all participants.</td>
</tr>
</tbody>
</table>

### 7 AM - 11 PM

- **7 PM** Social Evening at the Langelinie Pavilion

### 7 AM - 6 PM

- **7 AM** - **6 PM** Speaker Ready Room – Room 21
- **7 AM** - **6 PM** Registration – Hall F6 - F7 Lobby
- **8 AM** - **6 PM** Exhibits/Posters Session B – Hall C

### 8 AM - 6 PM

- **8 AM** - **6 PM** Lactation Room – Meeting Room 28

### 10 - 11:30 AM

- **10 - 11:30 AM** PLENARY SESSION
- **11:30 AM - 1 PM** COMMITTEE MEETINGS
- **11:30 AM - 1 PM** Lunch/Poster Session B/Exhibits – Hall C

### 1 - 2:30 PM

- **1 - 2:30 PM** ORAL PRESENTATIONS
- **Psychotropic Use Around the World C1M0**
- **Mending Hearts and Brains Conference Room C1M1**
- **Lightning Session 2 C1M2**
- **Methods: Machines Making Predictions Congress Hall D4**
- **Study Design Approaches to Assessing Thrombosis Risk Congress Hall D2**
- **What’s the Risk? Cancer Risk & Common Medications Congress Hall D5**

### 2:40 - 3:50 PM

- **2:40 - 3:50 PM** ANNUAL MEETING of ISPE Members & Awards Ceremony
- **Congress Hall D4**

### 4:15 - 5:45 PM

- **4:15 - 5:45 PM** SYMPOSIA & WORKSHOPS
- **Drug Safety on the Cutting Edge: What are the Implications of EMA’s To-Be-Released Risk Minimisation Guidance on Pharmacopoenidemological Methods and Practice in Developed and Developing Countries? C1M0**
- **Real-World Evidence Studies in the post-COVID-19 Era: Methodological Considerations for Pandemic Related Disruptions – C1M1**
- **Late Breakers (Oral presentations) – C1M2**
- **HARmonized Protocol to Enhance Reproducibility (HARPER): An ISPE-ISPOR Joint Task Force of the RWE Initiative C1M5**
- **Cloning, Censoring, and Weighting— Oh My! Applications of Target Trial Emulation for Evaluating Cancer Interventions When Study Eligibility, Intervention Initiation, and Start of Follow-up are Not Aligned Congress Hall D2**
- **COVID-19 Vaccine Safety Monitoring: Opportunities, Challenges and Lessons Learned for Pharmacopoenidemology Congress Hall D5**

### 6 - 7 PM

- **6 - 7 PM** COUNCIL MEETINGS
- **Academic Conference Room C1M0**
- **Student Conference Room C1M1**
- Open to all participants.

### 7 AM - 6 PM

- **7 AM** - **6 PM** Speaker Ready Room – Room 21
- **7 AM** - **6 PM** Registration – Hall F6 - F7 Lobby
- **8 AM** - **6 PM** Lactation Room – Meeting Room 28
- **8 AM** - **6 PM** Exhibits/Posters Session B – Hall C

### 7 AM - 11 PM

- **7 PM** Social Evening at the Langelinie Pavilion
# Schedule-at-a-Glance

**Sunday, August 28**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 AM</td>
<td>Speaker Ready Room – Room 21</td>
</tr>
<tr>
<td>8 AM</td>
<td>Registration – Hall F6 - F7 Lobby</td>
</tr>
<tr>
<td>7 AM</td>
<td>Lactation Room – Meeting Room 28</td>
</tr>
<tr>
<td>8 AM</td>
<td>Exhibits – Hall C</td>
</tr>
<tr>
<td>8 AM</td>
<td>Posters Session C – Hall C</td>
</tr>
<tr>
<td>7 AM</td>
<td>ORAL PRESENTATIONS</td>
</tr>
<tr>
<td>8:30 - 10 AM</td>
<td>Around the World With Real-World Evidence – C1M0</td>
</tr>
<tr>
<td>8:30 - 10 AM</td>
<td>SGLT2s and Cardiovascular Endpoints – C1M1</td>
</tr>
<tr>
<td>8:30 - 10 AM</td>
<td>Welcoming Novel Methods in Pregnancy Research – C1M2</td>
</tr>
<tr>
<td>8:30 - 10 AM</td>
<td>Examining Equity: Who? Where and What? Congress Hall D2</td>
</tr>
<tr>
<td>8:30 - 10 AM</td>
<td>Pandemic Prescription Patterns (Plus Pneumonia) – Congress Hall D4</td>
</tr>
<tr>
<td>8:30 - 10 AM</td>
<td>Methods: Validation – Congress Hall D5</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>SYMPOSIA &amp; WORKSHOPS</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Emulation Differences versus Bias: Implications of Large-scale Emulation of Randomized Clinical Trials Using Clinical Practice Data (RCT-DUPLICATE) – C1M0</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>COVID-19 Vaccine Use During Pregnancy: Accelerating Innovative Evidence Generation Platforms to Meet Current and Future Challenges – C1M1</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Shaping the Future of Pharmacoepidemiology – C1M5</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Updating the Public on COVID-19 Vaccine Safety – Considerations for Pharmacoepidemiologists – Congress Hall D5</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Spotlight Poster Session C – Hall E South</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Lunch/Poster Session C/Exhibits – Hall C</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>ISPE Board of Directors’ Lunch – Meeting Room 19</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>ORAL PRESENTATIONS</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Safety Issues Concerning DM and Antidiabetic Drugs – C1M0</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Evaluating the Vaccines Against the Nasty Bugs: Safety First Round II – C1M1</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Lightning Session 3 – C1M2</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Novel Approaches to Pharmacovigilance – C1M5</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Fractures and Osteoporosis Medication – Congress Hall D2</td>
</tr>
<tr>
<td>12:15 - 1:15 PM</td>
<td>Use it or Lose Out: Trends in Anti-Cancer and Biologic Utilization – Congress Hall D5</td>
</tr>
<tr>
<td>1:30 - 3 PM</td>
<td>ORAL PRESENTATIONS</td>
</tr>
<tr>
<td>1:30 - 3 PM</td>
<td>The Final Word – Congress Hall D4</td>
</tr>
<tr>
<td>3:15 - 4:45 PM</td>
<td>Hot Topic Session – Congress Hall D4</td>
</tr>
<tr>
<td>4:45 - 5:30 PM</td>
<td>The 2023 Scientific Program Committee Meeting Room 20 – Open to ISPE members.</td>
</tr>
</tbody>
</table>
Pre-Conference Program Schedule

Tuesday, August 23

2:00 - 6:00 PM

Speaker Ready Room / Meeting Room 21
Only required if you need to upload your presentation, or update/replace an already-uploaded presentation. Please complete uploads 24-hours in advance of your session.

Lanyard Selection
Please choose the color lanyard that best illustrates your comfort level with interactions at the conference.
Green: Ok to Contact, e.g. hug or handshake
Yellow: Minimal Contact, e.g. fist bump
Red: No Close Contact, e.g. no touching, maintain social distancing

4:00 - 6:00 PM

Registration / Hall F6-F7 Lobby
If you plan to attend a course on Wednesday morning, it is strongly recommended that you check-in Tuesday evening to avoid delays.

Mask Wearing Mandate
Unless presenting, eating or drinking, mask wearing is required at all times during the conference and at all ISPE-flagged events (this also means social events) using Type IIR or FFP2 (or equivalent or better) grade masks. You might forfeit your conference registration if you are not in compliance. For your convenience, ISPE will provide free masks at the registration desk.

ISPE Exchange
With this exclusive membership benefit, 3,500+ members connect with peers, share ideas and get involved within ISPE communities. Members can also participate in our Mentor Match and search for colleagues within the membership directory.
PRE-CONFERENCE
Program Schedule

WEDNESDAY, AUGUST 24

7:30 AM - 6:00 PM
SPEAKER READY ROOM / MEETING ROOM 21
Only required if you need to upload your presentation, or update/replace an already-uploaded presentation. Please complete uploads 24 hours in advance of your session.

7:30 AM - 6:00 PM
REGISTRATION / HALL F6-F7 LOBBY

7:30 AM - 6:00 PM
LACTATION ROOM / MEETING ROOM 28
Sponsored by EPI Excellence, LLC

7:30 AM - 6:00 PM
PRE-CONFERENCE COURSES – VIRTUAL COURSES
The following courses will be made available online shortly after the conclusion of ICPE.

Cancer Pharmacoepidemiology and Genomics: What You Should Know in the Era of Precision Medicine
FACULTY
Bruce Carleton, FISPE | Andrew Freedman, FISPE
Gillian Bartlett-Esquiland, FISPE | Kelly Filipski
Geoffrey Liu, FISPE | Donna Rivera, FISPE
Leah Sansbury, FISPE | Wei Zhou, FISPE

How to Design a Real-World Study of Biologics Including Biosimilars
FACULTY
Jaclyn Bosco, FISPE | Rohini Hernandez
Thijs Giezen | Gianluca Trifiro, FISPE

Introduction to Pharmacogenomics & Precision Medicine for Pharmacoepidemiologists
FACULTY
Amalia Issa, FISPE | Gillian Bartlett-Esquiland, FISPE
Bruce Carleton, FISPE | Stephen Kimmel, FISPE
Leah Sansbury, FISPE
Anke-Hilse Maitland-van der Zee, FISPE

Pediatric Pharmacoepidemiology
FACULTY
Tamar Lasky, FISPE | Jenny Sun | Ann McMahon, FISPE
Rima Izem | Steven Bird | Mehmet Burcu | Daniel Horton

Regulatory Pharmacoepidemiology
FACULTY
Danica Marinac-Dabic, FISPE | Gerald Dal Pan, FISPE
Katherine Donegan

8:30 AM - 12:30 PM
PRE-CONFERENCE COURSES – HALF-DAY MORNING COURSES
Pre-purchase required.

Pharmacoepidemiologist’s Toolbox for Professional Empowerment – Room C1M5
FACULTY
Caitlin Knox | Juan Hincapie-Castillo
Mary Beth Ritchey, FISPE | Christopher Rentsch
Yola Moride, FISPE

Principles of Pharmacoepidemiology – Room C1M0
FACULTY
Tobias Gerhard, FISPE | Almut Winterstein, FISPE
Anton Pottegård

Risk Minimization and Communication: Science-based Approaches and Case Studies for Designing and Evaluating Effective Interventions for the Safe Use of Medicinal Products – Room C1M2
FACULTY
Priya Bahri | Meredith Smith, FISPE | Peter Mol
Elaine Morrato

12:30 - 2:00 PM
LUNCH ON YOUR OWN
There are limited dining choices within walking distance of the Bella Center. Please plan to purchase food at one of the pop-up cafes provided for your convenience.

1:00 - 5:00 PM
ISPE BOARD OF DIRECTORS’ MEETING – MEETING ROOM 18 & 19
Open to all ISPE members; please contact info@pharmacoepi.org if you are interested in attending this meeting.
PRE-CONFERENCE PROGRAM SCHEDULE

2:00 - 6:00 PM

PRE-CONFERENCE COURSES – HALF-DAY AFTERNOON COURSES
Prepurchase required.

Adherence to Medication – Conference Room C1M0
FACULTY
Jacqueline Hugtenburg | Robert Gross, FISPE
Julie Lauffenburger | Job Van Boven

Foundations in Causal Inference – Conference Room C1M4
FACULTY
Joshua Gagne, FISPE | Geetha Iyer

Introduction to Machine Learning for Pharmacoepidemiologists – Conference Room C1M5
FACULTY
Lisa Weiss | Dana Teltsch | Harriet Dickinson
Victoria Strauss | Orla Doyle | Kathryn Rough
Joseph Zabinski

Practical Skills in Protocol Writing and Statistical Analytic Programming Relevant to Pharmacoepidemiology – Congress Hall D2
FACULTY
Christian Hampp, FISPE | Jessica Jalbert
Mingfeng Zhang | Nicole PrattSoko | Setoguchi, FISPE

Pragmatic Trials: Design, Methods, and Implementation – Room C1M2
FACULTY
Jennifer Christian, FISPE | Priscilla Velentgas
Cynthia Girman, FISPE | Anne Trontell
Bodil Kjeldgaard Vistisen | Margaret Mazzeo

Using Field Studies to Value-add in Pharmacoepidemiology – Meeting Room 20
FACULTY
Katja Taxis, FISPE | Lisa Pont, FISPE | Veronika Wirtz
Anna Birna Almarsdottirarm

Using Pharmacoepidemiology Database Resources to Address Drug Safety Research – Congress Hall D5
FACULTY
Kevin Haynes, FISPE | Daniel Beachler | Gillian Hall, FISPE
Sudha Raman
THURSDAY, AUGUST 25

7:30 AM - 6:00 PM
SPEAKER READY ROOM / MEETING ROOM 21
Please arrive 24 hours before your presentation start time to upload or check your presentation.

7:30 AM - 6:00 PM
REGISTRATION / HALL F6-F7 LOBBY

7:30 AM - 6:00 PM
LACTATION ROOM / MEETING ROOM 28
Sponsored by EPI Excellence, LLC

8:30 AM - 12:30 PM
PRE-CONFERENCE COURSES – HALF-DAY MORNING COURSES
Prepurchase required.

Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounders – Conference Room C1M5
FACULTY
Michele Jonsson Funk, FISPE | Sudha Raman
Jennifer Lund, FISPE | Mugdha Gokhale | Jessica Young
Til Stürmer, FISPE

Introduction to Drug Utilization Research and the Conduct of Real-World Drug Utilization Studies: Describe and Compare – Meeting Room 20
FACULTY
Gillian Caughey | Mina Tadrous | Lisa Pont, FISPE
Jodie Hillen | Bjorn Wettermarkarm, FISPE

Modern Pregnancy Pharmacoepidemiology: Emulating Target Trials – Congress Hall D2
FACULTY
Andrea Margulis, FISPE | Krista Huybrechts, FISPE
Brian Bateman | Sonia Hernandez-Diaz, FISPE

New Frontiers for Pharmacoepidemiology: Using New and Mixed Methods for Data Collection – Congress Hall C1M4
FACULTY
Nancy Dreyer, FISPE | Christina Mack, FISPE
William Dixon | Nabarun Dasgupta | Rachel Williams

12:30 - 2:00 PM
LUNCH ON YOUR OWN
There are limited dining choices within walking distance of the Bella Center. Please plan to purchase food at one of the pop-up cafes provided for your convenience.

12:45 - 2:00 PM
NEW MEMBER & EARLY-STAGE INVESTIGATOR LUNCH – ROOM C1M5
By invitation only; registration required.

2:00 - 6:00 PM
PRE-CONFERENCE COURSES: HALF-DAY AFTERNOON COURSES
Prepurchase required.

Pharmacovigilance and Signal Detection – Conference Room C1M0
FACULTY
Judith Maro | Niklas Noren | Gregory Powell
Monica Munoz

Propensity Scores in Pharmacoepidemiology – Congress Hall D5
FACULTY
John Seeger, FISPE | Jeremy Rassen, FISPE

Intermediate/Advanced Topics in Vaccine Epidemiology – Room C1M2
FACULTY
Cathy Panozzo | Jennifer Gerber | Hui-Lee Wong
Daina Esposito | Kaatje Bollaerts | Hector Izurieta
Deshayne Fell | Rebecca Chandler

Advanced Drug Utilization Research – Conference Room C1M2
FACULTY
Gillian Caughey | Mina Tadrous | Katja Taxis, FISPE
Petra Denig, FISPE

Applied Sensitivity Analyses in Pharmacoepidemiology Database Studies – Congress Hall D5
FACULTY
Sebastian Schneeweiss, FISPE | Jeremy Rassen, FISPE
Nicolle Gatto | Elizabeth Garry
Medical Device Epidemiology – Meeting Room 20
FACULTY
Mary Beth Ritchey, FISPE | Christina Mack, FISPE
Mackenzie Herzog | Paul Coplan, FISPE

Advanced Pharmacoepidemiology Methods: Mitigating Missing Data Concerns with External or Internal Subset Validation Populations – Conference Room C1M1
FACULTY
Judith Maro | Lourens Bloem | Jenny Sun
Corinne de Vries | Janick Weberpals

Real-World Evidence (RWE) Generation for Rare Disease Drug Development and Orphan Drug Approvals – Room C1M4
FACULTY
Emily Bratton | Rima Izem | Xabier Garcia de Albeniz | Jie Li

Weighing the Benefits & Risks: The Science and Methods of Benefit-Risk Assessment in Drug Development – Conference Room C1M0
FACULTY
Alicia Gilsenan, FISPE | Juhaeri Juhaeri
Christine Poulos | Bennett Levitan

6:00 - 7:30 PM
WELCOME RECEPTION / HALL E-SOUTH
Sponsored by IBM Watson Health
Vin Lo Re, FISPE, ISPE President
Anton Pottegård, Chair
ICPE 2022 Scientific Program Committee
Jesper Hallas, FISPE, Co-Chair
ICPE 2022 Scientific Program Committee

REGIONAL INTEREST GROUP & ACADEMIC SHOWCASE
Brigham and Women’s Hospital Division of Pharmacoepidemiology & Pharmacoeconomics
London School of Health and Tropical Medicine
McGill University, Department of Epidemiology, Biostatistics, and Occupational Health
University of Florida, College of Pharmacy
Department of Pharmaceutical Outcomes and Policy
University of North Carolina at Chapel Hill

Most diseases aren’t siloed or stagnant. So why should your research be?

Specialized Datasets
for a fuller view of patient journeys, outcomes, and endpoints

Research Analytics
to identify hidden insights by using our epi, biostats, data science, and clinical data expertise as an extension of your teams

OM1 Real-World Data

AI & Predictive Analytics
for enriching data, finding patients, and discovering patterns and insights

Automated Research Networks
for increasing speed and reducing costs of generating evidence through fully or partially prospective data collection

Visit the OM1 booth #201 or contact us at info@om1.com to learn more.
**SPEAKER READY ROOM / MEETING ROOM 21**
Only required if you need to upload your presentation, or update/replace an already-uploaded presentation. Please complete uploads 24-hours in advance of your session.

**REGISTRATION / HALL F6-F7 LOBBY**

**LACTATION ROOM / MEETING ROOM 28**
Sponsored by EPI Excellence, LLC

**COFFEE WITH EXHIBITORS / HALL C**

**Poster Session A set-up – Hall C**
**Spotlight Poster Session set-up – Hall E South**

**WELCOME / CONGRESS HALL D4**
Vin Lo Re, FISPE, ISPE President
Anton Pottegård, Chair
ICPE 2022 Scientific Program Committee
Jesper Hallas, FISPE, Co-Chair
ICPE 2022 Scientific Program Committee

**KEYNOTE PLENARY**
Strategies for Successful Mass Vaccination Rollout: Balancing Science, Politics, Communication and Trust – Congress Hall D4

**KEYNOTE SPEAKER**
Søren Brostrøm, MD, PhD, MPA
Director General, Danish Health Authority

Dr. Søren Brostrøm, Director General of the Danish Health Authority, will discuss strategies for successful mass vaccination rollout primarily from the Danish experience, but also drawing on international perspectives. The focus will be on the importance, from his experience during the pandemic, of ‘evidence-based government’ and ‘radical transparency’ and how not everything can be simplified to just ‘communication’ but is instead about having a good case to communicate, i.e., that science is more important than communication skills.

**BREAK WITH POSTERS & EXHIBITORS – HALL C**
CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

Using Real-World Data and Pharmacoepidemiologic Methods to Advance the Science of Deprescribing Research [26] – C1M5
Shahar Shmuel | Daniela Moga | Joshua Niznik
Julie Lauffenburger | Lucas Morin | Danijela Gnjidic
Xiaojuan Li | Kaley Hayes (United States)

Sonia Hernandez-Diaz FISPE | Leyla Sahin
Christina Chambers | Andrea Margulis FISPE
Krista Huybrechts FISPE | Corinne de Vries (United States)

Representing and Leveraging Heterogeneity Between Data Sources in Multi-database Pharmacoepidemiologic Studies [28] – C1M0
Rosa Gini | Romin Pajouheshnia | Gillian Hall FISPE
Robert Platt | Soko Setoguchi FISPE
Susana Perez-Gutthann FISPE | Corinne Willame (Italy)

Data Harmonization, Standardization, and Quality Assessment in Distributed Health Data Networks: Lessons from Around the World [29] – Congress Hall D2
Jeffrey Brown | Lisa Lix | Judith Maro | Matvey Palchuk
Robert Reynolds | Xavier Kurz (United States)

Bjorn Wettermark, FISPE | Cristina Ghiciuc | Job Van Boven
Monique Elseviers | Gaye Hafez | Catherine Goetzinger
Maria Herdeiro | Enrica Menditto
Francisca Leiva-Fernandez | Maria Dimitrova
Zorana Kovačević | Virginia Aguiar Leiva (Sweden)

CONCURRENT SESSIONS: ORAL PRESENTATIONS

A Tivoli Gardens Distillery of Applied Methods – Room C1M5

1:30 PM
Inverse Probability Weighting or Multiple Imputation for Nonmonotone Missing Data? [31]
Rachael Ross | Stephen Cole | Daniel Westreich
Julie Daniels | Jeffrey Stringer | Jessie Edwards (United States)

1:45 PM
Sampling Biases in Analyses of Prescription Durations [32]
Henrik Stovring | Anton Pottegård
Jesper Hallas FISPE (Denmark)

2:00 PM
The Impact Of Parametric Assumptions on the Bias-variance Tradeoff for Causal Analysis of Time-to-event Outcomes [33]
Andrew Allmon | Samantha Effert
Alexander Breskin (United States)
### 2:15 PM
**Successful Implementation of Inverse-probability-of-screening Weights to Address Differential Outcome Screening: Effects of Statin Persistence on Breast Cancer Risk in Denmark**

Sophie Mayer | Jesper Hallas FISPE | Jessie Edwards
Louise Henderson | Til Stürmer FISPE (United States)

---

### 2:30 PM
**Analytic Methods for Elucidating Continuous Dose-response Associations in the Presence of Spike-effects: Avoiding the Illusion of a Safe Dose**

Andrew Wiese | Carlos Grijalva | Margaret Adgent
Sarah Osmundson | Amelie Pham | Sharon Phillips
Ed Mitchel | Andrew Spieker (United States)

---

### 2:45 PM
**Antidepressant Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Pharmacoepidemiologic Screening to Detect Three-way Drug Interaction Signals**

Charles Leonard, FISPE | Cheng Chen | Sean Hennessy
Colleen Brensinger | Emily Acton | Warren Bilker
Todd Miano | Thanh Phuong Pham Nguyen (United States)

### Antidiabetics – Not Just About Diabetes –
**Congress Hall D2**

### 1:30 PM
**Incretin-based Drugs and the Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Among Patients with Type 2 Diabetes**

Richeek Pradhan | Sally Lu | Hui Yin | Oriana Hoi Yun Yu
Pierre Ernst | Samy Suissa | Laurent Azoulay (Canada)

### 1:45 PM
**Association Between Sodium Glucose Co-transporter 2 Inhibitors and Incident Glaucoma in Patients with Type 2 Diabetes: A Multi-institutional Cohort Study in Taiwan**

Shih-Chieh Shao | Edward Lai | Jia-Horung Hung (Taiwan)

### 2:00 PM
**Heterogeneous Treatment Effect of Glucagon-like Peptide 1 Receptor Agonists on Asthma/COPD exacerbation: Machine-learning Analysis of Two Nationwide Cohorts**

Tiansheng Wang | John Buse | Corinne Keet
Alexander Keil | Richard Wyss | Virginia Pate
Michele Jonsson Funk, FISPE | Michael Kosorok (United States)

### 2:15 PM
**Risk of Hepatic Events Associated with Sodium-glucose cotransporter-2 Inhibitors in Patients with Type 2 Diabetes: A Nationwide Cohort Study**

Sungho Bea | Han Eol Jeong | Sohee Park | Yosoo Chang
Dong Hyun Sinn | Oriana Hoi Yun Yu | Ju-Young Shin (Republic of Korea)

### 2:30 PM
**Incretin-based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes**

Sally Lu | Hui Yin | Oriana Hoi Yun Yu
Laurent Azoulay (Canada)

### 2:45 PM
**Association of Glucagon-like peptide-1 Receptor Agonists with Serious Liver Events: Scandinavian Cohort Study**

Arvid Engström | Victor Wintzell | Mads Melbye
Henrik Svanström | Björn Eliasson | Sofia Gudbjörnsdottir
Kristian Hveem | Christian Jonasson (Sweden)

### From Motherhood to Childhood, Moody to Healthy –
**Congress Hall D5**

### 1:30 PM
**Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and the Risk of Preterm Birth**

Guy Amit | Alice Tang | Chen Yanover | Maytal Bivas-Benita
Pinchas Akiva | Irena Girshovitz | Brian Le
Tomiko Oskotsky (Israel)

### 1:45 PM
**Lisdexamfetamine in Early Pregnancy and Risk of Major Congenital Malformations**

Jacqueline Cohen | Carolyn Cesta | Øystein Karlstad
Johan Reutfors | Kari Furu (Norway)

### 2:00 PM
**Psychostimulant Use During Pregnancy and the Risk of Neurodevelopmental Disorders in Children**

Elizabeth Suarez | Brian Bateman
Sonia Hernandez-Diaz FISPE | Loreen Straub | Yanmin Zhu
Helen Mogun | Krista Huybrechts FISPE (United States)

### 2:15 PM
**Antidepressant Treatment in Pregnancy and Maternal Mental Health in the Postpartum Year: A Danish Registry Linkage Study in Pregnant Women with Obsessive-compulsive Disorder**

Nhung Trinh | Birgitte Dige Semark | Trine Munk-Olsen
Xiaqin Liu | Liselotte Vogdrup Petersen | Angela Lupattelli (Norway)
2:30 PM
Topiramate During Pregnancy and the Risk of Neurodevelopmental Disorders in Children [47]
Sonia Hernandez-Diaz FISPE | Loreen Straub
Brian Bateman | Elizabeth Suarez | Yanmin Zhu
Helen Mogun | Page Pennell | Krista Huybrechts, FISPE (United States)

2:45 PM
Association of Prenatal Antidepressant Exposure with Trajectories and Acceleration of Body Mass Index in Children from 6 Week to 8 Years of Age [48]
Angela Lupattelli | Michele Pedroncelli | Sina Rostami
Nhung Trinh (Norway)

Challenges in Healthy Aging – C1M0

1:30 PM
Serious Hypoglycemia and the Risk of Dementia: A Population-based Cohort Study Using Exposure Density Sampling [49]
Wajd Alkabbani | Colleen Maxwell | Ruth Ann Marrie
Suzanne Tyas | Iliana Lega | John-Michael Gamble (Canada)

1:45 PM
Evaluation of Fall-related Injuries Following a Potential Calcium Channel Blocker — Loop Diuretic Prescribing Cascade [50]
Scott Vouri | Grace (Hsin Min) Wang | Earl Morris
Laurence Solberg | Michael Daniels | Carl Pepine
Todd Manini | Daniel Malone (United States)

2:00 PM
Translation of a Medicare Claims-based Frailty Index from International Classification of Diseases 9th Revision to 10th Revision [51]
Emilie Duchesneau | Shahar Shmuel | Keturah Faurot
Jihye Park | Musty Allison | Virginia Pate | Alan Kinlaw
Til Stürmer FISPE (United States)

2:15 PM
Tobacco Smoking, Intensity, and Duration are Associated with Frailty Among People with HIV [52]
Stephanie Ruderman | Heidi Crane | Allison Webel
Annette Fitzpatrick | Michelle Odden | Paul Crane
Amanda Willig | Robin Nance (United States)

2:30 PM
Impact of Different Poststroke Antihypertensive Regimens on Cardiovascular Outcomes and Mortality in People with Dementia: Four Continents for Dementia (4C4D) Study [53]
Jenni Ilomaki | Xiwen Simon Qin | Celine SL Chui
Gang Fang | Wallis Lau | Stephen J. Wood | Stella Kim
Miriam TY Leung (Australia)

2:45 PM
Frailty-gradient Risk of Mortality Comparing Primary Endocrine Therapy and Surgery in Treating Women with Early Breast Cancer [54]
Yubo Wang | Douglas Steinke, FISPE | Sean Gavan
Li-Chia Chen (United Kingdom)

Moving from Trials to Real-World Evidence, Back and Forth – Congress Hall D4

1:30 PM
Using Bias Correction Methods with Hybrid Randomized Controlled Trial (RCT) Plus Real World (RW) Controls to Replicate Results of a Phase lib RCT of Baricitinib for Rheumatoid Arthritis (RA) [55]
Anita Loughlin | Kristin Sheffield | Oksana Pugach
Mingyang Shan | Douglas Faries | Paul Lakin
Samantha Kerti | Zhanglin Cui (United States)

1:45 PM
Better Analysis of RCTs [56]
Tim Feeney | Stephen Cole (United States)

2:00 PM
Risk Ratios versus Hazard Ratios in Comparative Effectiveness Research: An Illustration Using Clinical Trial Data [57]
Chase Latour | I-Hsuan Su | Megan Delgado | Virginia Pate
Charles Poole | Jessie Edwards | Til Stürmer, FISPE
Jennifer Lund, FISPE (United States)

2:15 PM
Differential Misclassification of Overdose Safety in a Prominent Comparative Effectiveness RCT Comparing Buprenorphine and Naltrexone for Opioid Dependence [58]
Nabarun Dasgupta | Elizabeth Ajazi | Todd Schwartz
Stephen Marshall (United States)
2:30 PM  
Predicting Treatment Effects of a New Drug in a Target Population Based on Randomized Controlled Trial Results [59]  
HoJin Shin | Shirley Wang, FISPE | Dae Kim  
Mufaddal Mahesri | Lily Bessette | Joshua Gagne, FISPE  
Sebastian Schneeweiss, FISPE | Mehdi Najafzadeh (United States)

2:45 PM  
How Choosing the Risk Ratio or the Risk Difference Changes Sufficient Adjustment Sets for External Validity [60]  
Michael Webster-Clark | Alexander Keil (Canada)

Medicating for Two: Pregnancy, Maternal, and Infant Outcomes – C1M2

1:30 PM  
Does Treating Genital Herpes Infection During Pregnancy Reduce the Risk of Preterm Delivery? A Prospective Cohort Study of 89,000 Pregnant Women [61]  
DeKun Li | Jeannette Ferber | Roxana Odouli  
Piero Garzaro | Lyndsay Avalos | Charles Quesenberry (United States)

1:45 PM  
Prenatal Antibiotic Exposure and Subsequent Infections in Infancy: A Register-based Cohort Study in Sweden with Sibling Analysis [62]  
Aya Nakitanda | Helle Kieler | Ingvild Odsbu | Samuel Rhedin  
Catarina Almqvist | Björn Pasternak | Laura Pazzagli (Sweden)

2:00 PM  
Evaluating the Safety of Antiemetic Combination Use on Pregnancy Loss [63]  
Thuy Thai | Joshua Brown | Stephan Schmidt  
Judith Maro | Sonja Rasmussen | Almut Winterstein, FISPE (United States)

2:15 PM  
COVID-19 Vaccines During Pregnancy and Birth Defects: Preliminary Data from V-Safe COVID-19 Vaccine Pregnancy Registry, United States 2021 [64]  
Jennita Reefhuis | Lauren Zauche | Sabrina Madni  
Janet Cragan | Cynthia Moore | Regina Simeone  
John Nahabedian | Emily Petersen (United States)

2:30 PM  
Initiation of Atenolol versus Methyldopa During Pregnancy and the Risk of Intrauterine Growth Restriction/small for Gestational Age [65]  
Brian Bateman | Yanmin Zhu | Krista Huybrechts, FISPE  
Sonia Hernandez-Diaz, FISPE | Lockwood Taylor  
Rita Ouellet-Hellstrom | Yong Ma  
Yandong Qiang (United States)

2:45 PM  
Characteristics and Medication Use Patterns of Pregnancies with COVID-19 in the Sentinel System [66]  
Mayura Shinde | Jennifer Lyons | Susan Andrade  
Austin Cosgrove | Jolene Damon  
Elizabeth Messenger-Jones | Danijela Stojanovic  
Ben Wong (United States)

3:00 - 3:30 PM  
BREAK/POSTERS/EXHIBITS – HALL C

3:30 - 5:00 PM  
CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

Considerations of Misclassification and Confounding on COVID-19 Vaccines Effectiveness Studies – A Vaccine SIG Endorsed Symposium [67] – Congress Hall D2  
John Seeger, FISPE | Michele Jonsson Funk, FISPE  
J. Bradley Layton, FISPE | Taiyna Clarke (United States)

Advanced Methods for Covariate Balancing: Going Beyond Propensity Score Matching and Weighting Using Optimization Techniques [68] – Room C1M0  
Stephen Johnston | Pranjal Tewari | Paul Coplan, FISPE (United States)

Methods and Considerations for Hypothesis-free Signal Detection Studies Accommodating Various Types of Medications, Populations, and Regions [69] – Room C1M1  
Miyuki Hsing-Chun Hsieh | Edward Lai | Andrew Bate  
Nicole Pratt | Nam-Kyong Choi | Judith Maro  
Lars Christian Lund | Sengwee Toh (Taiwan)
Meeting the Need for Research on Drug Safety During Lactation: An Overview of Approaches [70] – Congress Hall D5
Kristin Palmsten | Bandoli Gretchen | Christina Chambers
Hedvig Nordeng, FISPE | Shinya Ito | Marie Teil
Lynne Yao (United States)

It Takes a Village: Strategic Global Collaborations to Advance RWE within ISPE [71] – C1M5
Helga Gardarsdottir, FISPE | Shirley Wang, FISPE
Susana Perez-Gutthann, FISPE | Carla Rodriguez-Watson
Olaf Klungel, FISPE | Donna Rivera, FISPE (Netherlands)

5:00 - 5:15 PM
BREAK

5:15 - 6:45 PM
CONCURRENT SESSIONS:
ORAL PRESENTATIONS

Methods – Comparators, Controls, and Unmeasured Confounding – Room C1M5

5:15 PM
Using Active Comparators in Self-controlled Case Series: An Application to Two Studies in the Clinical Practice Research Datalink [72]
Anna Schultze | Jeremy Brown | John Logie
Marianne Cunnington | Stephen Evans | Ian Douglas
Nicholas Galwey (United Kingdom)

5:30 PM
Negative Control Outcomes to Assess the Comparability of Biologics versus Small-molecule Therapeutics for Osteoporosis: Considerations for Differential Non-adherence [73]
Lydia Feinstein | Alexander Breskin | Peter S. Samai
M. Alan Brookhart (United States)

5:45 PM
Evaluation of Methods for Unmeasured Confounding Control in Pharmacoepidemiology Using Healthcare Databases: An Empirical Study Concerning Drugs Inducing Prematurity [74]
Chi Hong Duong | Romain Demailly | Sylvie Escolano
Anne Thiébaut | Pascale Tubert-Bitter | Ismail Ahmed (France)

5:00 PM
Alternative Analytic and Matching Approaches for the Prevalent New-user Design: A Simulation Study [75]
Michael Webster-Clark | Panagiotis Mavros | Elizabeth Garry
Til Stürmer | Shahar Shmuel | Jessica Young
Cynthia Girman, FISPE (Canada)

6:15 PM
Proton Pump Inhibitors and Myocardial Infarction: An Application of Active Comparators in a Self-controlled Case Series [76]
Angel Wong | Celine SL Chui | Ka Shing Cheung
Jeremy Brown | Ian Douglas | Ian Wong | Esther W. Chan (United Kingdom)

6:30 PM
Advantages of Splitting Switchers and New Users in the Prevalent New User Design [77]
Jessica Young | Michael Webster-Clark | Panagiotis Mavros
Til Stürmer, FISPE | Elizabeth Garry | Shahar Shmuel
Cynthia Girman, FISPE (United States)

6:00 PM
Pharmacoepidemiologic Methods and SARS-CoV-2 – Congress Hall D4

5:15 PM
Influence of Incomplete Death Information on Cumulative Risk Estimates in United States Claims Data [78]
Julie Barberio | Timothy Lash | Ashley Niami
Rachel Patzer | Christopher Kim | M. Alan Brookhart
David Gilbertson | Brian Bradbury (United States)

5:30 PM
Elizabeth Garry | Imaani Easthausen | Sarah Vititoe
Andrew Weckstein | Alok Chakravarty | Tamar Lasky
Marie Bradley | Silvia Perez-Vilar (United States)

5:45 PM
Adjusting for Calendar Time in Analyses of COVID-19 Vaccine Safety and Effectiveness: A Simulation Study [80]
Lars Christian Lund | Jesper Hallas, FISPE | Henrik Stovring (Denmark)
Main Conference
 Program Schedule

6:00 PM
Evaluating the Comparative Effectiveness and Safety of Repurposed Drugs for COVID-19 [81]
Eng Hooi (Cheryl) Tan | Dalia Dawoud | Faaizah Arshad
Jennifer Lane | James Weaver | Talita Duarte-Salles
Scott DuVall | Thomas Falconer (United Kingdom)

6:15 PM
Adjusting for Data Observation Delay in near Real-time Safety Surveillance of COVID-19 Vaccines Using Administrative Claims Databases [82]
Yoganand Chillarige | Mao Hu | Yuhui Feng | Xiangyu Shi
Cindy Zhou | Hui-Lee Wong | Yixin Jiao | Patricia Lloyd (United States)

6:30 PM
Near Real Time Safety Surveillance of COVID-19 Vaccines in the UK [83]
Katherine Donegan | Jemma Walker | Nick Andrews (United Kingdom)

Drug Utilization Studies in Cardiovascular Disease and Diabetes – Congress Hall D5

5:15 PM
UK Trends in Prescribing Preferences for Antidiabetic Medications Among Type 2 Diabetes Patients with and without Chronic Kidney Disease, 2006-2020 [84]
Julia Liaw | Meera Harhay | Soko Setoguchi, FISPE
Tobias Gerhard, FISPE | Chintan Dave (United States)

5:30 PM
Contemporary Trends in the Utilization of Second-line Pharmacological Therapies for Type 2 Diabetes in the United States [85]
Devin Abrahami | Elvira D’Andrea | Seo Young Kim
Julie Paik | Deborah Wexler | Elisabetta Patorno (United States)

5:45 PM
Sex Disparities in Treatment Patterns After Metformin Initiation Among Patients with Type 2 Diabetes Mellitus [86]
Monika Oktora | Stijn De Vos | Sieta de Vries | Eelko Hak
Petra Denig, FISPE (Netherlands)

Pediatric Medicine Use: Safe Kids in an Uncertain Landscape – Room C1M0

5:15 PM
Trends in High-risk Prescribing to US Pediatric Dental Patients, 2012-2019 [90]
Katherine Kim | Tumader Khouja | Charlesnika Evans
Gregory Calip | Jacqueline Burgette | Walid Gellad
Katie Suda (United States)

5:30 PM
Identifying Acute Neuropsychiatric Events in Children and Adolescents [91]
James Antoon | James Feinstein | Carlos Grijalva
Yuwei Zhu | Emily Dickenson | Justine Stassun
Jakobi Johnson | Mert Sekmen (United States)

5:45 PM
Comprehensive Assessment of Paediatric SARS-CoV-2 Infection: A Danish Population-based Cohort Study [92]
Helene Kildegaard | Lars Christian Lund | Mikkel Hoejland
Lone Graff Stensballe | Anton Pottegård (Denmark)
FRI

Program Schedule

6:00 PM
Inappropriate Antibiotic Prescriptions and the Risk of Adverse Drug Events Among Children Treated for Common Infections [93]
Anne Butler | Derek Brown | Michael Durkin
John Sahrmann | Katelin Nickel | Caroline O'Neil
Margaret Olsen | David Hyun (United States)

6:15 PM
KiDSafe – Improving Medication Safety for Children and Adolescents: Implementation and Evaluation of a New Form of Care [94]
Irmgard Toni | Jochem König | Dorothée Malonga Makosi
Michael S. Urschitz | Wolfgang Rascher | Antje Neubert (Germany)

6:30 PM
Comparative Safety of Tozinameran in Children versus Adolescents: An Analysis of First Pharmacovigilance Data [95]
Francois Montastruc | Clément Karsenty Durrieu Geneviève | Clara Flumian | Laurent Chouchana
Camille Brehin (France)

Smörgåsbord – Room C1M1

5:15 PM
Association Between Children Prescription Drug Costs for New Medications and Their Parent’s Adherence to Chronic Medication [96]
Julie Lauffenburger | Renee Barlev | Niteesh Choudhry (United States)

5:30 PM
The Impact of Using Pictorial Aids in Caregivers’ Understanding of Patient Information Leaflets of Pediatric Pain Medications: A Quasi-experimental Study [97]
Aljoharah Algabbani | Khalid Alzahrani | Sarah Sayed
Meshael Alrasheed | Deema Sorani | Omar Almohammed Amani Alqahtani (Saudi Arabia)

5:45 PM
Does Left Atrial Dilation Predict Atrial Fibrillation Severity and Post-ablation Outcomes Among Individuals with Atrial Fibrillation? [98]
Paul Coplan, FISPE | Amit Doshi | Liat Tsoref
Yariv Avraham Amos | Mati Amit | Charlene Wong
Guy Cafri | Rahul Khanna (United States)

6:00 PM
Patient Groups in Rheumatoid Arthritis Identified by Deep Learning Respond Differently to Biologic or Targeted Synthetic Disease Modifying Antirheumatic Drugs [99]
Theresa Burkard | Maria Kalweit | Andrea Burden
Thomas Hügle (Switzerland)

6:15 PM
Anticoagulant Therapy and Risk of Kidney Disease – A Nationwide Cohort Study [100]
Ane Emilie Friis Vestergaard | Christian Christiansen
Simon Jensen | Kasper Adelborg | Henrik Birn
Uffe Heide-Jørgensen (Denmark)

6:30 PM
Costs Associated with Healthcare Resources Utilization Among Empagliflozin vs GLP-1RA Initiators in Routine Clinical Care in Denmark [101]
Reimar Thomsen | Lotte Brix Christensen | Johnny Kahlert
Jakob Knudsen | Anastasia Ustyugova
Susanne Sandgaard | Pia Holmgaard | Lars Ehlers (Denmark)

LIGHTNING FORUM SESSION 1 – ROOM C1M2

5:15 PM
Risk of Myasthenia Gravis with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases [102]
Luis Velez-Nandayapa | Amit Saxena | Miguel Izquierdo
Maria Nicolaides | Pierre de Zeeuw | Alicia Rossiter
Johannes Eisinger | Christiane Michel (Switzerland)

5:20 PM
Breast Cancer and Subsequent Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis [105]
Nanna Jordt | Kasper Kjærgaard | Reimar Thomsen
Signe Borgquist | Deirdre Cronin-Fenton (Denmark)

5:25 PM
Risk of Pancreatitis and Pancreatic Carcinoma for Anti-diabetic Medications: Evidence Synthesis from Disproportionality Analysis [103]
Asif Muhammed | Christy Thomas | Krishna Undela (India)
5:30 PM
Cardiovascular Risk Among Adolescents and Young Adults Initiating Cardiotoxic Cancer Chemotherapy and Concurrent QTc Interval-prolonging Antidepressants [107]
Oluwadamilola Onasanya | Susan DosReis, FISPE
Eberechukwu Onukwugha | Wendy Camelo Castillo
(United States)

5:35 PM
Cancer Panel Discussion

Drug Utilization Research

5:45 PM
Longer-term Effectiveness of Home Blood Pressure Self-monitoring Plus Self-titration of Antihypertensive Medication for Poorly Controlled Hypertension in Primary Care: An Extension of the ADAMPA Trial [108]
Gabriel Sanfelix-Gimeno | Patricia Martínez-Ibáñez
Irene Marco-Moreno | Celia Robles-Cabaniñas
Eugenia Avelino-Hidalgo | Laura Bellot-Pujalte
Ignacio Barreira-Franch | Lucía Martínez-Ibáñez (Spain)

5:50 PM
The Impact of COVID-19 Pandemic on Drug Utilization Patterns: A Population-based Cohort Study in Manitoba, Canada [111]
Laila Aboulatta | Payam Peymani | Christine Vaccaro
Christine Leong | Kaarina Kowalec | Joseph Delaney
Jamie Falk | Silvia Alessi-Severini (Canada)

5:55 PM
Morbidity Consequences of Misuse of Psychoactive Prescription Drugs in Portugal: The MisuMedPT Project [106]
Ana Araujo | Rita Casal | João Goulão | Ana Martins
(Portugal)

6:00 PM
Global Trends in Antidepressant, Atypical Antipsychotic, and Benzodiazepine Use: A Cross-sectional Analysis of 64 Countries [113]
Orges Alabaku | Katie Suda | Simone Vigod | Mina Tadrous
(United States)

6:05 PM
Drug Utilization Research Panel Discussion

Diabetes

6:15 PM
Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study [110]
Phyo Htoo | Helen Tesfaye | Julie Paik | Deborah Wexler
Mehdi Najafzadeh | Robert Glynn | Anouk Deruaz-Luyet
Soulmaz Farsani (United States)

6:20 PM
Association Between Glycemic Control and Risk of Venous Thromboembolism in Diabetic Patients: A Nested Case-control Study [112]
Sarah Charlier | Christian Meier | Susan Jick
Christoph Meier | Claudia Becker (Switzerland)

6:25 PM
Diabetes Severity and the Risks of COVID-19 Infection and Severe COVID-19 Outcomes [109]
Sascha Dublin | James Floyd | Rod Walker | Jennifer Kuntz
Susan Shortreed | Stephen Fortmann | Elizabeth Bayliss
Laura Harrington (United States)

6:30 PM
Liraglutide and Unexpected Psychiatric Adverse Events in Patients with Obesity: A Pharmacovigilance Study with Machine Learning Approach [104]
Ji-Hwan Bae | Hyesung Lee | Sungho Bea | Ju-Young Shin
(Republic of Korea)

6:35 PM
Diabetes Panel Discussion
FRIDAY

**ISPE SPECIAL INTEREST GROUP MEETINGS**
Open to all attendees.
- MiPal – Congress Hall D2
- Vaccine – Congress Hall D5
- Rare Disease – Conference Room C1M0
- Drug-Drug Interaction – Conference Room C1M1
- Pediatric – Conference Room C1M4
- Geriatric Pharmacoepidemiology – Meeting Room 18
- Cancer – Meeting Room 19
- Adherence – Meeting Room 20

**ISPE SPECIAL INTEREST GROUP MEETINGS**
Open to all attendees.
- Biologics – Conference Room B5M1
- Medical Device – Conference Room B5M2
- Brace – Conference Room B5M3
- Digital Epi – Conference Room B5M4
- CER – Conference Room B4M2
- Genomics and Precision Medicine – Conference Room B4M4
- Drug Utilization Research – Conference Room C1M5

**STUDENTS/EARLY CAREER PROFESSIONALS MEET & GREET –**
Hosted by the ISPE Student Council
Midsommar Biergarten og Rooftop Bar, Nørrebrogade 18 B, 2200 Copenhagen
www.midsommar.dk
Midsommar Biergarten og Rooftop Bar is a 15-minute taxi ride from the Bella Sky Hotel. No ISPE transportation is available for this event; attendees must make their own way to the venue.

The power of **knowledge**. The value of **understanding**.

Our expert team of epidemiologists are no strangers to real-world evidence. We have long-standing research collaborations with over 20 research partners across Europe and North America. You can trust our background and expertise to guide you to the right evidence to help you answer your pharmacoepidemiology, risk management, benefit-risk, and real-world evidence questions.
**Program Schedule**

**SATURDAY, AUGUST 27**

7:00 AM - 6:00 PM

**SPEAKER READY ROOM / MEETING ROOM 21**

Only required if you need to upload your presentation, or update/replace an already-uploaded presentation. Please complete uploads 24-hours in advance of your session.

7:00 AM - 6:00 PM

**REGISTRATION / HALL F6-F7 LOBBY**

7:00 AM - 6:00 PM

**LACTATION ROOM / MEETING ROOM 28**

Sponsored by EPI Excellence, LLC

7:00 - 8:00 AM

**COFFEE WITH EXHIBITORS / HALL C**

7:00 - 8:00 AM

**REGIONAL INTEREST GROUPS**

Open to all attendees.

Africa – Meeting Room 20
Latin America – Meeting Room 18

7:00 - 8:00 AM

Poster Session B set-up – Hall C
Spotlight Poster Session set-up – Hall E South

8:00 AM - 6:00 PM

**EXHIBITS/POSTER SESSION B – HALL C**

8:00 - 9:30 AM

**CONCURRENT SESSIONS:**

**ORAL PRESENTATIONS**

Methods for Generating RWE Through Emulation of Target Trials – Room C1M5

8:00 AM

One Design to Rule Them All: The Clone-Censor-Weight Design as a General Framework for Epidemiologic Studies [114]
Alexander Breskin (United States)

8:15 AM

Effect of Different Durations of Treatment with Antihypertensive Drugs with Anticholinergic Effects on the Risk of Dementia: A Target Trial Emulation Study [115]
Jaume Aguado | Lia Gutierrez | Kenneth Rothman | Xabier Garcia de Albeniz (United States)

8:30 AM

Evaluation Metrics for Data-driven Propensity Score Estimation: A Simulation Study [116]
Yuchen Guo | Daniel Prieto-Alhambra | Victoria Y. Strauss | Sara Khalid (United Kingdom)

8:45 AM

Emulating a Sequence of Target Trials to Avoid Immortal Time Bias in Pregnancy Studies — an Application to Antibiotic Initiation and Preterm Delivery [117]
Ellen Caniglia | Rebecca Zash | Christina Fennell | Modiegi Diseko | Gloria Mayondi | Jonathan Heintz | Mompati Mmalane | Joseph Makhema (United States)

9:00 AM

Comparing the Effects of Neoadjuvant Versus Adjuvant Chemotherapy in Stage II-III, Triple-negative Breast Cancer: Illustration of Trial Emulation Using the Clone-Censor-Weight Method [118]
I-Hsuan Su | Charles Gaber | Stephanie Downs-Canner | Emilie Duchesneau | Jennifer Lund, FISPE (United States)

9:15 AM

Emulating Stratified Randomized Trials by Propensity Score Methods [119]
Phyo Htoo | Robert Glynn | Shirley Wang, FISPE | Julie Paik | Sebastian Schneeweiss, FISPE | Elisabetta Patorno (United States)
Drug Utilization Potpourri – Congress Hall D2

8:00 AM
Method of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy: A Population-based Register Study [120]
Marie Linder | Carolyn Cesta | Helena Kopp Kallner
Silvia Segovia Chacón | Sofie Graner (Sweden)

8:15 AM
The Characteristics of Gabapentinoid Users with Chronic Non-cancer Pain in the Primary Care of United Kingdom [121]
Xinchun GU | Teng-Chou Chen | Douglas Steinke, FISPE
Li-Chia Chen (United Kingdom)

8:30 AM
Sedative Load Before and After Entry to Residential Aged Care [122]
Gillian Caughey | Catherine Lang | Janet Sluggett
Steve Wesselingh | Maria Inacio (Australia)

8:45 AM
Prescription Patterns in Patients with Incident Trigeminal Neuralgia [123]
Pilar Hernandez-Con | Haesuk Park | Michael Maguire
Shailina Keshwani | Juan Hincapie-Castillo (United States)

9:00 AM
Non-adherence to Chronic Medications Used in COPD and Its Association with Adverse Events: A Longitudinal, Population-based Study [124]
Daniala Weir | Kay James | Kednapa Thavorn
Sara Guilcher | Salmaan Kanji | Sunita Mulpuru | Chris Bai
Walter Wodchis (Netherlands)

9:15 AM
South Peace Polypharmacy Reduction Project: Impact Evaluations of Medication Reviews and Online Workshops in Rural British Columbia [125]
Colin Dormuth | Greg Carney | Lina Al-Sakran | Anat Fisher
Malcolm Maclure (Canada)

Opioids and Addiction – The Other Pandemic? – Congress Hall D5

8:00 AM
Trajectories of Use in Elderly Incident Benzodiazepine Users of Norway [126]
Kristian Svendsen (Norway)

8:15 AM
Patterns of Buprenorphine Initiation Treatment for Opioid Use Disorder and Association with Opioid-related Overdose Deaths [127]
Svetla Slavova | Feitong Lei | Daniela Moga | Emily Slade
Lindsey Hammerslag | Nabarun Dasgupta | Michelle Lofwall
Patricia Freeman (United States)

8:30 AM
Secular Trends of Dispensed Opioid Prescriptions in Catalonia, Spain, 2007-19: A Population-based Cohort Study of over 5 Million Individuals [128]
Junqing Xie | Victoria Y. Strauss | Gary S. Collins
Sara Khalid | Antonella Delmestri | Aleksandra Turkiewicz
Martin Englund | Mina Tadrous (United Kingdom)

8:45 AM
Association of Opioid Dose Reduction with Opioid Overdose and Opioid Use Disorder Among Patients on High-dose Long-term Opioid Therapy in North Carolina [129]
Bethany DiPrete | Shabbar Ranapurwala
Courtney Maierhofer | Naoko Fulcher | Paul Chelminski
Christopher Ringwalt | Timothy Ives | Nabarun Dasgupta
(United States)

9:00 AM
Geographic Variation of High-risk Prescription Opioid Use Measures Among Disabled Medicare Beneficiaries, 2011-2018 [130]
Motomori Lewis | Lili Zhou | Walid Gellad
Juan Hincapie-Castillo | Diana Wilkie | Richard Segal
Debbie Wilson | Weihsan Jenny Lo-Ciganic (United States)

9:15 AM
The Association Between Trajectories of Prescription Opioid Use and Opioid Overdose Risk Among Nonmetastatic Breast Cancer Survivors [131]
Weihsan Jenny Lo-Ciganic | Juan Hincapie-Castillo
Ching-Yuan Chang | Bobby Jones | Haesuk Park
Coy Heldermon | Vikaramoko Diaby | Debbie Wilson
(United States)
Across the Globe: Injury and Neurologic Pharmacoepidemiology – Room C1M0

8:00 AM
β2-adrenoceptor Agonists and Risk of Parkinson's Disease: Nested Case-control Study of People with Asthma or Chronic Obstructive Pulmonary Disease [132]
Anne Paakinaho | Miia Tiihonen | Heikki Koskela
Marjaana Koponen | Jari Tiihonen | Sirpa Hartikainen
Anna-Maija Tolppanen (Finland)

8:15 AM
Trends in the Use of Non-prescription Medications for Intentional Self-poisoning: A Review of Data from the United States Poison Control Centers [133]
Silvia Perez-Vilar | Jummai Apata | Dinci Pennap
Andrew Mosholder (United States)

8:30 AM
Dosing Profiles of Opioid and Benzodiazepine Use Associated with Risk of Injurious Falls Among US Medicare Beneficiaries: Group-based Multi-trajectory Models [134]
Juan Hincapie-Castillo | Walid Gellad | Bobby Jones
Jeannie Lee | James Huang | Ching-Yuan Chang
Debbie Wilson | Gary Reisfield (United States)

8:45 AM
Bacillus Calmette-Guérin Therapy for Bladder Cancer and Risk of Alzheimer's Disease in Denmark [135]
Signe Sørup | Trine Frøslev | Mette Nørgaard
Jørgen Bjerggaard Jensen (Denmark)

9:00 AM
Effect of Reductions in Opioid Prescribing on Opioid Use Disorder and Fatal Overdose in the United States: A Dynamic Markov Model [136]
G. Caleb Alexander | Jeromie Ballreich | Omar Mansour
David Dowdy (United States)

9:15 AM
Fatal Overdoses in a Cohort of Chronic Pain Patients [137]
Aleksi Hamina | Ingvild Odsbu | Vidar Hjellvik
Linn Gjersing | Torger Lid | Thomas Clausen
Svetlana Skurtveit (Norway)

Safety First! – Room C1M1

8:00 AM
Use of Antipsychotics and the Risk of Acute Respiratory Failure [138]
Onyekachukwu Illoh | Susan DosReis, FISPE (United States)

8:15 AM
Evaluating the Long-term Effect of Allopurinol Use in Gout Using Marginal Structural Models: A Primary Care Electronic Health Records Study [139]
Trishna Rathod-Mistry | Edward Roddy | Kelvin Jordan
Christian Mallen | Milisa Blagojevic-Bucknall (United Kingdom)

8:30 AM
Association Between Fluoroquinolones and Uveitis, Retinal Detachment and Aortic Aneurysm or Dissection: An Application of Self-controlled Study Designs with Active Comparators [140]
Jeremy Brown | Kevin Wing | Stephen Evans
Clémence Leyrat | Kathryn Mansfield | Liam Smeeth
Angel Wong | David Yorston (United Kingdom)

8:45 AM
Death, Cardiac Event and Acute Liver Injury Associated with Bedaquiline or Delamanid in Patients with Multidrug Resistant Tuberculosis: A Nationwide Cohort Study [141]
Han Eol Jeong | Ju Hwan Kim | Hyesung Lee | In-Sun Oh
Sungho Bea | Ju-Young Shin (South Korea)

9:00 AM
Risk of Depressive Disorders Associated with Medical Cannabis Authorization: A Propensity Score Matched Cohort Study [142]
Jerry Liwono Yana | Jason Dyck | Dean Eurich
Arsène Zongo (Canada)

9:15 AM
Risk of Mortality Associated with Pimavanserin Compared with Atypical Antipsychotics in Patients with Parkinson's Disease-related Psychosis [143]
J. Bradley Layton, FISPE | Lisa McQuay | Joan Forns
Heather Danysh | Colleen Dempsey | Mary Anthony
Mary Ellen Turner (United States)
Disease Epidemiology Potpourri – Room C1M2

8:00 AM
Inhaled Corticosteroids and COVID-19 Risk and Outcomes—Findings from a Population-based Cohort within the SCIFI-PEARL Project \([144]\)
Brian Kirui | Marina Labor | Fredrik Nyberg, FISPE
Lowie Vanfleteren (Sweden)

8:15 AM
Risk Factors for Mortality and Intensive Care Requirements Among Pediatric Patients Hospitalized with COVID-19 in the United States \([145]\)
Nuvan Rathnayaka | Alexander Breskin | Angela Cook
Catherine Wiener | M. Alan Brookhart (United States)

8:30 AM
Temporal Trends, In-hospital Outcomes and Comorbidity Profile in US Asthma Hospitalizations Between 2004 and 2017 \([146]\)
Salwa Zghebi | Mohamed Mohamed | Mamas Mamas
Evangelos Kontopantelis (United Kingdom)

8:45 AM
Healthcare Costs and Disease Duration Associated with Mild, Moderate and Severe COVID-19: A Payer Perspective \([147]\)
Chantal Holy | Brandon Patterson | Fayolah Richards
Antoine El khoury | Jill Ruppenkamp | Ronita Debnath
Jessica deMartino | Brahim Bookhart (United States)

9:00 AM
Clustering of HbA1c Longitudinal Trajectories in Type 2 Diabetes Mellitus (T2DM) \([148]\)
Adrian Martinez de la Torre
Maria Luisa Marques de Sá Faquetti | Fernando Perez-Cruz
Stefan Weiler | Andrea Burden (Switzerland)

9:15 AM
Women's Mortality Following Childbirths Affected by Vaginal Bleeding Due to Threatened Miscarriage: A Danish Cohort Study with up to 40 Years of Follow-up \([149]\)
Elena Dudukina | Erzsebet Horvath-Puho
Henrik Toft Sørensen | Vera Ehrenstein (Denmark)

9:30 - 10:00 AM
BREAK/POSTERS/EXHIBITS – HALL C

10:00 - 11:30 AM
PLENARY SESSION
Updates from the COVID-19 Pharmacoepidemiological Battlefield: Recent Victories and Battles Ahead – Congress Hall D4

In this session, our four esteemed speakers will both look back over the many contributions from the pharmacoepidemiological society to the handling of the COVID-19 pandemic, as well as outline both learnings and likely challenges that lies ahead. Specifically, we will discuss the value of coordinated global collaborations in addressing urgent safety issues, what methodological insights we should take from these recent years, what regulators have learned and will expect from the pharmacoepidemiological society in the future, and what areas of the pandemic that will likely provide the study questions of the future.

Anton Pottegård
Professor, University of Southern Denmark Odense C, Denmark

Daniel Prieto-Alhambra, FISPE
Professor of Pharmaco- and Device Epidemiology, University of Oxford

J. Bradley Layton, FISPE
Director, Epidemiology, RTI Health Solutions

Miriam Sturkenboom, FISPE
Prof. Dr., University Medical Center Utrecht

Catherine Cohet, PhD
Pharmacoepidemiology/RWE Senior Specialist, European Medicines Agency
Transforming the Language of Life into Vital Medicines

At Amgen, we believe that the answers to medicine’s most pressing questions are written in the language of our DNA. As pioneers of biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness—to dramatically improve their lives.

Amgen is a proud sponsor of the 38th International Conference on Pharmacoepidemiology. Epidemiologic research at Amgen focuses on benefiting patients with grievous illnesses and advancing knowledge in our field. For more information, please visit www.amgen.com.

©2021 Amgen Inc. All rights reserved.
1:00 - 2:30 PM

CONCURRENT SESSIONS:
ORAL PRESENTATIONS

Methods: Machines Making Predictions – Congress Hall D4

1:00 PM
Comparative Evaluation of Automated Approaches for Confounder Selection in Ultra High-dimensional Data with Rare Outcomes [151]
Richard Wyss | Mark van der Laan | Susan Gruber | Xu Shi
Hana Lee | Sarah Dutcher | Sengwee Toh
Jennifer Nelson (United States)

1:15 PM
Fracture Risk Estimation in Post-menopausal Women: A Comparison of Machine Learning Methods and Software Systems [152]
David Pritchard | Matthew Phelan | M. Alan Brookhart
(United States)

1:30 PM
A New Artificial Intelligence Guided Method for Identifying Add-on and Switch in Secondary Data Sources: A Case Study on Antiseizure Medications in Danish Registries [153]
Maurizio Sessa (Denmark)

1:45 PM
Claims-based Model to Predict Obesity in Older Patients [154]
Karine Suissa | Zhigang Lu | Lily Bessette
Cassandra York | Richard Wyss | Joshua Lin
(United States)

2:00 PM
Development of a Multivariate Prediction Model to Identify Possible Signal Triggering Reports from Spontaneous Individual Case Safety Reports [155]
Florence van Hunsel | Helen Gosselt | Liza Bazelmans
Thomas Lieber | Linda Harmark (Netherlands)

2:15PM
Predicting Wilson Disease Progression Using Machine Learning with Real-World Electronic Health Records [156]
Caihua Liang | Scott Kelly | Rongjun Shen | Ling Li
Kasia Lobello | Steven Arkin | Kui Huang | Xiaofeng Zhou
(United States)

Study Design Approaches to Assessing Thrombosis Risk – Congress Hall D2

1:00 PM
Risk of Venous Thromboembolism in Patients Receiving Targeted Anti-cancer Therapy – A Nationwide Cohort Study [157]
Erzsebet Horvath-Puho | Florian Moik | Cihan Ay
John-Bjarne Hansen | Frits Mulder | Nick van Es
Henrik Toft Sørensen (Denmark)

1:15 PM
Arterial and Venous Thrombotic Events in Patients with COVID-19 Compared to Influenza [158]
Noelle Cocoros | Sarah Dutcher | John Connolly
Silvia Perez-Vilar | Dena Carbonari | Terese Defor
Djeneba Audrey Djibo | Laura Harrington (United States)

1:30 PM
Synergistic Effects of PM2.5 and Use of Corticosteroids on Cardiovascular and Thromboembolic Events Among Older Adults: Evidence of Environment-Drug Interaction [159]
Kevin Josey | Rachel Nethery | Benjamin Bates,
Aayush Visaria | Poonam Gandhi | Jung Hyun Kim
Soko Setoguchi, FISPE (United States)

1:45 PM
Association Between Phentermine and Risk of Major Adverse Cardiovascular Events: A Suite of Self-Controlled and Comparative Cohort Studies to Conquer Confounding [160]
Amir Sarayani | Christian Hampp, FISPE | William T. Donahoo
Joshua Brown | Almut Winterstein, FISPE (United States)

2:00 PM
Use of Chlorprothixene and the Risk of Diabetes and Major Adverse Cardiovascular Events: A Nation-wide Cohort Study [161]
Rikke Wesselhoeft | Mikkel Hoejlund | Christina Wagner
Kjeld Andersen | Anders Fink-Jensen
Jesper Hallas, FISPE (Denmark)

2:15PM
Use of Combined Oral Contraceptives and Risk of Venous Thromboembolism: A Nested Case-control Analysis in German Claims Data [162]
Tania Schink | Christina Princk | Malte Braitmaier
Ulrike Haug (Germany)
What's the Risk? Cancer Risk & Common Medications – Congress Hall D5

1:00 PM
5-alpha Reductase Inhibitor Use and Risk of Colorectal Cancer in Men with Benign Prostatic Hyperplasia: A Population-based Cohort Study [163]
Niamh Doherty | Christopher Cardwell | Peter Murchie
Christopher Hill | Laurent Azoulay | Blánaid Hicks
(United Kingdom)

1:15 PM
Parity, Use of Statins and Low-dose Aspirin, and Breast Cancer Risk—Data from Two Large Cohort Studies [164]
Julie Schmidt | Agnès Fournier | Manon Cairat
Aurélie Mailhac | Henrik Toft Sørensen | Marc Gunter
Deirdre Cronin-Fenton (Denmark)

1:30 PM
Statins and Breast Cancer Recurrence: A Danish Nationwide Cohort Study with Up to 23 Years of Follow-up [165]
Elisabeth Solmunde | Rikke N. Pedersen | Lene Mellemkjær
Søren Friis | Bent Ejlertsen | Thomas P. Ahern
Mette Nørgaard | Deirdre Cronin-Fenton (Denmark)

1:45 PM
The Association Between Menopausal Hormone Therapy and Gastric and Colorectal Cancer Risk in Korean Women: A Nationwide Population-based Cohort Study [166]
Ji-Eun Kim | Chaewon Baek | Aesun Shin
Seokyung Hahn | Hee-Kyung Park | Ji-Yeob Choi
(South Korea)

2:00 PM
Sodium-glucose Co-transporter 2 Inhibitors and the Risk of Early Bladder Cancer Events [167]
Devin Abrahami | Helen Tesfaye | Hui Yin | Seanna Vine
Blánaid Hicks | Oriana Yu | Robert Platt
Sebastian Schneeweiss, FISPE (United States)

2:15 PM
Thiazide Diuretics and Risk of Colorectal Cancer [168]
Julie Rouette | Emily McDonald | Tibor Schuster
Ilan Matok | James Brophy | Laurent Azoulay (Canada)

Psychotropic Use Around the World – Room C1M0

1:00 PM
Antidepressant Use Among Children and Adolescents Across the Scandinavian Countries [169]
Lotte Rasmussen | Peter Jensen | Johan Reutfors
Lena Brandt | Kari Furu | Svetlana Skurtveit | Randi Selmer
Per Damkier (Denmark)

1:15 PM
Attention Deficit Hyperactivity Disorder Medication Consumption in 64 Countries from 2015 to 2019: A Longitudinal Study [170]
Adrienne Chan | Tian-Tian Ma | Wallis Lau | Patrick Ip
David Coghill | Le GAO | Yogini Jani | Yingfen Hsia
(Hong Kong)

1:30 PM
Patterns of ADHD Medicine Use: A Population-based Study Among Australian Children and Adults (2013-2020) [171]
Claudia Bruno | Alys Havard | Malcolm Gillies
David Coghill | Jonathan Brett | Adam Guastella
Sallie-Anne Pearson | Helga Zoega (Australia)

1:45 PM
An Overview of Psychotropic Pharmacotherapy at Time of Death by Suicide: An Australian-wide Case Series Study Using Administrative and Coronial Data [172]
Kate Chitty | Nicholas Buckley | Jessy Lim | Zein Ali
Jennifer Schumann | Rose Cairns | Benjamin Daniels
David Preen (Australia)

2:00 PM
Prescription of Psychotropic Medications in Patients with Cancer: A Population-based Study in Hong Kong [173]
Chun Sing Lam | Chui Ping Lee | Joey Wing Yan Chan
Yin Ting Cheung (Hong Kong)

2:15 PM
Antidepressant Adherence Patterns over Time Among Adults with Depression—an Application of Group-based Trajectory Modeling Using Commercial Claims Data from 2007-2015 [174]
Jannat Saini | Danya Qato | Susan DosReis, FISPE (United States)
A Partnership for the Real World.

As the industry’s best-in-class complete real world evidence solution, Target RWE cultivates a distinctly collaborative enterprise to unify unique real world data and advanced RWE analytics in a cohesive ecosystem. Now fully integrated with NoviSci, Target RWE is shifting the paradigm in healthcare for how decisions are made to improve lives.

Together, we’re redefining real world evidence. Meet with the Target RWE team and visit our many posters and presentations at ICPE 2022!

Find out how Target RWE delivers:

- **Unique Data:** Unique, granular, and connected data sets across multiple therapeutic areas from diverse patients in academic and community settings

- **Advanced Analytics:** Rigorous, interactive, and advanced RWE analytics to extract deeper insights from real world data

- **Unmatched Collaboration:** A distinctly collaborative community of KOLs, patients, and healthcare stakeholders brought together in a powerful, dynamic model

Visit Target RWE at ICPE 2022

### Posters

**Discharged where? The importance of understanding discharge dispositions when estimating in-hospital mortality**

M. Alan Brookhart, PhD

**The effect of remdesivir for the treatment of COVID-19 on mortality among hospitalized patients**

Alexander Breskin, PhD, MPH

**In-hospital treatment patterns among patients hospitalized with COVID-19 in the United States**

Nuvan Rathnayaka, PhD

### Podium Presentations

**Friday, August 26**

1:30 - 3:00 p.m. CEST The impact of parametric assumptions on the bias-variance tradeoff for causal analysis of time-to-event outcomes

Presented by Andrew Allmon, DrPH

**5:15 - 6:45 p.m. CEST Negative control outcomes to assess the comparability of biologics versus small molecule therapeutics for osteoporosis: considerations for differential non-adherence**

Presented by Lydia Feinstein, PhD

**Saturday, August 27**

8:30 - 10:00 a.m. CEST One design to rule them all: The clone-censor-weight design as a general framework for epidemiologic studies

Presented by Alexander Breskin, PhD, MPH

8:30 - 10:00 a.m. CEST Risk factors for mortality and intensive care requirements among pediatric patients hospitalized with COVID-19 in the United States

Presented by Nuvan Rathnayaka, PhD

1:00 - 2:30 p.m. CEST Fracture risk estimation in post-menopausal women: a comparison of machine learning methods and software systems

Presented by David Pritchard, PhD, MS
Program Schedule

Mending Hearts and Brains – Room C1M1

1:00 PM
Comparative Effectiveness of Direct Oral Anticoagulants versus Warfarin Among Nursing Home Residents with Atrial Fibrillation [175]
Hemalkumar Mehta | Huijun An | Jodi Segal, FISPE
James Goodwin | G. Caleb Alexander (United States)

1:15 PM
The Effectiveness and Safety of Extended Anticoagulant Treatment in Patients with Venous Thromboembolism [176]
Nazleen Khan | Geetha Iyer | Helen Tesfaye | Gregory Brill
Katsiaryna Bykov (United States)

1:30 PM
Using Real-World Data to Assess Comparative Effectiveness and Safety of Apixaban and Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation in the UK [177]
Liza Gibbs | Priya Govil | Seamus Kent | Stephen Duffield
Shaun Rowark | Manuj Sharma | Ayad Ali | Amanda Patrick (United States)

1:45 PM
Prophylactic Anticoagulation with Low Molecular Weight Heparin in COVID-19: Cohort Studies in Denmark and Sweden [178]
Lars Christian Lund | Pontus Hedberg
Anne Helms Andreasen | Janne Petersen | Tonny Petersen
Anton Pottegård | Jacob Bodilsen | Pontus Naucler (Denmark)

2:00 PM
Risk of Ischemic Stroke Associated with DOAC Discontinuation on Patients with Non-valvular Atrial Fibrillation [179]
Tobias Alvaro Thomsen | Jorge Mesa Guadalupe
Lucía Cea Soriano | Consuelo Huerta | Airam De Burgos (Spain)

2:15 PM
High-intensity versus Low- or Moderate-intensity Statin Treatment for Patients with Ischemic Stroke: Nationwide Cohort Study [180]
Frederikke Bach | Nils Skajaa | Buket Öztürk Esen
Cecilia Fuglsang | Erzsebet Horvath-Puho
Henrik Toft Sørensen | Kasper Adelborg (Denmark)

LIGHTNING FORUM SESSION 2 – ROOM C1M2

Vaccines

1:00 PM
Risk of Appendicitis After mRNA COVID-19 Vaccination: A Population-based Cohort Study [191]
Helene Kildegaard | Louise Ladebo | Jacob Harbo Andersen
Peter Jensen | Lotte Rasmussen | Per Damkier
Anton Pottegård (Denmark)

1:05 PM
Impact of Individual Case Reports for COVID-19 Vaccines on the Ability to Detect Future Safety Signals with Other Medicinal Products [192]
Sara Hedfors Vidlin | Oskar Gauffin | Daniele Sartori
Niklas Noren (Sweden)

1:10 PM
The Impact of Data Truncation on Rates of Vaccine-associated Adverse Events Utilizing Open and Closed Claims: Lessons from Post-Marketing Safety Surveillance of the SARS-CoV-2 mRNA-1273 Vaccine [186]
Christopher Bush | Daina Esposito | Deesha Patel
Alice Gelman | Sahar Syed | Priyadarshani Dharia
Katie Mues | David Martin (United States)

1:15 PM
The Comparative Risk of Thrombosis with Thrombocytopenia Associated with Different COVID-19 Vaccines: International Network Cohort Study Including 5 European Countries and the US [182]
Xintong Li | Edward Burn | Talita Duarte-Salles | Can Yin
Christian Reich | Antonella Delmestri | Katia Verhamme
Peter Rijnbeek (United Kingdom)

1:20 PM
Vaccines Panel Discussion
Program Schedule

**Biologics/Biosimilars**

**1:30 PM**
Predictors of Effectiveness of First-line Biologic Disease Modifying Antirheumatic Drug(s) (bDMARD) or Targeted Synthetic DMARD (tsDMARD) Treatment with a Tumor Necrosis Factor Inhibitor in Patients with Rheumatoid Arthritis [189]
Alexander Liede | Whitney Krueger | Linyan Li
Yuhang Liu | Yi Pan | Michelle Brauer | Seoyoung Kim
Earl Steinberg (Ireland)

**1:35 PM**
Effect Modification of Biologic Survival by Patient Characteristics: A Step Towards Precision Medicine in the Treatment of Psoriasis [184]
Zenas Yiu | Gabrielle Becher | Brian Kirby | Philip Laws Nick Reynolds | Catherine Smith | Richard Warren
Christopher Griffiths (United Kingdom)

**1:40 PM**
Application of a Systems Biology Approach to Address Confounding by Indication for Immune-mediated Disorders in Spontaneous Reports Data: A Case Study of Vedolizumab-associated Pancreatitis in Inflammatory Bowel Disease [187]
Jodie Hillen | Katherine Duszynski | Ty Stanford
Michael Ward | Elizabeth Roughead | Lisa Kalisch
Nicole Pratt (Australia)

**1:45 PM**
Discontinuation of Infliximab Treatment in IBD Patients: A Comparison Between Patients Who Retransitioned to Originator and Those Who Remained on Biosimilar [185]
Rosanne Meijboom | Helga Gardarsdottir, FISPE
Matthijs Becker | Kris Movig | Johan Kuijvenhoven
Toine Egberts | Thijs Giezen (Netherlands)

**1:50 PM**
Biologics/Biosimilars Panel Discussion

**Benefit-Risk Assessment, Communication, and Evaluation (BRACE)**

**2:00 PM**
Mortality Among Parkinson's Disease Patients Treated with Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare [188]
Sandia Akhtar | Andrew Mosholder | Yong Ma
Gerald Podskalny | Yuhui Feng | Hai Lyu | Jiemin Liao
Yuqin Wei (United States)

**2:05 PM**
Post-market Safety Communication for New Drugs Approved in Australia 2010-2016 [190]
Barbara Mintzes | Alice Bhasale | Lucy Perry | Eliza McEwin
Annim Mohammad | Ashleigh Hooimeyer | Atse Huisman (Australia)

**2:10 PM**
Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study [181]
Richard Morrow | Barbara Mintzes | Patrick Souverein
Christine Hallgreen | Bilal Ahmed | Elizabeth Roughead
Marie Louise De Bruin | Sarah Kristiansen (Canada)

**2:15 PM**
Duration of the Evaluation of Additional Risk Minimization Measures: The Need for Speed [183]
Sharon Essink | Inge Zomerdijk | Sabine Straus
Marie Louise De Bruin (Netherlands)

**2:20 PM**
Benefit-Risk Assessment, Communication, and Evaluation (BRACE) Panel Discussion
2:40 - 3:50 PM

ANNUAL MEETING OF ISPE MEMBERS & AWARDS CEREMONY – CONGRESS HALL D4

Call to Order & President's Address
Vin Lo Re, FISPE, ISPE President

Financial Report
Wei Zhou, FISPE, Vice President/Finance

Strategic Plan 2020-2024 Update
Tobias Gerhard, FISPE, Chair, Strategic Planning Committee

New Business

Awards Ceremony

ISPE Board Transition
RETIRING BOARD MEMBERS & OFFICERS
Olaf Klungel, FISPE  |  Fredrik Nyberg, FISPE
Lisa Pont, FISPE  |  Jennita Reefhuis
Mary Beth Ritchey, FISPE  |  Wei Zhou, FISPE

INDUCTION OF NEW DIRECTORS
Ursula Kirchmayer, FISPE
Government/Regulator (Europe/Africa)
Andrea Margulis, FISPE
Industry/Service Provider (Europe/Africa)
Gillian Caughey
Academic (Asia/Pacific)
Efe Eworuke
Government/Regulator (Americas)
Jessica Franklin
Industry/Service Provider (Americas)

INSTALLATION OF 2022-2023 OFFICERS
Tobias Gerhard, FISPE, President
Caitlin Knox, Vice President/Finance
Vin Lo Re, FISPE, Immediate Past President
Lisa Pont, FISPE, President-Elect

3:50 - 4:15 PM

BREAK/POSTERS/EXHIBITS – HALL C

4:15 - 5:45 PM

CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS

Shirley Wang, FISPE  |  Donna Rivera, FISPE  |  William Crown
Peter Arlett  |  Wim Goettsch (United States)

Cloning, Censoring, and Weighting—Oh My! Applications of Target Trial Emulation for Evaluating Cancer Interventions When Study Eligibility, Intervention Initiation, and Start of Follow-up are Not Aligned [201] – Congress Hall D2
Jennifer Lund, FISPE  |  Xabier Garcia de Albeniz
Camille Maringe  |  Charles Gaber  |  Richard Wyss,
Maribel Salas, FISPE  |  Armen Ghazarian (United States)

COVID-19 Vaccine Safety Monitoring: Opportunities, Challenges and Lessons Learned for Pharmacoepidemiology [202] – Congress Hall D5
Alicia Gilsenan, FISPE  |  Miriam Sturkenboom, FISPE
Cynthia De Luise  |  Catherine Cohet  |  Jeffrey Brown
Susana Perez-Gutthann, FISPE  |  Patricia Lloyd  |  Joseph Kim (United States)

Drug Safety on the Cutting Edge: What are the Implications of EMA's To-be-released Risk Minimisation Guidance on Pharmacoepidemiological Methods and Practice in Developed and Developing Countries? [203] – Conference Room C1M0
Meredith Smith, FISPE  |  Priya Bahri  |  Elaine Morrato
Parthasarathi Gurumurthy (United States)

Real-World Evidence Studies in the Post-COVID-19 Era: Methodological Considerations for Pandemic Related Disruptions [204] – C1M1
Anne Butler  |  Mehmet Burcu  |  Helga Gardarsdottir, FISPE
G. Caleb Alexander (United States)
# Program Schedule

## LATE BREAKERS – CONFERENCE ROOM C1M2

### 4:15 PM
**Alternative Approaches to Defining COVID-related Inpatient Encounters in IBM® Marketscan® Data**

Kathleen Andersen | Andy Surinach | Qiao Mu
Tamuno Alfred | Deepa Malhotra | Leah McGrath
Jennifer Nguyen | Jennifer Judy *(United States)*

### 4:30 PM
**Use of the New ICD-10-CM Diagnosis Code for Post-COVID-19 Condition in Routine Clinical Practice in the United States**

Leah McGrath | Amie Scott | Andy Surinach
Richard Chambers | Michael Benigno | Deepa Malhotra *(United States)*

### 4:45 PM
**Rapid Surveillance on the Use of Neutralising Monoclonal Antibodies and Antivirals in Patients with COVID-19 in Scotland Using Administrative and Purposely Collected Data**

Tanja Mueller | Euan Proud | Holly Tibble | Elliott Hall
Amanj Kurdi | Marion Bennie *(United Kingdom)*

### 5:00 PM
**Increasing Use of Antidepressants, Hypnotics and Psychostimulants During the COVID-19 Pandemic Among Danish Children, Adolescents, and Young Adults**

Mette Bliiddal | Lotte Rasmussen | Jacob Harbo Andersen
Anton Pottegård | Trine Munk-Olsen | Helene Kildegaard
Rikke Wesselhøeft *(Denmark)*

### 5:15 PM
**Female Preconception Vaccination Against COVID-19 and Spontaneous Abortion in a Prospective Preconception Cohort Study**

Jennifer Yland | Amelia Wesselink | Krista Huypbrechts, FISPE
Sonia Hernandez-Diaz, FISPE | Lauren Wise *(United States)*

### 5:30 PM
**Comparative Effectiveness of Sotrovimab and Molnupiravir for Prevention of Severe COVID-19 Outcomes in Non-hospitalised Patients: An Observational Cohort Study Using the OpenSAFELY Platform**

Bang Zheng | Amelia Green | John Tazare | Stephen Evans
Ian Douglas | Brian MacKenna | Ben Goldacre
Laurie Tomlinson *(United Kingdom)*

---

## 6:00 - 7:00 PM

### COUNCIL MEETINGS

**Academic – Conference Room C1M0**
**Student – C1M1**

---

## 7:00 - 11:00 PM

### Social Evening at the Langelinie Pavillonen

*Badge or guest ticket required for entry.*

Located at Langelinie 10, DK-2100 Copenhagen
Shuttle from Bella Center Entrance 6 starting at 6:00 pm
SUNDA Y, AUGUST 28

**7:00 AM - 3:30 PM**

**SPEAKER READY ROOM / MEETING ROOM 21**
Only required if you need to upload your presentation, or update/replace an already-uploaded presentation. Please complete uploads 24-hours in advance of your session.

**7:00 AM - 4:30 PM**

**REGISTRATION / HALL F6-F7 LOBBY**

**7:30 AM - 4:30 PM**

**LACTATION ROOM / MEETING ROOM 28**
Sponsored by EPI Excellence, LLC

**7:00 - 8:00 AM**

**COFFEE WITH EXHIBITORS / HALL C**

**7:00 - 8:00 AM**

Poster Session C set-up – Hall C
Spotlight Poster Session set-up – Hall E South

**8:00 AM - 3:15 PM**

**POSTERS – HALL C**

**8:00 AM - 4:30 PM**

**EXHIBITS – HALL C**

**8:30 - 10:00 AM**

**CONCURRENT SESSIONS:**
**ORAL PRESENTATIONS**

**Methods: Validation – Congress Hall D5**

**8:30 AM**
Validation of an International Classification of Disease (ICD) 10 Algorithm for Hypoglycemia in Administrative Claims Data [205]
Qua Her | Sara Dejene | Jea Young Min | Virginia Pate
Michele Jonsson Funk, FISPE | James Flory (United States)

**8:45 AM**
Evaluation of Mortality Data Sources Compared to the National Death Index in the Healthcore Integrated Research Database [206]
Aziza Jamal-allial | Todd Sponholtz | Shiva K Vojjala
Anahit Papazian | Biruk Eshete
Seyed Hamidreza Mahmoudpour | Patrice Verpillat
Daniel Beachler (United States)

**9:00 AM**
Adaptability of High Dimensional Propensity Score Procedure in the Transition from ICD-9 to ICD-10 in the US Healthcare System [207]
Amir Sarayani | Joshua Brown | Christian Hampp, FISPE
William T. Donahoo | Almut Winterstein, FISPE (United States)

**9:15 AM**
Reproducibly Estimating Drug Exposure from Free-text Prescriptions [208]
William Dixon | Belay Yimer | David Selby | Meghna Jani
Mark Lunt | Goran Nenadic (United Kingdom)

**9:30 AM**
A Bootstrap Approach for Validating Groups Identified by Latent Class Growth Models [209]
Marc Simard | Miceline Mésidor | Caroline Sirois
Denis Talbot (Canada)

**9:45 AM**
Can Administrative Claims Data Be Used to Determine Pre-treatment HbA1c Among Adults with Type 2 Diabetes? [210]
Jenna Wong | Xiaojuan Li | David Arterburn
Dongdong Li Elizabeth | Messenger-Jones | Rui Wang
Sengwee Toh (United States)
Program Schedule

Examining Equity: Who? Where and What? – Congress Hall D2

8:30 AM
Alyaa Ajabnoor | Salwa Zghebi | Rosa Parisi
Darren Ashcroft | Martin Rutter | Tim Doran
Matthew Carr | Mamas Mamas (United Kingdom)

8:45 AM
Racial Disparities in Clinical Trial Participation: Evidence from Real-World Oncology Data [213]
Harlan Pittell | Gregory Calip | Amy Pierre
Jenny Guadamuz (United States)

9:00 AM
Socioeconomic Inequalities in COVID-19 Vaccination and Infection Among Adults Living in Urban Areas of Catalonia, Spain: A Population-based Cohort Study [214]
Elena Roel | Berta Raventós | Edward Burn
Andrea Pistillo | Daniel Prieto-Alhambra
Talita Duarte-Salles (Spain)

9:15 AM
Geographic Variation and Racial Disparities in Novel Glucose-lowering Drugs Adoption Among US Medicare Beneficiaries with Type 2 Diabetes [215]
Wei-Han Chen | Yujia Li | John M. Allen | Hui Shao
William Donahoo | Steven Smith | Serena Jingchuan Guo (United States)

9:30 AM
The Association of Ethnicity and Social Deprivation and Choice of Second-line Antidiabetic Treatment in People with Type 2 Diabetes: A Cross-sectional Study [216]
Patrick Bidulka | Rohini Mathur | David Lugo-Palacios
Stephen O'Neill | Anirban Basu | Richard Silverwood
Paul Charlton | Andrew Briggs (United Kingdom)

9:45 AM
Differences in Opioid Use After Hip Fracture by Race and Post-acute Care Use Among US Older Adults [217]
Kaley Hayes | Meghan Cupp | Abednego Commey
Francesca Beaudoin | Richa Joshi | Andrew Zullo (United States)

Pandemic Prescription Patterns (Plus Pneuomial) – Congress Hall D4

8:30 AM
Does COVID-19 Pandemic Impacted on Quality of Antibiotic Use in the Community? An Interrupted Time-series Analysis [218]
Carla Torre | Antonio Teixeira Rodrigues
Mariana Dominques | José Guerreiro | João Rocha
Bruno Sepodes (Portugal)

8:45 AM
Systemic Corticosteroids for COVID-19 in US Outpatient Settings [219]
Marie Bradley | David Graham | Efe Eworuke | Hana Lee
Sandia Akhtar | Hai Lyu | Kushal Naik | Yogand Chillarge (United States)

9:00 AM
Utilization of Broad- Versus Narrow-spectrum Antibiotics for the Treatment of Outpatient Community-acquired Pneumonia [220]
Katelin Nickel | Anne Butler | Michael Durkin
Margaret Olsen | John Sahrmann | Caroline O’Neil (United States)

9:15 AM
Impact of COVID-19 Pandemic on the Prescription Trends of Antiseizure Medications [221]
Alekhya Lavu | Donica Janzen | Laila Aboulatta
Payam Peymani | Brianne Desrochers | Silvia Alessi-Severini
Sherif Eltonsy (Canada)

9:30 AM
The Effect of the COVID-19 Pandemic on Medicines Utilisation in England [222]
Danielle Robinson | Jonathan Pearson-Stuttard
Benjamin Bray (United Kingdom)

9:45 AM
Impact of COVID-19 on Psychotropic Medication Use Among Children and Adolescents Receiving Mental Health Services [223]
Alejandro Amill-Rosario | Haeyoung Lee
Chengchen Zhang | Susan DosReis, FISPE (United States)
Around the World with Real-World Evidence –  
*Room C1M0*

**8:30 AM**
HIV Pre-exposure Prophylaxis (PrEP) Effectiveness in the Real World: A Nested Case-control Study Among 46,706 Men at High Risk of HIV Infection in France [224]
Hugo Jourdain | Sophie Billioti de Gage | David Desplas  
Rosemary Dray-Spira (France)

**8:45 AM**
Use of Central Nervous System Drugs in Combination with Selective Serotonin Reuptake Treatment: A Bayesian Screening Study for Risk of Suicidal Behavior [225]
Zheng Chang | Tyra Lagerberg | Arvid Sjölander  
Robert Gibbons | Patrick Quinn | Brian D’Onofrio  
Clara Hellner | Paul Lichtenstein (Sweden)

**9:00 AM**
Long-acting Injectable Antipsychotics and Risk of Treatment Failure in a Population-based Cohort [226]
Donica Janzen | James Bolton | Christine Leong  
I fan Kuo | Silvia Alessi-Severini (Canada)

**9:15 AM**
The Effect of Remdesivir for the Treatment of COVID-19 on Mortality Among Hospitalized Patients [227]
Alexander Breskin | Catherine Wiener | M. Alan Brookhart (United States)

**9:30 AM**
Association Between Very High PD-L1 Expression versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-small Cell Lung Cancer [228]
Syed Mohsin Mahmood Shah | Melina Marmarelis  
Ronac Mamtani | Rebecca Hubbard | Sean Hennessy (United States)

**9:45 AM**
Does Hydroxychloroquine Prevent Cardiovascular Events in Systemic Lupus Erythematosus Patients? [229]
Lamiae Grimaldi | Tom Duchemin | Philippe Attias  
Yann Hamon | Jacques Benichou | Yola Moride  
Lucien Abenhaim (France)

SGLT2s and Cardiovascular Endpoints –  
*Room C1M1*

**8:30 AM**
Sodium-glucose Co-transporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study [230]
Arvid Engström | Victor Wintzell | Mads Melbye  
Anders Hviid | Björn Eliasson | Soffia Gudbjörnsdottir  
Kristian Hveem | Christian Jonasson (Sweden)

**8:45 AM**
Cardiovascular Outcomes in Patients with Type 2 Diabetes Who Added Either GLP1 Receptor Agonists or DPP4 Inhibitors to SGLT2 Inhibitor Therapy [231]
Katsiaryna Bykov | Seoyoung Kim | Chintan Dave  
Raisa Levin | Deborah Wexler | Elisabetta Patorno (United States)

**9:00 AM**
Cardiovascular Effectiveness of Sodium—Glucose Cotransporter 2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RA) in Routine Care of Frail People with Type 2 Diabetes [232]
Alexander Kutz | Chandrasekar Gopalakrishnan  
Dae Hyun Kim | Elisabetta Patorno (United States)

**9:15 AM**
Cardiovascular Effectiveness of SGLT2 Inhibitors: Head-to-head Comparisons [233]
Devin Abrahami | Elvira D’Andrea | Julie Paik  
Deborah Wexler | Brendan Everett | Seoyoung Kim  
Elisabetta Patorno (United States)

**9:30 AM**
Cardiovascular Effectiveness of Empagliflozin vs Glucagon-like peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study [234]
Phyo Htoo | Helen Tesfaye | Julie Paik  
Deborah Wexler | Mehdi Najafzadeh | Robert Glynn  
Anouk Deruaz-Luyet Soulmaz Farsani (United States)

**9:45 AM**
Using Iterative Causal Forest to Identify Heterogeneous Treatment Effects: Sodium-glucose Cotransporter-2 inhibitors versus Glucagon-like Peptide-1 Receptor Agonists on Hospitalization for Heart Failure [235]
Tiansheng Wang | Alexander Keil | Siyeon Kim  
Richard Wyss | Phyo Htoo | Michele Jonsson Funk, FISPE  
John Buse | Michael Kosorok (United States)
**Welcoming Novel Methods in Pregnancy Research – Room C1M2**

8:30 AM
Associations of Prenatal Exposure to Antibiotics and Paracetamol with Trajectories of Wheezing up to 2 Years of Age [236]
Marleen Van Gelder | Michelle G.A. Clevis | Sharon Essink
Jol Roukema | Nel Roeleveld | Chris Verhaak
Peter Merkus (Netherlands)

8:45 AM
Development and Validation of Claims-based Algorithms for Estimating Gestational Age of Spontaneous Abortion and Termination [237]
Krista Huybrechts, FISPE | Yanmin Zhu
Sonia Hernandez-Diaz, FISPE | Brian Bateman
Kathryn Gray | Loreen Straub | Lockwood Taylor
Rita Ouellet-Hellstrom (United States)

9:00 AM
Estimating the Association Between Initial Postpartum Discharge Adgent Prescription Dose and Subsequent Opioid Use: The Role of Different Modeling Strategies [238]
Andrew Wiese | Carlos Grijalva | Margaret adgent
Sarah Osmundson | Amelie Pham | Sharon Phillips
Ed Mitchel | Andrew Spieker (United States)

9:15 AM
Hierarchical Clustering Analysis to Inform Classification of Congenital Malformations for Surveillance of Medication Safety in Pregnancy [239]
Loren Straub | Sonia Hernandez-Diaz, FISPE
Shirley Wang, FISPE | Kathryn Gray | Lewis Holmes
Brian Bateman | Helen Mogun | Krista Huybrechts, FISPE (United States)

9:30 AM
A Novel Framework to Assess Reproductive Toxicity: Pregnancy Outcomes Intensive Monitoring (PRIM) [240]
Lisa Prach | Bita Rezaallah | Valentine Jehl (Switzerland)

9:45 AM
Quantification of Medication-mediated Effects on Pregnancy Outcome in Women with Rheumatic Conditions [241]
Gretchen Bandoli | Kristin Palmsten | Chelsey Smith
Christina Chambers (United States)

10:00 - 10:30 AM
BREAK/POSTERS/EXHIBITS – HALL C

10:30 AM - 12:00 PM
**CONCURRENT SESSIONS: SYMPOSIA & WORKSHOPS**

**Shaping the Future of Pharmacoepidemiology [242] – Meeting Room C1M5**
Vicki Osborne | Deborah Layton, FISPE | Amie Goodin
Almut Winterstein, FISPE | Andrew Bate | Catherine Cohet
Xavier Kurz | Lisa Pont, FISPE | David Moeny
Olaf Klungel, FISPE | Simone Pinheiro | John Seeger, FISPE
K. Arnold Chan, FISPE | Stanley Edlavitch, FISPE
Hugh Tilson, FISPE | Joshua Brown (United Kingdom)

Ulka Campbell | Sangmi Kim | Sengwee Toh
Seamus Kent | Jeffrey Brown | Carla Rodriguez-Watson (United States)

**Updating the Public on COVID-19 Vaccine Safety – Considerations for Pharmacoepidemiologists [244] – Congress Hall D5**
Mathias Møllebæk | Priya Bahri | Nabarun Dasgupta
Barbara Mintzes | Anton Pottegård | Peter Mol (Denmark)

**Emulation Differences versus Bias: Implications of Large-scale Emulation of Randomized Clinical Trials Using Clinical Practice Data (RCT-DUPLICATE) [245] – Conference Room C1M0**
Shirley Wang, FISPE | Sebastian Schneeweiss, FISPE
Peter Arlett | Hans-Georg Eichler | Melvin Olson (United States)

Kourtney Davis, FISPE | Diego Wyszynski
Wilhelmine Meeraus | Lydie Marcelon | Nicole Baker
Emily Yost (United States)
12:00 - 1:30 PM
LUNCH/POSTER SESSION C/EXHIBITS – HALL C

12:00 - 1:30 PM
ISPE BOARD OF DIRECTORS’ LUNCH – MEETING ROOM 19
Open to all ISPE members; please contact info@pharmacoepi.org if you are interested in attending this meeting.

12:15 - 1:15 PM
SPOTLIGHT POSTER SESSION C – HALL E SOUTH
Health Equity
Medical Devices
Medications in Pregnancy and Lactation
Pediatrics
Rare Diseases
Vaccines
Novel Approaches to Pharmacovigilance – Room C1M5

1:30 PM
Surveillance of Antidepressant Safety (SADS): Comparison of Signal Detection of Serious Medical Events Using Tree-based Scan Statistics and Repeated Cohort Studies [247]
Mia Aakjaer | Murat Kulahci | Marie Louise De Bruin Abdul Rauf Khan | Morten Andersen (Denmark)

1:45 PM
Myocarditis and Pericarditis Associated with SARS-CoV-2 Vaccines in Four European Countries Using Large Electronic Health Care Data Sources: A Population-based Descriptive Cohort and a Nested Self-controlled Risk Interval Study [248]
Judit Riera Arnau | Sophie Bots | Anna Schultze Davide Messina | Svetlana Belitser | Carlos Duran Ema Alsina | Ian Douglas (Spain)

2:00 PM
Screening for Statin-related Prescribing Cascades Using High-throughput Sequence Symmetry Analysis [249]
Scott Vouri | Earl Morris | Marta Walsh Leonie Hochleitner | Matthew Muschett | Jessica Agalliu Alyssa Dempsey | Stephan Schmidt (United States)

2:15 PM
Detecting Adverse Drug Events in Dermatology Through Natural Language Processing of Physician Notes [250]
Lawrence Rasouliyan | Vikas Kumar | Veyssel Kocaman David Talby (United States)

2:30 PM
Preliminary Results from HERO-together: A Post-emergency Use Authorization Observational Cohort Study to Evaluate the Safety of the Pfizer-BioNTech COVID-19 Vaccine in US Healthcare Workers and Community Members [251]
Emily OBrien | Cherise Wong | Jack Shostak | Laura Webb Lauren Cohen | Heather Rubino | Patrick Caubel Amy Abernethy (United States)

2:45 PM
Use of Anxiolytic, Hypnotic and Antidepressant Drugs After Dispensation of a Levonorgestrel 52 mg Intra-uterine System Compared to a 19.5 mg Intra-uterine System: A Nationwide Matched-cohort Study [252]
Noemie Roland | Bérangère Baricault | Jeremie Bottin Lise Duranteau | Rosemary Dray-Spira | Alain Weill Mahmoud Zureik (France)

Fractures and Osteoporosis Medication – Congress Hall D2

1:30 PM
Concurrent Use of Prescription Opioids with Other Medications and Risk of Fall and Fracture in Rheumatoid Arthritis Patients [253]
Nazleen Khan | Katsiaryna Bykov | Jeffrey Katz Robert Glynn | Seanna Vine | Seoyoung Kim (United States)

1:45 PM
Effectiveness of Osteoporosis Medications on the Risk of Fracture: A French Population-based Cohort Study [254]
Pauline Bosco-Levy | James O’Kelly | Karine Briot Nadia Mehsen-Cetre | Alban Fabre | Régis Lassalle Abdellah Abouelfath | Angela Grelaud (France)

2:00 PM
A Translational Approach to Study Drug-Drug Interaction with Hormonal Contraceptives: From Pharmacoepidemiology to Mechanistic Modelling [255]
Amir Sarayani | Brian Cicali | Stephan Schmidt Joshua Brown | Almut Winterstein, FISPE (United States)

2:15 PM
Comparison of Denosumab versus Bisphosphonates on Progression-free and Overall Survival in Newly Diagnosed Multiple Myeloma: A New User, Active Comparator Analysis of Real-World Data [256]
Jenny Guadamuz | Mustafa Ascha Ghulam Rehman Mohyuddin | Brian C.-H. Chiu Pritesh R. Patel | Karen Schweiss, | Rebecca Rohrer Amy Pierre (United States)

2:30 PM
The Difference Between Pregabalin and Gabapentin in the Risk of Fragility Fractures – A Nationwide High-dimensional Propensity Score Matched Cohort Study [257]
Daniel Henriksen | Emilie Jørgensen | Per Damkier Jesper Hallas, FISPE (Denmark)
2:45 PM
Treatment Heterogeneity in Comparative Effectiveness of Teriparatide vs Bisphosphonates: Multi-database Cohort Study [258]
Alexandros Rekkas | Annika Joedicke | David van Klaveren
Daniel Prieto-Alhambra | Peter Rijnbeek (Netherlands)

Use it or Lose Out: Trends in Anti-cancer and Biologic Utilization – Congress Hall D5

1:30 PM
Utilization Patterns of Systemic Immunomodulating Drugs in Patients with Atopic Dermatitis in Clinical Practice [259]
Maria Schneeweiss | Priyanka Anand
Sebastian Schneeweiss, FISPE (United States)

1:45 PM
Trends in Access to Essential Cancer Medicines in Low and Middle Income Countries, 2015-2020 [260]
Dima Qato | Andrew Shooshtari | Jonathan Cohen
Prashant Yadav (United States)

2:00 PM
End-of-life Endocrine Treatment of Older Hormone Receptor-positive Metastatic Breast Cancer Patients: A Nationwide Swedish Retrospective Cohort Study [261]
Máté Szilcz | Jonas Wastesson | Henrik Lindman
Kristina Johnell (Sweden)

2:15 PM
Real-World Treatment Patterns Before and After Receiving PD-L1 Test Results in Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) [262]
Wenzhen Ge | Scott Antonia | Ning Wu
Jean-Francois Pouliot | Hilary Dietz | Jessica Jalbert
Ruben GW Quek | James Harnett (United States)

2:30 PM
Triptan Consumption Before and After the Initiation of an Anti-CGRP mAb: A Descriptive Drug Utilization Study in Tuscany Region, Italy [263]
Giulia Hyeraci | Olga Paoletti | Luigi Francesco Iannone
Rosa Gini | Francesco De Cesaris | Silvia Benemei
Pierangelo Geppetti | Giuseppe Roberto (Italy)

2:45 PM
The Association Between Trajectories of Adherence to Endocrine Therapy and the Risk of Breast Cancer Recurrence Among Nonmetastatic Breast Cancer Survivors [264]
Juan Hincapie-Castillo | Weihsuan Jenny Lo-Ciganic
Ching-Yuan Chang | Bobby Jones | Haesuk Park
Coy Heldermon | Vakaramoko Diaby | Debbie Wilson (United States)

Safety Issues Concerning DM and Antidiabetic Drugs – Room C1M0

1:30 PM
Long-acting Insulin Analogues versus Neutral Protamine Hagedorn Insulin and the Risk of Severe Hypoglycemia Among Patients in Type 2 Diabetes in the United Kingdom [267]
Vanessa Brunetti | Kristian Filion | Oriana Hoi Yun Yu, Robert Platt (Canada)

1:45 PM
Dipeptidyl peptidase-4 Inhibitors and the Risk of Acute Liver Injury Among Patients with Type 2 Diabetes [268]
Richeek Pradhan | Hui Yin | Oriana Hoi Yun Yu
Laurent Azoulay (Canada)

2:00 PM
The Comparative Safety of Individual SGLT2 Inhibitors and the Risk of Diabetic Ketoacidosis [269]
Devin Abrahami | Elvira D’Andrea | Seoyoung Kim
Deborah Wexler | Julie Paik | Elisabetta Patorno (United States)

2:15 PM
Risk of New-onset Type 2 Diabetes in Antidepressant Users: A Population-based Cohort Study in Denmark [270]
Reeha Sharon | Morten Andersen | Theis Lange (Denmark)

2:30 PM
Risk of Hypoglycemia with Sodium Glucose cotransporter-2 Inhibitors vs Alternative Glucose Lowering Medications in Patients with and without Baseline Use of Insulin or Sulfonylurea [265]
Phyo Htoo | Deborah Wexler | Seoyoung Kim | Julie Paik
Ethan Alt | Dae Kim | Elisabetta Patorno (United States)

2:45 PM
Concomitant Use of Sulfonylureas and Warfarin and the Risk of Severe Hypoglycemia: A Population-based Cohort Study [266]
Jenny Dimakos | Ying Cui | Robert Platt | Christel Renoux
Kristian Filion | Antonios Douros (Canada)
Evaluating the Vaccines Against the Nasty Bugs: Safety First Round II – Room C1M1

1:30 PM
COVID-19 Vaccination During Pregnancy and Risk of Preterm Birth, Small-for-gestational-age Birth, and Stillbirth [271]
Deshayne Fell | Sheryll Dimanlig-Cruz | Annette Regan
Siri Haberg | Christopher Gravel | Laura Oakley
Gilian Alton | Tavleen Dhinsa (Canada)

1:45 PM
Risk of Myocarditis and Pericarditis Following BNT162b2 and mRNA-1273 COVID-19 Vaccination [272]
Nicola Klein | Kristin Goddard | Edwin Lewis
Bruce Fireman | Ousseny Zerbo | Thomas Boyce
Kayla Hansen | James Donahue (United States)

2:00 PM
COVID-19 Vaccination and Acute Neurological Events in England: A Self-controlled Case Series Using the OpenSAFELY Platform [273]
Anna Schultze | Jemma Walker | John Tazare
Arina Tamborska | Bhagteshwar Singh | Katherine Donegan
Julia Stowe | Caroline Morton (United Kingdom)

2:15 PM
Assessment of the Risk of Myocardial Infarction, Stroke, and Pulmonary Embolism Following Different COVID-19 Vaccines in Adults Under 75 Years of Age in France [274]
Stephane Le Vu | Jeremie Botton | Marie-Joëlle Jabagi
Marion Bertrand | Bérangère Baricault | Jérôme Drouin
Alain Weill | Paddy Farrington (France)

2:30 PM
Genetic Risk and Incident Venous Thromboembolism in Middle-aged and Older Adults Following COVID-19 Vaccination [275]
Junqing Xie | Victoria Y. Strauss | Albert Prats-Uribe
Dipender Gill | Roger Paredes | Daniel Prieto-Alhambra (United Kingdom)

2:45 PM
mRNA COVID-19 Vaccination Early in Pregnancy and Risk of Spontaneous Abortion in an International Pregnancy Registry [276]
Omar Mansour | Diego Wyszynski
Sonia Hernandez-Diaz, FISPE (United States)

1:30 - 3:00 PM
LIGHTNING SESSION 3 – ROOM C1M2

Informatics
1:30 PM
The Impact of Electronic Health Record Discontinuity on Prediction Modeling [282]
Lily Bessette | Joshua Lin | Shreyas Kar | Richard Wyss
Aaron Kesselheim (United States)

1:35 PM
Target Fishing and Drug Repurposing for Pancreatic Ductal Adenocarcinoma: An Integrated Bioinformatic and Computational Approach [277]
Gouri Nair | Aina Shaju | Subeesh Kulangara Viswam (India)

1:40 PM
Mohsen Askar | Kristian Svendsen | Lars Småbrekke
Lars Ailo Bongo (Norway)

1:45 PM
Web and Social Media Listening Using AI/NLP for COVID-19 Vaccine Safety Monitoring [287]
Alena Khromava | Chathuri Daluwatte | Yuning Chen
Laurence Serradell | Anne-Laure Chabanon
Anthony Chan-Ou-Teng | Kiran Mahadeshwar
Cliona Molony (Canada)

1:50 PM
Informatics Panel Discussion

Disease Epidemiology
2:00 PM
Temporal Changes in Incidence of Acute Pyelonephritis: A 19-year Population-based Danish Cohort Study [278]
Lise Svingel | Christian Christiansen | Kirstine Søgaard
Henrik Birm | Mette Nørgaard (Denmark)

2:05 PM
Predicting Risks of Intracranial Bleeding in Older Adults with Atrial Fibrillation to Aid Prescribing Decisions [283]
Lily Bessette | Joshua Lin | Daniel Singer | Dae Kim (United States)
2:10 PM
Estimating the Incidence of Co-occurring Thrombosis and Thrombocytopenia in a Healthcare Database [279]
Yanfang Liu | Choo Hua Goh | Dereck Shen
Kuan-Chih Huang | Hong Qiu | Man Luo | Zhangjing Chen
Chao-Hsiun Tang (United States)

2:15 PM
Individualized Treatment Rule Identification in Heart Failure Patients Using Precision-medicine Methods [286]
Arti Virkud | Jessie Edwards | Michele Jonsson Funk, FISPE
Emily Gower | Michael Kosorok | Patricia Chang
Abhi Kshirsagar (United States)

2:20 PM
Disease Epidemiology Panel Discussion

Pregnancy and Lactation

2:30 PM
Exposure to Known or Suspected Teratogenic Drugs Prior to Conception in a Commercially Insured Population of Pregnant Women [284]
Ryan Seals | Alicynne Glazier-Essalmi | Florence Wang
(United States)

2:35 PM
Antibiotic Use in Early Pregnancy and Risk of Gestational Diabetes Mellitus: A Nationwide Cohort Study of 3 Million Pregnancies [285]
Yunha Noh | Eun-young Choi | Ahhyung Choi
Seung-Ah Choe | Ju-Young Shin (South Korea)

2:40 PM
Associations of Prenatal Depression and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment with Early Child Development [280]
Lyndsay Avalos | Nerissa Nance | Ayesha Sujan
Kathryn Ridout | DeKun Li | Charles Quesenberry
Meghan Davignon | Lisa Croen (United States)
Program Schedule

2:45 PM
Associations of Prenatal Exposure to Non-steroidal Anti-inflammatory Drugs with Preterm Birth and Small-for-gestational Age Among Women with Autoimmune Disorders [463]
Erin Delker | Christina Chambers | Diana Johnson
Gretchen Bandoli (United States)

2:50 PM
Pregnancy and Lactation Panel Discussion

3:00 - 3:15 PM
BREAK/EXHIBITS/POSTERS - Hall C

3:15 - 4:45 PM
HOT TOPIC SESSION
How Can We Mitigate Publication of Poorly Conducted RWE Studies? Keynote Session – Congress Hall D4
The growing acceptance of RWE in clinical and regulatory decision-making as well as the increasing availability of healthcare data coupled with automated analytic approaches have contributed to a marked expansion of RWE studies. Commensurate with this, there has been increasing concern about inappropriate applications of RWE, violating causal inference principles with inappropriate use of data and methods. At the height of the 2020s COVID-19 pandemic, urgency for data elucidating the effects of various COVID-19 treatments may have created additional pressure to relax standards regarding the level and rigor of scientific review, resulting in "pandemic-related research waste", including two papers published in, and then retracted from, NEJM and The Lancet. This symposium will discuss ways that we as pharmacoepidemiologists can contribute to better governance of RWE studies, including appropriate study conduct, transparency, publication and peer review.

SPEAKERS
Almut Winterstein, FISPE
Distinguished Professor, University of Florida
Vera Ehrenstein, MPH, DSc, Aarhus University
Jeffrey Brown, PhD, Chief Scientific Officer, TriNetX
Til Stürmer, FISPE
Nancy A. Dreyer Distinguished Professor and Chair, University of North Carolina at Chapel Hill
Meredith Smith, FISPE, AstraZeneca

4:45 - 5:30 PM
THE FINAL WORD – CONGRESS HALL D4
38th ICPE Awards
Anton Pottegård
Chair, ICPE 2022 Scientific Program Committee
Jesper Hallas, FISPE
Co-Chair, ICPE 2022 Scientific Program Committee
Review of Abstract Admission Categories
Newcomer Track
Moderator Subcommittee
Spotlight Poster Sessions
Spotlight Poster Awards
Wendy Camelo Castillo
Chair, Spotlight Poster Sessions

5:45 - 6:45 PM
2023 SCIENTIFIC PROGRAM COMMITTEE – MEETING ROOM 20
Open to all attendees.

FUTURE MEETINGS
14th Asian Conference on Pharmacoepidemiology (ACPE)
Tainan, Taiwan | October 21-23, 2022
Soto Setoguchi
Program Chair

Mid-Year Meeting, Reykjavík
Iceland | April 23-25, 2023
Helga Gardarsdottir, FISPE
Program Chair

39th ICPE: Halifax
Nova Scotia, Canada | August 23-27, 2023
Robert Platt
Chair, ICPE 2023 Scientific Program Committee
OVERVIEW
Poster sessions are intended to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.
Neither ISPE nor the Bella Convention Center will be responsible for any material left on display overnight or is lost or damaged.

POSTER SESSIONS EXPLAINED
There are two separate and distinct Spotlight and General poster sessions each day at the Bella Convention Center. The Spotlight Poster Session is scheduled for Hall E South. The General Poster Session is scheduled for Hall C. Each day is allocated a Session and scheduled at the following times:

Session A: Friday, August 26 | 8 AM - 6 PM
Session B: Saturday, August 27 | 8 AM - 6 PM
Session C: Sunday, August 28 | 8 AM - 1:30 PM

SETUP/TAKE DOWN
7:00am-8:00am; all posters must be in place by 8:00am. The poster area must be cleared of tubes, obstacles, trip hazards, and other materials.

All posters for a specific day's session must be removed at the end the session, by 7:00pm on Friday and Saturday, and by 3:00pm on Sunday. Posters not removed by these times will be assumed to be abandoned and will be discarded.

DISCUSSION TIME

General Session
Presenting Authors must be at their posters at the following times for discussion:
Friday (Session A): 12:00 - 1:30 PM
Saturday (Session B): 11:30 AM - 1:00 PM
Sunday (Session C): 12:00 - 1:30 PM

Spotlight Poster
Presenting Authors must be at their posters at the following times for discussion:
Friday (Session A): 12:15 - 1:15 PM
Saturday (Session B): 11:45 AM - 12:45 PM
Sunday (Session C): 12:15 - 1:15 PM

Spotlight Sessions
Organized by ISPE Special Interest Groups (SIGs). Spotlight sessions showcase select posters and give presenters the opportunity to share and discuss their work with an audience. When the spotlight session chair and audience stop at your poster, please give a brief, 3-minute, presentation and be prepared to answer questions about your research.

Spotlight posters are organized in the following topic areas:

Friday (Session A)
Adherence | ASPEN | Biologics | BRACE
Cancer | Comparative Effectiveness Research

Saturday (Session B)
Databases | Digital Epidemiology | Drug Utilization Research
Drug-Drug Interaction | Genomics | Geriatrics

Sunday (Session C)
Health Equity | Medical Devices | Medications in Pregnancy and Lactation | Pediatrics | Rare Diseases | Vaccines

Spotlight Session Prizes
A group of judges will select the best posters of each Spotlight Session. The best presenters will receive an invitation to display their posters for the duration of the conference. The winners will be announced at The Final Word session on Sunday, August 28.

Numbering System
Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster listed in this program. The poster board number is the first number listed. The publication number, for use in locating abstracts in the program book, is listed after the abstract title.

Example
97 – Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy [176]
Greta A. Bushnell | Alice White | Til Stürmer | Bradley Gaynes
Virginia Pate | Deborah Azrael | Matthew Miller (United States)

Key: 97 – Poster Board Number [176] – Publication Number
### Poster Session A

#### SPOTLIGHT POSTERS

<table>
<thead>
<tr>
<th>Category</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHERENCE</td>
<td>63</td>
</tr>
<tr>
<td>ASPEN</td>
<td>63</td>
</tr>
<tr>
<td>BIOLOGICS</td>
<td>64</td>
</tr>
<tr>
<td>BENEFIT-RISK ASSESSMENT, COMMUNICATION, AND EVALUATION (BRACE)</td>
<td>64</td>
</tr>
<tr>
<td>CANCER</td>
<td>65</td>
</tr>
<tr>
<td>COMPARATIVE EFFECTIVENESS RESEARCH (CER)</td>
<td>65</td>
</tr>
<tr>
<td>BENEFIT-RISK ASSESSMENT, COMMUNICATION, AND EVALUATION (BRACE)</td>
<td>66</td>
</tr>
<tr>
<td>DISEASE EPIDEMIOLOGY/CLINICAL COURSE</td>
<td>67</td>
</tr>
<tr>
<td>DRUG UTILIZATION RESEARCH</td>
<td>70</td>
</tr>
<tr>
<td>HEALTH EQUITY</td>
<td>74</td>
</tr>
<tr>
<td>METHODS IN PHARMACOEPIDEMIOLOGY</td>
<td>76</td>
</tr>
<tr>
<td>MOLECULAR EPIDEMIOLOGY/ BIOMARKERS/ PHARMACOGENETICS</td>
<td>79</td>
</tr>
<tr>
<td>PHARMACOVIGILANCE</td>
<td>79</td>
</tr>
<tr>
<td>PREGNANCY AND LACTATION</td>
<td>81</td>
</tr>
<tr>
<td>RARE DISEASE</td>
<td>85</td>
</tr>
<tr>
<td>SAFETY END POINTS</td>
<td>86</td>
</tr>
</tbody>
</table>
**ADHERENCE**

A – Primary Hydroxychloroquine Adherence in Lupus Pregnancy [291]
Julia F Simard | Emily F. Liu | Eliza Chakravarty
Amadeia Rector | Miranda Cantu | Daniel Kuo | Gary Shaw
Maurice Druzin | Michael Weisman | Monique Hedderson (United States)

Anna M. Rzepka | Tara Gomes | Angela M. Cheung
Sandra Kim | Maha Chaudhry
Suzanne M. M. Cadarette (Canada)

C – Trends in Opioid New Users and Subsequent Long-Term Use Among Patients with Rheumatic and Musculoskeletal Diseases Between 2006-2020 [293]
Meghna Jani | Joyce (Yun-Ting) Huang | David A. Jenkins
Belay Yimer | Jose Benitez-Aurioles | Niels Peek
Mark Lunt | William Dixon (United Kingdom)

**ASPEN**

Tien Hoang Tran | Seung-Kwon Myung
Thao Thi Kim Trinh (Vietnam)

H – Incidence and Prevalence of Prescription Opioid Use During Australian COVID-19 Restrictions [298]
Monica Jung | Dickson Lukose | Suzanne Nielsen
J. Simon Bell | Geoffrey Webb | Jenni Ilomaki (Australia)

I – Impact of Clinical Pharmacist Interventions on Patients' Quality of Life (QoL) and Influencing Risk Factors Associated with Poor QoL in Systemic Lupus Erythematosus Disorder Patients [299]
Sujit Kumar Sah | Ramesh Madhan
Subramanian Ramaswamy (India)

J – Economic Evaluation of Sacubitril/Valsartan for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) in Indonesia [300]
Erna Kristin | Dwi - Endarti | Ratih Puspita Febriasari
Dwi Aris Agung Nugrahaningsih | Woro Rukmi Pratiwi
Sudi Indrajaya (Indonesia)

K – Risk of Mortality with Early-Stage Nonadherence to the Regimen in Patients with Drug-Susceptible Tuberculosis: A Nationwide Linkage Database [301]
Hyesung Lee | Sungho Bea | Ju Hwan Kim | Bin Hong
Ju-Young Shin (Republic of Korea)

L – Comparative Cardiovascular Events Associated with Denosumab vs Zoledronate in the Elderly: A 5-Year Follow-Up Propensity Score Matching Cohort [302]
KaiCheng Chang | Fang-Yi Li | Shih-Chieh Shao
Hui-Yu Chen (Taiwan)

BIOLOGICS BIOLOGICS

O – Depression, Anxiety and Adjustment Disorder Among Patients with Psoriasis Receiving Systemic Agents: A Retrospective Cohort Study in Quebec, Canada [305] Raymond Milan | Jacques Lelorier | Marie-Josée Brouillette Raymond Milan | Jacques Lelorier | Marie-Josée Brouillette Anne Holbrook | Ivan V. Litvinov | Elham Rahme (Canada) Anne Holbrook | Ivan V. Litvinov | Elham Rahme (Canada)


N – Triazole Anti-fungals Associated with Acute Pancreatitis: A Disproportionality Analysis in a Spontaneous Reporting Database [304] Lipin Lukose | Aina Shaju | Mohammed Asif Lipin Lukose | Aina Shaju | Mohammed Asif Subeesh Kulangara Viswam (India) Subeesh Kulangara Viswam (India)


S – TNF-Alpha Inhibitors Biosimilar Use in France: A 207,118 Patients Longitudinal Study [309] Hugo Jourdain | Mahmoud Zureik | Léa Hoisnard Hugo Jourdain | Mahmoud Zureik | Léa Hoisnard Emilie Sbidi (France) Emilie Sbidi (France)


CANCER

Z – Incidence of Opportunistic Infections Among Patients with Multiple Myeloma: Real-World Evidence from a Large US National Claims Database [316]
Alexi Archambault | Martha Makaratzi
Karen Rodriguez Lorenç | Glenn Kroog | Christian Hampp (United States)

AA – Proton Pump Inhibitors and Colorectal Cancer Mortality: A Population-based Nationwide Cohort Study [317]
Jannik Wheler | Deirdre Cronin-Fenton | Anders Kjærsgaard
Timothy Lash | Rune Erichsen | Veronika Fedirko (Denmark)

AB – Risk of Venous Thromboembolism Events in Prostate Cancer Patients [318]
Lu Wang | Mitchell M. Conover | James Weaver
J. Kellogg Parsons | Sabine D. Brookman-May | Dina Gifkins (United States)

AC – 5-Alpha Reductase Inhibitor Use and Risk of Kidney and Bladder Cancer in Men with Benign Prostatic Hyperplasia: A Population-based Cohort Study [319]
Niamh Doherty | Christopher Cardwell | Peter Murchie
Christopher Hill | Laurent Azoulay | Blánaid Hicks (United Kingdom)

AD – Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Patients: The National Health Insurance Service Database of Korea [320]
Ji-Eun Kim | Jaseung Choi | Jooyong Park | Wonshik Han
Daehae Kang | Ji-Yeob Choi (South Korea)

AE – Use of Selective Serotonin Reuptake Inhibitors (SSRI) and Risk of Breast Cancer [321]
Tomas Log | Marit Waaseth (Norway)

AF – Hypothesis-Free Screening for Carcinogenic Effects of Drugs [322]
Anton Pottegård | Kasper Bruun Kristensen | Søren Friis
Lars Christian Lund | Jesper Hallas | Christopher Cardwell
Bettina K. Andreassen | Laurel A. Habel (Denmark)

AG – Mineralocorticoid Receptor Antagonists and Prostate Cancer Risk in Patients with Heart Failure [323]
Chengsheng Ju | Wallis Lau | Li Wei (United Kingdom)

COMPARATIVE EFFECTIVENESS RESEARCH (CER)

AH – Antipsychotic Polytherapy Versus Monotherapy in Specific Dose Categories in the Maintenance Treatment of Schizophrenia [324]
Heidi Taipale | Antti Taskanan | Jari Tiihonen (Finland)

AI – Comparative Risk of Opioid Overdose with Concomitant Use of Prescription Opioids and Skeletal Muscle Relaxants [325]
Nazleen Khan | Katsiaryna Bykov | Michael Barnett
Robert Glynn | Seanna Vine | Joshua J. Gagne (United States)

AJ – Association of Mortality by Statin Intensity in Chronic Liver Disease Patients with Atherosclerotic Cardiovascular Disease: A Nationwide Cohort Study [326]
Sungho Bea | In-Sun Oh | Ju Hwan Kim | Dong Hyun Sinn
Yoo-soo Chang | Seungho Ryu | Ju-Young Shin (Republic of Korea)

AK – Macrolide Treatment Failure Due to Drug-Drug Interactions: Real-World Evidence to Evaluate a Pharmacological Hypothesis [327]
Brian Cicali | Stephan Schmidt | Markus Zeitlinger
Joshua Brown (United States)

AL – Real World Effects of Oral Anticoagulants in AF: A Cohort Study with Validation Against Results from a Randomised Controlled Trial [328]
Emma M L Powell | Ian Douglas | Kevin Wing
Usha Gungabissoon | Liam Smeeth (United Kingdom)

AM – Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome [329]
Joel F. Farley | Arun Kumar | Pamela Lutsey
Wendy St. Peter, | Jon Schommer | Jeremy Van’T Hof
Abhijeet Rajpurohit (United States)

AN – Real-World Evidence for the Effectiveness of Vitamin D Supplementation in the Reduction of Total and Cause-specific Mortality. Results from Half a Million Participants of the UK Biobank Cohort Study [330]
Sha Sha | Hermann Brenner | Ben Schoettker
Thi Mai Ngoc Nguyen | Sabine Kuznia | Tobias Niedermaier
Anna Zhu (Germany)

AO – A Real-World Assessment of Sex Differences in the Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin [331]
Meijia Shao | Ai Ni | Macarius Donneyong (United States)
1 – Pharmacopoeiologic and Benefit/Risk Management Strategies in Clinical Trials with Cell-based Combination Products [332]
Marina A. Malikova (United States)

2 – Application of The BRACE Framework for Benefit-Risk Assessment, Communication, and Evaluation of Pexidartinib [333]
Eric Wang | Charles Dharmani | Maribel Salas (United States)

3 – Estimates of Dietary Exposure to Antibiotics Among a Community Population in East China [334]
Yingying Wang | Yurong Li | Jinxin Zang | Xiaolian Dong
Bingbing Zhu | Na Wang | Lufang Jiang | Feng Jiang
Xinping Zhao | Qingwu Jiang | Chaowei Fu (China)

4 – Evaluation of Consumers’ Knowledge, Beliefs and Risk Assessment Regarding Protein [335]
Paraskvi Basdeki | Erini-Georgia Deligiannidou
Diamanto Lazari | Christos Kontogiorgis (Greece)

5 – Guidance for Pediatric Use in Prescription Information for Novel Medicinal Products in the EU and the US [336]
Helle Christiansen | Christine Hallgreen | Sven Frokjaer
Marie Louise De Bruin (Denmark)

6 – Fetal Exposure to Isotretinoin in Saudi Arabia: Real-World Data Analysis from 2015-2020 [337]
Yasser Albogami | Ohoud A. Almadani | Sultan Alshehri
Abdullah Alkhebri | Mona Anzani | Sumaya Almohareb
Abdulaziz Alhossan | Adel A. Alrwisan (Saudi Arabia)

7 – Research Impact Assessment: An Example from the Canadian Network for Observational Drug Effect Studies [338]
Ingrid Sketris | Amy Freier | Alexandra M. Yip
Natasha Rodney-Cail | Nancy Carter (Canada)

8 – Prenatal Exposure to Teratogenic Drugs: Contrasts Between Publicly and Privately Insured Persons [339]
Nicole Smolinski | Yanning Wang | Thuy Thai
Amir Sarayani | Celeste Ewig | Sonja Rasmussen
Almut Winterstein (United States)

9 – Readability of Information Imprinted in Patient Information Leaflets (PILs) in Saudi Arabia: The Case of Antihypertensive Medications [340]
Aljoharah M. Algabbani | Shahad Alzahrani | Slawa Moaman Radwan Hafiz (Saudi Arabia)

10 – Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation [341]
Md Azharuddin | Manju Sharma (India)

11 – A Review of Patient-Reported Outcomes for European Medicines Agency Regulatory Approval of Oncologic Drugs Between 2017 and 2020 [342]
Carla Torre | Maria Manuel Teixeira | Fabio Cardoso Borges
Paula Barão | João Rocha | Bruno Sepodes (Portugal)

12 – Targets for Quality Improvement? Top 10 Teratogenic Drugs Used During Pregnancy in the US [343]
Yanning Wang | Nicole Smolinski | Thuy Thai
Amir Sarayani | Celeste Ewig | Sonja Rasmussen
Almut Winterstein (United States)

13 – Effectiveness of Risk Minimization Plan for Concentrated Insulin Lispro in France, Germany and Sweden [344]
Ayad K. Ali | Melissa L. Ewing (United States)

14 – A Comprehensive Review on the Teratogenic Risks for Twelve Drugs with Risk Evaluation and Mitigation Strategy (REMS) to Prevent Prenatal Exposure [345]
Tansu Miriam Isilay Aydogan | Nicole Smolinski | Thuy Thai
Sebastian Jugl | Amir Sarayani | Celeste Ewig
Almut Winterstein (Germany)

15 – Contribution of Real-World Evidence to Support Efficacy Claims in Centralised Marketing Authorisation Applications Submitted to EMA in 2018-2019 [346]
Elisabeth Bakker | Kelly Plueschke | Carla Jonker
Viktoria Starokozhko | Peter Mol | Xavier Kurz (Netherlands)
Chris Schneiderman | Dianlin Guo | Bruce Barger (United States)

17 – A Cross-Sectional Analysis of Systemic Lupus Erythematosus: Younger Patients Have Higher Inpatient Readmission Rates and Older Patients Have Higher Inpatient Resource Use and Mortality [348]
Laura A. Clark | Evelyn Rizzo | Rosa C. Banuelos
Koen Degeling | Kathy Belk (United States)

18 – Trends in The Incidence of Chronic Inflammatory Demyelinating Polyneuropathy Over a 10-Year Period in a US Commercially Insured Population [349]
Nicole Tsao | Venkatesh Harikrishnan
William A. Blumentals (United States)

19 – Estimating Incidence and Case Fatality of Thyroid Storm in Germany Between 2007 and 2017: A Claims Data Analysis [350]
Katharina Platzecker | Arulmani Thiyagarajan
Till Ittermann | Henry Völzke | Ulrike Haug (Germany)

20 – Using Healthcare Claims to Evaluate Long Haul COVID-19 Disease [351]
Rachel Ogilvie | Jessica Franklin | Michael C. Doherty
Heather Norman | John Seeger (United States)

21 – Suicide Poisoning Mortality: A Comparison of the National Poison Control Center and CDC National Datasets [352]
Silvia Perez-Vilar | Jummai Apatu | Dinci Pennap
Andrew Mosholder (United States)

22 – Type 2 Diabetic Patients with a Single Cardiovascular or Renal Comorbidity: 5-Year Risk of a New Cardiovascular Renal Complication Using the French Nationwide Claims Database [353]
Patrick Blin | Michael Joubert | Philippe Zaoui
Estelle Guizard | Dunia Sakr | Caroline Dureau-Pourmin
Marie-Agnès Bernard | Régis Lassalle
Florence Thomas-Delecourt | Sébastien Bineau
Nicholas Moore | Cécile Droz-Perroteau
Patrick Jourdain (France)

23 – Prevalence and Clinical Burden of Genetic Dilated Cardiomyopathy in the United States: Results from The Optum® Electronic Health Records Database [354]
Scott Kelly | Yaa Ababio | Robert Moccia | Franca S. Angeli
Joanne Berghout | Kui Huang | Kathy Liu | Sara Burns
Cynthia Senerchia | Gabriel C. Brooks (United States)

24 – The Burden of Sudden Cardiac Death Among Older Adults Diagnosed with Cancer [355]
Jennifer Lund | Courtney Slusher
Sharon Peacock Hinton | Emilie Duchesneau
Disha Subramaniam | Magdalene M. Assimon (United States)

25 – Diabetes and Cardiovascular Diseases in Women with Pregancies Complicated by Vaginal Bleeding: Danish Population-based Cohort Study [356]
Elena Dudukina | Erzsebet Horvath-Puho
Henrik Toft Sørensen | Vera Ehrenstein (Denmark)

26 – Type 2 Diabetes, the Epic: Trends in Prevalence, Treatment and Risk-Factor Control, 2004-2020 [357]
Jetty Overbeek | Karin Swart | Marieke Blom | Petra Elders
Giel Nijpels | Ron Herings (Netherlands)

Weihsuan Jenny Lo-Ciganic | Seonkyeong Yang
Shu Huang | Juan Hincapie-Castillo | Xuehua Ke
Jonathan Schelfhout | Helen Ding | Mandel Sher
Debbie Wilson (United States)

28 – Treatment Rates for Glaucoma and Intraocular Hypertension in the United Kingdom, 2000-2019 [359]
Luis Velez-Nandayapa | Laura Eggenschwiler | Susan Jick
Christoph Meier | Claudia Becker (Switzerland)

Ambrish Singh | Siddharth Kumar Das | Arvind Chopra
Debashish Danda | Binoy J. Paul | Lyn March
Ashish Jacob Mathew | Padmanabha Shenoy
Carolyn Gotay | Andrew J. Palmer | Benny Antony (Australia)
30 – Socioeconomic Position, Psychiatric Medical Treatment and Risk of Breast Cancer Recurrence and Mortality: A Danish Population-based Cohort Study [361]
Fanny B. Asmussen | Cathrine Hjorth | Oleguer Plana-Ripoll Aurelie Mailhac | Deirdre Cronin-Fenton (Denmark)

31 – Risk of COVID-19 Among Patients with Atopic Dermatitis: A Targeted Literature Review [362]
Ihtisham Sultan | Ashley Howell | Andrea Marcus (United States)

32 – Age- and Gender-specific Epidemiology of Urinary Tract Infection, Pneumonia, Sepsis, Cholecystitis and Cellulitis Among the Elderly: A 20-Year Nationwide Study [363]
Hung-Yu Lin | Shih-Tsung Huang | Liang-Kung Chen Fei-Yuan Hsiao (Taiwan)

Nicole Tsao | Venkatesh Harikrishnan William A. Blumentals (United States)

34 – Evaluating the Effectiveness of Implementing Diagnostic Stewardship in the Management of Acute Pharyngitis: Insights from India [365]
Aleena Issac | Jose J. Kochuparambil Jais Vayalikunnel (India)

35 - Uropathogens and Their Antimicrobial Sensitivity Patterns to Choose Empirical Antibiotic: Study from a Public Hospital in India [366]
Aleena Issac | Jose J. Kochuparambil Jais Vayalikunnel (India)

36 – Treatment Patterns for Inflammatory Bowel Disease in Japan and the US (2010-2019) [367]
Michiyo Yamazaki | Hsingwen Chung | Hong Qiu Md, PhD (United States)

37 – Assessment of Neurological Complications in Hemodialysis Patients [368]
Sunil G M | Savitha Sanathan | Manjunath Shetty Ronald Castelino | Santhrupth H V (India)

38 – The Willingness and Attitude of Healthcare Providers on Medication Self-Management by Hospitalized Patients with Schizophrenia or Bipolar Disease [369]
Elke Loots (Belgium)

39 – Associations Between Oral Diseases and Chronic Diseases Modified by Trajectories of Lifestyle Behaviors: A Nationwide Population-based Study in Korea [370]
Ji-Yeob Choi | Jaseung Choi | Seokyung Hahn Hee-Kyung Park | Seo-Young Park (South Korea)

Nadia Howlader | Kathleen A. Cronin | Angela Mariotto Manami Bhattacharya | Elad Sharon (United States)

41 – A-1 Adrenergic Receptor Antagonists and Risk of Severe COVID-19 [372]
Elizabeth Smith | David Graham | Hector Izurieta Di Zhang | Armen Avagyan | Hai Lyu | A. Wiederhorn Yun Lu | Andrew Mosholder | Yueqin Zhao Shanlai Shangguan | Huei-Ting Tsai | Dinci Pennap Alexander Sandhu | Michael Wernecke | Thomas E. Macurdy Jeffrey Kelman | Richard A. Forshbee (United States)

42 – Migraine and Risk of Gastrointestinal Cancer: A Danish Population-based Cohort Study [373]
Cecilia Fuglsang | Holly Elser | Nils Skajaa | Vera Ehrenstein Dóra Körmandiné Farkas | Henrik Toft Sørensen (Denmark)

43 – Baseline Study for Improving Diagnostic Stewardship at Secondary Health Care Facilities in Nigeria [374]
Abiodun Egwuenu | Adaora Ejikeme | Sara Tomczyk Olaniyi Ayobami | Oluwaseun Odeibajo | Samuel Akhibi Constance Agulanna | Osayande Osagie | Stella Inweregbu Ridwan Yahaya | Tochi Okwor | Hannah Dada-Adegbola Ikeoluwapo Ajayi | Abdulhakeem Olorukooba Tim Eckmanns | Chinwe Lucia Ochu Chikwe Ihekweazu (Nigeria)
Poster Session A

44 – Epidemiology of Pseudomonas and Multidrug-resistant Pseudomonas Species in Patients Hospitalized with Community-acquired Bacterial Pneumonia [375]
Adeniyi J. Idigo | J Michael Wells | Matthew L. Brown
Howard Wiener | Russell Griffin | Gary Cutter
Sadeep Shrestha | Rachael A. Lee (United States)

45 – Development and Validation of a Chronic Kidney Disease Phenotype Using Combined Electronic Health Record and Claims Data [376]
Lily Bessette | Julie Paik | Richard Wyss
Juliana M. Mastrorili | Zhigang Lu | Theodore Tsacogianis
Joshua Lin (United States)

46 – Characteristics of Asthma Patients with COVID-19 by Disease Severity and Across Age Groups – A Swedish Population-based Analysis within the SCIFI-PEARL Project [377]
Brian K. Kirui | Ailiana Santosa | Lowie Vanfleteren
Caroline Stridsman | Fredrik Nyberg (Sweden)

47 – Assessment of Incidence, Pattern and Risk Factors Associated with Opportunistic Infections Among HIV Seropositive Patients [378]
Balaji Sathyarayana Gupta | Alan James
Ramesh Madhan (India)

Epi Excellence is pleased to announce the addition of Haley Kaplowitz and Doug Watson to the team!

Our 35+ epidemiologists and scientists are readily available to provide a range of epidemiology services:
• Literature review (simple to complex, narrative to systematic, for any purpose)
• Study development and support (strategic planning; protocol, SAP, report, or manuscript writing)
• Strategic consulting
• Other tasks, no matter how small

Epi Excellence is a small business, honored to be certified as a Women’s Business Enterprise and a Minority Business Enterprise.

Proud sponsor of ICPE’s Lactation Room – Bella Center Room 28
Call or Text: +1 215.920.7680 | Email: eming@epiexcellence.com
Web: epiexcellence.com
<table>
<thead>
<tr>
<th>Poster Session A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DRUG UTILIZATION RESEARCH</strong></td>
</tr>
<tr>
<td>48 – Effect of the COVID-19 Pandemic on Medicines Prescription for Children in Portugal [379]</td>
</tr>
<tr>
<td>Ana Silva</td>
</tr>
<tr>
<td>49 – Post-Myocardial Infarction Guideline-recommended Therapy Utilization Sankey Diagrams [380]</td>
</tr>
<tr>
<td>Montika Bush</td>
</tr>
<tr>
<td>Gang Fang (United States)</td>
</tr>
<tr>
<td>50 – Characterization and Treatment Patterns of Systemic Lupus Erythematosus Patients – Data from a Large Israeli Health Maintenance Organization [381]</td>
</tr>
<tr>
<td>Vered Rosenberg</td>
</tr>
<tr>
<td>Daphna Paran (Israel)</td>
</tr>
<tr>
<td>51 – The Use of Metamizol and Other Non-opioid Analgesics in Switzerland Between 2014 and 2019: A Descriptive Study [382]</td>
</tr>
<tr>
<td>Stephan Gut</td>
</tr>
<tr>
<td>Manuel Haschke</td>
</tr>
<tr>
<td>Julia Spoendlin (Switzerland)</td>
</tr>
<tr>
<td>52 – Titanium Dioxide in Drugs Available on the French Market [383]</td>
</tr>
<tr>
<td>Manon Cairat</td>
</tr>
<tr>
<td>53 – A Factorial Randomized Trial of Personalized Prescribing Portraits and Evidence Letters to Reduce Long-term Proton Pump Inhibitor Prescribing in Primary Care [384]</td>
</tr>
<tr>
<td>Greg Carney</td>
</tr>
<tr>
<td>Malcolm Maclure</td>
</tr>
<tr>
<td>54 – Protocol for Implementing and Evaluating Online Physician Prescribing Portraits: Scalable Low-Cost Audit and Feedback Delivery and Improvement [385]</td>
</tr>
<tr>
<td>Greg Carney</td>
</tr>
<tr>
<td>Colin Dormuth (Canada)</td>
</tr>
<tr>
<td>55 – Initial Choice and Switching of P2Y12 Inhibitors Among Patients with Acute Coronary Syndrome (ACS) After Percutaneous Coronary Intervention (PCI) [386]</td>
</tr>
<tr>
<td>Yehua Wang</td>
</tr>
<tr>
<td>Almut Winterstein (United States)</td>
</tr>
<tr>
<td>56 – Drug Treatment in Older Patients According to Indicators of Potentially Rational Prescribing [387]</td>
</tr>
<tr>
<td>Naldy Parodi Lopez</td>
</tr>
<tr>
<td>Nkuchia M. Mikanatha</td>
</tr>
<tr>
<td>Heather Tate (United States)</td>
</tr>
<tr>
<td>58 – Current Trends in Continuous Peripheral Nerve Block Use in Total Knee Arthroplasty [389]</td>
</tr>
<tr>
<td>Sachinkumar Singh</td>
</tr>
<tr>
<td>Mohammadhossein Hajiabrahami</td>
</tr>
<tr>
<td>Fredrik Nyberg (Sweden)</td>
</tr>
<tr>
<td>60 – Trends of Thromboprophylaxis Among Newly Diagnosed Multiple Myeloma Patients Initiating Immunomodulatory Drug-based Regimens, 2010 to 2018 [391]</td>
</tr>
<tr>
<td>Abdullah Abdelaziz</td>
</tr>
<tr>
<td>Brian C.-H. Chiu</td>
</tr>
<tr>
<td>61 – Assessment of Drug-Drug Interactions and Their Associated Risk Factors in Patients with Systemic Lupus Erythematosus: A Cross-Sectional Study [392]</td>
</tr>
<tr>
<td>Sujit Kumar Sah</td>
</tr>
<tr>
<td>62 – Use of Prescription Medicines Among Incarcerated Individuals in the United States [393]</td>
</tr>
<tr>
<td>Jill Curran</td>
</tr>
<tr>
<td>G. Caleb Alexander (United States)</td>
</tr>
<tr>
<td>63 – The Availability of Essential Medicines for Cardiovascular Diseases in Low- and Middle-income Countries: A Case Study of Bangladesh [394]</td>
</tr>
<tr>
<td>Md Jamal Uddin</td>
</tr>
</tbody>
</table>
64 – Utilisation and Prescribing Patterns of Antipsychotic Medication in the Scottish Primary Care Setting (2010-2020) [395]
Fatema Mahmoud | Siobhan Mcbride | Amanj Kurdi
(United Kingdom)

65 – Association of Medication Clusters and Labor Market Marginalization in Refugee Youths and Swedish-Born with Common Mental Disorder in Sweden [396]
Jiaying Chen | Ellenor Mittendorfer-Rutz | Heidi Taipale
Syed Rahman | Thomas Niederkrotenthaler
Peter Klimek (Austria)

Chloe C. H. Smit | Katja Taxis | Kris Rogers
Hamish Robertson | Lisa Pont (Australia)

67 – Off-Label Low Dose Amitriptyline for Insomnia Disorder: Patient-Reported Outcomes [398]
Mette H. Bakker | Jacqueline Hugtenburg | Marcel Smits
Henriette Van Der Horst | Pauline Slottje (Netherlands)

68 – Measuring Access to Medicines for Children: The Robustness of a Child-Specific Indicator [399]
Rianne Van Den Ham | Iris Joosse | Aukje Mantel-Teeuwisse
Veronika J. Wirtz | Fatima Suleman (Netherlands)

69 – Evaluating Brazil’s National Administrative Claims Data for Real-World Pharmacoepidemiologic Studies: Trends in Rheumatoid Arthritis Using DATASUS (2010-2020) [400]
Alexander Liede | Marina G. Birck | Marco Curi
Whitney Krueger | Guilherme Julian (Ireland)

70 – Temporal Trends and Correlates of Early Life Exposure to Acid-suppressant Therapy [401]
Gabriel Chodick | Inbal Goldshtein | Tomer Achler
Ron Shaoul | Shlomi Cohen | Amir Ben Tov (Israel)

71 – Epidemiology Assessment of Poly-pharmacy Among Metabolic Syndrome Patients Based on Prescriptions of Iranians Health Insurance Service Data Sets, a Cross Sectional Study [402]
Mojdeh Daneshmand | Hamidreza Jamshidi
Farshad Farzadfar | Mohammadhadi Farjoo
Salehe Mortazavi | Mohsen Shati (Iran)

72 – Machine Learning-based Prediction Models for Outpatient Prescription of Japanese Kampo Formulations: Development and Validation Using a Health Insurance Claims Database [403]
Hayato Yamana (Japan)

73 – Choice of Initial Treatment with Cholesterol Lowering Drugs in Patients with Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, or Increased Risk of Atherosclerotic Cardiovascular Disease [404]
Jakob Kronkvist Hoe | Camilla B. Jensen | Susanne Hansen
Rasmus Huan Olsen | Tina Johansen
Espen Jimenez-Solem | Janne Petersen (Denmark)

74 – Community Pharmacists’ Knowledge, Attitude, and Practices Towards Antibiotic Use in Bulgaria [405]
Hristina Lebanova | Stefan Balkanski | Nadia Veleva (Bulgaria)

75 – Drug Utilization of Anxiolytics and Sedatives Among New Users in Sweden [406]
Elin Dahlen | Carola Bardage | Paulina Tuvedal
Maria Grünewald | Rickard Ljung (Sweden)

77 – Incidence of Antipsychotic Use Among Community Dwellers with and without Parkinson’s Disease [408]
Mia Tiihonen | Satu Lilja | Anna-Maija Tolppanen
Sirpa Hartikainen (Finland)

78 – Time Trends in the Prescription of Overactive Bladder Agents in England [409]
Kathryn Richardson | Yoon K. Loke | Nicholas Steel
Duncan Edwards | Jalesh N. Panicker | Stuart Irving
Katharina Mattishent | Chris Fox | Louise Robinson
Irene Petersen (United Kingdom)
79 – Improving Patient Safety: A Qualitative Study of the Implementation of the 'Know Check Ask' Medication Safety Campaign Among Healthcare Professionals, Patients and Carers [410]
John E. Hughes | B. O'Donovan | C. Kirke | M. Pate
S. McHugh | Kathleen E. Bennett | Caitriona Cahir (Ireland)

80 – Self-Sufficiency and Pharmaceutical Local Production of Chronic Diseases Medicines in Saudi Arabia: The Case of Type Two Diabetes Medications [411]
Amal Alshatri Almotiry | Abduallah Al shareef Abdulaali Almutairi | Abdulmohsen Bahlwa Abdullah Alshehri | Omar Almazroo Mohammed Ghazwani (Saudi Arabia)

81 – Less Timely Initiation of Glucose-lowering Medication Among Younger and Male Patients with Diabetes and Similar Initiation of Blood Pressure-lowering Medication Across Age and Sex: Trends Between 2015 and 2020 [412]
Petra Denig | Martina Ambroz | Sieta De Vries Klaas Hoogenberg (Netherlands)

82 – Antibiotic Use for Diarrheal Illness in Patients with a Positive Molecular Gastrointestinal Pathogen Panel Result [413]
Samantha Eiffert | Emily Ciccone | Natalie Mackow Banks Kookien | Melissa B. Miller | Alan Kinlaw (United States)

83 – Storage and Disposal of Medicines by Households in Kathmandu Valley, Nepal [414]
Nisha Jha | Sajala Kafle | Shital Bhandary Pathiyil Ravi Shankar (Nepal)

84 – Population, Outcome, and Treatment Changes in Secondary Data Early in the COVID-19 Pandemic [415]
Michael Webster-Clark | Joyce Pak (Canada)

85 – Changes in Use of Glucose-Lowering Drugs and Physician Responsibility: A Danish Nationwide Study [416]
Anton Pottegård | Reimar Thomsen | Jacob Harbo Andersen Jens Søndergaard | Tina Vilsbøll (Denmark)

86 – Impact of Angiotensin-Receptor-Blocker (ARB) Recalls Due to Nitrosamine Contamination on ARB Utilization in the US, Canada, and Denmark [417]
Efe Eworuke | Mayura Shinde | Laura Hou Michael Paterson | Peter Jensen | Judith Maro | Ashish Rai Daniel Scarnecchia | Daniel Woronow | Anton Pottegård Robert Platt | Hana Lee | Dinci Pennap | Marie Bradley (United States)

87 – Impact of Implementing a Guide on Intravenous Fluids to Minimise the Risk of Hospital-acquired Hyponatraemia in Denmark [418]
Per Sindahl | Christian Overgaard-Steensner Helle Wallach-Kildemoes | Marie Louise De Bruin Kaare Kemp | Helga Gardarsdottir (Denmark)

89 – Utilization Patterns and Predictors of Persistence for Anti-osteoporosis Treatment Initiators in Denmark: A Population-based Cohort Study [420]
Vera Ehrenstein | Alma Becic Pedersen | Nickolaj Risbo George Kafatos | David E. Neasham | James O’kelly (Denmark)

90 – The Utilisation of Low-Dose Rivaroxaban in Patients with Atherosclerotic Cardiovascular Disease in the United Kingdom and The Netherlands [421]
Nicholas B. Hunt | Allan Sallih | Marloes Bazelier Bjorn Wettermark | Sander Van Doorn | Helga Gardarsdottir Olaf H. Kungel | Romin Pajouheshnia (Netherlands)

91 – Time Trends in Antidepressant Use Among Women Aged 45-75 in Germany [422]
Wiebke Schaefer | Miriam Heinig | Ulrike Haug (Germany)

92 – Initiation of Antihypertensive Drugs to Patients with Confirmed COVID-19 – A Population-based Cohort Study in Sweden [423]
Bjorn Wettermark | Salar Issa Moussa | Fredrik Nyberg Mohammadhossein Hajiebrahim | Rebecka Bertilsson Jonatan Nåtman | Ailiana Santosa (Sweden)
93 – Trends of Antiseizure Medications Utilization in Pregnant People: Population-Level Data from Two Canadian Provinces Over Two Decades [424]
Sherif Eltonsy | Payam Peymani | Brandace Winquist
Joseph Delaney | Walid Shouman | Alekhya Lavu
Kaarina Kowalec | Marcus Ng (Canada)

94 – Opioid Prescriber Responsibility: A Danish Drug Utilization Study [425]
Lotte Rasmussen | Anne Mette Skov Soerensen
Morten Olesen | Anton Pottegård (Denmark)

95 – Opioid Overdose Risk Prediction in a State Medicaid Program: How Does Predicted Risk Change Over Time? [426]
Serena Jingchuan Guo | Walid Gellad | Qingnan Yang
Jeremy C. Weiss | Julie M. Donohue | Gerald Cochran
Adam J. Gordon | Daniel Malone | Kent Kwoh
Courtney C. Kuza | Debbie Wilson
Weihsuan Jenny Lo-Ciganic (United States)

96 – Epilepsy: Trends in Real-World Treatment Patterns in the United States [427]
Lawrence Rasouliyan | Amanda G. Althoff | Vikas Kumar
Stacey Long | Mitesh B. Rao (United States)

97 – Impact of Risk Minimisation Measures on the Use of High-dose Cyproterone Acetate in France [428]
Anke Neumann | Pauline Dayani | Isabelle Yoldjian
Mahmoud Zureik | Sébastien Froelich | Alain Weill (France)

98 – Agreement on Drug Interactions from Two Drug Information System: An Analysis from a Population-based Survey in the Brazilian Amazon, 2019 [429]
Tais Freire Galvao | Tayanny Margarida M. Almeida Biase
Giulia Brunieri | Marcus Silva (Brazil)

99 – Implementation of a Living Lab Intervention in Family Medicine Groups to Improve Medication Use for Seniors with Neurocognitive Disorders [430]
Dylan Bonnan | Edeltraut Kröger | Anne Maheu
Lise Poisblaud | Laurianne Bélanger | Isabelle Vedel
Machelle Wilchesky | Yves Couturier | Nadia Sourial
Michèle Morin | Line Guénette (Canada)

100 – The Association of Patients’ Demographics with Glucose-lowering Drugs Prescription Among Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Observational Studies [431]
Fatema Mahmoud | Haya Yasin | Nouf Abutheraa
Amanj Kurdi (United Kingdom)

101 – Antibiotic Use During Pregnancy: A Swedish Drug Utilization Study from 2006 to 2019 [432]
Aya Nakitanda | Ingvild Odsbu | Pär Karlsson
Laura Pazzaglì (Sweden)

102 – Drug Utilization Pattern of Non-steroidal Anti-Inflammatory Drugs Among Pre-end-stage Renal Disease Patients in Taiwan [433]
Yu-Huan Shih | Ju-Ling Chen | Yu-Ching Chang
Chien-Huei Huang | Ching-Lan Cheng (Taiwan)

103 – Differences in the Use of Medications for Treated ADHD Patients Between Children and Adults from Real-World Data in Korea [434]
Yoon Cho | Hankil Lee (South Korea)

104 – Impact of Angiotensin-Receptor-Blocker (ARB) Recalls Due to Nitrosamine Contamination on ARB Utilization in Germany: A Multinational Study with a Common Protocol Led by FDA [435]
Chantal Quinten | Chantal Quinten | Xavier Kurz
Marie Bradley | Hana Lee | Efe Eworuke (Netherlands)

Raissa Carolina Fonseca Candido | Cristiane Aparecida A. Menezes De Pádua
Ana Paula Melo (Brazil)

106 – Impact of Regulatory Interventions on Ulipristal Acetate (Esmya) Use in Spain: An Interrupted Time-series Analysis [437]
Raquel Gutierrez Machín | Marta Monreal | Diana González
Belén Castillo | Consuelo Huerta | Alfonso Rodríguez
Dolores Montero (Spain)
HEALTH EQUITY

107 – Women’s Autonomy in Choosing Methods for HIV Prevention [438]
Raissa Carolina Fonseca Candido | Ana Carolina Mayrink
Cristiane Aparecida A. Menezes De Pádua (Brazil)

108 – Health Determinants and the Number of Deaths Caused by COVID-19 in Brazil Regions – An Ecological Analysis at the Initial Period of the Pandemic [439]
Raissa Carolina Fonseca Candido | Alicia Amanda M. Costa
Higor José Souza | Paula Drummond | Jéssica Malta
Cristiane Aparecida A. Menezes De Pádua (Brazil)

109 – Disparity Among Racial Groups for Tibial Fracture Treatments in a Medicaid Database [440]
Chantal Holy | Mari Vanderkarr | Jill Ruppenkamp
Mollie Vanderkarr | Anjani Parikh | Charisse Sparks
Paul Coplan | Toni M. Mclaurin (United States)

110 – Disparity Among Racial Groups for Humeral Fracture Treatments in a Medicaid Database [441]
Chantal Holy | Mari Vanderkarr | Jill Ruppenkamp
Mollie Vanderkarr | Anjani Parikh | Charisse Sparks
Paul Coplan | Toni M. Mclaurin (United States)

111 – Disparity Among Racial Groups for Femoral Fracture Treatments in a Medicaid Database [442]
Chantal Holy | Mari Vanderkarr | Jill Ruppenkamp
Mollie Vanderkarr | Anjani Parikh | Charisse Sparks
Paul Coplan | Toni M. Mclaurin (United States)

112 – Differences in Heart Failure Hospitalization Risk Following Initiating SGLT2 Inhibitors vs DPP4 Inhibitors Across Race/Ethnicity and Rural/Urban Areas [443]
Serena Jingchuan Guo | Yujia Li | Jiang Bian
Daniel T. Lackland | Stephen Kimmel | Desmond A. Schatz
Almut Winterstein (United States)

Xiaofeng Zhou | Ling Li | Rongjun Shen | Leo Russo
Oladayo Jagun (United States)

114 – Are Women with Rheumatoid Arthritis Really Less Likely to Achieve Remission with Biologics? A Cohort Study in the Swiss Clinical Quality Management Cohort [445]
Enriqueeta Vallejo-Yague | Julia N. Pfund | Theresa Burkard
Carole Clair | Raphael Micheroli | Burkhard Möller
Axel Finckh | Andrea Burden (Switzerland)

115 – Repurposing Metformin Among Older Adults with Alzheimer’s Disease and Other Dementias: Health Disparities and Equity Implications [446]
Kevin Lu | Xiaomo Xiong | Minghui Li (United States)

116 – A Survey Among Urban Community Pharmacists and Their Knowledge, Attitude and Practice Towards Travel-related Infectious Diseases [447]
Janga Monisha Reddy | Mahalekshmi M S | Mahima Murali
Lalmalsawmi Renthlei | Savitha Sanathan (India)

117 – Beta-Blockers in Atrial Fibrillation Patients with Heart Failure [448]
Zhen-Fang Lin (Taiwan)

Wenxi Huang | Inmaculada Hernandez | Shangbin Tang
Nico Gabriel | Nasser Sharareh | Nirmish Patel
Lucas A. Berenbrok | Sean Dickson
Serena Jingchuan Guo (United States)

119 – Applying Parkinson’s Disease (PD) Clinical Trial Eligibility Criteria to US Claims Data by Demographic Distribution [450]
Jeremy D. Furtado | Feiby L. Nassan | Henry Krzywy
Susan Eaton | Nicholas J. Everage | Nancy Maserejian (United States)
122 – Impact of Alzheimer’s Disease and Related Dementias on Colorectal Cancer Screening Utilization, Knowledge, and Associated Health Disparities [453]
Xiaoxia Wang | Gang Lv | Xiangxiang Jiang | Minghui Li | Kevin Lu (United States)

123 – Measuring Social Determinants of Health in Real-World Data: A Review of Pharmacoepidemiology Studies [454]
Leah Mcgrath | Amanda Miles | Andy Surinach | Deepa Malhotra (United States)

124 – COVID-19 and Breast Cancer Care in Ireland: A Survey Study to Investigate the Impact of the Pandemic on Breast Cancer Services [455]
Charlotte Myers | Kathleen E. Bennett | Caitriona Cahir (Ireland)

125 – Time-Dependent Risk of Major Dental Treatment Over 10 Years in Cancer Patients Compared to the General Population Using a National Claims Database [456]
Areum Han | Eun-Gee Park | Jeong-Hwa Yoon | Ji-Yeob Choi | Hee-Kyung Park | Seokyung Hahn (South Korea)

Office of the Chief Medical Officer
Global Epidemiology Organization
126 – Use of a Potential Outcomes Framework to Simulate Bias Due to Unidirectional Treatment Switching in Real-World Studies [457]
Imaani Easthausen | Elisha Beebe | Elizabeth M. Garry
David Lenis | Ulka Campbell | Nicolle Gatto (United States)

Nicole Tsao | Anil Mor | Venkatesh Harikrishnan
Sarah-Jo Sinnott (United States)

128 – The State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies [459]
Jeong-Eun Park | Zafar Zafari | Chintal H. Shah
Susan Dosreis | Emily F. Gorman | Wei Hua | Yong Ma
Fang Tian (United States)

129 – Validity of Adverse Clinical Outcomes in Routine Health Data for COVID-19 Vaccines and Therapies [460]
Belene Podmore | Nawab Qizilbash | Kirsty Andresen
Marina Hinojosa-Campos | Marianne Cunnington (Spain)

130 – Evaluation of a Cross-School, Student-led Reading Club on Facilitating Learning in Pharmacoepidemiology – Experience of the Tea & Crêpe Reading Club from Taiwan [461]
Hsiang-Te Tsai | Hsuan-Yu Su | Nai-Yu Chen | Chin-Yao Shen
Miyuki Hsing-Chun Hsieh | Yea-Huei Kao Yang
Edward Lai (Taiwan)

131 – Changes in Incidence and Characteristics of Juvenile Idiopathic Arthritis Diagnoses from ICD-9-CM to ICD-10-CM [462]
Lauren E. Parlett | Amanda Neikirk | Cecilia Huang
Stephen Crystal | Amy Davidow | Kevin Haynes
Tobias Gerhard | Carlos D. Rose | Brian L. Strom
Daniel B. Horton (United States)

132 – Accounting for Time Trends in Classification Parameters Using the Adaptive Validation Approach [463]
Katherine Lawson-Michod | Julie Barberio
Richard Maclehose | Thomas P. Ahern | Timothy Lash
Lindsay J. Collin (United States)

133 – Can Machine Learning Models Help Predict Potentially Inappropriate Medication Use in Older Adults? A Population-based Cohort Study [464]
Yohann M. Chiu | Barbara Roux | Marie-Eve Gagnon
Marc Simard | Denis Talbot | Caroline Sirois (Canada)

Astrid Coste | Angel Wong | Marleen Bokern | Andrew Bate
Ian Douglas (United Kingdom)

135 – Validation of an Algorithm to Identify Venous Thromboembolism (VTE) in Health Insurance Claims Data Among Patients with Rheumatoid Arthritis [466]
Sangmi Kim | Carolyn Martin | John C. White
Maureen H. Carlyle | Shiyao Gao | Claudia A. Salinas
Bonnie Bui (United States)

136 – Validation of an Algorithm for Unusual Site Thrombosis with Thrombocytopenia Syndrome (TTS) within Electronic Health Records (EHRs) [467]
Shayan Hobbi | Patrick Saunders-Hastings | Cindy Zhou
Patricia Lloyd | Nader Alawar | Taiyia Clarke | Lisa Kowarski
Jeffrey Beers | Ananth Srikrishnan | Timothy Burrell
Hui-Lee Wong | Steven Anderson (United States)

137 – Assessing the Robustness of COVID-19 Vaccine Effectiveness Studies to Bias [468]
Sophie Graham | Elise Tessier | Julia Stowe
Jamie Lopezbernal | Nick Andrews | Jemma Walker
Helen Mcdonald (United Kingdom)

138 – Comparing Study Designs in Case-crossover Studies of Chronic Medications Versus Acute Medications in a Systematic Review [469]
Hsiao-Ching Huang | Wen-Chin Li | Todd A. Lee

Helene Denis | Eleonore Herquelot | Nada Assi
Fanny Raguideau (France)

140 – Accuracy and Validity of Reported Opioid Prescription Days’ Supply [471]
Dustin K. Miracle | Sveta Slavova | John Brown
Nabarun Dasgupta | Sarah Harris | Patricia Freeman (United States)

141 – A Novel Method for Estimating Survival Parameters Under Conditionally Independent Left Truncation [472]
Arjun Sondhi (United States)
<table>
<thead>
<tr>
<th>Poster Session A</th>
</tr>
</thead>
</table>
| **142 – Diabetes and IBD: Utilization of High Dimensional Propensity Score Methods for Screening and Balancing Risk Factors Between Type 2 Diabetes and Non-diabetes Population in Risk of IBD Assessment** [473]  
Ling Zhang (United States) |
| **143 – Extending Treatment Effects from a Randomized Trial Using Observational Data** [474]  
Anthony Matthews | Issa J. Dahabreh | Ole Fröbert  
Bertil Lindahl | Stefan James | Maria Feychting  
Tomas Jernberg | Anita Berglund | Miguel A. Hernán (Sweden) |
| **144 – Validation of Diagnostic Codes to Identify Carbon Monoxide Poisoning in Taiwan’s Claim Data** [475]  
Shu-Chen Liao | Shih-Chieh Shao (Taiwan) |
| **145 – Co-Producing a Pharmacoepidemiology Online Knowledge Hub** [476]  
Annie Jeffery | Sophie Eastwood | Matthew Adesuyan (United Kingdom) |
| **146 – Validation of New Medication User Definitions in Single-specialty EHR Data** [477]  
Jeffrey Curtis | Yujie Su | Michael George | Cassie Clinton  
Patrick Stewart | Fenglong Xie (United States) |
| **147 – A Review of Algorithms Used to Identify People Who Use Nonmedical or Psychotropic Drugs in Electronic Healthcare Records and Claims Data** [478]  
Mary C. Figgatt | Asher J. Schranz | Juan Hincapie-Castillo  
Yvonne M. Golighty | Stephen Marshall | Nabarun Dasgupta (United States) |
| **148 – The Effect of Continuous Use of Antidepressants, with or without Anticholinergic Properties, for At Least 4 Months Versus No Treatment on the Incidence of Dementia: A Target Trial Emulation** [479]  
Joan Forns | Jaume Aguado | Elena Rivero-Ferrer  
Estel Plana | Barbra A. Dickerman  
Xabier Garcia De Albeniz (Spain) |
| **149 – Inverse Probability Treatment Weighting Versus Propensity Score Matching in the Sentinel System: A Test Case** [480]  
Marie Bradley | Talia Menzin | Joy Kolonoski | Mayura Shinde  
Rongmei Zhang | Efe Eworuke | David Graham | Laura Hou  
Adebola Ajao | Po-Yin Chang | John Connolly (United States) |
| **150 – Association of Benzodiazepines, Z-Drugs, Pregabalin and Melatonin with Traffic Accidents** [481]  
Merete Osler | Martin Balslev Jørgensen (Denmark) |
| **151 – Validation of Medical Code Lists for Defining Mental Health Conditions with Primary Care Data: A Mixed Qualitative and Quantitative Study** [482]  
Juan Carlos Jc Bazo Alvarez | Christina Avgerinou  
Danielle Nimmons | Joseph F. F. Hayes | Claudia Cooper  
David Osborn | Irene Petersen | Kate Walters (United Kingdom) |
| **152 – Representativeness of the PHARMO Electronic Health Records (EHRs) from Primary Care** [483]  
Jetty Overbeek | Eline Houben | Karin Swart  
Fernie J. Penning-Van Beest | Ron Herings (Netherlands) |
| **153 – Data Source Heterogeneity in Multi-data Base Pharmacoepidemiologic Studies: An ISPE-sponsored Scoping Review** [484]  
Rosa Gini | Romin Pajouheshnia | Gillian Hall | Robert Platt  
Soko Setoguchi | Marloes Bazelier | Sigal Kaplan  
Xiaofeng Zhou | Stephan Lanes | Kenneth Man | Lin Li  
Mehmet Burcu | Giuseppe Roberto | Caitlin Dodd  
Carlos Duran | Angelika Wentzek-Fleischmann  
Kanaka Soman | Edward Lai | Karine Marinier  
Dimitri BennettHelga Gardarsdottir (Italy) |
| **154 – Identifying Hospitalizations in Patients with Medicare Supplemental Insurance** [485]  
Virginia Pate | Jessica Young | Jennifer Lund | Til Stürmer  
Michele Jonsson Funk (United States) |
| **155 – Discharged Where? The Importance of Understanding Discharge Dispositions When Estimating In-hospital Mortality** [486]  
M. Alan Brookhart | Catherine Wiener | Alexander Breskin (United States) |
| **157 – Addressing Residual Confounding Using Propensity Score Matching Versus Cardinality Matching** [488]  
Stephen Fortin | Martijn Schuemie (United States) |
| **158 – The Autopsy of a Failed Instrumental Variable: Plasmode Simulation as a Tool to Assess Unconfoundedness of an IV** [489]  
Albert Prats-Uribe | Daniel Prieto-Alhambra  
Victoria Y. Strauss (United Kingdom) |
159 – Development and Application of a Claims-based Frailty Index (CFI): A Systemic Review [490]
Shu Ping Huang (Taiwan)

160 – Optimizing Clinicaltrials.gov as a Tool to Evaluate the Potential of Real World (RW) Data Sources for Use as External Comparator Arms [491]
Danielle Chun | John Garrity | David Tabacco
Emily Brouwer (United States)

161 – Opportunities and Challenges for Decentralized Clinical Trials: The European Regulators’ Perspective [492]
Amos De Jong | Tessa Van Rijssel | Yared Santa-Ana-Tellez
Mira Zuidgeest | Scott Askin | Ghislaine Van Thiel
Jaime Fons-Martinez | Tim De Smedt | Anthonius De Boer
Helga Gardarsdottir (Netherlands)

162 – Evaluation of the Case-Time-Control Design to Examine the Association between Anticancer Drug Use and Acute Kidney Injury [493]
Philip Munch | Simon Jensen | Uffe Heide-Jørgensen
Mette Nørgaard | Henrik Birn
Christian Christiansen (Denmark)

AETION.

Real world evidence for real world change

Real change takes confidence. Aetion transforms real world data into the vital, impactful insights and evidence you need to make the decisions that will change health care.

• Ground-breaking technology
• Industry-leading scientific expertise
• Standard-setting data optimization

Visit us at Booth 305 to start a conversation about the ways you want to drive change.

aetion.com | sales@aetion.com
**Molecular Epidemiology/ Biomarkers/ Pharmacogenetics**

163 – Colorectal Cancer Cohort Comparison Among Four Real-World Databases [494]
Wei Zhou | Ching-Yu Wang | Changxia Shao
Alicia Mcdonald | Edward A. Bortnichak | Xinyue Liu
(United States)

164 – Genetic Polymorphisms of CYP2C19 Gene, Clopidogrel Use, and Risk of Mortality: The Rotterdam Study [495]
Negin Soroush | Mkamran Ikram | Bruno H. Stricker
Fariba Ahmadizar (Netherlands)

165 – In-Silico Determination of Therapeutic Possibilities for Contact Eczema: A Gene Database Linked Analysis [496]
Neha Maria Thomas (India)

166 – Drug Interactions with Tamoxifen in a Danish Premenopausal Breast Cancer Cohort [497]
Kirsten M. Woolpert | Lindsay J. Collin | Thomas P. Ahern
Per Damkier | Anders Kjærsgaard | Henrik Toft Sørensen
Stephen Hamilton-Dutoit | Bent Ejertsen
Peer Christiansen | Rebecca Silliman | Timothy Lash
Deirdre Cronin-Fenton (Denmark)

**Pharmacovigilance**

167 – Community Pharmacists-Reported Barriers and Facilitators for Adverse Drug Reaction Reporting: Findings of a Focus Group Study [498]
Atiqulla Shariff | Srikanth Malavalli Siddalingegowda
Aishwarya Mahesh Kumar Padmini | Hariss Mohanram
Sidharth Soman (India)

169 – Post-Marketing Safety Profile of Cannabis Products: Signals from the FDA Adverse Event Reporting System [500]
Valentina Giunchi | Michele Fusaroli | Carlotta Lunghi
Arsène Zongo | Emanuel Raschi | Elisabetta Poluzzi (Italy)

170 – Pulmonary Related Adverse Events Associated with Bruton’s Tyrosine Kinase Inhibitor: A Disproportionality Analysis in a Spontaneous Reporting Database [501]
Subeesh Kulangara Viswam | Amrutha Shettigar
Zeba Zeba | Ashwin Dhas | Aarushi Kheterpal
Gursimran Kaur | Lipin Lukose (India)

171 – Unintended Impact of Medicines Regulatory Interventions: A Systematic Review Focusing on Data and Methods [502]
Tomas Lasys | Yared Santa-Ana-Tellez | Satu Siiskonen
Rolf H Groenwold | Helga Gardarsdottir (Netherlands)

172 – Pembrolizumab and the Potential Risk of Cholestasis: A Review of Pharmacovigilance Data [503]
Abdulaziz Nasser Alakeel | Roaa M. Alamri
Abdulrahman Almutairi | Mohammed Fouda (Saudi Arabia)

173 – Teriparatide and Potential Risk of Multiple Myeloma [504]
Waad Altayyar | Hadir Aljohani | Nouf Alfadel
Fawaz F. Alharbi (Saudi Arabia)

174 – Establishment and Validation of Automatic Monitoring Module for Drug-induced Arrhythmia Based on Hospital Information System Data [505]
Haili Guo | Daihong Guo | Ao Gao | Bo Zhang
Boy Li | Jiaxi Wang (China)

175 – Distinguishing Patterns Associated with Statin-Related Myopathy Using Korea Adverse Event Reporting System Database: Unsupervised Machine Learning Methods [506]
Jeong-Yeon Kim | Sewon Park | Min Taek Lee
Sun-Young Jung (South Korea)

176 – A National Viewpoint of Community Pharmacists of Pharmacovigilance and Adverse Drug Reaction Reporting in Saudi Arabia [507]
Moudi M. Alasmari | Mona Y. Alsheikh (Saudi Arabia)

177 – Post-Marketing Safety Profile of Pethidine in Indonesia [508]
Jonathan Hasian Haposan | Jarir At Thobari
Muhammad Nurwahidin | Lukman Ade Chandra
Nastia Hidayati | Rianiisa Karunia Dewi
Dyah Juliana Pudjiati (Indonesia)
<table>
<thead>
<tr>
<th>Poster Session A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>178</strong> – Drugs-Associated with Red Man Syndrome: An Integrative Approach Using Disproportionality Analysis and PHARMIP [509]</td>
</tr>
<tr>
<td>Aina Shaju</td>
</tr>
<tr>
<td>V. Lakshmi Prasanna Marise</td>
</tr>
<tr>
<td>Subeesh Kulangara Viswam (India)</td>
</tr>
<tr>
<td><strong>179</strong> – Descriptive Analysis of Disproportionate Medication Errors and Associated Patient-Characteristics in the Food and Drug Administration's Adverse Event Reporting System [510]</td>
</tr>
<tr>
<td>Victor Pera</td>
</tr>
<tr>
<td>Johan Van Der Lei</td>
</tr>
<tr>
<td>Erik Van Mulligen</td>
</tr>
<tr>
<td>Katia M. Verhamme (Netherlands)</td>
</tr>
<tr>
<td><strong>180</strong> – Sex Differences in the Number and Type of Adverse Drug Reactions Reported for Common Cardiovascular Medications in a Cardiac Outpatient Population [511]</td>
</tr>
<tr>
<td>Sophie Bots</td>
</tr>
<tr>
<td>Igor I. Tulevski</td>
</tr>
<tr>
<td>Hester M. Den Ruijter (Netherlands)</td>
</tr>
<tr>
<td><strong>181</strong> – Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb [512]</td>
</tr>
<tr>
<td>Florence Van Hunsel</td>
</tr>
<tr>
<td>Eugene Van Puilenbroek (Netherlands)</td>
</tr>
<tr>
<td><strong>182</strong> – Impact of the COVID-19 Pandemic on Drug Safety Surveillance: An Analysis of the Canadian Spontaneous Reporting Database [513]</td>
</tr>
<tr>
<td>Yola Moride</td>
</tr>
<tr>
<td>Anne-Marie Castilloux (Canada)</td>
</tr>
<tr>
<td><strong>183</strong> – An Examination of How Serious Infection are Reported in Spontaneous Reports [514]</td>
</tr>
<tr>
<td>Gregory Powell</td>
</tr>
<tr>
<td>Tayisr Chamem</td>
</tr>
<tr>
<td>Andrew Bate (United States)</td>
</tr>
<tr>
<td><strong>184</strong> – Lopinavir Induced Hypospadias: New Signal Detection for Lopinavir by Disproportionality Analysis Using USFDA Database [515]</td>
</tr>
<tr>
<td>Eswaran Maheswari</td>
</tr>
<tr>
<td>Khushboo Kumari</td>
</tr>
<tr>
<td><strong>185</strong> – Risk of Ischemic Stroke Among a Nationwide Cohort of Patients Receiving Antipsychotics: Role of A1-Adrenergic and 5-HT1A Antagonism [516]</td>
</tr>
<tr>
<td>Francois Montastruc</td>
</tr>
<tr>
<td>Etienne Very</td>
</tr>
<tr>
<td>Antoine Yrondi</td>
</tr>
<tr>
<td><strong>186</strong> – Medication Errors Among Patients Admitted with Cardiovascular Disorders at the Critical Care Unit of a National Referral Hospital in Kenya [517]</td>
</tr>
<tr>
<td>Sylvia Atisa Oponga</td>
</tr>
<tr>
<td><strong>187</strong> – Comparative Study of Osteonecrosis of the Jaw with Bisphosphonates and Denosumab in Two Pharmacovigilance Database [518]</td>
</tr>
<tr>
<td>Thierry Trenque</td>
</tr>
<tr>
<td>Federica Tralongo</td>
</tr>
<tr>
<td><strong>188</strong> – How Has Machine Learning Been Used in Patient Safety? [519]</td>
</tr>
<tr>
<td>Priyanka Yalamanchili</td>
</tr>
<tr>
<td>Omar Aimer</td>
</tr>
<tr>
<td>Toluwalope Junaid</td>
</tr>
<tr>
<td><strong>189</strong> – Appendicitis Associated with Pemrolizumab Use: Adverse Events – Signal Review [520]</td>
</tr>
<tr>
<td>Abdulrahman Almutairi</td>
</tr>
<tr>
<td><strong>190</strong> – Pancreatic Carcinoma Associated with Liraglutide Use: Adverse Events – Signal Review [521]</td>
</tr>
<tr>
<td>Abdulrahman Almutairi</td>
</tr>
<tr>
<td>Robert Philip Wise</td>
</tr>
<tr>
<td><strong>192</strong> – Conducting Observational Multi-Country Studies for Regulatory Decision Making During COVID-19 Pandemic: The Strategic Role of the Scientific Project Manager [523]</td>
</tr>
<tr>
<td>Natasha Yefimenko</td>
</tr>
<tr>
<td>Gianmarco Di Mauro</td>
</tr>
<tr>
<td><strong>193</strong> – Screening and Monitoring Testing of HIV Pre-Exposure Prophylaxis Use Among Commercially Insured Patients, 2016-2019 [524]</td>
</tr>
<tr>
<td>Ikenna Unigwe</td>
</tr>
<tr>
<td>Haesuk Park (United States)</td>
</tr>
</tbody>
</table>
Poster Session A

194 – Optic Neuritis Associated with PD-1/PD-L1 Checkpoint Inhibitors: Case Series Utilizing the WHO Global Database of Individual Case Safety Reports (ICSRs) [525]
Maha Alghamdi | Nouf Alfadel
Fawaz F. Alharbi (Saudi Arabia)

195 – Exposure to Integrase-inhibitor Antiretroviral Drugs During Pregnancy and Congenital Abnormalities: A Case/Non-case Study from the International Pharmacovigilance Database Vigibase® [526]
Anna-Belle Beau | Agnès Sommet | Laura Saint-Lary
Isabelle Lacroix | Valériane Leroy (France)

PREGNANCY AND LACTATION

196 – Social Vulnerability and Initiation of Pharmacotherapy for Gestational Diabetes in a Medicaid Population [527]
Sarah Osmundson | Amelie Pham | Andrew Wiese
Andrew Spieker | Kayla Johnson | Sharon Phillips
Margaret Adgent | Carlos Grijalva (United States)

197 – Association Between Morning Sickness and Having a Girl – Myth or Fact? [528]
Lars J. Kjerpeseth | Kari Furu | Jacqueline Cohen (Norway)

198 – Extracting Pregnancies from Heterogeneous Data Sources in Europe: A Novel Algorithm in the Conception Project [529]
Giorgio Limoncella | Claudia C. Bartolini | Carlos Duran
Anna Girardi | Giulia Hyeraci | Judit Riera Arnau
Ana Llorente | Lucía Cea Soriano | Mar Martin-Perez
Patricia García-Poza | Francisco Sanchez-Saez
Gabriel Sanfelix-Gimeno | Hedvig Nordeng | Eimir Hurley
Luigi A. Maglanoc | Emily Holthuis | Karin Swart
Valentina lentiile | Matilde Tanaglia | Jeremy BrownKevin Wing
Tania Schink | Romin Pajouheshnia | Marianne Cunnington
Miriam Sturkenboom | Rosa Gini (Italy)

199 – Association Between Antidepressant Use Patterns on the Long-term Trajectories of Depressive and Anxiety Symptoms and Health-related Quality of Life [530]
Nhung Trinh | Flavie Perrier | Hedvig Nordeng
Angela Lupattelli (Norway)

200 – Postpartum Episode of Eating, Mood, or Anxiety Disorder in Women with Eating Disorders Who Continue or Discontinue Antidepressant Treatment in Pregnancy [531]
Nhung Trinh | Birgitte Dige Semark | Trine Munk-Olsen
Xiaojin Liu | Øyvind Ro | Cynthia Bulik | Leila Torgersen
Angela Lupattelli | Liselotte Vogdrup Petersen (Norway)

201 – Frequent Drug Exposures During Pregnancy: A Population-based Cohort Study with SIDIAP Database [532]
Maria Giner-Soriano | Marta Lestón Vázquez
Ainhoa G. Gomez-Lumbreras | Oriol Prat-Vallverdu
Carles Vilaplana-Carnerero | Rosa Morros
Cristina Vedia (Spain)

202 – Spontaneous Abortion and Drug Exposure. Case-control Study with SIDIAP Database [533]
Maria Giner-Soriano | Oriol Prat-Vallverdu
Marta Lestón Vázquez | Carles Vilaplana-Carnerero
Cristina Vedia | Ainhoa G. Gomez-Lumbreras
Rosa Morros (Spain)

203 – Recording of Chronic Diseases and Adverse Obstetric Outcomes During Hospitalizations for a Delivery in the National Swiss Hospital Medical Statistics Dataset Between 2012 and 2018: An Observational Cross-Sectional Study [534]
Carole Anna Marxer | Marlene Rauch | Clementina Lang
Alice Panchaud | Christoph Meier
Julia Spoendlin (Switzerland)

204 – Risk of Gestational Hypertension in Women Treated with Serotonin and Norepinephrine Reuptake Inhibitors: A Comparative Study in the EFEMERIS Database [535]
Isabelle Lacroix | Mélanie Araujo | Julie Waser
Caroline Hurault-Delarue | Christine Damase-Michel (France)

205 – Proton Pump Inhibitors Use During Pregnancy and Risk of Congenital Malformations: A Nationwide Cohort Study of 2.7 million Pregnancies [536]
Ahhyung Choi | Yunha Noh | Han Eol Jeong
Eun-Young Choi | Dong Keon Yon | Ju-Young Shin (South Korea)
206 – Use of Antiepileptic Drugs During Pregnancy and Neonatal Birth Weight Outcomes: A Systematic Review and Meta-Analysis [537]
Alekhya Lavu | Christine Vaccaro | Enav Zusman
Laila Nabil Mahmoud Helmy Aboulatta | Basma Aloud
Rasheda Rabbani | Payam Peyman | Walid Shouman
Silvia Alessi-Severini | Sherif Eltonsy (Canada)

207 – Prescription of Asthma-Control Medications Dispensed During Pregnancy in Belgium: The Trends Between 2003 and 2018 Using a Medico-administrative Database [538]
Lionel Larcin | Güngör Karakaya | Philippe Van Wilder
Christine Damase-Michel | Fati Kirakoya (Belgium)

208 – Neonatal and Maternal Adverse Outcomes Following Use of Buprenorphine and Methadone for Treatment of Opioid Use Disorder in Pregnancy [539]
Elizabeth Suarez | Krista Huybrechts | Loreen Straub
Sonia Hernandez-Diaz | Hendree Jones | Hilary Connery
Jonathan Davis | Kathryn Gray | Barry Lester
Mishka Terplan | Helen Mogun | Brian Baterman (United States)

209 – Evaluating Awareness of Pregnancy Exposure Registries Among Women [540]
Kristin Veley | Courtney G. Norris | Jennifer McCall, PhD (United States)

210 – Demographic Representativeness of Participants in Pregnancy Registries [541]
Kristin Veley | Katheryne Downes, PhD, MPH
Rebecca Morris Buus, PhD | Payal Pozin
Lindsey Wilson, MPH | Sandra Okala, PhD (United States)

211 – The Risk of SARS-CoV-2 Infection in Pregnant Women. An Observational Cohort Study Using BIFAP Database [542]
Airam De Burgos Gonzalez | Mercedes Mota Pérez
Ana Llorente | Consuelo Huerta | Lucía Cea Soriano (Spain)

212 – Associations Between Late-onset Preeclampsia and The Use of Calcium-based Antacids and Proton Pump Inhibitors During Pregnancy: A Prospective Cohort Study [543]
Marleen Van Gelder | Pim Beekers | Eugene Van Puijenbroek
Joris Van Drongelen | Niel Roeleveld | Luc Jm Smits (Netherlands)

213 – Use of Isotretinoin Among Girls and Women of Childbearing Age and Exposure During Pregnancy [544]
Jonas Reinold | Bianca Kollhorst | Ulrike Haug (Germany)

214 – Decisional Conflicts About Antidepressant Treatment in Pregnant Women in Norway [545]
Angela Lupattelli | Lana Jalal Shabat
Fatima Tauqueer (Norway)

215 – Prenatal Exposure to Antidepressants and Risk of Overweight and Obesity in Offspring at Age 8 Years [546]
Angela Lupattelli | Michele Pedroncelli | Sina Rostami Nhung Trinh (Norway)

John E. Hughes | Niamh Buckley | Yvonne Looney
Gráinne Kirwan | Maeve Mullooly
Kathleen E. Bennett (Ireland)

217 – Most Common Diagnoses During Pregnancy in a Commercially Insured Population of Women [548]
Rachel Ogilvie | Katherine C. Hughes | Stephen M. Ezzy
Michael C. Doherty | Monica Bertoia | John Seeger (United States)

218 – Drug Utilization Among Hospitalized Pregnant Women with Severe COVID-19 Disease and Assessment of the Safety Profile [549]
Yesenia Rodriguez | Anaís Lazarte | Raquel Delgado (Peru)

219 – Exposure to Non-Insulin 2nd-line Antidiabetic Medications in Early Pregnancy and Risk of Major Congenital Malformations [550]
Carolyn Cesta | Ran Rotem | Krista Huybrechts
Brian Baterman | Gabriel Chodick | Ellen W. Seely
Elisabetta Patorno | Sonia Hernandez-Diaz (Sweden)

Jennita Reehuis | Elizabeth Ailes | Weiming Zhu
Elizabeth Clark | Ya-Lin Huang | Margaret Lampe
Athena Kourtis | Karen Hoover (United States)

221 – Linking Male Parents to Pregnancies and Infants in a Health Insurance Claims Database [552]
Monica Bertoia | Claire Pernar | Michael C. Doherty
John Seeger (United States)
Poster Session A

222 – Identification of Preterm Birth in an Administrative Claims Database Using Maternal Claims, Infant Claims, and Gestational Age
Andrea K. Chomistek | Michael C. Doherty | Robert Gately
Monica Bertoia | Katherine C. Hughes | Florence Wang
John Seeger (United States)

223 – Prenatal Opioid Exposure and Well-child Care in the First 2 Years of Life – A Population-based Cohort Study
Andi Camden | Teresa To | Joel G. Ray | Tara Gomes
Li Bai | Astrid Guttmann (Canada)

224 – Validity of Healthcare Administrative Data to Identify Infants with Low Birth Weight
Loreen Straub | Brian Bateman | Yanmin Zhu
Sonia Hernandez-Diaz | Seanna Vine | Krista Huybrechts (United States)

225 – Medication Use Among Lactating Persons: An Electronic Health Record (EHR)-based Approach
Kristin Palmsten | Gabriela Vazquez-Benitez
Meghan M. Jaka | Bandoli Gretchen | Katherine A. Ahrens
Elyse Kharbanda (United States)

226 – Use of Rivaroxaban During Pregnancy and Description of Pregnancy Outcomes
Tania Schink | Nadine Wentzell | Annemarie Voss
Bianca Kollhorst | Ulrike Haug (Germany)

227 – Treatment with Tumor Necrosis Factor Alpha Inhibitors During Pregnancy and Occurrence of Severe Infections Among Infants: A Descriptive Analysis Based on German Claims Data
Ulrike Haug | Christina Princk | Bianca Kollhorst
Kathrin Thöne | Julia Borst-Ohlraun | Christof Schaefer,
Marlies Onken | Katarina Dathe (Germany)

Optum

Let’s work together to catalyze innovation, insight and impact that truly transform care.

Our trusted, robust real-world data and experienced consultants connect the dots in ways that:

- Answer tough questions
- Illuminate new possibilities
- Improve patients’ lives

Visit booth #106 to meet our world-renowned experts, including Dr. John Seeger
228 – Characteristics of Linked and Unlinked Mother-infant in the Healthcare Integrated Research Database [559]
Aziza Jamal-Allial | Maria Guzman | Christopher L. Crowe
Kerrin Gallagher | Brett Doherty | Sarah Hoffman
Ramya Avula | Geetika Kalloo | Biruk Eshete (United States)

Sarah Hoffman | Christopher L. Crowe | Maria Guzman
Brett Doherty | Kerrin Gallagher | Aziza Jamal-Allial
Geetika Kalloo (United States)

230 – Design Considerations for Using the Tree-based Scan Statistic in Surveillance of Maternal Outcomes Following Medication Use During Pregnancy [561]
Thuy Thai | Almut Winterstein | Elizabeth Suarez
Daniejla Stojanovic | Jane Liedtka | Abby F. Anderson
Di Zhang | Yueqin Zhao | Monica Munoz
Wei Liu
Inna Dashlevsky | Talia Menzin | Elizabeth Messenger-Jones
Elizabeth Siranosian | Judith Maro (United States)

231 – Distribution of Gestational Age by Maternal and Infant Characteristics in US Birth Certificate Data: Toward Informing Gestational Age Assumptions When Clinical Estimates are Not Available [562]
Andrea Margulis | Brian Calingaert | Alison Tse Kawa
Elena Rivero-Ferrer | Mary Anthony (Spain)

Sascha Dublin | Paige D. Wartko | Umesh Singh
Anna Howe | Susan Shortreed | Stephanie D'souza
Sharon Fuller | Rita M. Mangione-Smith (United States)

Odette De Bruin | Hilde Engjom | Nicola Vousden
Marian Knight | Serena Donati | Miriam Sturkenboom
Kitty Wm Bloemenkamp (Netherlands)

Laura A. Yochum | Katherine C. Hughes | Michael Miller
Michael C. Doherty | Ritika Pandey | Robert Gately
Monica Bertoia (United States)

235 – Dilemma of Belimumab Therapy (Dis) Continuation During Pregnancy: Results of a Retrospective Study in EudraVigilance [566]
Nafise Ghalandari | Hubertina Johanna Maria Josephina Crijns
Radboud Dolhain | Mieke Hazes | Eugene Van Puijenbroek (Netherlands)

236 – Reported Congenital Malformations After Exposure to Non-TNF-A Inhibitors: A Retrospective Comparative Study in EudraVigilance Database [567]
Nafise Ghalandari | Hubertina Johanna Maria Josephina Crijns
Jorieke Bergman | Radboud Dolhain
Eugene Van Puijenbroek | Mieke Hazes (Netherlands)

237 – A Landscape Analysis of Post-marketing Studies Registered in EU PAS Register and Clinicaltrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project [568]
Leonardo Lrp Roque Pereira | Carlos Duran
Deborah Layton | Georgios Poulentzas
Panagiotis Nikolaos Lalagkas | Christos Kontogiorgis
Miriam Sturkenboom (United Kingdom)

238 – Uses of Antiepileptic Drugs Among Pregnant Women with Epilepsy and Risk of Adverse Obstetric Outcomes; A Group-based Trajectory Analysis [569]
Yi-Chin Lin | Chih-Wan Lin | Shih-Tsung Huang
Fei-Yuan Hsiao (Taiwan)

239 – Maternal and Infant Morbidity in Relation to Caesarean Section in a Large Commercially Insured Population in the US in 2019 and 2020 [570]
Brett Doherty | Stephanie A. Lynch | Aneesh Naavaal
Chrisssie Li | Kimberly Cole | Leslie Macphee
Leslie Banning | Anup Sharma | Michael Grabner
Eric Stanek | Tiffany Inglis (United States)

240 – Congenital Malformations Among Offspring of Women with Type 1 Diabetes Using Insulin Pump: A Prospective Cohort Study [571]
Ida H. Thorius, Lise Lotte N Husemoen | Rikke B. Nordsborg
Amra C. Alibegovic | Mari-Anne Gall | Janne Petersen
Elisabeth Mathiesen (Denmark)

241 – Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis of Pharmacoepidemiological Studies [572]
Mohammad Salman Hussain | Ambrish Singh | Benny Antony
Jitka Klugarova | M. Hassan Murad | Aarthi S. Jayraj
Alena Langaufová | Miloslav Klugar (Czech Republic)
242 – Levothyroxine Use and the Risk of Pregnancy Loss Among Pregnant Women with Subclinical Hypothyroidism: An Observational Study Emulating a Target Trial [573]
Sonia M. Grandi | Ya-Hui Yu | Pauline Reynier | Robert Platt
Oriana Ho Yun Yu | Kristian Filion (Canada)

243 – Antidepressant Use Patterns During Pregnancy and Birth Outcomes Among Pre-conception Antidepressant Users [574]
Lyndsay Avalos | Nerissa Nance | Sylvia E Badon
Kathryn Ridout | Jennifer Ahern | Dekun Li
Charles Quesenberry (United States)

244 – Neonatal and Maternal Outcomes Following Exposure to Non-steroidal Anti-Inflammatory Drugs During Early Pregnancy: A Nationwide Cohort Study [575]
Eun-Young Choi | Han Eol Jeong | Yunha Noh
Ahhyung Choi | Dong Keon Yon | Ju-Young Shin (South Korea)

245 – Characterization of Pregnancy Data Reported by Health Care Professionals Versus Patients in International Case Safety Reports – A ConcePTION Study [576]
Yrea Van Rijt-Weetink | David Lewis | Laura Yates
Eugene Van Puijenbroek (Netherlands)

Sara A. Ephross | Jessica D. Albano | Nicole Carneal-Frazer
Charles Coombs (United States)

247 – Adverse Fetal Outcomes Associated with Gabapentin Use in Pregnancy: A Population-based Cohort Study and Meta-Analysis [578]
Brianne Desrochers | Aekhya LaVu | Eunice Valencia
Christine Vaccar | Sherif Eltonsy (Canada)

248 – Adverse Birth Outcomes Associated with Drug Use in Pregnancy at a Referral Teaching Hospital in Kenya [579]
Nelly Muthee | Margaret N. Oluka | Faith A. Okalebo
(United States)

249 – Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and the Risk of Child’s Neurodevelopmental Disorders [580]
Guy Amit | Chen Yanover | Maytal Bivas-Benita
Irena Girshovitz | Pinchas Akiva | Tal Helbitz
Vered Bar (Israel)

Geetika Kalloo | Maria Guzman | Christopher L. Crowe
Brett Doherty | Kerrin Gallagher | Aziza Jamal-Allial
Sarah Hoffman (United States)

251 – Utilization of Biologics Before, During and After Pregnancy Among Patients with Autoimmune Conditions [582]
Celeste Ewig | Nicole Smolinski | Yanning Wang
Thuy Thai | Amir Sarayani | Sebastian Jugl
Sonja Rasmussen | Almut Winterstein (United States)

252 – Sarcoidosis in Patients After Solid Organ Transplantation Treated with mTOR Inhibitors Versus Calcineurin Inhibitors [583]
Emese K. Vágó | Matthew C. Baker | Suzanne Tamang
Henrik Toft Sørensen | Erzsebet Horvath-Puho (Denmark)

Flemming Axelsen | Katharina Buesch | Rongrong Zhang
Kasia Szczepanska | Gregory Fuest | Alexis Russell (Denmark)

254 – Epidemiology of Palmpoplantar Pustulosis in Urban China and a Systematic Review [585]
Jingnan Feng | Qian Zhang | Jinzhu Guo | Lin Zhuo
Shengfeng Wang | Wenhui Wang | Siyan Zhan (China)

255 – Survival Benefit of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria [586]
Ami Patel | Jesse Metzger | Louis Terriou
Christopher Patriquin | Morag Griffin | Jong Wook Lee
Philippe Gustovic | Wei Jiang | Jeff Szer (United States)

256 – Treatment Patterns for Depression and Anxiety Among Patients with Progressive Supranuclear Palsy (PSP) [587]
Sara J. Snell Taylor | Jessica Shurer | Kristophe Diaz
Nelson Pace (United States)

257 – Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Literature Review [588]
Anne Broe | Katharina Buesch | Nermina Ferizovic
Erik Landfeldt (Denmark)
258 – Prevalence of Postural Orthostatic Tachycardia Syndrome (POTS) in the US [589]
Jessica Jalbert | Dana Murdock | Ying Li | Ethan Marin
Scott Mellis | Mohamed Hussein (United States)

259 – Marketing Authorisation Pathways and Clinical Evidence Supporting Approval of Orphan Medicinal Products in EU Between January 2015 and October 2021 [590]
Christine Hallgreen | Mathias Møllebæk
Ertugrul Corap (Denmark)

260 – The Development of a Conceptual Model to Describe the Health-related Quality of Life Impacts of Living with Friedreich Ataxia [591]
Christina Qian | Katharina Buesch | Andrea Bever
Jessica Dunne | Shelagh Szabo (Canada)

261 – Outcome Measures Relevant for Assessing Health Related Quality of Life and Utility in Friedreich Ataxia [592]
Christina Qian | Katharina Buesch | Tina Li | Andrea Bever
Jessica Dunne | Shelagh Szabo (Canada)

262 – Frequency of Sleep Disorders and Insomnia in Patients with Wilson Disease Identified in Electronic Health Records [593]
Mary Dozier | Elissa H. Wilker | Jawad Hasan | Shona Fang (United States)

263 – Clinical Evaluation of Code-based Algorithms to Identify Pulmonary Arterial Hypertension Patients in Coded Healthcare Databases [594]
Eva-Maria Didden | Di Lu | Andrew Hsi | Haley Hedlin
Monika Brand | Roham T. Zamanian (Switzerland)

264 – A Non-interventional Study Using Multiple Data Sources to Evaluate Potential Sight Threatening Events and Severe Visual Loss Among Patients Exposed to Crizotinib [595]
Kui Huang | Jingping Mo | Elizabeth Kim
Jayeta Chakrabarti | Keith Wilner | Cynthia De Luise
Patrick J. Arena (United States)

Matthew P. Gray | Sandra Kane-Gill (United States)

266 – The Effect of Antibiotics Prescription and Length of Hospitalization on Mortality in Patients with Sepsis [597]
Onyinye O. Akunne | Aduragbenro D. Adeedapo (South Africa)

267 – Effect of Cardiovascular Disease and Diuretic Use on Amputation Risk with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes [598]
Sohee Park | Han Eol Jeong | Sungho Bea
Oriana Hoi Yun Yu | Ju-Young Shin (Republic of Korea)

268 – Is Statin Use Associated with an Increased Risk of Adrenal Insufficiency? A Nested Matched Case-control Study [599]
Julien Bezin | Sandy Maumus-Robert | Ana Jarne-Munoz
Antoine Pariente | Thomas Duroux | Lise Duranteau (France)

269 – Risk of Suicidal Behavior Associated with Benzodiazepines: A Nationwide Case-crossover Study [600]
Julien Bezin | Marie Tournier | Anne Bénard-Laribièreme
Fabrice Jollant | Emilie Hucteau | Papa-Youma Diop
Antoine Pariente | Emmanuel Oger (France)

270 – Real-World Safety of Factor Xa Inhibitors and Warfarin in Obese and Morbidly Obese Nonvalvular Atrial Fibrillation (NVAF) Patients Using a University Health Center Electronic Medical Record Database in the United States [601]
Mohammed Alsultan | Ana L. Hincapie | Patricia Wige
Diego F. Cuadros | Alex C. Lin | Jeff J. Guo (United States)

271 – Comparative Safety of Beta-Blocker and Calcium Channel Blockers in Patients with Chronic Obstructive Pulmonary Disease and Atrial Fibrillation: A National Population Cohort Study in Taiwan [602]
Shan-Ju Lin | Nai-Yu Chen | Yu-Ching Chang
Ching-Lan Cheng (Taiwan)
Dana Alsugeir | Matthew Adesuyan | Basma Alfageh
Li Wei | Ruth Brauer (United Kingdom)

273 – Risk of Clostridium Difficile Infection Associated with Use of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in Taiwan Hospitalized Patients [604]
Yi Hsuan Liu | Yea-Huei Kao Yang | Lu Hsuan Wu
Chien-Chou Su (Taiwan)

274 – A Study of Statins and the Risk of Venous Thromboembolism [605]
Lade Ayodele | Susan Jick | David Mcmanus
Howard J. Cabral (United States)

275 – Evaluation of a Web-based Application Monitoring Thiopurine Therapy in the Veterans Health Administration (VHA) [606]
Anthony Au | Von Moore | Muriel Burk
Francesca Cunningham (United States)

276 – Use of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) and Risk of Parkinson’s Disease [607]
Miyuki Hsing-Chun Hsieh | Edward Lai (Taiwan)

277 – “Take Up to Eight Tablets Per Day”: The Impact of Incorporating the Uncertainty of Free-text Medication Instructions for Drug Exposure Data Preparation [608]
Meghna Jani | Belay Yimer | David Selby | Mark Lunt
Goran Nenadic | William Dixon (United Kingdom)

278 – Diabetes Mellitus, Antidiabetic Use and the Risk of Treated Depression in the UK [609]
Claudia Becker | Delia Bornand | Susan Jick
Christoph Meier (Switzerland)

279 – Use of Oral Contraceptives or Hormone Therapy and Risk of COVID-19 Infection or Hospitalization: A Multisite Cohort Study [610]
Sascha Dublin | Laura Harrington | John Powers
Elizabeth Bayliss | Stephen Fortmann | Susan Shortreed
Rod Walker | James Floyd | Jennifer Kuntz | Sharon Fuller
Ladia Albertson-Junkans | Mi Lee
Lisa Temposky (United States)

280 – Warfarin and Sulfonylureas in Individuals with Type 2 Diabetes and Risk of Bleeding: A UK Population-based Cohort Study [611]
Hassan Hasan Alwafi | Abdallah Naser (Saudi Arabia)

281 – Leuprolide and Fracture Risk in Patients with Central Precocious Puberty [612]
Yandong Qiang | Talia Menzin | Christian Hampp
Hye Seung Lee | Shannon Sullivan | Yueqin Zhao
Ting-Ying Huang (United States)

282 – Aromatase Inhibitors and the Incidence of Parkinson’s Disease: Population-based Cohort Study [613]
Francois Montastruc | Farzin Khosrow-Khavar
Laurent Azoulay | Jean-Louis Montastruc
Christel Renoux (France)

283 – Association Between Concomitant Use of Direct Oral Anticoagulants and Statins and Major Bleeding in Patients with Non-valvular Atrial Fibrillation [614]
Airam De Burgos Gonzalez | Lucía Cea Soriano
Consuelo Huerta (Spain)

284 – Evaluate the Risk of Cardiovascular Event in Rheumatoid Arthritis Patient Receiving Tofacitinib and TNF Inhibitors in Taiwan [615]
Chin-Yao Shen | Edward Lai (Taiwan)

285 – Associations of Thiazide Use with Skin Cancers: A Systematic Review and Meta-Analysis [616]
Yi-Hung Chen | Shih-Chieh Shao | Edward Lai
Ching-Chi Chi (Taiwan)

Amar Ashok Maske | Christy Thomas
Krishna Undela (India)

287 – A Replication of the Incidence Rate Estimates of Selected Adverse Events of Special Interest (AESIs) from the vACCine COVID-19 monitoring readinESS (ACCESS) in the EU with US Real World Data [618]
Stephen Schachterle | Ling Li | Rongjun Shen
Charles Wentworth | Jill Dreyfus | Scott Kelly
Ann Madsen | Xiaofeng Zhou (United States)
288 – Cardiovascular Efficacy and Safety of Incretin Mimetics and Sodium-Glucose Co-Transporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of RCTs [619]
Gifty Lawrance | Christy Thomas | Krishna Undela (India)

289 – To Use Antipsychotics or Not to Use Antipsychotics? A Population-based Nested Case-control Study in Patients with Hospital-acquired Delirium After Discharge [620]
Hsiang-T e Tsai | Wei-Hung Chang | Edward Lai (Taiwan)

290 – Risk of Intentional Self Harm and Suicide Among 5-Alpha Reductase Inhibitor Users and Alpha-Blocker Users [621]
Sandia Akhtar | Dinci Pennap | Adobela Ajao | Elena Boley
Sai Dharmarajan | Kushal Naik | Natasha Flowers
Michael Wernecke | Jeffrey Kelman | Andrew Mosholder
David Graham | Thomas E. Macurdy (United States)

291 – Acute Myocardial Infarction, Stroke, and MACE in COPD Patients Treated with Aclidinium and Other Inhaled Bronchodilators [622]
Nuria Saigi-Morgui | Cristina Rebordosa | Estel Plana
Annalisa Rubino | Jaume Aguado | David Martinez
Alejhandra Lei | Sami Daoud | Peter Mcmahon
Susana Perez-Gutthann | Elena Rivero-Ferrer (Spain)

292 – Atypical Antipsychotic Use and Mortality Risk in Parkinson's Disease [623]
Thanh Phuong Pham Nguyen | Dylan Thibault
Daniel Weintraub | Allison Willis (United States)

293 – Opioid-Induced Nausea – A Population-based Active-comparator Symmetry Analysis [624]
Daniel Henriksen | Kamilla Caspersen | Lars Christian Lund
Per Damkier | Jesper Hallas (Denmark)

294 – Association Between Initiation of Medical Therapy and Hypo- or Hyperthyroidism – A Population-based Symmetry Analysis Screening Study [625]
Daniel Henriksen | Lars Folkestad | Sara Ali | Per Damkier
Jesper Hallas (Denmark)

Caitlin Dodd | Sara Burns | April Duddy
Marten Van Den Berg | Tiffany Siu Woodworth (United States)

296 – Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis Treated with Tofacitinib vs Select TNF Inhibitors: Assessing the Concordance of Trial Findings Using Real-World Data [627]
Gulce Askin | Amanda Kong | Julia Pitino
Dionna Atkinson | Tancy Zhang | Jennifer Polinski
Ryan Kilpatrick | Dongmu Zhang | Whitney Krueger (United States)

297 – Flecainide and Risk of Skin Cancer: A Large Population-based Case-control Study in Spain and Denmark [628]
Carlen Reyes | Luz María M. León-Muñoz
Andrea Pistillo | Sigrún Alba Jóhannesdóttir Schmidt
Kasper Bruun Kristensen | Anton Pottegård
Consuelo Huerta | Talita Duarte-Salles
Diana Puente (Spain)

298 – Predicting Individual Risk of Muscle Disorders in Patients Eligible for Statin Treatment: Derivation and External Validation of STRATIFY-StatinMD Prediction Model [629]
Ting Cai | Constantinos Koshiaris | Jennifer A. Hirst
F. D. Richard Hobbs | James P. Sheppard (United Kingdom)

299 – Identifying Hospitalizations for Heart Failure in Healthcare Databases: Algorithm Development and Validation [630]
Yu-Ru Liu | Chih-Fan Yeh | Tsung-Yu Ko | Chi-Chuan Wang
Fang-Ju Lin (Taiwan)

Jenny Dimakos | Ying Cui | Robert Platt | Christel Renoux
Kristian Filion | Antonios Douros (Canada)

301 – Buprenorphine and Tramadol Prescriptions in Major Depressive Disorder Settings [632]
Onyekachukwu Illoh | Eberechukwu Onukwugha
Julia F. Slejko (United States)

302 – Risk of Malignancy in Patients with Rheumatoid Arthritis Treated with Tofacitinib vs Select TNF Inhibitors: Assessing the Concordance of Trial Findings Using Real-World Data [633]
Gulce Askin | Amanda Kong | Julia Pitino | Dionna Atkinson
Tancy Zhang | Jennifer Polinski | Ryan Kilpatrick
Dongmu Zhang | Whitney Krueger (United States)
Poster Session B

SPOTLIGHT POSTERS

DATABASES ................................................................. 90
DIGITAL EPIDEMIOLOGY .................................................. 90
DRUG UTILIZATION RESEARCH ........................................... 91
DRUG-DRUG INTERACTION ................................................ 92
GENOMICS ................................................................. 92
GERIATRICS ............................................................... 93

DISEASE EPIDEMIOLOGY/CLINICAL COURSE ........................................ 93
DRUG EFFECTIVENESS .................................................... 95
DRUG UTILIZATION RESEARCH ............................................. 100
GERIATRIC PHARMACOEPIDEMIOLOGY ......................................... 103
HEALTH ECONOMICS/OUTCOMES RESEARCH ................................ 106
LATE BREAKERS ............................................................. 110
MEDICAL DEVICES ........................................................ 112
METHODS IN PHARMACOEPIDEMIOLOGY .................................... 113
PHARMACOVIGILANCE .................................................... 115
SATURDAY, AUGUST 27 | 8 AM – 6 PM

SPOTLIGHT POSTERS

DATABASES

A – Identification and Classification of Asthma Patients Using a Computerized Database - Data from a Large Israeli Health Maintenance Organization [634]
Vered Rosenberg | Gabriel Chodick | Neville Berkman (Israel)

B – Quality of Life in Patients with Post-COVID-Syndrome: Combining Data from Electronic Health Records and Questionnaires [635]
Rinske Van Den Hoek | Karin Hek, Eelko Hak | Isabelle Bos
Lisa Bosman | Robert Verheij | Tim Olde Hartman
Lilian Peters | Jean Muris | Sjoukje Van Der Bij
Liset Van Dijk (Netherlands)

Eng Hooi (Cheryl) Tan | Danielle E Robinson
Annika Joedicke | María Sanchez-Santos | Mees Mosseveld
Katrine Bødkergaard Nielsen | Carlen Reyes
Annemarie Voss | Ettore Marconi | Francesco Lapi
Jonas Reinold | Katia M Verhamme | Lars Pedersen
Marcel De Wilde | Marc Far Ruiz | María Aragón
Pauline Bosco-Levy | Régis Lassalle
Daniel Prieto-Alhambra (United Kingdom)

Joshua Lin | Yinzhu Jin | Sebastian Schneeweiss
Dave Merola (United States)

E – Changes in Sensitivity and Positive Predictive Value in Phenotype Algorithms for Myocardial Infarction and Ischemic Stroke Over Time in Multiple Observational Databases [663]
Joel N Swerdel | Patrick Ryan (United States)

F – Time Trends in Performance of Different Mortality Data Sources Compared to the National Death Index in the Healthcare Integrated Research Database [664]
Todd Sponholtz | Aziza Jamal-Allial | Shiva K Vojjala
Anaheit Papazian | Biruk Estete | Seyed Hamidreza Mahmoudpour | Patrice Verpillat | Daniel Beachler (United States)

G – Selection of Censoring Schemes for Analyzing Overall Survival in Real-World Data with Linked Mortality Information [665]
Wei-Chun Hsu | Aaron Crowley | Susan Oliveria
Craig Parzynski (United States)

H – Concordance of Efficacy Data Collected in a Clinical Trial Setting Versus a Registry Study Setting: Example of Use of Real-World Data to Support Drug Regulatory Approval of Abatacept for Acute Graft Versus Host Disease Prophylaxis [666]
Christopher Bond | Tzuyung Douglas Kou | Leslie Kean
Linda J. Burns | Karissa Lozenski | Roxanne Kapikian
Xiao-Ying Tang | Mei-Jie Zhang | Michael Hemmer
Sean Connolly | Martin Polinsky | Brian Gavin
Andres Gomez | Marcelo Pasquini (United States)

DIGITAL EPIDEMIOLOGY

I – New Tools for Pharmacoepidemiological Studies: Developing a Lightweight Modular Analytics Framework Based on a Nordic Common Data Model (NCDM) and a General Model of Person-Time-Event Data [659]
Morten Andersen | Reeha Sharon | Sarah Kristiansen
Mia Aakjær (Denmark)

J – Machine Learning to Automate Data Extraction for Systematic Literature Reviews [660]
Antonia Panayi | Juan M Ortiz | Katherine Ward | Antonio Santiago Ibanez Lopez | Andrew Xia | Regina Barzilay (Switzerland)
Poster Session B

K – Predicting Early Readmission and Death After Hospitalization for Chronic Obstructive Pulmonary Disease Exacerbation Using Machine Learning [661]
Chih-Ying Wu | Chien-Ning Hsu | Charlotte Wang
Jung-Yien Chien | Chi-Chuan Wang | Fang-Ju Lin (Taiwan)

L – Identifying Protective Drugs for Parkinson’s Disease: Large Screening of The French National Healthcare Database with Signal Detection Machine Learning Algorithms [670]
Émeline Courtois | Thi Thu Ha Nguyen | Agnès Fournier
Sylvie Escolano | Laure Carcaillon-Bentata
Pascale Tubert-Bitter | Alexis Elbaz | Anne Thiébaut
Ismail Ahmed (France)

DRUG UTILIZATION RESEARCH

N – Respiratory Drugs and Antibiotics Use Before and During COVID-19 in Asthma and COPD Patients: A Quasi-Experimental Study [638]
Laila Nabil Mahmoud Helmy Aboulatta | Emily M. Barr
Christine Leong | Kaarina Kowalec | Joseph Delaney
Jamie Falk | Silvia Alessi-Severini | Sherif Eltonsy (Canada)

O – Variation in The Impact of a Policy to Restrict Coverage of Lidocaine 5% Plasters in Ireland [639]
Frank Moriarty | Molly Mattsson (Ireland)

P – In-Hospital Treatment Patterns Among Patients Hospitalized with COVID-19 in the United States [640]
Nuvan Rathnayaka | Catherine Wiener | Alexander Breskin
Angela Cook | M. Alan Brookhart (United States)

Q – Utilization of Antipsychotics for Delirium After Hospitalization for COVID-19 and Other Infections [641]
Lily Bessette | Yichi Zhang | Cassandra York | Joshua Lin (United States)

R – Agreement and Correlation Between Different Topical Corticosteroid Potency Classification Systems [642]
Mina Tadrous | Alexa C Bowie | Alexander Egeberg
Jane Harvey | Stephanie Lax | Jacob Thyssen
Aaron M. Drucker (Canada)

M – Development of a Tool for Visualizing Patient Journeys Using Disease Blogs on the Internet [671]
Shinichi Matsuda | Takumi Ohtomo | Masaru Okuyama
Hiraku Miyake (Japan)

S – Use of Methotrexate in Girls and Women of Childbearing Age and Occurrence of Methotrexate-Exposed Pregnancies in Germany [643]
Nadine Wentzell | Bianca Kollhorst | Ulrike Haug (Germany)

Courtney Maierhofer | Shabbar Ranapurwala
Bethany Diprete | Naoko Fulcher | Christopher Ringwalt
Paul Chelmins | Timothy Ives | Nabarun Dasgupta
Vivian Go | Brian Pence (United States)

U – Statin-Related Adverse Drug Reactions in UK Primary Care Consultations: A Retrospective Cohort Study to Evaluate the Risk of Cardiovascular Events and All-cause Mortality [645]
Widya Norma Insani | Cate Whittlesea | Chengsheng Ju
Kenneth Man | Hassan Hasan Alwafi | Alaa Alsharif
Sarah Chapman | Li Wei (United Kingdom)
**DRUG-DRUG INTERACTION**

Tais Freire Galvao | Gustavo Magno B Tiguman
Tayann Margarida M. Almeida Blase | Marcus Silva (Brazil)

X – Age and Sex Differences in Polypharmacy Patterns in New Users of Metformin: A UK-based Descriptive Study [647]
Maria Luisa Marques De Sa Faquetti | Theresa Burkard
Adrian Martinez De La Torre | Andrea Burden (Switzerland)

Y – The Impact of Polypharmacy on Antidepressant Discontinuation in Comorbid Depression and Type 2 Diabetes: A UK Primary Care Record Cohort Study [648]
Annie Jeffery | Kate Walters | David Osborn | Ian Wong
Joseph F. F. Hayes (United Kingdom)

Z – Polypharmacy Trends Among US Middle-aged Adults from 2007 to 2020 [649]
April Duddy | Lu Zhang | Tiffany Siu Woodworth (United States)

AA – Adverse Events of Myopathy After Comedication of Statin-Contraindicated Drugs: Case/Noncase Study Using Korea Adverse Event Reporting System (KAERS) Database, 2016-2020 [672]
Sewon Park | Min-Ju Koo | Sun-Young Jung (South Korea)

AB – Concomitant Use of Sodium-Glucose Co-transporter 2 Inhibitors and Statins and the Risk of Myotoxicity - A Pharmacovigilance Study [673]
Antonios Douros | Christopher Gravel | Daniel KreWSki
Donald Mattison (Canada)

AC – A Population Based Assessment of Concomitant Use of Sulfonylureas and Beta-Blockers and the Risk of Severe Hypoglycemia [674]
Jenny Dimakos | Ying Cui | Robert Platt | Kristian Filion
Christel Renoux | Antonios Douros (Canada)

**GENOMICS**

AD – KRAS PG12 Mutated Advanced Non-Small Cell Lung Cancer: Characteristics and Outcomes from a Danish Nationwide Retrospective Observational Study [636]
Matilde Frost | Ditte Resendal Gotfredsen
Kristoffer Jarlov Jensen | Anne Mette Skov Soerensen
Karly Louie Nicholas Sroczynski | Erik Jakobsen
Jon Andersen Espen Jimenez-Solem
Tonny Petersen (Denmark)

AE – Shifting Treatment Landscape and Overall Survival by PD-L1 Expression Level Among Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC) [650]
Wenzhen Ge | Hillary Dietz | Ning Wu | Ruben Gw Quek
Jean-Francois Pouliot | Scott Antonia | Jessica Jabber
James Harnett (United States)

AF – Evolution of The Treatment Landscape in Patients with Advanced or Metastatic Cancers Following the Approval of Immuno-Oncology Treatments: Analysis of The England National Cancer Registry [651]
Patrice Verpillat | Seyed Hamidreza Mahmopard
Craig Knott | Amerah Amin | Emmanuelle Boutrmy (Germany)

AG – Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using Swiss Claims Data [667]
Nina L. Wittwer | Christoph Meier | Carola A Huber
Henriette E. Meyer | Zu Schwabedissen | Samuel Alleman
Cornelia Schneider (Switzerland)

AH – Determinants of Higher Metformin Daily Dosage Among Type 2 Diabetic Patients: A Genetic Risk Score Analysis in The Rotterdam Study [668]
Soroush Mohammadi Jouabadi | Payam Peymani
Bruno H. Stricker | Fariba Ahmadizar (Netherlands)

AI – Comparison of FDA and EMA Regulatory Routes and Approval Timing for Personalized Medicines [669]
Carla Vossen | Tara Isherwood | Jessica D Albano (Netherlands)
GERIATRICS

AJ – Urinary Retention and the Risk of Delirium Among Elderly Patients with Benign Prostatic Hyperplasia [652]
Sheng-Yung Chang | Chin-Yao Shen | Edward Lai (Taiwan)

AK – Polypharmacy and Trajectories of Health-Related Quality of Life in Older Adults: A National Cohort Study [653]
Edwin CK Tan | Muhamad Aljeaidi
Miriam Haaksma (Australia)

AL – Classifying Polypharmacy: A Latent Class Analysis in Older Adults in Quebec, Canada [654]
Maude Gosselin | Denis Talbot | Marc Simard
Miceline Mesidor | Yohann M Chiu | Caroline Sirois (Canada)

AM – Comparison of Potentially Inappropriate Medications in Nursing Homes and the Community: A Nationwide Cross-Sectional Study in Older Persons [655]
Solene Drusch | Thienn Le Tri | Joel Ankri
Hugues Michelon | Mahmoud Zureik | Marie Herr (France)

AN – Time Series Analysis of Blood Pressure-lowering Drug Prescribing Trends Among Dementia Patients in Hong Kong [656]
Edmund Cl Cheung | Celine Sl Chui | Miriam Leung
Gary Kk Lau | Hao Luo | Eric Yf Wan
Ian Wong (Hong Kong)

AO – One-Year Opioid Use Following Discharge from Post-Acute Care After Hip Fracture [657]
Andrew Zullo | Meghan Cupp | Francesca Beaudoin
Richa Joshi | Melissa Riester | Kaley Hayes (United States)

AP – Longitudinal Progression of Fraility in Older Population and Risk of Mortality: An Application of Joint Latent Class Models [658]
Leena Mohamed Elabbas Elhussein | Danielle E. Robinson
Antonella Delmestri | Daniel Prieto-Alhambra | Alan Silman
Victoria Y. Strauss (United Kingdom)

DISEASE EPIDEMIOLOGY/CLINICAL COURSE

1 – The Risk of Acute Infection in Association with Newly Diagnosed Depression: A Cohort Study [675]
Noah Aebi | Christoph Meier | Susan Jick | Undine E. Lang
Julia Spoendlin (Switzerland)

2 – The Impact of Sex on Migraine-associated Risks of Premature Stroke and Myocardial Infarction: A Danish Population-based Cohort Study [676]
Cecilia Fuglsang | Morten Schmidt | Lars Pedersen
Henrik Toft Sørensen (Denmark)

3 – The Impact of COVID Passport Mandates on The Number of Cases of and Hospitalizations With COVID-19 in the UK: A Difference-In-Differences Analysis [677]
Kim López Güell | Albert Prats-Urbi | Martí Català
Daniel Prieto-Alhambra | Clara Prats
Jotun Hein (United Kingdom)

4 – Trends and Risk Factors of Adult Oral Disease: Results from a Nationwide Population-based Study in Korea [678]
Jaseung Choi | Seo-Young Park | Seokyoung Hahn
Hee-Kyung Park | Ji-Yeob Choi (South Korea)

5 – Response to Electroconvulsive Therapy in Treatment Resistant Depression: A Nationwide Register-based Study [679]
Adam Nygren | Johan Reutfors | Lena Brandt
Robert Bodén | Axel Nordenskjöld | Mikael Tiger (Sweden)

6 – Patterns of Adverse Event Reporting for Long-acting Benzodiazepines [680]
Ju Won Lee | Yuseon Jung | Seung-Hun You | Dal Ri Nam
Sun-Young Jung (Republic of Korea)

7 – Heart Failure Phenotype Transitions in Early Diagnosis [681]
Mai Duong | Phillip R Hunt | Alison Booth | Nahila Justo
Javier Cid Ruzafa | Ignacio Hernández | Beatriz Palacios
Juan J. Delgado | Aido Maggioni (United Kingdom)

8 – COVID-19: Multifactorial Modelling to Predict Long-Term Trends [682]
Chris Schneiderman | Leon Raskin | Alexander Liede (United States)
9 – Heart Failure Following ST-Segment Elevation (STEMI) and Non-ST-Segment Elevation Myocardial Infarction (NSTEMI): Incidence, Characteristics and Its Impacts on Mortality in Taiwan [683]
Huimin Chuang | Shih-Tsung Huang | Fei-Yuan Hsiao (Taiwan)

10 – The Medikeye Project: The First European Study on in Utero Medicine Exposure and Congenital Anomalies of Eyes [684]
Charlotte Dubucs | Anthony Caillet | Van Ngo
Amanda Neville | Helen Dolk | Maria Loane | Ester Garne
Babak Khoshnood | Nathalie Lelong | Anke Rissmann
Mary O’mahony | Anna Pierini | Miriam Gatt
Hermien De Walle | Maciej R Krawczynski
Anna Latos-Bielenska | Luis Echevarría González De Gariba
Clara Cavero Carbonell | Marie-Claude Addor | David Tucker
Sue Jordan | Vera Nelen | Ingeborg Barisic
Hanitra Randrianaivo | Monique Courtade-Saïdi
Isabelle Lacroix | Caroline Hurault-Delarue
Christine Damase-Michel (France)

11 – The Completeness of the Swedish National Patient Register in Terms of Cancer Diagnoses [685]
Sakura Sakakibara | Laura Pazzagli | Marie Linder (Sweden)

12 – Factors Influencing Diabetes Risk Assessment; a Systematic Comparison of Two Diabetes Risk Assessment Tools [686]
Atiqulla Shariff | Srikanth Malavalli Siddalingegowda
Sathvik Belagodu Sridhar | Anjali Pradhan
Muskan Singh (India)

13 – Prevalence of Osteoporosis, Fractures, and Preventive Therapy Among Patients with Moderate to Severe Chronic Kidney Disease Patients Using National Heath and Examination Survey (NHANES) [687]
Sherin Ismail Atta | Michele Jonsson Funk (United States)

14 – Evaluating The Mortality in Women with Newly Diagnosed Early-Stage Breast Cancer Comparing Surgery Against Primary Endocrine Therapy [688]
Yubo Wang | Douglas Steinke | Sean Gavan | Li-Chia Chen (United Kingdom)

15 – National Trends of Dementia and Its Clinical Outcomes in Taiwan from 2004 to 2017: A Claim-based Nationwide Study [689]
Shih-Tsung Huang | Liang-Kung Chen
Fei-Yuan Hsiao (Taiwan)

16 – Type 2 Diabetes Phenotypes and Polyneuropathy: A Prevalence Study in the DD2 Cohort [690]
Frederik Pagh Kristensen | Diana Christensen
Brian Callaghan | Helene Svané | Jacob Stidsen
Jens Nielsen | Kurt Højlund | Henning Beck-Nielsen
Troels Jensen | Henning Andersen | Peter Vestergaard
Niels Jessen | Michael Olsen | Torben Hansen
Charlotte Brøns | Allan Vaag | Henrik Toft Sørensen
Reimar Thomsen (Denmark)

17 – Characteristics and Treatment Patterns in Patients with Locally Advanced and Metastatic Bladder Cancer in Denmark 2015–2020 [691]
Mette Nørgaard | Aurélie Mailhac | Karin Fagerlund
Torsten Strunz-Mckendry | Jørgen Bjerggaard Jensen (Denmark)

Mackenzie Herzog | Leigh Weiss | Rebecca Lee
Christina Mack (United States)

19 – Prevalence and Clinical Outcomes of Lipodystrophy: A US National Cohort [693]
Seonkyeong Yang | Caitlin Knox (United States)

20 – Representativeness in Clinical Trial Planning: An Epidemiologic Examination of Race and Ethnicity Leveraging Multiple Real-World Data (RWD) Sources in the United States [694]
Emily W Bratton | Michel Denarie | Robert Stolper
Monica Goins | Eric Gemmen (United States)

21 – Applying Sequence Clustering Methods to Characterize Healthcare Pathways of Patients at Different Prostate Cancer Stages in the French Nationwide Healthcare Database (SNDS) [695]
Nicolas H. Thurin | Régis Lassalle | Roméo Baulain
Jérémy Jové | Dunia Sakr | Marine Gross-Goupil
Magali Rouyer | Patrick Blin | Cécile Droz-Perroteau (France)

22 – Cutaneous Lupus Erythematosus in a Large, Longitudinal Electronic Health Record Database in the United States: Demographics, and Comorbidities – A Focus on African Americans [696]
Fariba Mirzai | Li Li (United States)

23 – Validation of a Cohort of Rheumatoid Arthritis (RA) Patients in CPRD Aurum [697]
David E. Neasham | George Kafatos | Joe Maskell | Susan Jick (United Kingdom)
### Poster Session B

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>Evaluating The Burden of Peripheral Neuropathy in Multiple Myeloma Using Two Real-World Data Sources from the United States</td>
<td>Alexi Archambault, Martha Makaratzi, Karen Rodriguez Lorenc, Glenn Kroog, Christian Hampp</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Epidemiology of Select Clinical Events of Interest Following a Myocardial Infarction</td>
<td>Darcy E. Ellis, James Brash, Xiaoyu Lin, Sarah Seager, Christian Reich, Max Waschbusch, Nicole L Baker</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Osteoarthritis Imaging Patterns in US Clinical Practice</td>
<td>Angelika Manthripragada, Ravi Iyer, Dana Murdock, James Jackson, Mia Unsworth, Chloe A Walker, Wenhui Wei</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Characterization and Treatment Pathways of Heavy Menstrual Bleeding (Champion-HMB): A Network Cohort Study</td>
<td>Federica Edith Pisa, Kristina Gemzell-Danielsson, Oskari Heikinheimo, Ronald Herrera, Bruno Imthurn, Carsten Moeller, Inês Neves, Christian Reich, Juliane Schoendorf, Gabriele Schuhmann-Giampieri, Marco Serrani, James Yang</td>
<td>United States, Germany</td>
</tr>
</tbody>
</table>

---

### DRUG EFFECTIVENESS

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Effect of Obeticholic Acid in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Patients: A Systematic Review and Meta-Analysis</td>
<td>Nadella Mounika</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Characterizing Extension Studies in Intervventional Research: Twenty Year Trends</td>
<td>Andrew M Bevan, Brian M. Frankel, Debra A. Schaumberg</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Comparative Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Reducing Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes</td>
<td>Ghadeer Dawwas, James D. Lewis, Sean Hennessy</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Jak Inhibitors for Atopic Dermatitis: A Network Meta-Analysis of Adverse Events</td>
<td>Ana Penedones, Carlos Alves, Diogo Mendes Francisco Batel Marques</td>
<td>Portugal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Numbers Needed to Treat to Benefit (NNTB) and to Harm (NNTH) for COVID-19 Medicines</td>
<td>Ana Penedones, Diogo Mendes, Carlos Alves Francisco Batel Marques</td>
<td>Portugal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Efficacy of Bictegravir /Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir Combinations in HIV-1 Adult Population: A Systematic Review and Meta-Analysis</td>
<td>Anto Amith Biju J, Aina Shaju, Manoj Kumar Mudigubba</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Efficacy and Safety of Corticosteroids in COVID-19: An Overview of Meta-Analyses</td>
<td>Sreedharan Nair, Muhammed Rashid, A.H. K. Rajan Ambalapotta Hafis, Viji Chandran, Girish Thunga, Vishal Shanbhag, Souvik Chaudhuri</td>
<td>India</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>The Association Between Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies</td>
<td>Matthew Adesuyan, Ruth Brauer, Yogini Jani</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

---

icpe2022.org | #ICPE22 | @IntPharmacoEpi | 95
39 – Comparative Effectiveness of Different Corticosteroid Regimens in Patients with Acute Respiratory Distress Syndrome [713]
Muhammed Rashid | Sreedharan Nair | Girish Thunga
Vijayanarayana Kunhiyatt | Vishal Shanbhag | Viji Chandran
Asha K. Rajan | Raviaraja Acharya (India)

40 – Sociodemographic Factors and Medications for Opioid Use Disorder (MOUD) Initiation and Retention: A Review [714]
Catherine Psaras | Sophia L. Balkovski | Marissa Seamans (United States)

41 – Effectiveness and Safety of Warfarin Use After Bariatric Surgery in Patients with Atrial Fibrillation and Venous Thromboembolism: A Real-World Analysis [715]
Abdullah Abdulaziz Alaw | Jeffrey Friedman
Haesuk Park | Richard Segal (Saudi Arabia)

42 – Identifying Factors with and Effects of Metformin on the Risk of Alzheimer’s Disease and Other Dementias: A Machine Learning Approach [716]
Xiaomo Xiong | Minghui Li | Kevin Lu (United States)

43 – Comparative Effectiveness of Adjuvant Chemotherapy Versus Chemotherapy Plus Targeted Therapy After Resection of Both Primary Tumor and Metastases in Patient with Colorectal Cancer [717]
Yi-Chia Su | Chih-Chien Wu | Yu-Ching Chang | Yea-Huei Kao Yang (Taiwan)

44 – Association Between Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure Readmission Among Patients with Type 2 Diabetes [718]
Sohee Park | Han Eol Jeong | Hyesung Lee
Ju-Young Shin (Republic of Korea)

45 – Safety and Efficacy of Perampanel in Epilepsy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials [719]
Alekhya Lavu | Laila Nabil Mahmoud Helmy Aboulatta
Ahamed M. Abou-Setta | Basma Aloud | Nicole Askin
Rasheda Rabbani | Walid Shouman | Ryan Zarychanski
Sherif Eltonsy (Canada)

46 – Impact of Romosozumab on Bone Mineral Density in Postmenopausal Osteoporosis [720]
Md Azharuddin | Manju Sharma (India)

47 – Hospital Readmission and Mortality in Patients with Heart Failure Treated with Sacubitril/Valsartan versus Enalapril in Hong Kong [721]
Xuxiao Ye (Hong Kong)

48 – Efficacy and Safety of a Personalized Vitamin D3 Loading Dose Followed by 2,000 IU Per Day to Raise Serum 25-Hydroxyvitamin D Levels in Colorectal Cancer Patients with Vitamin D Insufficiency. Interim Analysis of a RCT [722]
Ben Schoettker | Hermann Brenner | Sabine Kuznia (Germany)

49 – Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) Versus Dipeptidyl Peptidase 4 Inhibitors (DPP-4i) in T2D Patients Across Different HbA1c Levels [723]
Elvira D’andrea | Deborah Wexler | Julie Paik | Ethan Alt
Seoyoung Kim | Elisabetta Patorno (United States)

50 – Effect of Low-Dose Aspirin on the Primary Prevention of Colorectal Cancer in Patients with Type 2 Diabetes Taking Metformin [724]
Jessica Shami | Vincent Kc Yan | Yue Wei | Ian Wong
Esther W. Chan (Hong Kong)

52 – Statins and LDL-Cholesterol Control in the Long-Term: A Retrospective Cohort Study Using Electronic Health Records [726]
Juan Carlos Jc Bazo Alvarez | Kingshuk Pal | Tim P Morris
James R Carpenter | Rafel Ramos | Goya Wannamethee
Irene Petersen (United Kingdom)

53 – Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Metformin as First-Line Treatment for Type 2 Diabetes [727]
Hojin Shin | Sebastian Schneeweiss | Robert Glynn
Elisabetta Patorno (United States)

54 – Sodium Glucose Cotransporter 2 Inhibitors and the Risk of Respiratory Outcomes Among Patients with Type 2 Diabetes: A Nationwide Cohort Study [728]
Han Eol Jeong | Sohee Park | Yunha Noh | Kristian Filion
Oriana Hoi Yun Yu | Seung Hun Jang | Ju-Young Shin (South Korea)
55 – Daily Tenofovir Disoproxil Fumarate/ Emtricitabine and Hydroxychloroquine for Pre-exposure Prophylaxis of COVID-19: A Double-Blind Placebo Controlled Randomized Trial in Healthcare Workers. A Randomized Clinical Trial [729]
Xabier Garcia De Albeniz | Rosa Polo | Carolina Teran
Miguel Morales | David Rial-Crestelo | Ma García
Miguel Garcia Del Toro | César Hita | JI Gómez-Sirvent
Luis Buzón | Alberto Díaz De Santiago | JI Perez, Jesús Sanz
P. Bachiller | Elisa Martínez | Vicens Díaz-Brito | Mar Masía
Alicia Hernandez-Torres | José Guerra
Piedad Arazo-Jose Arribas | Pablo Martínez De Salazar
Santiago Moreno | Miguel A. Hernán | Julia Del Amo (Spain)

Xabier García De Albeniz | Julia Del Amo | Rosa Polo
Jose Miguel Morales-Asencio | Miguel A. Hernán | Julia Del Amo (Spain)

57 – Survival Analysis of Riluzole for Patients with Motor Neuron Disease in Hong Kong: A Population-based Cohort Study [731]
Min Fan | Gary Kk Lau | Xue Li | Edmund Ck Cheung
Le Gao | Ian Wong | Celine Si Chui (Hong Kong)

58 – Use of Riluzole and Risk of Hospitalization for Patients with Motor Neuron Disease in Hong Kong: A Self-Controlled Case Series Study [732]
Min Fan | Gary Kk Lau | Xue Li | Le Gao
Edmund Ck Cheung | Ian Wong | Celine Si Chui (Hong Kong)

59 – Risk of Falls and Fractures with Concomitant Use of Prescription Opioids and Other Medications in Osteoarthritis Patients [733]
Nazleen Khan | Katsiaryna Bykov | Jeffrey Katz
Robert Glynn | Seanna Vine | Seoyoung Kim (United States)

60 – Inhaled Corticosteroid Combinations in COPD-Safety and Efficacy: A Systematic Review of Real-World Data [734]
Ramesh Madhan | Christy Thomas | Chalasani Sri Harsha
Krishna Murti (India)

© 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
Poster Session B

61 – The Impact of Expanded Access to Direct Acting Antivirals for Hepatitis C on Patient Outcomes in Canada [735]
Cherry Chu | William Wong | Kevin Schwartz
Jason Guertin | Tara Gomes | Tony Antoniou | Jordan Feld
Naveed Janjua | Jeff Kwong | Mina Tadrous (Canada)

62 – Prevalence of Use of GABA Receptor Positive Allosteric Modulator Use and Associations with Treatment Discontinuation Among Patients Receiving Cancer Immunotherapy [736]
Jyotirmoy Sarker | Gregory Calip (United States)

63 – Potential Unknown Benefits of Rabeprazole: Real-World Evidence Generated Using the REWARD Framework [737]
Justin Bohn | James Gilbert | Geoffrey Rezvani
Saberi Rana Ali | Zhong Yuan | Linda Hannemann
David M. Kern (United Kingdom)

64 – Hydrochlorothiazide and Non-Melanoma Skin Cancer in Residents of the Province of Ontario, Canada [738]
Marina G. Birck | Cristiano Moura | Coraline Danieli
Michal Abrahamowicz | Louise Pilote
Sasha Bernatsky (Canada)

65 – Biological Disease-Modifying Anti-rheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study with Prevalent New-User Design [739]
Shahab Abtahi | René Cordtz | Lene Dreyer | Johanna H. M. Hm Driessen | Annelies Boonen | Andrea Burden (Netherlands)

66 – Restricted Mean Survival Time for Analysis of Real-World Cardiovascular Effect Associated with SGLT2 Inhibitor Use: A Population-based Study [740]
Zi-Yang Peng | Chun-Ting Yang | Chih-Hsing Wu
Huang-Tz Ou (Taiwan)

67 – Effect of Statins on Coronary Artery Calcification: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [741]
Mitra Nekouei Shahraki | Soroush Mohammadi Jouabadi | Daniel Bos | Bruno H Stricker | Fariba Ahmadizar (Netherlands)

68 – Real-World Effectiveness of Methadone Maintenance Treatment on the Reduction of Suicidal Attempts in Patients with Opioid Use Disorder [742]
Eric Cheng-Chan Shih | I-Lin Hsu, Edward Lai (Taiwan)

69 – Evaluating Crisaborole 2% Ointment’s Role in Improving Quality of Life in Patients Three Months and Older with Mild to Moderate Atopic Dermatitis: A Systematic Review [743]
Feng-Hua Loh | Ahmad Naeem (United States)

70 – Long-Term Relative Effectiveness of Anti-Hypertensive and Anti-Hyperlipidemic Drug Monotherapy in Primary Prevention of Cardiovascular Events [744]
Xuechun Li | Maarten J Bijlsma | Jens H. J. Bos
Catharina C. M. Schuling-Veninga | Eelko Hak (Netherlands)

71 – Real-World Effectiveness and Safety of Ramucirumab in Hepatocellular Carcinoma Patients: A Retrospective Study in Taiwan [745]
Min Hua Hung | Kaicheng Chang | Hui-Yu Chen (Taiwan)

72 – Real World Effectiveness of Lipid-lowering Medication in Denmark [746]
Camilla B. Jensen | Jakob Kronkvist Hoe | Susanne Hansen
Rasmus Huan Olsen | Tina Johansen
Espen Jimenez-Solem | Janne Petersen (Denmark)

73 – Efficacy and Safety of Baloxavir in the Treatment of Influenza: A Systematic Review and Meta-Analysis [747]
Lara Haidar | Laila Nabil Mahmoud Helmy Aboulatta
Alekhya Lavu | Sherif Eltonsy | Rania Azar (Canada)

74 – A Real-World Effectiveness of Second-line Osimertinib in NSCLC Patients: A Multi-Institutions Study in Taiwan [748]
Hui-Yu Chen | Kaicheng Chang | Shih-Chieh Shao
Yueh-Fu Fang (Taiwan)

75 – Comparative Effectiveness of Regorafenib and Nivolumab as Sequential Therapies in Patients After Sorafenib Failure for Hepatocellular Carcinoma Patients: A Cohort Study in Taiwan [749]
Tzuyu Yeh | Kaicheng Chang | Hui-Yu Chen (Taiwan)

76 – Disease Relapse, Healthcare Utilization and Adverse Events Associated with the Use of Long-acting Injectable Antipsychotics Versus Oral Antipsychotics in People with Schizophrenia: A Self-controlled Case Series Study [750]
Yue Wei | Vincent Kc Yan | Wei Kang | Ian Wong
David J. Castle | Le Gao | Celine Si Chui | Kenneth Man
Joseph F. F. Hayes | Wing Chung Chang | Esther W. Chan (Hong Kong)
Poster Session B

77 – Real-World Impact of Non-Clinical Inhaler Switching on Asthma or COPD Patients: A Systematic Review [751]
John Bell | Omar Usmani | Sinthia Bosnic-Anticevich
Richard Dekhuijzen | Federico Lavorini | Neda Stjepanovic
Stephanie L. Swift | Nicolas Roche (United Kingdom)

78 – Medication Self-Management in Hospitalised Patients with Schizophrenia or Bipolar Disorder: The Perceptions of Patients and Healthcare Providers [752]
Elke Loots (Belgium)

79 – Efficacy and Safety of Amphotericin B and Oral Miltefosine Combination in Patients with Visceral Leishmaniasis: A Systematic Review and Meta-Analysis [753]
Christy Thomas | Mandava Satish | Krishna Undela (India)

80 – Comparative Effectiveness and Safety of First-Line Treatments of Metastatic Colorectal Cancer in Real-World Settings: A Systematic Review and Meta-Analysis [754]
Haya Yasin | Amanj Kurdi, Fatema Mahmoud | Tanja Mueller
Natalie Weir | Marion Bennie (United Kingdom)

81 – Efficacy and Safety of Inhaled Corticosteroid Containing Combinations in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis [755]
Christy Thomas | C. Sri Harsha | Krishna Murti
Krishna Undela | Ramesh Madhan (India)

82 – High-Intensity Thromboprophylaxis Is Not Associated with Reductions in COVID-19 Worsening, Severe Disease, or Death [756]
Corey Joseph | Kayte M Andersen | Hemalkumar Mehta
Michael B Streiff | Joshua Betz | Robert C. Bollinger
Arielle Fisher | Amita Gupta | Charles F. Lemaistre
Matthew Robinson | Yanxun Xu | Derek K. Ng
G. Caleb Alexander | Brian Garibaldi (United States)

83 – Comparative Effectiveness of First-Line SGLT2 Inhibitor Use on Heart Failure Hospitalization Among Patients with Type 2 Diabetes Mellitus; A Target Trial Emulation [757]
Hiraku Kumamaru | Yoshinori Takeuchi | Shun Kohsaka
Hiroki Matsui | Hideo Yasunaga | Hiroaki Miyata (Japan)

84 – Hydroxychloroquine for Pre-Exposure Prophylaxis of COVID-19 in Health Care Workers: A Randomized, Multicenter, Placebo-controlled Trial (HERO-HCQ) [758]
Emily Obrien | Susanna Naggie | Kevin Anstrom
Lauren Cohen | Jack Shostak | Rachel Olson
Anne Friedland | Chris Woods
Adrian Hernandez (United States)

85 – Converging Evidence from Human Pharmacoepidemiology and Rodent Psychopharmacology Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder [759]
Mehdi Farokhnia | Christopher Rentsch | Vicky Chuong
Adrienne Mcginn | Sophie Elvig | Eliza Douglass
Jenna Sanfilippo | Renata Marchette | Brendan Tunstall
David Fiellin | George Koob | Amy C. Justice
Lorenzo Leggio | Leandro Vendruscolo (United States)

86 – Sodium-Glucose Cotransporter-2 Inhibitors and The Risk of Lung Cancer Among Patients with Type 2 Diabetes [760]
Samantha B. Shapiro | Hui Yin | Oriana Hoi Yun Yu
Laurent Azoulay (Canada)

87 – Use of Immunosuppressive Drugs (ISD) and The Effectiveness of Immune Checkpoint Inhibitor (ICI) Therapy Among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) in the United States (US) [761]
Brian Dreyfus | Ellen (Yan) Zhang | Charlotte Doran
Kim Le | C. Kola | Brooke E Sylvester | Rajeshwari Punekar
Lincy Lai | John Penrod | Stephanie L. Meadows-Shropshire (United States)

88 – Hemostatic Effectiveness of Four-factor Prothrombin Complex Concentrate for Treatment of Factor Xa Inhibitor-associated Acute Major Bleeds: A Meta-analysis [762]
Nicole L. Baker | Fidelia Ida | Rongrong Wang
Brahm Goldstein (United States)
Guillaume Favre | Eva Gerbier | Emeline Maisonneuve
Ursula Winterfeld | Leo Pomar | Miriam Sturkenboom
Emir Hurley | Hedvig Nordeng | Kitty Wm Bloemenkamp
Hilde Engjom | Odette De Bruin | Satu Siiskonen
David Baud | Alice Panchaud (Switzerland)

90 – Disparities in Access to Contraceptives and Abortion Medications Between High Income and Low- and Middle-Income Countries (LMICs) Before and During the COVID-19 Pandemic, 2015-2020 [764]
Dima Qato | Andrew Shooshtari | Jenny Guadamuz
Laura Ferguson | Denise Harrison (United States)

91 – Use of Antibiotics for Urinary Tract Infections Up to and After Nursing Home Admission in Denmark [765]
Emma Bjerk | Rune Aabenhus | Søren Larsen
Jesper Ryg | Daniel Henriksen | Carina Lundby
Anton Pottegård (Denmark)

92 – Using Real-World Data to Examine Treatment Patterns of Patients with Advanced Non-Small Cell Lung Cancer Treated with Systemic Therapies [766]
Jason Simeone | Nicole Croteau | Sabrina Mueller (United States)

Robert C. Reiner | Catherine Gillespie | John Giles
Christopher E. Troeger | Serena Santoni (United States)

94 – Estimating Patients’ Knowledge and Behavioral Traits Towards Generic Drugs in Greece [768]
Konstantinos Kassandros | Christos Kontogiorgis | Theodoros Constantinides (Greece)

95 – Adherence to Medications and Government Recommendations Among Breast Cancer Women During The COVID-19 Pandemic [769]
Charlotte Myers | Sophie Lauzier | Fanie Bourgault
Michel Dorval | Hermann Nabi | Josée Savard
Kathleen E. Bennett | Catiarona Cahir (Ireland)

96 – Variations in The Definitions for Prevalence of Chronic Post-Surgical Pain and Persistent Opioid Use After Surgery [770]
Neetu Bansal | Li-Chia Chen | Sheanne Ang (United Kingdom)

97 – Real-World Prescription Pattern Among Patients with Inflammatory Bowel Disease in Taiwan: A Multi-Institutional Electronic Medical Records Database Analysis [771]
Chon Hou Kou | Kaicheng Chang | Hui-Yu Chen (Taiwan)

98 – Psychotropic Drug Utilization in An Ambulatory Psychiatric Clinic of a Tertiary Care Hospital [772]
Srikanth Malavalli Siddalingegowda | Shivani B. | Kishore M. Atiquilla Shairff | Samaksha P. B. (India)

99 – The Initiation of Treatment and One-Year Treatment Non-Persistence Rates in Hypertensive Patients in Lithuania [773]
Indre Treciokiene | Nomeda Bratcikoviene | Jolanta Gulbinovic Bjorn Wettermark | Katja Taxis (Lithuania)

100 – Morbi-Mortality Consequences of Misuse of Psychoactive Prescription Drugs in Portugal: A Retrospective Observational Study – The MisuMedPT Project [774]
Ana Araujo | Ana Godinho | João Goulão
Ana Martins (Portugal)

101 – Changes in Anticoagulant and Antiplatelet Drug Supply at US Hospitals During the COVID-19 Pandemic [775]
Dima Qato | Paul Wong | Scott A Mosley | Tien M. Ng
Andrew Shooshtari | G. Caleb Alexander (United States)

102 – The Management of Adult Asthma: An Observational Study into Real-World Prescription Patterns of Inhalation Medication [776]
Irene Mommers | Catharina C. M. Schuiling-Veninga | Jens H. J. Bos | Job Van Boven | Maarten J. Blijisma Eelko Hak (Netherlands)

103 – Switching Patterns of Mixed Amphetamine Salt Products in the FDA’s Sentinel Distributed Database [777]
Jennifer Lyons | Maria Kempsner | Sarah Dutcher | Amanda Carruth | Kira Leishear | Jennifer Thompson
Corinne Woods | Aaron Hansbury | James Osterhout | Elizabeth Siranosian | Tali Menzin | Sruthi Adimadhayam Sukhminder Sandhu | Silvia Perez-Vilar (United States)
104 – Uptake of Antiviral Treatment of Chronic Hepatitis B: A Panel Data Analysis of 31 Provinces in China (2013-2020) [778]
Hanchao Cheng | Shiyang Liu | Simon Luo | Linh-Vi Le
Zhongdan Chen | Polin Chan | Jing Sun (China)

105 – Patient and Health System Factors Associated with Potentially Inappropriate Opioid Use in Non-Cancer Community-Dwelling Older Adults [779]
Carina D’aiuto | Carlotta Lunghi | Line Guénette
Djamal Berbiche | Karine Bertrand
Helen-Maria Vasiliadis (Canada)

106 – Performance of Three Sets of Criteria for Potentially Inappropriate Prescribing as Diagnostic Tools to Identify Inadequate Drug Treatment [780]
Susanna M. Wallerstedt | Johan Lönnbro
Staffan A. Svensson | Fredrik Hieronymus | Johan Fastbom
Mikael Hoffmann | Naldy Parodi Lopez (Sweden)

107 – Medication Use in the Year Before and After a Diagnosis of Cluster B Personality Disorder: Trends and Patterns Between 2002 and 2018 in Quebec, Canada [781]
Carlotta Lunghi | Lionel Cailhol | Victoria Massamba
Elhadji Anassou Laouan Sidi | Caroline Sirois
Elham Rahme | Louis Rochette | Suzane Renaud
Evens Villeneuve | Marion Koch | Robert Biskin
Pierre David | Cathy Martineau | Alain Lesage (Italy)

108 – Use of Pharmacological and Non-Pharmacological Treatments for Chronic Non-Cancer Pain Among People Using Opioids: A Longitudinal Cohort Study [782]
Ria E Hopkins | Gabrielle Campbell | Louisa Degenhardt
Suzanne Nielsen | Fiona Blyth, Milton Cohen | Natasa Gisev (Australia)

109 – Use of Analgesics in Denmark: A National Survey [783]
Alaa Burghle | Anton Pottegård | Malthe Rasmussen
Belinda Bruun | Jens Roost Hosbjerg | Carina Lundby (Denmark)

110 – Analysis of Discordantly Identified Criteria in STOPP/START – Problems Underlying Poor Reliability in Practice [784]
Naldy Parodi Lopez | Staffan A. Svensson
Susanna M. Wallerstedt (Sweden)

111 – Medication-Related Problems and Medication Incidents in a Neonatal Intensive Care Unit of a Tertiary Care Hospital [786]
Anjali Pradhan | Juny Sebastian (India)

113 – Real World Prevalence and Use of Immune Checkpoint Inhibitors Among Non-Small Cell Lung Cancer Patients in a Comprehensive Cancer Center [787]
Garima Mittal | Benjamin Bates | Maribel Salas
Meera G. Sundararajan | Mackenzie Henderson
Jyoti Malhotra | Haoqian Chen | Soko Setoguchi (United States)

114 – Secular Trends in Utilization of Pharmacologic and Non-Pharmacologic Pain Management Strategies Among Patients with Hip or Knee Osteoarthritis [788]
Nazleen Khan | Jeffrey Katz | Seanna Vine | Seoyoung Kim (United States)

115 – Evaluation of Drug-Utilization and Healthcare Facilities Use in Patients with Ulcerative Colitis and Treated with Biologic Therapy Using Data of An Italian Healthcare Administrative Database: Results from MICHELANGELO Study [789]
Sara Ferraro | Olga Paolelli | Sabrina Giometto
Silvia Tillati | Irma Convertino | Giulia Valdiserra
Emiliano Cappello | Marco Bonaso | Claudia C. Bartolini
Valentina Lorenzoni | Giuseppe Turchetti | Rosa Gini
Matteo Fornai | Ersilia Lucenteforte | Marco Tuccori (Italy)

Niccolò Lombardi | Valentina Brilli | Giada Crescioli
Ippazio Cosimo Antonazzo | Giampiero Mazzaglia
Stefano Fumagalli | Guido Mannai | Alfredo Vannacci
Rosa Gini (Italy)

117 – Development and Validation of a Virtual Reporting Tool for Diabetic Patients’ Conventional and Herbal Medicine Use and Treatment Outcomes at a National Referral Hospital in Kenya [791]
Sylvia Atisa Opanya | Esther N. Mburi
David N. Kimonge (Kenya)

118 – Factors Associated with Non-Persistence with Statin Treatment in Patients with Peripheral Arterial Disease [792]
Martin Wawruch | Jan Murin | Tomas Tesar (Slovakia)
Daniel Prieto-Alhambra | Sara Khalid | Antony G. Sena
Peter Rijnbeek (United Kingdom)

120 – Distribution of Samples of a New Preventive Migraine Drug and Potential Implications for Validity of Pharmacoepidemiology Studies Using Administrative Data [794]
Sarah Hoffman | Stephan Lanes | Christopher L. Crowe
Kimberly M. Daniels | Francis Mawanda
Krista Marie M. Schroeder (United States)

121 – Patterns of Psychotropic Medicine Use and Initiation in the Year Prior to Death by Suicide: A Population-based Study [795]
Andrea Schaffer | Nicholas A Buckley | Jennifer Schumann
Jessy Lim | Rose Cairns | Kate Chitty (Australia)

122 – Trends and Characteristics Associated with Nonadherence to Antidepressants Among Breast Cancer Survivors with Depression [796]
Weihsuan Jenny Lo-Ciganic | Ching-Yuan Chang
Juan Hincapie-Castillo | Haesuk Park | Coy Helderman
Vakaramoko Diaby | Seonkyeong Yang | Debbie Wilson (United States)

123 – Opioid Prescription Dispensing Patterns Among Patients with Schizophrenia or Bipolar Disorder [797]
Brittany Roy | Jinheng Li | Cathy Lally | Sarah C. Akerman
Maria A. Sullivan | James Fratantonio | W. Dana Flanders,
Made Wenten (United States)

Eileen Lee | Benjamin Bates | Nathaniel Kuhrt | Chang Xu
Aayush Visaria | Soko Setoguchi (United States)

125 – Utilization of Factor Xa Inhibitors and Warfarin in Obese Nonvalvular Atrial Fibrillation (NVAF) Patients: Analysis of University Health Center Electronic Medical Records in the United States (US) [799]
Mohammed Alsultan | Ana L Hincapie | Patricia Wige
Diego F. Cuadros | Alex C. Lin | Jeff J. Guo (United States)

126 – Prescribing Patterns for Glucagon-like Peptide-1 Receptor Agonists Following the Introduction of Semaglutide in Denmark and Norway [800]
Lotte Rasmussen | Jacob Harbo Andersen | Kari Furu
Øystein Karstad | Philip Brenner | Anton Pottegård (Denmark)

127 – Use of Riluzole Beyond Approved Therapeutic Indications in Three Italian Regions [801]
Ursula Kirchmayer | Marco Finocchietti | Niccolo’ Lombardi
Giada Crescioli | Emiliano Cappello | Giulia Valdiserra
Marco Tuccori | Alfredo Vannacci | Olga Paoletti
David Franchini | Marcello De Giorgi | Silvia Cascini
Anna Maria Bargagli | Teresa Anna Cantisani
Maria Grazia Celani | Paola Brunori | Nicola Vanacore
Francesco Sciancalepore | Antonio Ancidoni
Roberto Bonaiuti | Giulia Hyeraci | Rosa Gini
Giampaolo Bucaneve | Rosalba Elisabetta Rocchi
Mariangela Rossi | Valeria Belleudi | Antonio Addis (Italy)

128 – Profile of Statin Usage in Post-Myocardial Infarction Patients in a General Hospital in Banjarmasin During 2016-2020 [802]
Alfi Yasmina | Dwi Laksono Adiputro | Rizka Aprillia
Maghfirah | Djialluddin Djialluddin | Pandji Winata
Nurikhwan (Indonesia)

129 – ANTIBACDUS-PAN: Antibacterial Utilization Among Adult Patients at Koç University Hospital Before and During COVID-19 Pandemic Within 12-Months Period: A Hospital Pharmacoepidemiology Study [803]
Sinem Ezgi Gulmez | Mustafa Guldan | Ege Anlı Uçar
Mehmet Batuhan Karakuş | Selin Merve Şahin
Uluman Şişman | Arzu Baygül (Turkey)

130 – Buprenorphine Utilization Trends Resulting from Multiple State Insurance Reimbursement Policy Changes: An Exploratory Joinpoint Analysis [804]
Amie Goodin | Michael Maguire | Juan Hincapie-Castillo (United States)

131 – Children with COVID-19: The Real-World Hospital Experience [805]
Lawrence Rasouliyan | Vikas Kumar | Amanda G. Althoff
Stacey Long | Mitesh B. Rao (United States)
132 – Long-Term Trajectories of Prescription Opioid Use in New South Wales, Australia [806]
Natasa Gisev | Luke Buizen | Andrea Schaffer
Benjamin Daniels | Selal-Anne Pearson | Timothy Dobbins
Fiona Blyth | Sarah Larney | David C. Currow
Andrew Wilson | Louisa Degenhardt (Australia)

133 – Drug Utilization of Paliperidone and Risperidone in Adolescent Schizophrenia Patients in China [807]
Sijia Dong | Meng Shu | Tao Wu | Yongjing Zhang
Hong Qiu Md, PhD | Huaning Wang | Jun Chen (China)

134 – Antithrombotic Therapy in Atrial Fibrillation Patients with Intracranial Hemorrhage: Retrospective Cohort Study with Administrative Data in Japan [808]
Shinobu Imai | Masato Koizumi | Chi-Chuan Wang
Euna Han | Manabu Akazawa (Japan)

135 – Characteristics and 1-Year Mortality Outcome of ACS Patients Receiving ACEIs/ARBs: A 10-Year Retrospective Analysis of the Malaysian National Cardiovascular Database Registry [809]
Siti Zaleha Suki | Nur Lisa Zaharan
Ahmad Syadi Mahmood Zuhdi | Abqariyah Yahya (Malaysia)

136 – Antipsychotic Utilisation Within Primary Care in England from 2010-2020 [810]
Fatema Mahmoud | Amy Pavis | Amanj Kurdi (United Kingdom)

137 – Utilisation and Prescribing Patterns of Antipsychotics in Primary Care in Wales (2010-2020) [811]
Haya Yasin | Rania Lazrek | Amanj Kurdi (United Kingdom)

138 – Medication Errors Reported to the Danish Patient Safety Database During a Five-Year Period (2014-2018) [812]
Olga Tchijevitch | Jesper Hallas | Søren Bie Bogh
Søren Birkeland (Denmark)

139 – Investigation on Primary Management of Community-Acquired Pneumonia at the Emergency Department in Vietnam [813]
Tien Hoang Tran | Nhu Quynh Tran
Trang Nguyen Doan Dang (Vietnam)

140 – Impact of Cardiovascular Comorbidities on Bevacizumab Effectiveness and Safety in Older Patients with Metastatic Colorectal Cancer [814]
Pernelle Noize | Amandine Gouverneur | Clélia Favary
Jérémy Jové | Magali Rouyer | Emmanuelle Bignon
Francesco Salvo | Achille Tchalla | Elena Paillaud
Thomas Aparicio (France)

141 – Definition and Validation of Case Detection Algorithms Using Quebec Medico-Administrative Databases (Med-Echo and RAMQ) for Depression Among Seniors [815]
Giraud Ekanmian | Carlotta Lunghi | Helen-Maria Vasiliadis
Line Guénette (Canada)

142 – Clinically Significant Drug Interaction Alerts in Older Patients, and Related Medically Justified Action [816]
Staffan A. Svensson | Carina Tukukino | Naldy Parodi Lopez
Susanna M. Wallerstedt (Sweden)

143 – Shifting Patterns of Hospice Medication Use and Medicare Payments in the United States Between 2014-2018 [817]
Jennifer Tjia | Joshua Rumbut | Jon Furuno (United States)

144 – Assessment of Concomitant Opioid and Benzodiazepine Use and Fall Events in Older Adults with Cancer in the United States (2006-2017) [818]
Christy A. Xavier | Neal Bhachawat | Walter Agbor
Rafia Rasu (United States)

145 – The Link Between Prescription Opioid Intensity and Fall Events in Older Cancer Patients [819]
Christy A. Xavier | Walter Agbor | Neal Bhachawat
Rafia Rasu (United States)
146 – Variation in The Potentially Inappropriate Use of Antipsychotic Medications in Australian Long Term Care Facilities [820]
Daniela Gnjidic | Mouna J Sawan | Alexander Clough
Jodie Hillen | Andrew Zullo | Daniela Moga (Australia)

147 – Beta-Agonists and Risk of Parkinson's Disease: Meta-Analysis of Pharmacoepidemiological Studies [821]
Ambrish Singh | Md Salman Hussain | Benny Antony
(J Australia)

148 – Potentially Harmful Medication Prescribing to Nursing Home Residents with Dementia: The Role of Prescriber Specialization in US Nursing Homes [822]
Andrew Zullo | Kira Ryskina | Derrick Lo | Tingting Zhang
Lauren Gerlach | Julie Bynum | Theresa Shireman
(United States)

149 – Trends in COVID-19-Related Medication Use in United States Nursing Homes [823]
Andrew Zullo | Yuan Zhang | Kaley Hayes | Yoojin Lee
(United States)

150 – Identification of Frail Older Adults Using Routine Primary Care Data: Accuracy of Four Electronically Derived Algorithms [824]
Jetty Overbeek | Karin Swart | Marieke Blom | Amber Van
Der Heijden | Giel Nijpels | Hein Van Hout | Petra Elders | Ron Herings (Netherlands)

151 – Evaluation of Downstream Use of Medication Treatment for Overactive Bladder Following Potential Calcium Channel Blocker – Loop Diuretic Prescribing Cascade [825]
Scott M Vouri | Grace (Hsin Min) Wang | Earl Morris
Laurence Solberg | Michael Daniels | Carl Pepine
Todd Manini | Daniel Malone | Almut Winterstein
(United States)

152 – Use of Large-Scale Electronic Health Record Data to Examine Precise Antihypertensive Medication Exposures Immediately Before a Fall Among US Nursing Home Residents [826]
Kaley Hayes | Lori A Daielo | Andrew Zullo | Sarah Berry
(United States)

153 – Administrations of Pro Re Nata (PRN) Analgesics Among Skilled Nursing Facility Residents Following a Hip Fracture [827]
Kaley Hayes | Melissa Reister | Yuan Zhang
Francesca Beaudoin | Andrew Zullo (United States)

154 – Comparison of Approaches to Handle Missing Data for Estimating Longitudinal Patterns of Anticholinergic and Sedative Drug Load Among Older Adults [828]
Shahar Shmuel | Virginia Pate | Emilie Duchesneau
Jessie Edwards | Alan Kinlaw | Jennifer Lund (United States)

155 – Statin Discontinuation in Persons with and Without Alzheimer's Disease [829]
Heidi Taipale | Mai Thi Phuong Vu | Raimo Kettunen
Anna-Maija Tolppanen | Sirpa Hartikainen (Finland)

156 – Patterns of Statin Use in Oldest Old in Quebec, Canada, 2008-2018 [830]
Marc Simard | Caroline Sirois | Marie-Eve Gagnon
Véronique Boiteau | Annie Maltais (Canada)

157 – Changes in Multimorbidity Burden and Healthcare Utilization Before and After a Diagnosis of Dementia: A Claim-based Nationwide Cohort Study [831]
Shih-Tsung Huang | Liang-Kung Chen | Fei-Yuan Hsiao
(Taiwan)

158 – Patterns of Care Among Older Adults Diagnosed with Locally Advanced Esophageal Cancer Eligible for Trimodal Therapy [832]
Charles Gaber | Nicholas J. Shaheen | Robert Sandler
Jessie Edwards | Hazel B. Nichols | Hanna K. Sanoff
Jennifer Lund (United States)

159 – The Comparative Effectiveness of Trimodal Therapy Versus Definitive Chemoradiation in Older Adults with Locally Advanced Esophageal Cancer [833]
Charles Gaber | Nicholas J. Shaheen | Jessie Edwards
Robert Sandler | Hazel B. Nichols | Hanna K. Sanoff
Jennifer Lund (United States)

160 – Influenza Vaccine Uptake Among United States Nursing Home Residents: Measuring Geographic Variation in Racial Health Disparities [834]
Joe Silva | Chanelle Howe | John Jackson
Barbara Bardenheier | Melissa Reister | Robertus Van Aalst
Matthew Loiacono | Andrew Zullo (United States)

161 – Trends in Statin Initiation for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Older Adults [835]
Earl Morris | Kelly Ma | Rachel Reise | Nawaf Tokatly
Cherry Tortor | Scott M. Vouri (United States)
162 – Less Medicines in Older Patients in the Netherlands, The Lemon Study [836]
Jamila Abou (Netherlands)

164 – Prevalence of Drug-Drug Interactions in Older Community-Dwellers: A Systematic Review and Meta-Analysis [838]
John E. Hughes | Catherine Waldron | Kathleen E. Bennett
Caitriona Cahir (Ireland)

165 – The Association of Gabapentin Use and Change of Motor Functions in Older Adults with Normal Cognition [839]
Gyeon Oh | Daniela Moga | David Fardo | Erin L. Abner
(United States)

166 – Impact of Health Literacy on Medication Adherence in the Elderly [840]
Jehath M. Syed | Prathibha Pereira | Chalasani Sri Harsha
Ramesh Madhan | Tejaswini C. J. | Shilpa Avari-Beeli
Kshama Ramesh (India)

167 – Risk of Intrinsic Capacity Decline Associated with Potentially Inappropriate Medications and Polypharmacy in Elderly Patients [841]
Shao-En Weng | Tai-Yin Wu (Taiwan)

168 – Polypharmacy and The Risk of Fracture in Older Adults: A Systematic Review [842]
Marie-Eve Gagnon | Denis Talbot | Florence Tremblay
Marc-Antoine Tourville | Caroline Sirois (Canada)

169 – Prevalence of Frailty Among Older Inpatients with Dementia and Its Association with Medication Use: A Retrospective Cohort Study [843]
Linda G. Koria | Mouna J. Sawan | Mitchell Redston
Danijela Gnjidic (Australia)

170 – Evaluating Provider and Pharmacy Discordance in Potential Calcium Channel Blocker – Loop Diuretic Prescribing Cascades [844]
Asinamai Medugu Ndai | Earl Morris | Almut Winterstein
Scott M. Vouri (United States)

171 – US Emergency Department Visits for Prescription Opioid Adverse Events in Older Adults, 2016 to 2018 [845]
Christina Greene | Rose Radin | Saranrat Wittayakorn
Jennifer G. Naples | Candice L. Collins | Judy Staffa
(United States)

172 – Use of Medicines by the Elderly in Portugal in 2019 [846]
Ana Araujo | Elisabete Fernandes | Inês Ruivo
Claudia Furtado (Portugal)

173 – The Association Between Age and Low-Density Lipoprotein Cholesterol Response to Statins [847]
Giulia Corn | Mads Melbye | Mark A. Hlatky | Jan Wohlfahrt
Marie Lund (Denmark)

174 – Symptomatic and Preventive Medication Use in Frail Nursing Home Residents in Australia and Japan [848]
Shin J Liau | Shota Hamada | Agathe D Jadczak
Nobuo Sakata | Samanta Lalic | Renuka Visvanathan
J. Simon Bell (Australia)

175 – Association of Anticholinergic Burden and Risk of Cardiovascular Events: A Case-Crossover Study [849]
Wei-Ching Huang | Shuei-He Yang | Hsiang-Te Tsai
Edward Lai (Taiwan)

176 – Falling in Love with Nursing Home Electronic Health Record (EHR) Data: Greater Understanding of the Nature of Falls from Harnessing Information in Nurses’ Notes [850]
Samuel C. Spevack | Anam Khan | Kate Lapane
Jowanna Malone | Dustin Burns | Catherine Rogers Murray
Ekaterina Cleary | David D. Dore (United States)

177 – Perioperative Gabapentin Use and Adverse Clinical Events in Older Adults After Major Surgery: A Retrospective Cohort Study [851]
Chan Mi Park | Jessica Lie | Sharon K Inouye
Edward Marcantonio | Eran D. Metzger | Brian Bateman
Su Been Lee | Raisa Levin | Dae Hyun Kim (United States)

178 – Trajectories of Opioid Use Around Spousal Bereavement: A Nationwide Register-based Cohort Study of Older Adults [852]
Pierre-Olivier Biotiere | Gérard Maura | Jonas Wastesson
Kristina Johnell (Sweden)

179 – The Incidence of Benzodiazepine and Benzodiazepine-Related Drug Use in People with or without Parkinson’s Disease Before and After the Diagnosis [853]
Anna-Maija Tolppanen | Veera Lonka | Sirpa Hartikainen
Miia Tiihonen | Marjaana Koponen (Finland)
HEALTH ECONOMICS/OUTCOMES RESEARCH

Coralie Lecomte | Harriet Dickinson | Hanaya Raad
Jan Rudnik | Olga Pilipczuk | Mireia Aguila | Sahar Sayed
Dorothee B. Bartels | François-Xavier Lamy (France)

181 – Do More Rigorously Tested Drugs Garner Higher Prices Upon Market Launch? [855]
Jill Curran | Anni Fan | Jeromie Ballreich | Thomas J. Moore
G. Caleb Alexander (United States)

182 – Health-Related Quality of Life of Indonesian Cancer Patients: Comparison of EORTC QLQ C30 and EQ5D Questionnaires [856]
Dyah A. Perwitasari | Fredrick D. Purba
Susan F. Candradewi | Bayu Septiantoro (Indonesia)

183 – Safety and Efficacy of Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone in Moderate-To-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis [857]
Maya T. | Alisha Mathew | Elstine Anbu Raj S.
Rajesh Vilakkathala (India)

184 – The Quality of Reporting Methods and Results of Cost-Effectiveness Analyses in India: A Methodological Systematic Review [858]
Karun Donthineni | Christy Thomas | Krishna Undela (India)

185 – Assessment of Financial Toxicity and Its Association with Quality of Life Among Radiation Oncology Patients: A Cross-Sectional Study in India [859]
Mukhtar Ahmad Dar | Richa Chauhan
Sameer Dhingra (India)
<table>
<thead>
<tr>
<th>Poster Session B</th>
</tr>
</thead>
</table>
| **186** – The Best of All Worlds: Development of a Consolidated Data Model to Expand the Ability to Generate Real-World Evidence [860]  
Ariel Berger | Marielle Bassel | Teresa Wilcox  
Kathleen Hines (United States) |
| **187** – Clinical and Economical Impact of Parenteral Nutrition Among the Neonates Admitted to Neonatal Intensive Care Unit (NICU): A Prospective Interventional Study [861]  
Sai Siddharth M. | Juny Sebastian (India) |
| **188** – Patient-Reported Challenges for Self-management of Asthma; Findings of a Focused Group Study [862]  
Shilpa Palaksha | Mahesh P. A. | Diba Khonglein (India) |
| **189** – Incidence of Adverse Events of Special Interest in The Pre-Covid and Active Covid ERA as Historical Comparators for Post-Marketing Safety Surveillance of SARS-CoV-2 Vaccines [863]  
Katie Mues | Christopher Bush | Daina Esposito  
Deesha Patel | Alice Gelman | Sahar Syed  
Priyadarshani Dharia | David Martin (United States) |
| **190** – Health Related Quality of Life in HIV Patients: A Decennial Data Systematic Review and Meta-Analysis [864]  
Balaji Sathyarayana Gupta | Tenzin Thinley  
Rahul Krishna Puvvada | Ramesh Madhan (India) |
| **191** – Statistical Evaluation of Surrogate Endpoints to Optimise Trial Design and Speed Up Decision Making Through the Use of Early Outcomes: A Case Study Using Observational Patient-Level Data [865]  
Clementine Nordon Sanchez | Kirsty Rhodes  
Mario Ouwins (United Kingdom) |
| **192** – Systematic Literature Review on the Cost-effectiveness of Current Treatments for Chronic Cough [866]  
Jonathan Schelfhout | Vishal Bali | Ada Adriano  
Aidan Byrne | Katherine Akers | Andrew Frederickson (United States) |
| **193** – Systematic Literature Review on the Economic Burden of Chronic Cough [867]  
Jonathan Schelfhout | Vishal Bali | Ada Adriano  
Aidan Byrne | Katherine Akers | Andrew Frederickson (United States) |
| **194** – Systematic Literature Review on Health-Related Quality of Life Associated with Chronic Cough [868]  
Jonathan Schelfhout | Vishal Bali | Ada Adriano  
Aidan Byrne | Katherine Akers | Andrew Frederickson (United States) |
| **195** – Association Between Health Status and Access to Treatment in a Sample of Women Recovering from Substance Use Disorders [869]  
Phuong Tm Tran | Haeyoung Lee | Kay Connors  
Brijan Fellows | Olawunmi Ibraheem | Susan Dosreis (United States) |
| **196** – The Effect of Generic Market Entry on HIV Treatment Cost in Portugal [870]  
Claudia Furtado | Inês Henriques | Teresa Aires (United States) |
| **197** – Evaluation of a Community Pharmacy-based Diabetes Care: Patients Self-Reported Outcomes Using Validated Questionnaires and Clinical Outcomes [871]  
Fatima Salawu Abdulhakeem Ikolaba | Ellen I Schafheutle  
Douglas Steinke (United Kingdom) |
| **198** – Diagnostic Suspicion Bias in Studies of Thiazide and Non-Melanoma Skin Cancer – A Cohort Study [872]  
Anat Fisher | Jason D. Kim | Colin Dormuth (Canada) |
| **199** – The Care Cascade of Hepatitis C Virus in The Direct-Acting Antiviral Era: A Systematic Review and Meta-Analysis [873]  
Pilar Hernandez-Con | Hyun Jin Song | Ikenna Unigwe  
Munaza Riaz | Natalie Ourhaan | Xinyi Jiang  
Debbie Wilson | Amanda Joseph  
Haesuk Park (United States) |
| **200** – Cost of Illness and Economic Burden of COVID-19 in Private Tertiary Care Hospital [874]  
Rajesh Vilakkathala | Chaitanyamayee Kalakota  
Elstion Anbu Raj S. | Chandrasekar Uk | Muralidhar Varma  
Vijayanarayana Kunhikatta | Mahadev Rao  
Suruivelraj M. (India) |
| **201** – Assessment of Barriers for Medication Non-Adherence in Ambulatory Psychiatric Patients at Tertiary Care Hospital [875]  
Srikanth Malavalli Siddalingegowda | Premitha M. R.  
Kishore M. | Atiquilla Shariff | Samaksha P. B. (India) |
202 – Determinants of Treatment Outcomes in HIV Patients with Opportunistic Infections: A Prospective Study in Southern India [876]
Balaji Sathyanarayana Gupta | Vaishnavi Suryadevara
Ramesh Madhan (India)

203 – Healthcare Resource Utilisation Associated with Intermittent Oral Corticosteroid Use in Asthma [877]
William Henley | Heath Heatley | Trung N. Tran
Arnaud Bourdin | Andrew Menzies-Gow | David J. Jackson
Ekaterina Maslova | Jatin Chaparani | Victoria Carter
Jeffrey Shi Kai Chan | Cono Ariti | John Haughney
David Price (United Kingdom)

204 – Treatment Outcomes for Advanced and Recurrent Endometrial Cancer Following Platinum-based Chemotherapy in Canada [878]
Diana Martins | Dylan O’sullivan | Devon Boyne
Winson Y. Cheung | Odette Allonby | Justin Riemer (Canada)

205 – Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI) [879]
Matthew Wong-Pack | Elliot Hepworth
Mohammad Movahedi | Claire Bombardier | Arthur Lau
Sibel Aydin (Canada)

206 – Comparative Effect of Oral Anticoagulants on Home Time Loss and Cost: The Role of Frailty [880]
Lily Bessette | Joshua Lin | Mehdi Najafzadeh
Su Been Lee | Darae Ko | Dae Kim (United States)

207 – Medical Conditions Associated with Hospitalization Among Outpatients with COVID-19: Findings from Real-World Data [881]
Michael J. Munsell | Mark Friedman | Joseph Menzin (United States)

208 – Impact of Immunosuppressant Therapies and Transplantation on Health-Related Quality of Life Among Renal Transplant Recipients at a National Referral Hospital in Kenya [882]
Sylvia Atisa Oponga | Phaustine Adhiambo
David Nyamu (Kenya)

209 – Consumers Perceptions, Expectations & Satisfaction About Patient Care Services Provided by The Community Pharmacist [883]
Ur Rakshith | Atiqulla Shariff | Srikanth Malavalli Siddalingegowda (India)

210 – The Association of Opioid Use with Risk of ICU Admission and Mortality in the Adult Dutch Population [884]
Ajda Bedene | Willem M. Lijfering | M Sesmu Arbous
Frits R. Rosendaal | Albert Dahan | Eveline La Van Dorp (Netherlands)

Brenna Brady | Liisa Palmer (United States)

Brenna Brady | Liisa Palmer (United States)

214 – Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission [888]
Jeffrey Curtis | Kathleen Fox | Fenglong Xie | Yujie Su
David Collier | Cassie Clinton | Hafiz Oko-Osi (United States)

215 – Determining Patient Preferences for the Medical Management of Osteoporosis Using Conjoint Analysis [889]
Jeffrey Curtis | Xiaoyu Liu | Katherine Makaroff
Carine Khalil | So Yung Choi | Brennan Spiegel (United States)

Abdallah Naser | Mohmmed Hasan Yasin (Jordan)

Abdallah Naser | Dana Al Thabbah | Mohammad Al Mahirah (Jordan)

218 – Association of Joint Replacement Registries with Burden of Revision Changes [892]
Charles Ebuka Okafor | Son Nghiem | Joshua Byrnes (Australia)
219 – Screening For, Diagnosing and Surgically Treating Breast Cancer in the United States: Impact of the COVID-19 Crisis [893]
Brian Buysse | Charles Coombs | Jessica D. Albano
(United Kingdom)

220 – Cost-Effectiveness of IV Antibiotics Therapy for Children with Acute Gastroenteritis in a Secondary Care Hospital in South India [894]
Jose J. Kochuparambil | Aleena Issac | Jais Vayaliikkunnel (India)

221 – Adjuvant Radiation Therapy and Mortality in Older Women with Early-Stage Endometrial Cancer: An Analysis Using The SEER-Medicare Linkage [895]
Jihye Park | Jennifer Lund | Erin E Kent | Chelsea Anderson
Wendy Brewster | Andrew F. Olshan | Hazel B. Nichols
(United States)

222 – Cardiovascular and Renal Complications Among Patients with Chronic Kidney Disease (CKD) in the Netherlands [896]
Jetty Overbeek | Hilda J. De Jong
Martine Oudenhuijzen-Taanman | Jan Pander
Fernie J. Penning-Van Beest | Martine Oudenhuijzen
Marc Vervloet (Netherlands)

223 – Incidence of RSV Lower Respiratory Tract Infections Among Infants Considering Effects of Palivizumab Immunoprophylaxis [897]
Almut Winterstein | Phuong Tran | Sabina O. Nduaguba
Renata Shih (United States)

224 – Operating Characteristics of COVID-19 Diagnosis Code in Hospital Settings [898]
Cristiano Moura | Coraline Danieli | Fangming Liao
Surain Roberts | Fahad Razak | Amol A. Verma
David L. Buckeridge | Sasha Bernatsky (Canada)

225 – Healthcare Cost of Retreatment Following Ureteroscopy or Percutaneous Nephrolithotomy for Urinary System Stone Disease [899]
Stephen S Johnston | Brian Po-Han Chen | Pragya Rai
Philippe Grange | Harikumaran Dwarkanathan | Tony Amos
Barbara H. Johnson | Sudip Ghosh | Noor Buchholz
(United States)

226 – Risk of Second Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients with Extended Anticoagulant Treatment: A Retrospective Cohort Study [900]
Haesuk Park | Hye-Rim Kang | Pei-Lin Huang
Eric A. Dietrich | Christina E. Deremer
Weihsuan Jenny Lo-Ciganic (United States)

227 – Self-Reported and Objectively Measured Productivity and Absence Costs and Comorbidity Assessments for Employees with Back and Joint Disorders [901]
Richard A. Brook | Ian A. Beren | Alek A. Drnach
Nathan L. Kleinman | Eric M Rosenberg
Justin L Schaneman (United States)

228 – Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employees with Breast, Skin, GI, Female, Male, and "Other" Cancers [902]
Richard A. Brook | Nathan L. Kleinman | Ian A. Beren
Alek A. Drnach | Justin L. Schaneman | Eric M. Rosenberg
(United States)

229 – Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Cancer [903]
Richard A. Brook | Ian A. Beren | Nathan L. Kleinman
Alek A. Drnach | Justin L. Schaneman | Eric M. Rosenberg
(United States)

230 – Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines [904]
Richard A. Brook | Ian A. Beren | Nathan L. Kleinman
Alek A. Drnach | Justin L. Schaneman | Eric M. Rosenberg
(United States)

231 – Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Agency for Healthcare Research and Quality Skin Conditions [905]
Richard A. Brook | Ian A. Beren | Nathan L. Kleinman
Alek A. Drnach | Justin L. Schaneman | Eric M. Rosenberg
(United States)

232 – Real-World Cost-Effectiveness of Adrenocorticotropic Hormone Versus Oral Prednisolone for Children with West Syndrome [906]
Nagita Devi | Priyanka Madaan | Dipika Bansal
Jitendra Kumar Sahu (India)
233 – Ticagrelor for Acute Coronary Disease to Prevent Cardiovascular Events: Cost-Effectiveness Analysis in Indonesia [907]
Jarir At Thobari | Jonathan Hasian Haposan (Indonesia)

234 – Challenges of Using Real-World Evidence for Regulatory Decisions: 4 Key Issues [908]
Thomas J. Moore | Sonal Singh (United States)

235 – Healthcare Costs of COVID-19 Versus Flu and Pneumonia – A Payer Perspective [909]
Chantal Holy | Fayolah Richards | Brandon Patterson
Jill Ruppenkamp | Ronita Debnath | Antoine El Khoury
Jessica Demartino | Brahim Bookhart | Paul Coplan
(United States)

236 – Cost of Long COVID-19 Following Severe Disease – A Healthcare Database Analysis [910]
Chantal Holy | Brandon Patterson | Jill Ruppenkamp
Fayolah Richards | Jessica Demartino | Ronita Debnath
Brahim Bookhart | Antoine El Khoury | Paul Coplan
(United States)

Chantal Holy | Brandon Patterson | Jill Ruppenkamp
Fayolah Richards | Ronita Debnath | Antoine El Khoury
Jessica Demartino | Brahim Bookhart | Paul Coplan
(United States)

238 – A Web-based Survey of Patients Dispensed Viagra Connect Behind the Counter in the UK: An Evaluation of the Effectiveness of Additional Risk Minimization Measures [912]
Shaantanu Donde | Muhammad Younus | Jim Li
Joanna Lem | David Taylor | Janine Collins | Kelly H Zou
(United Kingdom)

240 – Estimated Costs of Severe Adverse Drug Reactions Resulting in Hospitalization in the Veterans Health Administration [914]
Anthony Au | Sherrie L. Aspinall | Von Moore
Francesca Cunningham | Peter Glassman (United States)

241 – The Health Economics of Metastatic Hormone Sensitive and Non-Metastatic Castration-Resistant Prostate Cancer – A Systematic Literature Review [915]
Ivan Yanev | Alice Dragomir | Jessy Gatete Jr. (Canada)

LATE BREAKERS

242 – Reducing Bias from Chronic Exposure in Case-Crossover and Case-Time-Control Studies: A Simulation Study [916]
Kiyoshi K. Kubota | Thu-Lan Kelly (Japan)

244 – Cannabidiol Exposures in Children, National Poison Data System, July 2014–June 2021 [918]
Silvia Perez-Vilar | Sara Karami | Karen Long | Kira Leishear
(United States)

245 – Spontaneous Abortions Case Definition and Gestational Age Estimation Methodological Differences [919]
Aziza Jamal-Allial | Maria Guzman | Kerrin Gallagher
Ramya Avula | Kimberly M. Daniels | Aaron B. Mendelsohn
(United States)

246 – Effectiveness of Monoclonal Antibodies and Antivirals Against Severe COVID-19 Outcomes in Community Settings in England: An Emulated Target Trial Using the OpenSAFE Platform [920]
John R Tazare | Linda Nab | Bang Zheng | Amelia Green
Helen Curtis | William Hulme | Alex Walker | Anna Schultz
Krishnan Bhaskaran | Stephen Evans | Ben Goldacre
Brian Mackenna | Ian Douglas | Laurie Tomlinson
(United Kingdom)

247 – Comparative Effectiveness of 5-Alpha-Reductase Inhibitors Vs. Alpha-Blockers on the Long-term Risk of Progression of Benign Prostatic Hyperplasia [921]
María B. Bengtsen | Uffe Heide-Jørgensen | Michael Borre
Mette Nørgaard (Denmark)

248 – The Role of The Excess Weight Status in The Risk of Hospitalizations for Patients with Depression Prescribed Obesogenic Antidepressants [922]
Svetlana Puzhko | Tibor Schuster | Christel Renoux
Tracie A. Barnett | Kimberly Munro | Gillian Bartlett-Esquillant
(Canada)

249 – Real-Time Survey of Vaccine Safety of the mRNA-1273 SARS-CoV-2 Vaccine in Workplace Vaccination at Keio University [923]
Azusa Hara | Kaho Okumura | Isa Inada | Daisuke Sugiyama
Takahiro Hoshino | Takahiro Yakoh | Hirokatsu Yokoyama
Hisashi Urushihara (Japan)
250 – The Risk of Posterior Reversible Encephalopathy Syndrome (PRES) with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases [924]
Luis Velez-Nandayapa | Anusmita Das | Amit Saxena
Vishaka Parulekar | Naveen Chhabra | Miguel Izquierdo
Pierre De Zeeuw | Edwin Schaart | Johannes Eisinger (Switzerland)

253 – Best Practice Implementation Project on Reporting of COVID-19 Vaccine Adverse Events Following Immunization in Kenya [927]
Henry Amdany | Barbara Koech (Kenya)

254 – Incidence of Rhabdomyolysis in the Elderly Patients in Combination Therapy of Cytochrome 3A4 Substrate and Inhibitor with the Korean Elderly Claims Data [928]
Sukhyang Lee | Junhyuk Chang | Rae Woong Park (South Korea)

255 – The Impact of Type 2 Diabetes on Complications After Primary Breast Cancer Surgery: A Danish Population-based Cohort Study [929]
Kasper Kjærgaard | Jannik Wheler | Looket Dihge
Peer Christiansen | Signe Borgquist | Deirdre Cronin-Fenton (Denmark)

Tanja Mueller | Amanj Kurdi | Aidan Morrison | Euan Proud
Niketa Platt | Karen Gronkowski | William Malcolm
Marion Bennie (United Kingdom)

257 – Totality of Evidence Evaluating the Effectiveness of Repurposed Therapies for COVID19: What Can We Learn from Real-World Studies & Randomized Controlled Trials? [931]
Nawab Qizilbash | Jaap Manndema | Hugh E. Montgomery
Louis Dron | Shuai Fu | Estelle Russek-Cohen
Christina Bromley | Samer Mouksassi | Amy Lalonde
Phil Ambery | Doug Mcnair | Stuart Pocock
Nevine Zariffa (Spain)

258 – Risk of Incident Venous Thromboembolism Associated with Atopic Dermatitis and Treatment with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis [932]
Ching-Chi Chi | Tai-Li Chen (Taiwan)

259 – Trends in Cardiovascular Medication Prescription Before and During the COVID-19 Pandemic [933]
Ugochinyere Vivian Uka | Robert Platt
Hedvig Nordeng (Canada)

260 – Establishment and Optimization of an Automatic Monitoring Module for Epileptic Seizures in Inpatients Based on HIS [934]
Jingchuan Lu (China)

261 – Analysis of 863 Spontaneous Cases of Drug-Related Severe Nervous System Adverse Reactions [935]
Jingchuan Lu (China)

262 – Analysis and Signal Mining on 1177 Reports of Adverse Drug Reactions Related to Antibacterial-Induced Coagulopathy [936]
An Fu (China)

Annika Joedicke | Martí Català | Edward Burn
Trishna Rathod-Mistry | Antonella Delmestri
Daniel Prieto-Alhambra (United Kingdom)

264 – Time to Reach an Adequately Powered Sample Size to Detect Risk of Major Congenital Malformations Using a Prospective Observational Pregnancy Registry and An Administrative Claims Database [938]
Sydney K. Willis | Geetika Kalloo | Kristen Hahn
Stephan Lanes | Matthew Reynolds | Emily W. Bratton
Lockwood Taylor (United States)

265 – Clinical Outcomes of Ceftazidime/Avibactam Therapy in The Treatment Carbapenem-Resistant Enterobacteriaceae (CRE) During the COVID-19 Pandemic: A Single Center Study [939]
Asmaa A. Abbas | Mohammad F. Zaitoun | Nehad Ahmed
Rozan Radwan | Manal Al Gethamy | Abdulmoeen Alqarni
Lujain Babkair | Abdul Haseeb Hanif (Saudi Arabia)

266 – Did Publication Urgency During the Pandemic Trade-Off for Epidemiological Rigorousness? Results from An Umbrella Review [940]
Grammati Sarri | Luke Zabotka | Andreas Freitag
Ravinder Claire | Grace Wangge (United Kingdom)
MEDICAL DEVICES

267 – Real-World Continuous Glucose Monitoring in Adults with Type 1 and Type 2 Diabetes [941]
Devin Abrahami | Sonia Hernandez-Diaz | Elisabetta Patorno (United States)

268 – Propensity Score Estimation Strategies for Inclusion of Surgeon Confounders Under Different Surgeon Impact on Treatment Allocation for Medical Device Epidemiology: A Simulation Study [942]
Mike Du | Victoria Y Strauss | Sara Khalid
Daniel Prieto-Alhambra (United Kingdom)

269 – Use of Intra-Uterine Devices in France in 2019 and Continuation Use 1 Year After: A Nationwide Observational Study [943]
Noemie Roland | Béragonère Baricault | Rosemary Dray-Spira
Alain Weill | Lise Duranteau | Mahmoud Zureik (France)

270 – Does The Shape of the Copper Intrauterine Device Affect Device Expulsion? Results from the Ongoing European Active Surveillance Study on LCS12 [944]
Tanja Boehnke | Anja Bauerfeind | Lisa Eggebrecht
Camille Cellier | Jens Lange | Klaas Heinemann (Germany)

271 – Operative Time Among Women Undergoing Hysterectomy in Two Hospital Systems: Predictors and The Relative Contributions of Patient/Procedure Factors vs Individual Surgeons [945]
Stephen S. Johnston | Divya Chakke | Keerthana Valsan
Barbara H. Johnson (United States)

272 – Real-World Performance of SARS-CoV-2 Serology Tests in the United States [946]
Carla V Rodriguez-Watson | Anthony Louder | Carly Kabelac
Christopher Frederick | Natalie E. Sheils
Elizabeth H. Eldridge | Nancy D. Lin | Jennifer Gatz
Shaun J. Grannis | Rohit Vashisht | Benjamin Pollock
Kanwal Ghauri | Camille Knepper | Sandy Leonard
Peter J. Embi | Garrett Jenkinson | Reyna J. Klesh
Ayan Patel | Lisa Dahm | Carrie Byington | Bridgit Crews
Atul J. Butte | Jeff Allen (United States)

Carla V. Rodriguez-Watson | Natalie E. Sheils
Anthony Louder | Elizabeth H. Eldridge | Nancy D. Lin
Benjamin Pollock | Jennifer Gatz | Rohit Vashisht
Kanwal Ghauri | Gina A. Valo | Aloka Chakravarty
Tamar Lasky | Mary Jung | Carly Kabelac
Camille Knepper | Sandy Leonard | Peter J. Embi
Garrett Jenkinson | Ayan Patel | Lisa Dahm
Carrie L. Byington | Bridgit Crews | Atul J. Butte | Jeff Allen (United States)

274 – Methods of Evaluating the Safety and Effectiveness of Cardiac Ablation Catheters Using Real-World Data: A Test-Case of the National Evaluation System for Health Technology Coordinating Center (NESTcc) [948]
Shumin Zhang | Sanket Dhruva | Jiajing Chen | Yue Yu
Guy Cafri | Peter A. Noseworthy | Amit Doshi
Guoqian Jiang | Kolade M. Agboola | Jeph Herrin
Kimberly Collison Farr | Meijia Zhou | Eric Brandt
Thomas Forsyth | Keondae Ervin | Joseph Ross
Joseph Drozda, Jr. | Paul Coplan (United States)

275 – Influence of Age and Other Risk Factors on Intrauterine Device Expulsion in a Real-World Safety Study - Results from EURAS-LCS12 [949]
Lisa Eggebrecht | Anja Bauerfeind | Tanja Boehnke
Camille Cellier | Jens Lange | Klaas Heinemann (Germany)
METHODS IN PHARMACOEPIDEMIOLOGY

Raquel Gutiérrez Machin | Marta Monreal | Diana González
Alfonso Rodríguez | Pilar Rayón | Dolores Montero
Consuelo Huerta (Spain)

277 – A Methodology Study to Evaluate External Comparator Arm Study Results Versus Randomised Controlled Trial Results: Multiple Myeloma Case Study [951]
Lisette Hoogendoorn | Héctor Sanz | Chantal Quinten
Francesco Pignatti | Joan Largent | Gerd Rippin (Netherlands)

278 – Linking Progression to Lines of Therapy in Triple Class Refractory Multiple Myeloma Patients: Experience from an Oncology Electronic Health Record Database [952]
Aster Meche | Sarasa Johnson | Patrick Hlavacek
Kevin Apodaca | Marco Dibonaventura | Francis Vekeman
Jinma Ren (United States)

279 – Definition of Outcomes and Success Criteria for Healthcare Professional or Patient Surveys Designed to Assess the Effectiveness of Risk Minimization Measures (eRMM) [953]
Alice Rouleau | Neil Brett | Mengyin Hong | Zaeem Khan
Véronique Pagé | Delphine Saragoussi (France)

280 – Remote Trial Elements Reported in Publicly Available Clinical Trial Protocols [954]
Amos De Jong | Renske Grupstra | Yared Santa-Ana-Tellez
Mira Zuidgeest | Anthonius De Boer | Helga Gardarsdottir (Netherlands)

281 – Patient Characteristics, Outcomes and Potential for Bias in Oncological Real-World Data Studies with Imaging-Derived Response Endpoints [955]
Janick Weberpals | Charlotte Fruechtenicht | Ryan Davis
Melanie Huntley | Yasuhiro Oki | Shelby Wyatt
Felipe A. Castro | Huong Trinh (Switzerland)

282 – Validation to Estimate Sensitivity Along with Positive Predictive Value: A Case Study [956]
Giorgio Limoncella | Anna Girardi | Giulia Hyeraci
Claudia C. Bartolini | Giuseppe Roberto | Edith Heintjes
Hilda J. De Jong | Josephina Kuiper
Anna Beckmeyer-Borowko | Sigrid Behr
Miriam Sturkenboom, Rosa Gini (Italy)

283 – Data Lag in a Large Open and Closed Claims Dataset: Navigating the Completeness-Timeliness Tradeoff [957]
Andrew Weckstein | Ulka Campbell | Monica Gierada
Emily Rubinstein | Reyna J. Klesh | Elizabeth M Garry
Nicolle Gatto (United States)

284 – Development of Real-World Cohorts Using Electronic Health Records (EHR) Supplemented with Administrative Claims Data for Pharmacoepidemiology Studies of Patients with IBD Initiating Biologic Therapy [958]
Lani Wegrzyn | Carrie Huisingh | Katherine Gilpin
Dionna Atkinson | Phillip Levine (United States)

Stephen S. Johnston | Aakash Jha | Sanjoy Roy
Esther Pollack (United States)

286 – Adapting Sufficient Component Cause Models to Pharmacoepidemiology: Mapping to Structural Equation Model Equivalents [960]
Michael Webster-Clark | Imaani Easthausen | Ulka Campbell
Elizabeth M. Garry | Nicolle Gatto (Canada)

287 – Distinguishing Death from Disenrollment: Applying a Predictive Algorithm to Reduce Bias in Estimating the Risk of Rehospitalization [961]
Jessica Young | Nabarun Dasgupta | Kenneth Pack
Sarah Bloomers | Toska Cooper | Bethany Diprete
Til Stürmer | Virginia Pate | Jennifer Lund | Debra E. Irwin
Teresa B. Gibson | Michele Jonsson Funk (United States)
<table>
<thead>
<tr>
<th>Poster Session B</th>
</tr>
</thead>
</table>
| **288 – Evaluating The Impact of Electronic Health Record (EHR) Loss to Follow-Up Data in Patients with Atherosclerotic Cardiovascular Disease (ASCVD)** [962]  
Miyuki Hsing-Chun Hsieh | Tzu-Chi Liao | Edward Lai (Taiwan) |
| **289 – Validity of An Electronic Health Record (EHR) and Claims-Derived Proxy Measure of Multiple Sclerosis (MS) Disability** [963]  
Paul Dillon | Spyros Roumpanis | Erwan Muros Le Rouzic (Switzerland) |
| **290 – Outcome Misclassification: Differences in Hip Fracture Identification Using Administrative Claims Data** [964]  
Natalia Konstantelos | Andrea Burden | Angela M. Cheung  
Sandra Kim | Paul Grootendorst | Maha Chaudhry  
Suzanne M. M. Cadarette (Canada) |
| **291 – Propensity Score-based Weighting Methods in The Context of Multiple Treatment Options** [965]  
Nazleen Khan | Robert Glynn | Kazuki Yoshida  
Katsiaryna Bykov (United States) |
| **292 – Claims-based Algorithm to Define Breast Cancer Recurrence in SEER-Medicare Data** [966]  
Benjamin Bates | Soko Setoguchi (United States) |
| **293 – Use of a Rate-based Sequence Symmetry Analysis to Assess Recurring Adverse Drug Events** [967]  
Earl Morris | Ching-Yu Wang | Joseph Antonelli  
Almut Winterstein | Jesper Hallas | Scott M. Vouri (United States) |
| **294 – Development and Validation of Elixhauser Summary Comorbidity Score for Use with ICD-10-CM Coded Data Among Older Adults** [968]  
Hemalkumar Mehta | Shuang Li | Huijun An  
James Goodwin | G. Caleb Alexander | Jodi Segal (United States) |
| **296 – Bias Amplification of Unobserved Confounding in Pharmacoepidemiological Studies: There Is No Free Lunch in Restricting the Sample to Those with a Particular Drug Indication** [970]  
Viktor H. Ahlqvist | Paul Madley-Dowd | Amanda Ly  
Jessica Rast | Michael Lundberg | Egill Jónsson-Bachmann  
Daniel Berglind | Dheeraj Rai | Cecilia Magnusson  
Brian K. Lee (Sweden) |
| **297 – Approaches to the Identification of Ulcerative Colitis Events in a Claims Database** [971]  
Xianying Pan | P. Shreyas | Jiayin Zhang | Yifan Zhang  
Hugh Kawabata (United States) |
| **298 – Discrepancies in ICD Codes Used to Identify Three Common Diseases in Cancer Patients in Real-World Settings and Their Implications for Disease Classification in Patients Without Cancer: A Literature Review and Descriptive Study** [972]  
Nora Tu | Mackenzie Henderson | Meera G. Sundararajan  
Maribel Salas |
| **299 – Utilization of Pharmacokinetic/Pharmacodynamics Modeling in Pharmacoepidemiologic Studies: A Systematic Review on Anti-Arrhythmic and Glucose-Lowering Medicines** [973]  
Soroush Mohammadi Jouabadi | Mitra Nekouei Shahraki  
Fariba Ahmadizar | Bruno H Stricker | Payam Peymani (Netherlands) |
Emily O'Brien | Heather Rubino | Jack Shostak  
Laura Webb | Lauren Cohen | Patrick Caubel  
Stacey Mangum | Amy Abernethy | Cherise Wong  
Katie Kendrick | Adrian Hernandez (United States) |
| **301 – Estimation of Years of Life Lost Using Electronic Health Records: Application on Patients with Multiple Myeloma in the SNDS Database** [975]  
Helene Denis | Eleonore Herquelot | Nada Assi  
Matthieu Javelot | Fanny Raguideau (France) |
| **302 – Ignoring Competing Event in Survival Analyses: The Amplitude of The Bias in Kaplan-Meier Estimates Assessed Through Simulations** [976]  
Helene Denis | Pauline Lemeille | Martin Prodel  
Eleonore Herquelot (France) |
303 – Impacts of the COVID-19 Pandemic on Assessment of Progression and Surveillance Bias in Advanced Non-Small Cell Lung Cancer [977]
Lauren E. Johns | Yihua Zhao | Xinran Ma
Rebecca A Miksad | Sandra D Griffith | Gregory Calip
(United States)

304 – Methodologic Considerations for Emulating Target Trial for Discontinuation of Antidepressant Treatment in Pregnancy [978]
Mollie Wood | Hedvig Nordeng | Eivind Ystrom
(United States)

305 – Validating The Standardized and ICD-9 Code of Type 2 Diabetes Mellitus in a Saudi Common Data Model [979]
Turki Ai Althunian | Meshael Alrasheed | Fatemah Alnofal
Rawan Tafish | Mahmood A. Mira | Raseel A. Alroba
Mohammed Kirdas | Tamir M Alshammari (Saudi Arabia)

PHARMACOVIGILANCE

306 – Assessing Causality in HIV-Positive Patients with Antituberculosis And/or Antiretroviral Therapy – Associated Liver Injury [980]
Hannah May Gunter | Karen Cohen | Gayle Tatz
Gary Maartens | Wendy Spearman | Ushma Mehta
(South Africa)

307 – Cardiovascular Adverse Events Associated with PARP Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System [981]
Subeesh Kulangara Viswam | Aarushi Khetarpal
Ashwin Dhas | Zeba Zeba | Amrutha Shettigar
Lipin Lukose | Gursimran Kaur (India)

308 – Evaluating The Efficacy of Clustering Methods Applied to Adverse Event Reports [982]
Nils Erlanson | Jim Barrett | Carlos Melgarejo
Joe Mitchell | Lucie Gattepaille | Henric Taavola (Sweden)

309 – Comparison of Post-Marketing Drug Safety Surveillance Research Required by Regulators of the United States and Europe Through the Case of Dapagliflozin [983]
Huieon Lee | Suvin Park | Na-Young Jeong | Hee-Jin Kim
Nam-Kyong Choi (South Korea)

310 – Drug Use Pattern and Adverse Reactions Among Pregnant Women Accessing Care at the University College Hospital, Ibadan, Nigeria [984]
Timothy Ao Oluwasola | Omolola Ogundare
Onyinye O. Akunne | Aduragbenro D. Adedapo (Nigeria)

311 – Community Pharmacists’ Vigilance Towards OTC Medication Abuse in Saudi Arabia [985]
Ahmed I. Fathelrahman | Mona Y. Alsheikh | Ali M. Alshahrani (Saudi Arabia)

312 – Gastrointestinal Adverse Events Associated with PI3K Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System [986]
Subeesh Kulangara Viswam | Raksha Kamath
Jovita Sharon | Adithya Shivakumar | Anjana Shenoy
Lipin Lukose | Gursimran Kaur (India)

313 – An Active Surveillance of Medication Error Monitoring Programme in a Tertiary Care Teaching Hospital: A Clinical Pharmacist Approach [987]
Ravina Ravi | Vikram Patil | Chalasani Sri Harsha
Ramesh Madhan (India)

314 – Assessing The Pattern of Hypersensitivity Reactions Associated with Analgesics: An Ambispective Study [988]
Shilpa Palaksha | Prudhvi Raj | Mahesh P. A. (India)

315 – Machine Learning to Predict Safety Signals Using Molecular Similarity and Disproportionate Reporting Rates [989]
Lucy A. Quirant | Annette Rudolph | Rachel Cavill
Eva-Lisa Meldau (Belgium)

Wanju Annabelle Lee | Chung-Han Ho | Wei-Pang Chung
Shih-Chieh Shao | Edward Lai (Taiwan)

317 – Ginkgo Biloba Interaction with Non-steroidal Anti-Inflammatory Drugs and the Potential Risk of Bleeding [991]
Mona A. Almaghrabi | Waad Alghamdi | Nofa Alfadel
Fawaz F. Alharbi (Saudi Arabia)
Poster Session B

318 – Risk of Oligospermia with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases [992]
Luis Velez-Nandayapa | Anusmita Das | Vishaka Parulekar
Naveen Chhabra | Miguel Izquierdo | Maria Nicolaides
Pierre De Zeeuw | Alicia Rossiter | Johannes Eisinger
Christiane Michel (Switzerland)

319 – Current Status of Spontaneous Adverse Event Reports Related to Polypharmacy in Korean Elderly Patients [993]
Heehyun Won | Hee-Jin Kim | Na-Young Jeong
Byung-Joo Park | Nam-Kyong Choi (South Korea)

320 – Association Between Oral Corticosteroid Prescribing Patterns and Appropriate Fracture Preventive Care in People with Atopic Eczema in the UK [994]
Julian Matthewman | Mina Tadrous | Kathryn Mansfield
Deva Thiruchelvam | Donald Redelmeier | Angela M. Cheung
Ilana Lega | Daniel Prieto-Alhambra | Lawrence Cunliffe
Sinéad Langan | Aaron M. Drucker (United Kingdom)

321 – A Retrospective Analysis of Adverse Drug Events Leading to Hospitalization or Prolonged Hospitalization in Saudi Arabia Using the Saudi Food and Drug Authority (SFDA) Spontaneous Reporting System [995]
Eman Khalid Alqadheeb | Fotoun Alblowi
Rayan Ibrahim Alolayet | Asma Al-Sadaawi
Muhannad Alharbi | Mobarak Alshahrani (Saudi Arabia)

322 – Pharmacovigilance Education in Pharmacy Programs’ Curricula in Saudi Arabia [996]
Mona Y Alsheikh, | Ahmed I Fathelrahman
Thamir M. Alshammari (Saudi Arabia)

323 – Lot-Specific Monitoring of Insulin Lispro Safety Following Changes in the Purification Process [998]
Ayad K. Ali | John D. Ayres (United States)

324 – Factors Associated with Compliance to the Hepatotoxicity Risk Management Guide in Primary Care Facilities in Casablanca, Morocco [999]
Boubacar Traore | Samira Nani | Samira Hassoune (Mali)

Intensive online short courses

Develop your skills in pharmacoepidemiology, pharmacovigilance, and real-world evidence with our modular short courses. Learn key concepts in epidemiology, statistics, and health economics from experts in a range of sectors, including academia, regulatory, and industry.

Block 1 (November) | Introduction to Pharmacoepidemiology
Block 2 (February) | Introduction to Pharmacovigilance
Block 3 (April) | Intermediate Pharmacoepi/Pharmacovigilance
Block 4 (October) | Real-World Evidence in Pharmacoepidemiology

Study any Block, or complete Blocks 1, 2 & 3 with a Project (in May) and Exam (in June) to achieve the Professional Certificate (30 credits).

Already know the basics? Our ‘Real-World Evidence in Pharmacoepidemiology’ short course (Block 4) provides practical, hands-on experience working with real-world data.

Contact email: shortcourses@lshtm.ac.uk
Find out more and apply: bit.ly/pepi-lshtm
Poster Session C

SPOTLIGHT POSTERS

HEALTH EQUITY ................................................................. 118
MEDICAL DEVICES ............................................................ 118
PEDIATRICS ................................................................. 119
MEDICATIONS IN PREGNANCY AND LACTATION ................................................................. 120
RARE DISEASES ............................................................ 120
VACCINES ................................................................. 121

BIOSIMILARS ................................................................. 122
DISEASE EPIDEMIOLOGY/CLINICAL COURSE ................................................................. 124
DRUG UTILIZATION RESEARCH ................................................................. 127
INFORMATICS ................................................................. 132
METHODS IN PHARMACOEPIDEMIOLOGY ................................................................. 133
PEDIATRIC PHARMACOEPIDEMIOLOGY ................................................................. 136
PHARMACOVIGILANCE ................................................................. 138
VACCINES ................................................................. 141
HEALTH EQUITY

A – Effect of The Refitted CKD-EPI Race-Free Formula to Estimate Glomerular Filtration Rate on The Chronic Kidney Disease Prevalence and Mortality in The Danish Population [1000]
Uffe Heide-Jørgensen | Søren Vestergaard | Henrik Birn Christian Christiansen (Denmark)

B – Description of Concurrent CKD and HF by Race and Ethnicity Distribution in the US [1001]
Daniel Fernandez Llaneza | Claudia Cabrera Moksnes Nitin Shivappa (United Kingdom)

C – A Dashboard to Visualize the Geographic Distribution of Incidence and Prevalence of Diseases by Race and Ethnicity in the United States Using Real-World Data [1002]
Brian Dreyfus | Siva Rayavaram | Leticia Ferri | Lorena Kuri (United States)

D – State-By-State Analysis of Medicaid Barriers to Medication for Opioid Use Disorder (MOUD) Access [1003]
Sophia L Balkovski | Catherine Psaras | Marissa Seamans (United States)

E – The Association Between Race, Social Determinants of Health, and Treatment for Major Depressive Disorder (MDD) in a Real-World Cohort [1004]
Jessica Paulus | Xi Qian | Pam Kumparatana Veena Hoffman | Zhaohui Su | Carl Marci (United States)

Wenxi Huang | Inmaculada Hernandez | Shangbin Tang Nico Gabriel | Nasser Sharareh | Nimish Patel Lucas A Berenbrok | Sean Dickson | Serena Jingchuan Guo (United States)

G – Impact of Contextual-Level Social Determinants of Health on Novel Antidiabetic Drug Adoption in Patients with Type 2 Diabetes [1006]
Yujia Li | Hui Hu | Yi Zheng | Jie Xu | Wei-Han Chen Ning Liu | Jiang Bian | Serena Jingchuan Guo (United States)

Sruthi Adimadhyam | Adebola Ajao | Maria Kempner Hye Seung Lee | Caroline Jingko | Jane Baumblatt Danijela Stojanovic | Yueqin Zhao | Joy Kolonoski Efe Eworuke (United States)

MEDICAL DEVICES

I – Development of a Python Notebook to Automate Predictive Modeling: Total Knee Arthroplasty Case Study [1008]
Chantal Holy | Harshita Vemu | Saurabh Menon Julia Hwang | Yifan Zhang | Jill Ruppenkamp | Paul Coplan (United States)

J – Differences in Outcomes Among Patients with Atrial Fibrillation Undergoing Catheter Ablation with Versus Without Intracardiac Echocardiography Use [1009]
Rahul Khanna | Rhea C. Pimentel | Neloufar Rahai Sonia Maccioni (United States)

Rahul Khanna | Amit Doshi | Sonia Maccioni Meghana Sarki (United States)

L – Clinical and Economic Burden Associated with Uncontrolled Surgical Bleeding: A Retrospective Database Analysis [1011]
Stephen S Johnston | Pranjal Tewari | Mosadoluwa Afolabi Walter Danker (United States)
M – Comparison of Outcomes for Major Contemporary Endograft Devices Used for Endovascular Repair of Intact Abdominal Aortic Aneurysms [1012]
Michael O. Falster | Sarah K. Garland | Louisa Jorm
C. Barry Bellas | Anthony J. Freeman | Art Sedrakyan
Oludamisola Sotade | Ramon L. Varcoe (Australia)

N – Do Methods Matter in Diagnostic Yield Assessment in Bronchoscopy?
A Simulation-based Analysis [1013]
Meijia Zhou | Anil Vachani | Fabien Maldonado
Balaji Laxmanan | Iftekhar Kalsekar | Philippe Szapary
Lisa Dooley | Septimiu Murgu (United States)

O – Association Between Use of Levonorgestrel-releasing and Copper Intrauterine Devices and The Risk for IUD Expulsion in Routine Clinical Practice: Results from EURAS-LCS12 [1014]
Lisa Eggebrecth | Anja Bauerfeind | Tanja Boehnke
Camille Cellier | Jens Lange | Klaas Heinemann (Germany)

Elyse M. Miller (United States)

Q – Trends in The Incidence of Varicella Cases with Complications Among Korean Children During 2010-2020 After the Universal One-Dose Varicella Vaccination Program [1016]
Hyunjeong Cho | Bongkyoo Choi | Eunbi Sun
Seoyoung Jeon | Seonghee Ann (Republic of Korea)

R – Risk of Infection in Children with Psoriasis Receiving Treatment with Ustekinumab, Etanercept, or Methotrexate [1017]
Maria Schneeweiss | Timothy J Savage | Richard Wyss
Julien Kirchgesner | Yinzhu Jin | Cassandra York
Joseph F. Merola | Sebastian Schneeweiss | Robert Glynn (United States)

S – Off-Label Use of Drugs in Paediatric (Specialised) Outpatient Clinics – What Has Changed Between 2009 and 2019? [1018]
Irmingard Toni | Jutta Hupfer | Christine Gerber
Wolfgang Rascher | Antje Neubert (Germany)

T – Association Between Prenatal Antipsychotic Exposure and The Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis [1019]
Zixuan Wang | Kirstie Wong | Ian Wong | Kenneth Man (United Kingdom)

U – Outpatient Antibiotic Prescribing in Early Life: A Population-based Study Comparing Birth Cohorts from Denmark and Germany [1020]
Ulrike Haug | Oliver Scholle | Lotte Rasmussen
Mette Reilev | Jost Viebrock (Germany)

Greta A Bushnell | Jenny Sun | Wendy Camelo Castillo
Angela Czaja | Susan Dosreis | Tobias Gerhard
Florentia Kaguelidou | Haeyoung Lee
Sangita Pudasainee-Kapri | Sudha Raman
O’mareen Spence | Durrieu Geneviève | Daniel B Horton (United States)

X – Association Between Antihistamine Exposure and Newly Diagnosed Juvenile Idiopathic Arthritis: A Nationwide Analysis [1022]
Daniel B. Horton | Tania J. Atanassova | Cecilia Huang
Joanna Madej | Sarah E. Mcguire | Tobias Gerhard
Brian L Strom (United States)

Ashish Rai | Emmanuel Ojo | Takashi Komatsu
Mayura Shinde | Danjela Stojanovic | Adebola Ajao
Hengrui Sun | Amy Bishara | Joy Kolonoski
Ann Mcmahon | Prabha Viswanathan (United States)
**MEDICATIONS IN PREGNANCY AND LACTATION**

**Z – COVID-19 Infection and Medication Use in Pregnancy (CONSIGN) – A Multinational Drug Utilisation Study Using Linked Healthcare Data [1024]**

Eimir Hurley | Beatriz Poblador-Plou
Gabriel Sanfelix-Gimeno | Francisco Sanchez-Saez
Isabel Hurtado | Clara Rodriguez-Bernal | Sue Jordan
Daniel Thayer | Ieuan Scanlon | Carys Jones
Claudia C. Bartolini | Rosa Gini | Giorgio Limoncella
Miriam Sturkenboom | Hedvig Nordeng (Norway)

**AA – Emulation of a Target Trial of Metformin in Pregnancy in Women with Pre-Gestational Type 2 Diabetes Mellitus [1025]**

Jennifer Yland | Krista Huybrechts | Amelia Wesselin
Lauren Wise | Sonia Hernandez-Diaz (United States)

**AB – National Trends and Utilization Patterns of Benzodiazepines and Z-Hypnotics Among 2,883,162 Pregnant Women in Taiwan: An Interrupted Time Series Analysis [1026]**

Lin-Chieh Meng | Chih-Wan Lin | Shih-Tsung Huang
Fei-Yuan Hsiao (Taiwan)

**AC – Intrauterine Exposure to SSRI Antidepressants and Risk of Emotional Disorder till Age 22: A Danish National Register Study [1027]**

Ardesheer Talati | Mette Bliddal | Rikke Wesselhoeft
Katrine Strandberg-Larsen | Myrna Weissman
Jay Gingrich | Anton Pottegård (United States)

**AD – Association of Maternal Levothyroxine Use During Pregnancy with Offspring Birth and Neurodevelopmental Outcomes [1028]**

Mengqin Ge | Edmund Ci Cheung | Kenneth Man
Patrick Ip | Wing Cheong Leung | Gloria Li | Annie Kung
Ching-Lung Cheung | Ian Wong (Hong Kong)

**AE – Application of Claims-based Algorithms to Ascertain Gestational Age Among Multiple Pregnancy Outcomes [1029]**

Jennifer Judy | Deepa Malhotra | Amy Law | David Oliveri
Jennifer Nguyen | Kimberly Shea (United States)

**RARE DISEASES**

**AF – Development and Testing of Diagnostic Algorithms for Identifying Subjects with Acromegaly in Administrative Claims Databases [1030]**

Salvatore Crisafulli | Andrea Fontana | Valentina Ientile
Luca L’abbate | Isabelo Alexandra Chiorean
Francesco Barone-Adesi | Gianluca Trifiro (Italy)

**AG – A Population-based Study on the Prevalence of Diagnosed Primary Immune Thrombocytopenia in the United States, 2016-2021 [1031]**

Sherry Xiao | Sara Burns | Stephen Schachterle
Lawrence Charnas | David Readett (United States)

**AH – Algorithm to Identify Patients with Hypereosinophilic Syndrome (HES) in Electronic Health Record Databases [1032]**

Sandra Joksaité | Gema Requena | Nicholas Galwey
Rupert Jakes | Melissa Van Dyke (United Kingdom)

**AI – Risk of Hospitalization for Vaso-Occlusive Episode in Patients with Sickle-Cell Disease After Out-patient Exposure to Systemic Corticosteroids [1033]**

Margaux Lafaurie | Ondine Walter | Pierre Cougoul
Julien Maquet | Pablo Bartolucci | Maryse Lapeyre-Mestre
Guillaume Moulis (France)

**AJ – The Use of United States Administrative Claims Data to Study Patients with Friedreich Ataxia: The Impact of Specific and Non-Specific Coding Periods [1034]**

Christina Qian | Katharina Buesch | Lauren Powell
Karissa Johnston (Canada)

**AK – An Innovative Way to Generate Blinded Data in Single Arm Clinical Trials [1035]**

Cynthia Girman | Katherine Brind’amour PhD
Susan Hartmaier PhD | Xiruo Zhang | Emma Rosen
David A. Weinstein Md Mmsc (United States)
Poster Session C

AL – Use of Provider Notes in Novel Identification of Cancer at the Gastroesophageal Junction [1036]
Katherine Gilpin | Gulce Askin | Clark Jackson
David Hallett | Wendy Sebby | Leon Raskin (United States)

AM – Natural History of Wilson's Disease in the United States Using Optum® Electronic Health Records [1037]
Scott Kelly | Karla Therese Sy | Kennedy Cook
Steven Arkin | Jose Francisco Cara | Marko Pregel
Kasia Lobello | Shawkat Hassan | Rongjun Shen
Xiaofeng Zhou | Calhua Liang | Kui Huang (United States)

VACCINES

AN – Characteristics Associated with Residual Risk of COVID-19 Hospitalisation After a Complete Vaccination Schedule in 28 Million People in France [1038]
Laura Semenzato | Jeremie Botton | Jérôme Drouin
Bérangère Baricault | Marion Bertrand
Marie-Joelle Jabagi | François Cuenot | Kim Bouillon
Stephane Le Vu | Rosemary Dray-Spira | Alain Weill
Mahmoud Zureik (France)

AO – Heterogeneity Across European Electronic Healthcare Data Sources: Identification of Adverse Events of Special Interest (AESI) and Impact in Multi-Databases Assessment – An ACCESS Study [1039]
Corinne Willame | Caitlin Dodd | Carlos Duran
Daniel Weibel | Olaf H Klungel | Miriam Strunkenboom
Roel Elbers | Rosa Gini | Elisa Barbieri | Nicolas H Thurin
Tania Schink | Felipe Villalobos | Ainara Mira-Iglesias
Patrick Souverein | Mar Martin-Perez | Régis Lassalle
Cécile Droz-Perroteau | Jérémy Jové | Consuelo Huerta
Airam De Burgos Gonzalez | Veronica Bryant
Patricia García-Poza | Maria Martinez-Gonzalez (Belgium)

AP – Cohort Monitoring of 29 Adverse Events of Special Interest Prior to and After COVID-19 Vaccination in Four Large European Data Sources [1040]
Miriam Strunkenboom | Davide Messina | Olga Paoletti
Airam De Burgos Gonzalez | Patricia García-Poza
Consuelo Huerta | Ana Llorente | Olaf H Klungel
Mar Martin-Perez | Maria Martinez-Gonzalez
Ivonne Martin | Jetty Overbeek | Marc Padros-Goossens
Patrick Souverein | Karin Swart, Daniel Weibel | Rosa Gini (Netherlands)

AQ – Vaccination and Acute Flares in Rheumatoid Arthritis: A Nationwide Case-crossover Study Using the French SNDS Health Care Databases [1041]
Lamiae Grimaldi | Yann Hamon | Tom Duchemin
Philippe Attias | Jacques Benichou | Lucien Abenhaim
Yola Moride (France)

AR – Changing Characteristics Over Time of Individuals Receiving COVID-19 Vaccines in Denmark: A Population-based Descriptive Study of Vaccine Uptake [1042]
Mette Reilev | Morten Olesen | Helene Kildegaard
Henrik Stevring | Jacob Harbo Andersen | Jesper Hallas
Lars Christian Lund | Louise Ladebo | Martin Ernst
Per Damkier | Peter Jensen | Anton Pottegård
Lotte Rasmussen (Denmark)

AS – Clinical Outcomes and Safety of Live-Attenuated Vaccines in Children Exposed to Biologics Response Modifiers in Utero [1043]
Ousseny Zerbo | Kristin Goddard | Edwin Lewis
Darios Getahun | Kristin Palmsten | Candace C Fuller
Bradley Crane | James Donahue | Matthew F Daley
Lisa A Jackson | Nicola Klein | Shararareh Modaressi (United States)

Kofi Asomaning | Mei Sheng Duh | Maral Dersarkissian
Cynthia De Luise | Catherine Nguyen | Mu Cheng
Angela Lax | Suna Park | Mianzhao Guo | Mingfang Zhang
Pierre Cremieux | Yinong Young-Xu (United States)

AU – Real-World Effectiveness of mRNA COVID-19 Vaccines Among Elderly US Nursing Home Residents [1045]
Hector Izurieta | Yun Lu | Arnstein Lindaas
Kathryn Matuska | Xiangyu Shi | Mikhail Menis
Whitney Steele | Michael Wernecke | Yoganan Chillarige
Hui-Lee Wong | Jeffrey Kelman | Richard A. Forshee (United States)
BIOSIMILARS

1 – Developing and Testing of Diagnostic Algorithms for the Identification of Inflammatory Bowel Diseases Using a Claims Database from Southern Italy [1046]
Elena Sofia Fiore | Ylenia Ingrasciotta | Valentina Isgrò
Valentina Ientile | Saveria S Foti | Luca L’abbate
Andrea Fontana | Michele Tari | Angela Albrandi
Gianluca Trifiro (Italy)

2 – Rheumatoid Arthritis, Psoriasis and Other Auto Immune Diseases – Prescribing Patterns and Characteristics of Patients Undergoing Biological Therapy in Portugal (2020) [1047]
Claudia Furtado | Isabel T ovar | Cristina Gaspar
(United States)

3 – Trends in The Use of Biologics for Treatment of Plaque Psoriasis in the Real-World Setting [1048]
Lawrence Rasouliyan | Amanda G. Althoff | Vikas Kumar
Carla Zema | Stacey Long | Mitsh B. Rao (United States)

4 – Comparative Risk of Herpes Zoster and Postherpetic Neuralgia in Patients with Psoriasis Receiving IL-17 Inhibitor and IL-12/23 Inhibitor Versus Traditional Systemic Immunosuppressants [1049]
Edward Lai | Chaw-Ning Lee | Miyuki Hsing-Chun Hsieh
Che-Yu Chen | Chao-Chun Yang | Tzu-Chi Liao (Taiwan)

5 – Evaluation of The Effectiveness and Safety of Biological Disease-Modifying Drugs for the Treatment of Ankylosing Spondylitis in the Unified Health System [1050]
Francisco De Assis Acurcio | Bárbara Santos
Gerusa A. Oliveira | Luíla C Henriques | Marina Morgado
Natália Dias Brandão | Isabella C. Ferreira
Fernanda De Frias Campos | Juliana Álvares-Teodoro (Brazil)

6 – Evaluation of The Rate of Discontinuation of Treatment with Biological Drugs in Patients with Ankylosing Spondylitis: Pre-Pandemic and Pandemic Period [1051]
Francisco De Assis Acurcio | Fernanda De Frias Campos
Bárbara Santos | Isabella C. Ferreira | Luíla C. Henriques
Gerusa A. Oliveira | Natália Dias Brandão | Marina Morgado
Juliana Álvares-Teodoro (Brazil)

7 – Evaluation of the Use Profile of Biological Medicines and Synthetic Target-Specific Medicines for the Treatment of Rheumatoid Arthritis in the Sus in the State of Minas Gerais, Brazil [1052]
Francisco De Assis Acurcio | Isabella C. Ferreira
Bárbara Santos | Fernanda De Frias Campos
Gerusa A. Oliveira | Natália Dias Brandão | Marina Morgado
Luíla C. Henriques | Juliana Álvares-Teodoro (Brazil)

8 – Brodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) Study of a Biological Anti-Psoriatic Drug Across Six European Countries [1053]
Mette Reilev | Peter Jensen | Henrik Støvring
Lise Skov Ranch | Rosa Gini | Claudia C. Bartolini
Gianluca Trifiro | Ursula Kirchmayer
Alessandro Cesare Rosa | Valeria Belleudi | Ulrike Haug
Sarina Schwarz | Wiebke Schaefer | Ron Herings
Elisabeth Smits | Jetty Overbeek | Emily Holthuis
Kari Furu | Karin Gembert | David Hägg
Michele Tari
Valentina Ientile | Ylenia Ingrasciotta | Alexander Egeberg
Jesper Hallas (Denmark)

9 – Traceability of Insulin Glargine’s Innovator and Its Biosimilar Products Adverse Drug Events Reports in Saudi Arabia [1054]
Fares Alrubaish | Solaiman Alhawas | Abdulrahman Alnuaim
Nouf Alfadel | Fawaz F Alharbi (Saudi Arabia)

10 – Exploring The Relationship Between Utilization Patterns of Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity in Rheumatoid Arthritis Patients [1055]
Irma Convertino | Massimiliano Cazzato | Silvia Tillati
Sabrina Giometto | Rosa Gini | Giulia Valdiserra
Emiliano Cappello | Sara Ferraro | Marco Bonaso
Claudia C. Bartolini | Olga Paolotti | Valentina Lorenzoni
Matteo Filippi | Giuseppe Turchetti | Michele Cristofano
Corrado Blandizzi | Marta Mosca | Ersilia Lucenteforte
Marco Tuccori (Italy)

11 – The Risk of Serious Infection in Crohn’s Disease Patients Treated with Biologics: An External Comparator Cohort Study [1056]
Nai-Yu Chen | Chiao-Hsiung Chuang | Yu-Ching Chang
Ching-Lan Cheng (Taiwan)
12 – A Regulatory Overview of Biosimilars Across Selected Countries [1057]
Luciane Lopes | Gustavo M Santos | Svetlana Doubova
Lisa Pont | Efe Eworuke | Martín Cañás | Marco Tuccori
Lily Iracema Gordillo Alas | Angela Acosta Santamaria
Gustavo H. Marin | José Crisóstomo Landeros
Flavia C. Albuquerque | Golnoosh Alipour Haris
Martin A. Urtasun | Boya Lin | Juan Roldán-Saelzer
Patricia Carmona-Sepulveda | Dino Viveros
Felipe D. Vera | Irma Convertino | Marco Bonaso
Claudia Garcia Serpa Osorio-De-Castro | Ursula Kirchmayer
Mariama G. Falcao | Fernanda Lacerda L Machado
Lourdes Abigail Orellana Tablas
Saul Eduardo Contreras Sanchez
Manuel Machado Beltrán (Brazil)

13 – Real-World Effectiveness and Persistence of Methotrexate Versus Adalimumab: A Comparative Study from The British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) [1058]
Oras Alabas | Kayleigh Mason | Zenas Yiu | Richard Warren
Mark Lunt | Catherine Smith | Christopher Griffiths (United Kingdom)

14 – Recent Biosimilar Uptake in the United States [1059]
Elizabeth Dee | Caitlin Elliott | Shangzhi Gao | Caitlin Dodd
Tiffany Siu Woodworth (United States)

15 – Assessment of the Issues on Understanding and Use of Biologics in Clinical Practice and Their Regulations [1060]
Imelda G. Peña | Bryan Paul I. Bulatao (Philippines)
DISEASE EPIDEMIOLOGY/ CLINICAL COURSE

16 – Long-Term Health Events and Healthcare Utilization After COVID-19 Hospitalization Among Children and Adults Insured by Medicaid, North Carolina, United States, 2020-2021 [1061]
Rachel Sendor | Sharon Peacock Hinton | Til Stürmer
Michele Jonsson Funk (United States)

17 – Association Between Tumor Location and Pathological Stage in Patients with Resectable Low Rectal Cancer: Evidence from 20-Years of Data in China [1062]
Qingqing Hu | Zheng Kuo Md | Yuting Yao | Yuan Zhou
Enda Yu Md | Zheng Lou Md | Guanyu Yu Md
Leqi Zhou Md | Yongjing Zhang | Hong Qiu Md, PhD
Wei Zhang (China)

18 – A Scoping Review of Drug Exposures and The Development of Parkinson's Disease [1063]
Takahiro Itaya | Brendan Hallam | Mine Orlu
Anette Schrag | Irene Petersen | Kate Walters
(United Kingdom)

20 – Treatment-Resistant Depression and Labor Market Affiliation in the Danish Welfare Society: A Register-based Study [1065]
Frederikke H. Gronemann | Thomas Lund | Louise Lindholdt
Kathrine Bang Madsen | Martin Balslev Jørgensen
Merete Nordentoft | Merete Osler (Denmark)

21 – Long-Term Clinical and Health Outcomes Following COVID-19 Disease: An Umbrella Review [1066]
Hu Li | Jin Xia | Dimitri Bennett | Fatima Roque
Rujuta Phadke | Ana Bárbara Tavares | Mugdha Gokhale
Fidelia Ida | Jinnie J. Rhee | Montse Soriano Gabarro
(United States)

22 – Incident Dementia Identified by Redeemed Prescriptions Recorded in The Danish National Prescription Registry [1067]
Cecilia Fuglsang | Nils Skajaa | Péter Szentkúti
Erzsebet Horvath-Puho | Henrik Toft Sørensen
Victor Henderson (Denmark)

23 – Comorbidity, Trauma and Mortality in Children and Young Adults Using ADHD Medications in Quebec Between 2000 and 2020 [1068]
Carlotta Lunghi | Helen-Maria Vasiliadis | Elham Rahme
Louis Rochette | Martin Gignac | Victoria Massamba
Fatoumata Binta Diallo | Alvine Fansi | Samuele Cortese
Alain Lesage (Italy)

24 – Comparison of Methods to Quantify Uncertainties in Averaging Incidence Estimates: An Illustration of Approximating Lyme Borreliosis (LB) Incidence in High-Risk Regions in Europe [1069]
Thao Mp Tran | Leah Burn | Maxim Blum | James H. Stark
(Belgium)

25 – Nursing Home Facility Characteristics and Occurrence of Severe COVID-19 Outcomes Among US Medicare Beneficiaries Ages 65 and Older in the Vaccine Era [1070]
Hector Izurieta | Mikhail Menis | Yun Lu | David Graham
Yixin Jiao | Heng-Ming Sung | Yue Wu | Yoganand Chilarge
Michael Wernecke | Jeffrey Kelman | Richard A. Forshee
(United States)

26 – Identification of Drugs Associated with Lower Risk of Parkinson's Disease Using Systematic Screening Approach in a Nationwide Nested Case-control Study [1071]
Anna-Maija Tolppanen | Marjaana Koponen | Anne Paakinaho
Julian Lin | Sirpa Hartikainen (Finland)

Asha K Rajan | Muhammed Rashid | Dhruv Patel
Viji Chandran | Sreedharan Nair | Vishal Shanbhag
Girish Thunga (India)

Simon Jensen | Uffe Heide-Jørgensen | Søren Vestergaard
Henrik Gammelager | Henrik Birn | Dorothea Nitsch
Christian Christiansen (Denmark)

29 – The Impact of Antidepressant Treatment on Insulin Commencement in Type 2 Diabetes: A UK Electronic Health Record Nested Case-control Study [1074]
Annie Jeffery | Kate Walters | David Osborn | Ian Wong
Joseph F. F. Hayes (United Kingdom)

G. Nethravathi | Pravallika Mudimala | Christy Thomas
Krishna Undela (India)
Poster Session C

31 – Antihypertensive Prescription and Blood Pressure Patterns in Patients with Chronic Kidney Disease at a Nephrology Outpatient Clinic in Lagos University Teaching Hospital, Ile-Ife, Nigeria [1076]
Ifedolapo Adesola Adejumo | Babawale Bello
Sunday O. Olayemi (Nigeria)

Cathrine Hjorth | Per Damkier | Tore BStage
Søren Feddersen | Stephen Hamilton-Dutoit | Bent Ejlersen
Timothy Lash | Henrik Bøggild | Henrik Toft Sørensen
Deirdre Cronin-Fenton (Denmark)

33 – Antiplatelet Drugs and Breast Cancer Risk in a Large Nationwide Danish Case-control Study [1078]
Manon Cairat | Anton Pottegård | Morten Olesen
Laure Dossus | Agnès Fournier | Blánaid Hicks (France)

34 – Techniques for Characterising Long COVID in Real World Data [1079]
Kristin Kostka | Evan Minty | Antonella Delmestri
Barrack Omondi | Daniel Prieto-Alhambra | Annika Joedicke (United States)

35 – Association Between Antiseizure Medication Prescribing and Its Indications During Pregnancy and Offspring Neuro-developmental Outcomes Between 1995 and 2020 in the UK [1080]
Paul Madley-Dowd | Harriet Forbes | Viktor H. Ahlqvist
Jessica Rast | Caichen Zhong | Brian K Lee | Dheeraj Rai (United Kingdom)

36 – A Nationwide Registry-Linkage Study of Mental Disorders in Chronic Pain Patients: Characteristics of Users of Opioid Versus Non-Opioid Analgesics [1081]
Line C. Gjerde | Marte Handal | Ragnar Nesvåg
Thomas Clausen | Torger G Lid | Aleks Haavind Sveivik
Svetlana Skurtveit | Ingvild Odsbu (Norway)

37 – Natural History of COVID-19 Among US Nursing Home Residents Ages >65 Years: Vaccine Era [1082]
Hector Izurieta | Yun Lu | Yixin Jiao | David Graham
Michael Wernecke | Mikhail Menis | Yoganand Chiarige
Heng-Ming Sung | Yue Wu | Jeffrey Kelman
Richard A. Forshee (United States)

38 – Urticaria and Risk of Cancer: A Danish Population-based Cohort Study [1083]
Dóra Körmendiné Farkas | Sissel Toft Sørensen
Christian Vestergaard | Sigrún Alba Jóhannsdóttir Schmidt
Lise Maria Lindahl | Cathrine Juel Lau
Henrik Toft Sørensen (Denmark)

39 – An Evaluation of Survival Comparing Women with Breast Cancer Receiving Surgery or Primary Endocrine Therapy and Women without Cancer [1084]
Yubo Wang | Douglas Steinke | Sean Gavan | Li-Chia Chen (United Kingdom)

40 – Bayesian Nonparametric Comorbidity Analysis of Type 2 Diabetes Mellitus (T2DM) [1085]
Adrian Martinez De La Torre | Fernando Perez-Cruz
Stefan Weiler | Andrea Burden (Switzerland)

41 – Establishing a Standing Cohort Using Claims Data to Mimic the Population of a Clinical Trial in The Cardiovascular Therapeutic Area [1086]
Nicole L. Baker | Darcy E Ellis | Quazi Ataher | James Brash
Sarah Seager | Christian Reich | Xiaoyu Lin (United States)

42 – Trends of Hospital Admissions Due to Neoplasms in England and Wales Between 1999 and 2019: An Ecological Study [1087]
Abdallah Naser | Hassan Hasan Alwafi (Jordan)

43 – Trends in Hospital Admissions for Mental, Behavioural and Neurodevelopmental Disorders in England and Wales Between 1999 and 2019: An Ecological Study [1088]
Abdallah Naser | Eman Zmaily Dahmash (Jordan)

44 – Health-Related Quality of Life of Multiple Myeloma Patients from a Brazilian Metropolis Improves After First Line of Treatment [1089]
Paula Drummond | Roberta M Santos | Adriano M Reis
Jéssica Malta | Lívia Silveira
Iwyson H Costa | Bárbara Marques
Cristiane Aparecida A Menezes De Pádua (Brazil)

45 – Incidence of First-Time HbA1c-Defined Prediabetes in Denmark 2012–2018 and Risk of Progression to Type 2 Diabetes: A Nationwide Study based on Routine Care Laboratory Data [1090]
Sia Nicolaelsen | Reimar Thomsen | Cathrine Juel Lau
Daniel Witte | Henrik Toft Sørensen | Lars Pedersen (Denmark)
46 – Metformin Use and Risk for COVID-19 Infection and Severe COVID-19 Outcomes [1091]
Sascha Dublin | Jennifer Kuntz | James Floyd | Rod Walker
Stephen Fortmann | Elizabeth Bayliss | Susan Shortreed
Laura Harrington | Mi Lee | Ladia Albertson-Junkans
John Powers | Sharon Fuller (United States)

47 – Comparisons of Twenty-Year Trends in Direct Costs, Absence Payments and Lost Time for Employee "Caregivers" of Patients with Breast, Skin, GI, Female, Male, and "Other" Cancers [1092]
Richard A. Brook | Ian A. Beren | Nathan L. Kleinman
Alek A. Drnach | Justin L. Schaneman | Eric M. Rosenberg
(United States)

48 – Outcome Predictability of Serum Uric Acid Among Non-Dialyzed Chronic Kidney Disease Patients – A Hospital Based Prospective Cohort Study [1093]
Ishfaq Rashid | Pramil Tiwari | Sanjay D Cruz
Shivani Jaswal (India)

49 – Changes in Weight Across the Life Span in Patients with Bipolar Disorder I Treated with Second Generation Antipsychotics [1094]
Veena Hoffman | Harry Cheng | Thomas Brecht
Jessica Paulus | Carl Marci (United States)

50 – Real-World Experience of Hospitalized COVID-19 Patients Requiring Mechanical Ventilation [1095]
Lawrence Rasouliyan | Amanda G. Althoff | Vikas Kumar
Stacey Long | Mitesh B Rao (United States)

Hilda J. De Jong | Eline Houben
Fernie J. Penning-Van Beest | Josephina Kuiper
Emily Holtzuis | Maxim Blum | Jozica Skufca
Margarita Riera-Montes | Bradford Gessner | Andreas Pilz
Andrew John Vyse | Elizabeth Begier | Mendwas Dzingina
Ron Herings | James H. Stark (Netherlands)

52 – Improving The Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data [1097]
Kazuki Yoshida | Tianrun Cai | Lily Bessette | Erin Kim
Su Been Lee | Luke E Zabotka | Alec Sun
Julianna M. Mastrorili | Theresa A. Oduol | Jun Liu
Daniel H. Solomon | Katherine P. Liao | Seoyoung Kim
(United States)

53 – Prevalence, Characteristics, and Impacts of Frailty Measured by Multimorbidity Frailty Index Developed Using The ICD-9 CM and ICD-10 CM Codes Among Patients with Heart Failure in Taiwan: A Nationwide Cohort Study [1098]
Hsi-Yu Lai | Shih-Tsung Huang | Liang-Kung Chen
Fei-Yuan Hsiao (Taiwan)

54 – All-Cause Readmission Rates, In-Hospital Mortality, and Resource Use Outcomes for Patients with Type 1 Vs. Type 2 Diabetic Nephropathy in the United States [1099]
Laura A. Clark | Rosa C. Banuelos | Evelyn Rizzo
Koen Degeling | Cathy Lally | Christopher Simpson
(United States)

55 – Demographic Distribution of Parkinson's Disease (PD) and LRRK2-PD in the United States [1100]
Nancy Maserejian | Feiby L. Nassan | Isha Mehta
Qiang Hou | Cathy Lally | Christopher Simpson
Jeremy D. Furtado | Nicholas J Everage (United States)

Sachiko Tanaka (Japan)

57 – Retrospective Study Estimating the Incidence of Acute Alcoholic Hepatitis in the United Kingdom [1102]
Olorunfemi A. Oshagbemi | Michelangelo N. Ribeiro
Sigrid Behr | Olessia Zorina (Switzerland)

58 – Treatment Pathway and Mortality-Causing Mechanism of Treatment-Resistant Depression: A Six-Year Population-based Retrospective Cohort Study [1103]
Vivien Ky Chan | Edmund C. Cheung | Min Fan | Hao Luo
Francisco Lai | Rosa Wong | Ian Wong | Xue Li (Hong Kong)

59 – Incidence of Second Primary Malignancies (SPMs) in Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Patients in England [1104]
Amanda M. Anderson | Montserrat Miret | Pooja Hindocha
Lorena Cirneanu | Christina Lymporopoulou
Emmanuil Markov | Svetomir Hitov | Ferdinando E Vegni
(United States)
**Poster Session C**

**DRUG UTILIZATION RESEARCH**

60 – Optimizing Monitoring Frequency for Clozapine Patients Across the Department of Veterans Affairs Health System [1105]
Paul Fina | John Roehm | Amy Ou | Oluwabusayo Akinola
Jennifer Martin | Francesca Cunningham (United States)

61 – Antidepressants and Antipsychotics Before and During Pregnancy in the Netherlands [1106]
Robiyanto Robiyanto | Ccm Schuiling -Veninga
Jens H. J. Bos | Eelko Hak | Eugene Van Puijenbroek (Netherlands)

62 – Immediate Release Fentanyl: Real-World Data on Abuse and Dependence in Spain [1107]
Raquel Gutierrez Machin | Diana González | Alfonso Rodríguez
Pilar Rayón | Marta Monreal | Dolores Montero
Consuelo Huerta (Spain)

63 – Community Pharmacist-Led Interventions and Their Impacts on Patients with Type 2 Diabetes in Low-and Middle-Income Countries: A Scoping Review [1108]
Indriastuti Cahyaningsih | Maarten Lambert | Taichi Ochi
Fang Li | Xinyu Li | Petra Denig | Katja Taxis (Netherlands)

64 – Antipsychotic Drugs Use in Spain During the COVID-19 Pandemic: A Time Series Analysis Using Autoregressive Integrated Moving Average (ARIMA) and Exponential Smoothing (ETS) Models [1109]
Raquel Gutierrez Machin | Diana González | Belén Castillo
Marta Monreal | Consuelo Huerta | Alfonso Rodríguez
Dolores Montero (Spain)

65 – Introducing the Dutch ISPE Student Chapter [1110]
Melissa Leung | David Liang | Taichi Ochi | Ajda Bedene
Helga Gardarsdottir (Netherlands)

66 – Drug Utilization Patterns During Pre-conception and Pregnancy Period in Women with Systemic Lupus Erythematosus in Korea [1111]
Yuseon Jung | Seung-Hun You | Sun-Young Jung (South Korea)

67 – Opioid Utilization Profile in Brazilian Federal Hospitals [1112]
Luciane Lopes | Patricia Krauze De Almeida | Claudia Garcia
Serpa Osorio-De-Castro | Elaine Silva Miranda (Brazil)

68 – Use of Symptomatic Treatments for Alzheimer’s Disease Dementia [1113]
Alicia Mcdonald | Julia Dibello | Wenjun Zhong
Jina Swartz | Xinyue Liu (United States)

69 – The Issue of Antibiotic Combinations Prescribing in Outpatients in Syria [1114]
Ana Tomas | Saleh Aljadeeah (Serbia)

70 – Antimicrobial Use in Sweden During the COVID-19 Pandemic: Prescription Filling and Inpatient Care Requisition Patterns [1115]
Aya Nakitanda | Pär Karlsson | Lukas Löfing
Carolyn Cesta | Ingvild Odsbu (Sweden)

71 – Assessments of Potential Adverse Drug Reactions According to a Trigger Tool – A Descriptive Analysis [1116]
Johan Lönnbro | Lina Holmqvist | Elisabeth Persson
Per Thysell | N. David Åberg | Susanna M Wallerstedt (Sweden)

Wenzhen Ge | Scott Antonia | Ning Wu | Ruben Gw Quek
Hilary Dietz | Jean-Francois Pouliot | Jessica Jalbert
James Harnett (United States)

73 – Persistence and Adherence to Antihypertensive Drugs in the Participants of Social Health Insurance Attending a Primary Care Clinic in Banjarmasin, Indonesia [1118]
Alfi Yasmín | Haura Maulida Rahmatika | Farida Heriyani
Djallalluddin Djallalluddin | Hendra Wana Nur’Amin (Indonesia)

74 – Persistence and Adherence to Antidiabetic Drugs in Social Health Insurance Participants Attending a Primary Care Clinic in Banjarmasin, Indonesia [1119]
Alfi Yasmín | Farida Heriyani | Muhammad Arifial Asyum
Djallalluddin Djallalluddin | Hendra Wana Nur’Amin (Indonesia)

75 – Use of Psychotropic and Antidepressant Medicines in the Brazilian Amazon: Analysis of Two Cross-Sectional Population-based Studies, 2015 and 2019 [1120]
Tais Freire Galvao | Gustavo Magno B. Tiguman
Marcus Silva (Brazil)
76 – Roll-Out of HIV Pre-Exposure Prophylaxis Use in France: A Nationwide Study from 2016 to 2021 [1121]
Sophie Billioti De Gage, David Desplas
Rosemary Dray-Spira (France)

77 – Facilitators & Barriers of Medication Adherence Amongst the Geriatric: A Developing Country Scenario [1122]
Chalasani Sri Harsha, Ramesh Madhan, Prathibha Pereira
Annmaria Thomas, Steby Mol Stephen
Mohamed Dharvees T., Sandy Crasta D.
Jehath M. Syed (India)

Robert H. Vander Stichele, Miriam Sturkenboom
Carlos Duran, Luc Nicolas, Dipak Kalra (Belgium)

79 – Risk of Major Adverse Cardiovascular Events in Patients with Rheumatoid Arthritis Using Janus Kinase Inhibitors [1124]
Seung-Hun You, Soo-Kyung Cho, Yeo-Jin Song
Yoon-Kyoung Sung, Sun-Young Jung (South Korea)

80 – Systemic and Biologic Therapy in Atopic Dermatitis [1125]
Lawrence Rasouliyan, Amanda G. Althoff, Vikas Kumar
Stacey Long, Carla Zema, Mitesh B Rao (United States)

81 – A Pharmacoepidemiologic Study of Antibiotics Prescription Patterns in a Tertiary Care Hospital [1126]
Sherif Eltonsy, Payam Peymani, Paria Oskuie
Navid Omidifar, Alekhya Lavu (Canada)

82 – Utilization, User Characteristics, and Adverse Outcomes of Insulin Glargine Originators and Follow-on Drug in Patients with Diabetes in the US [1127]
Aaron B. Mendelsohn, Young Hee Nam, James Marshall
Cara Mcdermott, Sengwee Toh, Cate Lockhart (United States)

83 – Angiotensin Converting Enzyme Inhibitors-Related Adverse Drug Reactions and the Risk of Subsequent Cardiovascular Events and All-Cause Mortality: A Retrospective Cohort Study in the United Kingdom [1128]
Widya Norma Insani, Cate Whittlesea, Chengsheng Ju
Kenneth Man, Hassan Hasan Alwafi, Matthew Adesuyan
Sarah Chapman, Li Wei (United Kingdom)

84 – Comparing Diabetes Care Outcomes of the Centrally Organized Hoorn Diabetes Care System with Regular Care by General Practitioners in the Netherlands [1129]
Jetty Overbeek, Karin Swart, Emma Van Der Pal
Marieke Blom, Joline Beulens, Giel Nijpels, Petra Elders (Netherlands)

85 – Trajectories of Concurrent Opioid and Benzodiazepine Use and Associated Opioid Overdose Risk Among Arizona Medicaid Beneficiaries [1130]
Weihsuan Jenny Lo-Ciganic, Seonkyeong Yang
Ching-Yuan Chang, Juan Hincapie-Castillo, Walid Gellad
Bobby Jones, Jeannie Lee, James Huang
Debbie Wilson, Gary Reisfield, Chian Kwoh
Khoa Nguyen, Chris Delcher, Christopher Harle
Yong Ge, Ronald Shorr, Pei-Lin Huang, Lauren Adkins (United States)

86 – Antihyperglycemic Use in Hemodialysis-Dependent Kidney Failure [1131]
Til Stürmer, Klara Klein, Virginia Pate
Magdalene M. Assimon, John Buse, Jenny Flythe (United States)

87 – Understanding Opioid Use Prior to and Immediately Following Cancer Diagnosis Using Group-based Trajectory Models (GBTM) [1132]
Benjamin Daniels, Tim Luckett, Michael O Falster
Winston Liauw, Natasa Gisev, Sallie-Anne Pearson (Australia)

88 – Dynamic Pattern of Anti-Epileptic Drug During Pregnancy Among Women with Epilepsy by Using Linking Database in Taiwan [1133]
Ju-Ling Chen, Yea-Huei Kao Yang, Ching-Lan Cheng (Taiwan)

Mina Tadrous, Ann Chang, Shanzeh Chaudhry
Daniel Mccormack, Tara Gomes, Anisa Shivji (Canada)

90 – International Trends in Prescription Opioid Sales Among Developed and Developing Countries Prior To, and During the COVID-19 Pandemic: A Cross-Sectional Analysis of 66 Countries [1135]
Mina Tadrous, Tara Gomes, Katie Suda
Katherine Callaway Kim, Ria Garg (Canada)
Poster Session C

Mina Tadrous | Yuna Choi | Katie Suda
Inmaculada Hernandez | Jared Magnani (Canada)

Ajda Bedene | Eveline La Van Dorp | Frits R. Rosendaal
Albert Dahan | Willem M Lijfering (Netherlands)

93 – Melatonin Use Among Children, Adolescents, and Young Adults: A Danish Nationwide Drug Utilization Study [1138]
Mette Bliddal | Helene Kildegaard | Lotte Rasmussen
Martin Ernst | Poul Jørgen Jennum | Stine Mogensen
Anton Pettegård | Rikke Wesselhoeft (Denmark)

Scott M. Vouri | Phuong Tran | Maryam Deravi | Eric Grieser
Almut Winterstein (United States)

Macarius Donneyong | Mohamed Elsaid | Ashley Felix (United States)

96 – Trends in Insulin Types and Devices Used by Adults with Type 2 Diabetes in the United States, 2016 to 2020 [1141]
James Heyward | Sudipa Sarkar | G. Caleb Alexander
Rita Kalyani (United States)

97 – Drug Utilization Pattern Among Patients with Benign Prostatic Hyperplasia in Korea: A Large Cohort Study [1142]
Nakyung Jeon | Minjune Yang (Republic of Korea)

98 – Primary Non-Adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data [1143]
Jeffrey Curtis | Yujie Su | Cassie Clinton | Patrick Stewart
Bryant England | Fenglong Xie (United States)

99 – Group-based Trajectory Modeling of Medication Refill Patterns of Novel Oral Anticoagulant (NOACs): An Analysis of the Pollow Cohort [1144]
Antonio Teixeira Rodrigues | José Guerreiro | Carla Torre (Portugal)

100 – Prevalence and Determinants of Over- and Undertreatment of Thyroid Dysfunctions in the Rhineland Study [1145]
Nersi Alaeddin | Rutchanna Ms Jongejan | Robin P Peeters
Yolanda B. De Rijke | Monique Mb Breteler
Folgerdiena M. De Vries (Germany)

Fatima Tauqeer | Angela Lupattelli | Anne Moen (Norway)

102 – A Point Prevalence Study of the Use of Antibiotics at Six Tertiary Care Hospitals in the Kathmandu Valley, Nepal [1147]
Nisha Jha | Bibechan Thapa | Samyam Bikram Pathak
Arathy Pandey | Estory Pokhrel | Pathiyil Ravi Shankar
Shital Bhandary | Ganesh Dangal (Nepal)

103 – Persistent Opioid Use in Lymphoma Survivors Following Treatment [1148]
Katherine Stafford | Anita J. Kumar | Virginia Pate
Alison Loren | Alan Kinlaw (United States)

104 – The Effects of a Patient-Centered Communication Training on Identifying Drug Related Problems – A Pre and Post Intervention Study in Pharmacy Practice in Denmark and the Netherlands [1149]
Ellen Van Loon | Stijn Crutzen | Ulla Hedegaard
Ramune Jacobsen | Armin Andersen | Marcia Vervloet
Laura Schackmann | Liset Van Dijk | Susanne Kaaber
Katja Taxis (Netherlands)

106 – The Effects of Virtual Care Use on Prescription Drug Claims Among Older Adults with Dementia Before and During COVID-19 [1151]
Cherry Chu | Vess Stamenova | Janette Brual
Jiming Fang | Cathleen Fleury | Onil Bhattacharyya
Mina Tadrous (Canada)
107 – Association of The Swissmedic Safety Alert Regarding Skin Cancer and The Use of Hydrochlorothiazide and Other Antihypertensives in Switzerland [1152]
Tamino Zappalà | Anton Pottegård | Carola A. Huber
Christoph Meier | Julia Spoendlin (Switzerland)

108 – Self-Reported Challenges Obtaining Ongoing Prescription Opioids Among Australians with Chronic Non-Cancer Pain [1153]
Ria E Hopkins | Gabrielle Campbell | Louisa Degenhardt
Nicholas Lintzeris | Briony Larance | Suzanne Nielsen
Natasa Gisev (Australia)

109 – Use of Fingolimod and Teriflunomide in Women of Childbearing Age and During Pregnancy in Germany [1154]
Katharina Platzbecker | Bianca Kollhorst | Ulrike Haug
(Germany)

110 – Psychotropic Medication Use After the COVID-19 Pandemic Transition to Telepsychiatry Services Among the Privately Insured in the United States [1155]
Alejandro Amill-Rosario | Haeyoung Lee
Chengchen Zhang | Susan Dosreis (United States)

111 – Mortality Consequences of Misuse of Psychoactive Prescription Drugs in Portugal – The MisuMedPT Project [1156]
Ana Araujo | Carolina Bulhosa | José Guerreiro
João Goulão | Ana Martins (Portugal)

112 – Profile of Antiplatelet Use in Patients After Myocardial Infarction in a General Hospital in Banjarmasin During 2016-2020 [1157]
Pandji Winata Nurikhwan | Muhammad Nur Mahmudi
Alfi Yasmina | Djallalluddin Djallalluddin
Dwi Laksono Adiputro (Indonesia)
113 – Profile of Antihypertensive Class Drug Usage in Post-Myocardial Infarction Patients in a General Hospital in Banjarmasin During 2016-2020 [1158]  
Pandji Winata Nurikhwan | Djallalluddin Djallalluddin  
Muhammad Nu'man Akmal | Alfi Yasmina  
Dwi Laksono Adiputro (Indonesia)

114 – Impact of National Negotiation and "4+7" Pilot Pooled Procurement on Hepatitis B Antiviral Treatment in Shanghai, China [1159]  
Shiyang Liu | Hanchao Cheng | Jing Sun | Simon Luo  
Linh-Vi Le | Zhongdan Chen | Polin Chan (China)

115 – Utilization of Biologics Used for Plaque Psoriasis: A Descriptive Study [1160]  
Nanna Engel-Andreasen | Jesper Hallas | Peter Jensen  
Alexander Egebjerg | Mette Reilev (Denmark)

116 – Sex Differences Among Users of NSAIDs and Opioids During COVID-19 Pandemic in Manitoba, Canada [1161]  
Roseanne Offiah | Laila Nabil Mahmoud Helmy Aboulatta  
Payarn Peymani | Basma Aloud | Kaarina Kowalec  
Christine Leong | Joseph Delaney | Jamie Falk  
Silvia Alessi-Severini | Sherif Eltonsy (United Kingdom)

117 – Susceptibility Reporting and Antibiotic Prescribing for UTIs in The Inpatient Setting: A Nudge Toward Improved Stewardship [1162]  
Madison Ponder | Kevin Alby | Lindsay M Daniels  
Ashlyn M. Norris | Alan Kinlaw (United States)

118 – Disparities and Changes in PReP Coverage for HIV Prevention Before and During the COVID-19 Pandemic in the US [1163]  
Mahdi Fallahi | Jenny Guadamuz | Carter McCormick  
Dima Qato (United States)

Ana Araujo | Carolina Bulhosa | José Guerreiro  
João Goulão | Ana Martins (Portugal)

120 – A Multivariate Interrupted Time Series Analysis Assessing the Impacts of Half-Pack Sizes and Increased Access Restrictions on Publicly Subsidised Opioids in Australia [1165]  
Forrest C. Koch | Jake Olivier | Sallie-Anne Pearson  
Benjamin Daniels (Australia)

121 – Prescribing Patterns of Codeine and Alternatives in Children Across Five EEA Countries Between 2010 and 2017 [1166]  
Kelly Plueschke | Robert Flynn | Aikaterini Christina Deli  
Patricia García-Poza | Miguel-Angel Macia-Martinez  
David B. Olsen | Rosemary Dray-Spira | Chantal Quinten (Netherlands)

122 – Personalized Prescribing in Type 2 Diabetes Following The 2015 UK Treatment Guidelines: Description of Non-Insulin Anti-Diabetic Drug (NIAD) Utilization and Polypharmacy Patterns [1167]  
Maria Luisa Marques De Sa Faqutti  
Adrian Martinez De La Torre | Theresa Burkard  
Andrea Burden (Switzerland)

123 – Evaluation of Antimicrobial Stewardship Metrics in Medical Intensive Care Unit: A Prospective Interventional Study [1168]  
Rekha B. | Ramesh Madhan | Chalasani Sri Harsha  
Jehath M. Syed | Subhash Chandra Bj | Sumana M. N. (India)

124 – Trends in Dispensing and Utilisation of Tapentadol in Australia [1169]  
Ximena Camacho | Andrea Schaffer | Nicholas A. Buckley  
Nicole Pratt | David Henry | Sallie-Anne Pearson (Australia)

125 – The Impact of Polypharmacy on Restarting Antidepressant Treatment in Individuals with Comorbid Depression and Type 2 Diabetes: A UK Primary Care Cohort Study [1170]  
Annie Jeffery | Kate Walters | David Osborn | Ian Wong  
Joseph F F Hayes (United Kingdom)

126 – Pharmacoepidemiologic Study on the Use of Psychiatric Medicines in Greece During the Period of 2015-2020 [1171]  
Foteini Dermiki-Gkana | Panagiotis Nikolaos Lalagkas  
Christos Kontogiorgis | Theodoros Constantinides  
Dimitra Hadjipavlou-Litina (Greece)
INFORMATICS

George SQ Tan | Erica K Sloan | Pete Lambert
Carl M. Kirkpatrick | Jenni Ilomaki (Australia)

128 – Agreement Between Interaction Alerts in Different Sources Regarding Classification and Suggested Clinical Management [1173]
Carina Tukukino | Walaa Hamdan | Frida Wallin Hybelius
Anna L. Eriksson | Susanna M. Wallerstedt (Sweden)

129 – Characterization of a Novel Oncology Electronic Health Records-Derived Data Linkage to Commercial Claims [1174]
Mustafa Ascha | Prakirthi Yerram | Jocelyn Wang
Samantha Reiss | Trevor Royce | Sarah Brake
Gregory Calip (United States)

130 – Linkage of German Healthcare Administrative Claims and The MSDS 3D Registry for Enhancing Real-World Evidence Capabilities in Multiple Sclerosis [1175]
Erwan Muros Le Rouzic | Marco Ghiani | Evi Zhuleku
Licinio Craveiro | Anja Dillenseger | Tjalf Ziemssen
Ulf Maywald | Thomas Wilke (Switzerland)

131 – Al Literature Search to Support Rapid Analytics in Epidemiology [1176]
Chris Leo Pashos | Matthew Michelson | Tiffany Chow
Jacob Kahrs | Nidia Rodriguez-Ormaza | Rennie Joshi
Changxia Shao | Mehmet Burcu | Nicole Cossrow (United States)

132 – Integrating Healthcare Databases to Establish Screening Cohort for Asian Nomadic Descendants in China Inner Mongolia Autonomous Region: Cohort Profile of Scan-China [1177]
Yuelin Yu | Xuefeng Lai | Yunjing Zhang | Guozhen Liu
Ruogu Meng | Jing Ren | Mingyuan Wang | Siyan Zhan
Yunfeng Xi | Shengfeng Wang (China)

133 – Distilling a High Precision Drug Adverse Effect Benchmark Using Wikipedia's Wisdom of The Crowd [1178]
Yonatan Bilu | Chen Yanover (Israel)

134 – Predicting Risk-Stratified Unmet Needs Among Adolescents and Young Adult Cancer Survivors in USA [1179]
Sujin Kim | Gyeon Oh (United States)

135 – Engagement with Digital Health Technologies for Self-Monitoring of Symptoms Among Adolescents with Mood Disorders Treated with Antidepressants [1180]
Wendy Camelo Castillo | Gloria Reeves | Susan Dosreis
Oluwadamilola Onasanya | Udim Damachi
Margaret Woodbury | Martine Solages | Michael C. Davis
Leonard Sacks (United States)

136 – Data-Driven Approaches to Improve Phenotype Sensitivity Using EHR Data [1181]
Sengwee Toh | David Carrell | Joshua C Smith
Daniel Park | Jill Whitaker | Michael F Mclemore
Elizabeth E Hanchrow | Dax Westernman | Joshua Osmaniski
Robert Winter | Saranrat Wittayanukorn
Danijela Stojanovic | Arvind Ramaprasan | Ann Kelley
Mary Shea | David J Cronkite | Jing Zhou | Yueqin Zhao
Kevin B. Johnson | David Aronoff (United States)

137 – Study Scripts Supporting Multiple Common Data Models [1182]
Rosa Gini | Olga Paoletti | Romin Pajouheshnia
Patrick Souverein | Nicolas H Thrin | Vera Ehrenstein
Manuel Barreiro-De Acosta | Miriam Sturkenboom
Lia Gutierrez | Susana Perez-Gutthann (Italy)

138 – Barriers and Facilitators in Reporting Medication Errors: A Nurse's Perspective [1183]
Chalasani Sri Harsha | Ravina Ravi | Janet Mathias
Ramesh Madhan (India)

139 – Developing a COVID-19 Vaccine Distribution and Tracking System for The Veterans Health Administration [1184]
Ashir Shumunov | Jennifer Martin | Francesca Cunningham (United States)

140 – The Utility of Data Tokenization for Real World Data (RWD) Access in Clinical Trials [1185]
Paul Petraro | Carla Heywood | Christian Niyonkuru
Ling Zhang | Devin Gilliam | Gordon Cummins (United States)
METHODS IN PHARMACOEPIDEMIOLOGY

141 – Scalable Feature Engineering from Electronic Free Text Notes to Supplement Confounding Adjustment of Claims-based Pharmacoepidemiologic Studies [1186]
Richard Wyss | Joseph M. Plasek | Li Zhou | Lily Bessette
Sebastian Schneeweiss | Jeremy Rassen
Theodore Tsacogianis | Joshua Lin (United States)

142 – Validation of Safety Outcomes in Routinely Collected Data: Lessons Learned from a Multinational Post-Approval Safety Study [1187]
Patrick J Arena | Kui Huang | Lukas Löfling
Shahram Bahmanyar | Jingping Mo | Stephen Schachterle
Anthony Nunes | Elisabeth Smits | Rosa Juuti
Fabian Hoti | Pasi Korhonen | Kasper Adelborg
Jens Sundbøll | Torben Rasmussen | Anders Løkke
Vera Ehrenstein (United States)

143 – Validation of a Case-Finding Algorithm for Endometrial Cancer Using ICD10 Diagnostic Codes in Insurance Claims [1188]
Djeneba Audrey Djibo | Andrea Margulis
Cheryl N. McMahan-Walraven | Catherine Saltus
Patricia Shuminski | James A. Kaye | Catherine B. Johannes
Brian Calingaert | Mark Libertin | Shelli Graham
(United States)

144 – Treatment Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in People Underrepresented from The ONTARGET Trial: Analysis of Routinely Collected Data Using Trial Replication Methods [1189]
Paris J. Baptiste | Angel Wong | Anna Schultze
Marianne Cunningham | Johannes F. Mann | Catherine Clase
Clémence Leyrat | Laurie Tomlinson | Kevin Wing
(United Kingdom)

145 – Imputation of Missing Diagnosis Date and Implications for Analyses in Registries: A Simulation Study [1190]
Elissa H. Wilker | Ema Rodrigues | J. Alexander Cole
(United States)

146 – Trajectories of Severity Pattern Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study [1191]
Seung-Hun You | Soo-Kyung Cho | Yoon-Kyoung Sung
Sun-Young Jung (South Korea)

147 – A Comparison of Structured Algorithms for Identifying Men with Metastatic Prostate Cancer within the Veterans Affairs Health Care System [1192]
Irene Shui | Jessica L. Janes | Shannon Stock
Michael Burns | Justin Waller | Amanda M. De Hoedt
Sameer Ghat | Jeri Kim | Thomas J. Polascik
Stephen J. Freedland (United States)

148 – External Validation of a Machine Learning Algorithm to Distinguish Death from Disenrollment in Claims Data [1193]
Bethany Diprete | Jessica Young | Nabarun Dasgupta
Kenneth Pack | Toska Cooper | Sarah Bloemers
Brian Pence | Debra E. Irwin | Teresa B. Gibson (United States)

149 – Two Component Claims-based Algorithm to Identify Heart Failure Ejection Fraction Phenotypes [1194]
Phillip R. Hunt | Karolina Andersson-Sundell
Hung-Ta Chen | Cindy Khordoc (United States)

150 – Multimorbidity Ascertainment in Health Administrative Data and Role of the Time Window [1195]
Marc Simard | Elham Rahme | Marjolaine Dubé
Véronique Boiteau | Caroline Sirois (Canada)

151 – Use of Patient Profiles to Validate Acute Myocardial Infarction in Claims Data [1196]
Tania Schink | Katharina Platzbecker | Annemarie Voss
Jonas Reinold | Anne Elbrecht | Wolfgang Biewener
Daniel Prieto-Alhambra | Annika Joedicke (Germany)

Sarah Hoffman | Nilesh Gangan | Xiaoxue Chen
Joseph L. Smith | Arlene K Tave | Yiling Yang
Michael Grabner (United States)

153 – A Pragmatic Comparison of Logistic Regression vs. Machine Learning Methods for Propensity Score Estimation [1198]
Daniel Beachler | Xiaodan Mai | Chia-Chen (Jenny) Teng
Yuwen Gao | Samuel B Governor | Xintong He
Sarah Hoffman | Geetika Kalloo (United States)
154 – Utilization and Timing of Z3A Codes in Pregnancy to Estimate Gestational Age Using Administrative Claims [1199]
Liza Gibbs | Clark Jackson | Debra E Irwin
Dawn G Albright | Emily Rubinstein | Amanda Patrick (United States)

155 – The Data Analysis and Real-World Interrogation Network (DARWIN EU®): A Federated Network of Data Sources and Services in the European Union [1200]
Xavier Kurz | Andrej Segec | François Domergue
Peter Arlett (Netherlands)

156 – A Longitudinal Early-Indicator of Overall Survival Based on Prognostic Scores [1201]
Hugo Loureiro | Tim Becker | Anna Bauer-Mehren (Germany)

157 – Standardizing to Specific Target Populations in Distributed Networks: A Proof of Concept [1202]
Michael Webster-Clark | Robert Platt (Canada)

158 – Adapting Sufficient Component Cause Models to Pharmacoepidemiology: Incorporating Continuous Variables [1203]
Michael Webster-Clark | Imaani Easthausen | Ulka Campbell
Elizabeth M Garry | Nicolle Gatto (Canada)

Gema Requena | Victoria Banks | Alexandrzesz Czira
Robert Wood | Theo Tritton | Olivia Massey | Rosie Wild
Afisi Ismaila (United Kingdom)

160 – Random Forests Quantile Classifier, a Novel Proposal to Account for Imbalanced Data Sets in The Prediction Model Development: A Feasibility Study Using Retrospective Registry Data of Kawasaki Disease in Japan [1205]
Masato Takeuchi (Japan)

161 – Bias in Observational Studies on the Effectiveness of Hydroxychloroquine in COVID-19 [1206]
Mirjam Hempeñius | Rolf Hh Groenwold | Anthonius De Boer
Olaf H. Klungel | Helga Gardarsdottir (Netherlands)

162 – Selective Sampling: A Novel Approach to Simulating Biased Samples for Methods Research [1207]
Megan Delgado | Chase Latour | I-Hsuan Su | Virginia Pate
Charles Poole | Jessie Edwards | Til Stürmer
Jennifer Lund | John Concato | Jie Li | Kenneth Quinto
Nahleen Lopez | Michele Jonsson Funk (United States)

163 – Development and Evaluation of The Algorithm Certainty Tool Kit (ACE-IT) to Evaluate Safety Outcomes Using Electronic Medical Record and Claims-based Algorithms [1208]
Sonal Singh | Julie Beyrer | Xiaofeng Zhou
Joel N. Swerdel | Raymond A. Harvey | Kenneth Hornbuckle
Léo Russo | Kanwal Ghauri | Ivan H Abi-Elias
Carla V. Rodriguez-Watson (United States)

164 – Benzodiazepine Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Pharmacoepidemiologic Screening to Detect Three-Way Drug Interaction Signals [1209]
Charles Leonard | Cheng Chen | Sean Hennessy
Colleen Brensinger | Emily Acton | Warren Bilker
Todd Miano | Thanh Phuong Pham Nguyen (United States)

165 – Length of Lookback Period for The Charlson Comorbidity Index and Prediction of Mortality Among Hip-Fracture Patients in Denmark [1210]
Morten Madsen | Morten Schmidt | Alma Becic Pedersen
Vera Ehrenstein | Johnny Kahler (Denmark)

166 – MINERVA: Metadata for Data Discoverability and Study Replicability in Observational Studies [1211]
Lia Gutierrez | Rosa Gini | Romin Pajouheshnia
Eleanor Hyde | Morris A. Swertz | Miriam Sturkenboom
Andrea Margulis | Carla Franzoni | Alejandro Arana
Vera Ehrenstein | Karin Gembert | Ella Jansen
Ron Herings | Nicolas H Thurin | Igor Locatelli
Janja Jazbar | Špela Žerovnik | Mitja Kos | Steven Smit
Srirangarsingh Metspalu | Silvia Zaccagnino
Maria Paula Busto | Bas Middelkoop
Manuel Barreiro-De Acosta | Francisco Sanchez-Saez
Clara Rodriguez-Bernal | Gabriel Sanfelix-Gimeno
Beatriz Poblador-Plou | Jonás Carmona-Piriz
Antonio Gimeno-Miguel | Miguel Gil | Wiebke Schaefer
Ulrike Haug | Stefania Simou | Chantal Quinten
Ana Cochinio | Paolo Alcini | Xavier Kurz
Susana Perez-Gutthann (Spain)
167 – Updated Core Competencies in Pharmacoepidemiology to Inform Contemporary Curricula and Training for Academia, Government, and Industry [1212]
Vicki Osborne | Deborah Layton | Amie Goodin
Almut Winterstein | Andrew Bate | Catherine Cohet
Xavier Kurz | Lisa Pont | David Moeny | Olaf H Klungel
Simone Pinheiro | John Seeger | K. Arnold Chan
Joshua Brown (United Kingdom)

168 – Poor Pain Control and Risk for Anxiety and Sleeping Disorders Among Older Patients with Dementia [1213]
Nistha Shrestha | Yu-Jung Jenny Wei (United States)

169 – Identification of Obesity and Tobacco Use in Claims Compared to Electronic Health Record (EHR) Data [1214]
Casie Horgan | Po-Yin Chang | Meg Her
Rebecca Hawrusik | Alexander Peters | Catherine Corey
David Graham | Judith Maro | Noelle M Cocoros (United States)

Alan Kinlaw | Alan Ellis | Chantel Martin
Michael Webster-Clark | Michele Jonsson Funk
Charles Poole | Virginia Pate | Qousa Her | Madison Ponder
Jennifer Lund | Til Stürmer (United States)

171 – Concordance Between Subgroup Disproportionality Scores and PRAC Discussions of Subgroup Risk [1216]
Olivia Mahaux | Gregory Powell | François Haguinet
Paulina Sobczak | Namrata Saini | Allen Barry
Amira Mustafa | Andrew Bate (Belgium)

Epiphane E. Kolla | Jérôme Drouin | David Desplas
Marion Taine | Alain Weill | Mahmoud Zureik
Lamiae Grimaldi-Bensouda (France)

Viktoria Starokozhko | Fatima Tarrahi | Patrick Jws Vrijlandt
Peter Gm Mol (Netherlands)

174 – Evaluation of Changes in Lung Cancer Care Patterns During The COVID-19 Pandemic [1219]
Thanh Gn Ton | Lu Chen | Huong Trinh | Ryan Ross
Lauren E. Johns | Shivani K Mhatre (United States)

175 – PHARMACOM-EPI: A Framework for Integrating Pharmacomometric Modelling into Pharmacoepidemiological Research Using Real-World Data [1220]
Hiie Soeorg | Eva Sverrisdóttir | Morten Andersen
Trine Meldgaard Lund | Maurizio Sessa (Denmark)

176 – Quantitative Bias Analysis in Comparative Effectiveness Research: A Cautionary Word [1221]
James Weaver | Patrick Ryan | Victoria Y. Strauss
Marc Suchard | Joel N. Swerdel | Daniel Prieto-Alhambra (United States)

Jasmin Schelhaas | Lourens Bloem | Jarno Hoekman
Aukje Mantel-Teeuwisse | Paula B. Hennik | Carla Herverts (Netherlands)

Hythem Sidky | Jessica Young | Andrew Girvin | Eileen Lee
Kenneth Wilkins | Soko Setoguchi | Yu Shao
Michele Jonsson Funk (United States)

179 – Developing a Framework for Rapid Analytics: A Self-Controlled Case Series Study Replication [1224]
Caitlin Dodd | Sara Burns | April Duddy
Marten Van Den Berg | Tiffany Siu Woodworth (United States)

180 – Patient Satisfaction, Outcomes and Experience Measures Amongst Patients Receiving Propofol: A Patient Reported Outcomes Measure Study [1225]
Arushi Garlapati | Chalasani Sri Harsha | Jalapa Pradhan
Spoorthy S. Murthy | C. Rozampuii | Mohan C. H. Ramesh Madhan | CI Gurudath | Jehath M. Syed (India)
181 – Acid Suppressive Medication and The Incidence of Chronic Childhood Immunological Diseases: A Scoping Review [1226]
Joanna Madej | Yingting Zhang | Tania J. Atanassova
Sarah M. McGuire | Daniel B. Horton (United States)

182 – Tolerated Juvenile Idiopathic Arthritis Disease Activity States in The Childhood Arthritis and Rheumatology Research Alliance Registry [1227]
Melissa L. Mannion | Fenglong Xie | Timothy Beukelman
Jeffrey Curtis for the Carra Registry Investigators (United States)

183 – Prevalence and Factors Associated with Guideline Concordant Antiviral Treatment in Children at High Risk for Influenza Complications [1228]
James Antoon | Matthew Hall | James Feinstein
Kathryn Kyler | Samir Shah | Sonya Tang Girdwood
Jennifer Goldman | Carlos Grijalva | Derek Williams (United States)

184 – The Challenges with Identifying Pediatric Recurrent Wheezing in Real World Data [1229]
Jacob Kahrs | Rennie Joshi | Nicole Cosssrow
Georges J. Nahhas | Patricia Saddier (United States)

185 – Prevalence of Childhood and Adolescent Overweight/Obesity in South Asian Countries: A Systematic Review and Meta-Analysis [1230]
Dipika Bansal | Nagita Devi | Karamsetty D Babu
Mohammed Safer (India)

186 – Common Diagnoses, Procedures and Medications in The First Year of An Infant’s Life [1231]
Bora Plaku | Stephen M. Ezzy | Monica Bertoia (United States)

187 – Continued Benefits of Pharmacological Treatment of ADHD on Unintentional Injuries: Emulation of a Target Trial with Swedish Real-World Data [1232]
Le Zhang | Laura Ghirardi | Patrick Quinn
Brian Donofrio | Henrik Larsson | Zheng Chang (Sweden)

188 – Healthcare Utilization and Treatment Among Newly Diagnosed and Prevalent Children with Juvenile Idiopathic Arthritis During the First Year of COVID-19 Pandemic in the US [1233]
Lauren E. Parlett | Yiling Yang | Cecilia Huang
Amanda Neikirk | Amy Davidow | Kevin Haynes
Tobias Gerhard | Carlos D. Rose | Brian L. Strom
Daniel B. Horton (United States)

189 – Epidemiology of Pediatric Ewing Sarcoma in the United States [1234]
Eric Wang | Charles Dharmanty (United States)

190 – Trends in Antiviral Use for Influenza Among Children in the US Between 2010-2019 [1235]
Jyotirmoy Sarker | Abdullah Abdelaziz | Pei-Wen Lien
Carlos Grijalva | Derek Williams | Todd A. Lee
James Antoon (United States)

192 – Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon A1b for Bronchiolitis in Children: A Systematic Review and Meta-Analysis [1237]
Jie-feng Luo | Mengting Yang | Linan Zeng
Xiangcheng Pan | Dan Liu | Sha Diao | Liang Huang
Ting Chen | Zhi-Jun Jia | Guo Cheng | Qin Yu
Lingli Zhang (China)

193 – Stimulant Drug Use in Children Before Six Years of Age and Antipsychotic Add-on Therapy: A Population Based Longitudinal Study [1238]
Hans Juergen Gober | Kathy H. Li | Mahyat Emirnan
Bruce Carleton (Austria)

194 – Prescription Pattern of Empirical Antibiotic Used and The Factors Affecting Death in Children with Bacteremia in Taiwan [1239]
Lu Hsuan Wu | Chien-Chou Su | Wen-Liang Lin
Ching-Yao Shih | Pei-Chin Lin | Mei-Hsien Lin
Pai-Hsiu Chien | Chiang-Lan Cheng (Taiwan)

195 – Differences in Psychotropic Drug Use Among Children and Adolescents in Scandinavia [1240]
Rikke Wesselhoeft | Anne Mette Skov Soerensen
Peter Jensen | Jacob Harbo Andersen | Johan Reutfors
Svetlana Skurteveit | Ingeborg Hartz | Kari Furu
Poul Jørgen Jenum | Carolyn Cesta
Katrine Strandberg-Larsen | Ardesheer Talati | Per Damkier
Anton Pottegård | Mette Bliddal
Lotte Rasmussen (Denmark)
196 – So Many Countries, So Many Customs: A Register-based Analysis of Conduct Disorder Prevalence and Treatment Patterns in Four Western Countries [1241]
Mette Bliddal | Christian Bachmann | Susan Dosreis
Ingvild Odsbu | Oliver Scholle | Svetlana Skurtveit
Annika Vivirito | Rikke Wesselhoeft
Stephen Scott (Denmark)

197 – Maternal Antibiotics Use in Pregnancy and The Risk of Neurodevelopmental Disorders in Children: A Systematic Review and Meta-Analysis [1242]
Le Gao | Hira Pirzada | Kenneth Man | Ian Wong
(Hong Kong)

198 – Reports of Adverse Events Related with Second Generation Antipsychotics in Children in The FDA Adverse Event Reporting System (FAERS) [1243]
Lorenzo Villa Zapata | Janese Bibbs | Mariah Crapps
Ainhoa Gomez Lumbreras | Daniel Malone (United States)

199 – Potential Drug-Drug Interactions in Pediatric Patients with Cancer: A Hospital-based Prospective Study [1244]
Sherif Eltonsy | Payam Peymani | Narges Zarsanj
Seyed Omid Reza Zekavat | Alekhya Lavu (Canada)

200 – Characterizing Infants in the Sentinel Distributed Database Mother-Infant Linkage Table [1245]
Ashley Martinez | James Marshall | Samantha Smith
Danijela Stojanovic | Catherine Corey (United States)

201 – Characterizing Pediatric Members in the Sentinel Distributed Database [1246]
Ashley Martinez | Emmanuel Ojo | Kimberly Barrett
Samantha Smith | Danijela Stojanovic (United States)
202 – Pediatric Drug Safety Surveillance in Saudi Arabia: A Description of Adverse Drug Reactions from The Saudi Vigilance Database [1247]
Meshael Alrasheed | Rayan Ibrahim Alolayet
Fawaz F. Alharbi | Aljoharah M. Algabbani | Radwan Hafiz (Saudi Arabia)

203 – New Child and Adolescent Users of Psychotropic Medication After the Start of the COVID-19 Pandemic [1248]
Haeyoung Lee | Susan Dosreis | Chengchen Zhang
Alejandro Amill-Rosario (United States)

204 – A Real-World Study of Incidence Rates of Safety Outcomes of Interest in Infants Aged 1 Month to < 1 Year and Patients Aged 1 to < 2 Years Treated with Intravenous Pantoprazole Sodium Using an Electronic Health Records Database from the US [1249]
Sampada K. Gandhi | Benjamin Taylor | Lexie Rubens
Nileesa Gautam | Kevin D. Wolter | Nancy A. Sherman
Kanti Chittuluru (United States)

205 – Role of Human Leukocyte Antigen in Anti-Epileptic Drugs Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Meta-Analysis [1250]
Girish Thunga | Asha K Rajan | Muhammed Rashid
Manik Chhabra | Viji Chandran | Sreeraman Nair
Ananth Kashyap | Rajesh Venkataraman (India)

Sara Waleed Almashari | Eman Ali Alghamdi
Mona A. Almghrabi | Nof Alfaied | Fawaz F Alhbari (Saudi Arabia)

207 – Disproportionality Analysis for Post-Manufacturing Change Safety Monitoring of Biologics: Example of Insulin Lispro [1252]
Ayad K Ali | John D. Ayres (United States)

208 – Overview of Biases Affecting the Interpretation of Signals Identified in Drug Safety Surveillance Systems [1253]
Ayad K. Ali (United States)

Lockwood Taylor | Ruben Hermans | Bernadette Dwan
Priscilla Velentgas | Elizabeth Powers (United States)

210 – Trends in FDA Post-Marketing Commitments and Requirements for Newly Approved Drugs, 2016-2021 [1255]
Jayashri Desai | Jane C. Casey | William Thatcher (United States)

211 – Non-Steroidal Anti-Inflammatory Drugs Use and Micronutrient Status [1256]
Omar M. Albalawi | Abdulrahman Almarshad
Adel A. Alrwisan (Saudi Arabia)

212 – Factors Associated with Under-Reporting of Adverse Drug Reactions: A Systematic Review [1257]
Carla Torre | Catarina Rego Costa | Patricia Abeijón
Adolfo Figueiras | Maria Herdeiro (Portugal)

213 – A Clinical Pharmacist-Led Integrated Approach for The Evaluation of Drug-Related Problems Among Critically Ill Patients [1258]
Chalasani Sri Harsha | Priya Aradhya | Ramesh Madhan
Subhash Chandra Bj (India)

214 – Patient Reported Adverse Events Following Anaesthesia: A Patient Centric Study [1259]
Chalasani Sri Harsha | Arushi Garlapati | Spoorthy S. Murthy
C. Rozampali | Jalapa Pradhan | Mohan C. H. | Ci Gurudath
Ramesh Madhan | Jehath M. Syed (India)

215 – Prevalence, Attributes, and Risk-Factors of QT-Interval Extending Drugs & Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital [1260]
Biswadeep Das | Aakash Agnihotri | Manjunath Bidaroll
Chayna Sarkar (India)

216 – Bidirectional Relationship Between Urinary Retention and The Use of Antipsychotics [1261]
Grace (Hsin Min) Wang | Scott M. Vouri | Edward Lai (United States)
217 – Risk of Osteoporosis Associated with HMG-CoA Reductase Inhibitors in Patients with Dyslipidemia [1262]
Hyeri Yang | Eunmi Choi | Dayoung Shim | Bonggi Kim
(South Korea)

218 – Safety and Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists for Depression: A Narrative Review [1263]
G. Caleb Alexander | Thomas J. Moore | Abdallah Alami
Donald Mattison (United States)

219 – A Description of Nephrolithiasis Associated with Sodium Glucose Co-Transporter 2 Inhibitors Use: A Vigibase Study [1264]
Andreea Maria Farcas | Ioana Frent | Daniel Leucuta
Camelia Bucsa | Cristina Mogosan (Romania)

220 – BBIBP-Corv Vaccine: An Analysis of Adverse Events on Health Personnel by a Peruvian Pharmacovigilance Center [1265]
Yesenia Rodriguez | Anaís Lazarte | Raquel Delgado
Violeta Saromo | Enrique Cachay | Tania Solis (Peru)

221 – Adverse Drug Reactions of Sulpha Drugs: High Burden, Adequate Treatment Outcome But Poor Reportage in Maiduguri, Northeast Nigeria [1266]
Sulayman Tunde Balogun | Emmanuel N. Linus
Bala Shamaki (Nigeria)

222 – Anti-NMDA Receptor Encephalitis and Vaccines [1267]
Thierry Trenque | Salomé Martin | Brahiam Azzouz
Federica Tralongo (France)

223 – A Description of Acute Renal Failure Associated with Sodium Glucose Co-Transporter 2 Inhibitors Use: A Vigibase Study [1268]
Camelia Bucsa | Ioana Frent | Daniel Leucuta
Andreea Maria Farcas | Cristina Mogosan (Romania)

224 – Psoriatic Conditions After Lithium Exposure: French Pharmacovigilance Data [1269]
Thierry Trenque | Brahiam Azzouz | Clara Khatib-Chahidi
Federica Tralongo | Salomé Martin (France)

225 – Medication Related Problems Among Adult Diabetic Outpatients at a National Referral Hospital in Kenya [1270]
Sylvia Atisa Ongua | Mary A. Mundia | Eric M. Guantai
Dorothy Aywak (Kenya)

226 – Determination of Predictors of Drug Related Problems Associated with Narrow Therapeutic Index Drugs [1271]
Ramesh Madhan | Charmi Chhatrala | Bhanu Kumar M.
Chalasani Sri Harsha | Jehath M Syed (India)

227 – Comparison of Hemorrhagic Profile Amongst Direct Acting Oral Anti-Coagulants (DOACs): Risk Quantification by Using US FDA Adverse Event Reporting System (FAERS) [1272]
Pudi Chiranjeevi | Saraswathy G. R.
Subeesh Kullangara Viswam | Ann Mary Swaroop (India)

228 – Gastrointestinal Adverse Events Associated with Hedgehog Pathway Inhibitors: A Real-World Pharmacovigilance Study [1273]
Aditya ShivaKumar | Anjana Shenoy | Jovita Sharon
Raksha Kamath | Lipin Lukose | Gursimran Kaur
Subeesh Kullangara Viswam (India)

229 – Investigating Self-Poisoning in the FDA Adverse Event Reporting System: Clinical Features and Lethal Dose Estimation [1274]
Michele Fusaroli | Guido Pelletti | Valentina Giunchi
Narmine Elena Necibi | Emanuel Raschi | Susi Pelotti
Elisabetta Poluzzi (Italy)

230 – Tumor Lysis Syndrome Associated with Bruton's Tyrosine Kinase Inhibitor: A Disproportionality Analysis in a Spontaneous Reporting Database [1275]
Subeesh Kullangara Viswam | Zeba Zeba
Amrutha Shettigar | Aarushi Kheterpal | Ashwin Dhas
Lipin Lukose | Gursimran Kaur (India)

231 – Adverse Effects Following Immunization (AEFI) of COVID-19 Vaccines in Two Tertiary Health Facilities in Lagos Nigeria [1276]
Ibrahim Adekunle Oreaoba | Adebowale Adewunmi (Nigeria)

232 – Purine Antimetabolites Associated with Pneumocystis Jiroveci Pneumonia: A Disproportionality Analysis in a Spontaneous Reporting Database [1277]
Lipin Lukose | Gursimran Kaur | Beulah E Thomas
Subeesh Kullangara Viswam (India)
233 – Cytomegalovirus Infection Reactivation in Multiple Myeloma Patients Administered Proteasome Inhibitor-combination Therapy: A Disproportionality Analysis in a Spontaneous Reporting Database [1278]
Gursimran Kaur | Lipin Lukose | Beulah E. Thomas
Subeesh Kullangara Viswam (India)

Daniele Sartori | Jeffrey Aronson | Igho Onakpoya (Sweden)

235 – What Makes EU Regulators Want to Communicate About Drug Safety Signals: Results from an Online Survey Study [1280]
Sonia Roldan | Douwe Postmus | Sieta De Vries
Hans Hillege | Peter Møl (Netherlands)

236 – Signal Detection for Adverse Events of Dapagliflozin Using the Korea Adverse Event Reporting System Database [1281]
Suvin Park | Huieon Lee | Hee-Jin Kim | Na-Young Jeong
Eunsun Lim | Nam-Kyong Choi (Republic of Korea)

237 – Dipeptidyl Peptidase-4 Inhibitors and Acute Pancreatitis - A Systematic Review of Descriptive Studies [1282]
Fathima Thashreefa Basheer | Leelavathi D. Acharya
Girish Thunga | Rashmi Shetty | Viji Pulikkel Chandran
Muhammed Rashid (India)

238 – QT Prolongation After the Combined Use of Haloperidol and Contraindicated Drugs: A Case/Non-Case Study Using Korea Adverse Event Reporting System (KAERS) Database, 2016-2020 [1283]
Dal Rî Nam | Da-Young Kim | Sun-Young Jung (South Korea)

239 – Performance of Subgrouped Proportional Reporting Ratios in the US Food and Drug Administration (FDA) Adverse Event Reporting System [1284]
Dan Dauner | Rui Zhang | Terrence Adam | Eleazar Leal
Joel F. Farley (United States)

240 – Incidence Rate of Skin Cancers in Adult Patients with Atopic Dermatitis [1285]
Huifang Liang | Brenna Kirk | Dionna Attinson
Dongmu Zhang | Jianzhong Liu | Ryan Kilpatrick (United States)

241 – Evaluation of Published Data on Risk Minimization Measures in the Gulf Region: A Systematic Review [1286]
Leena A. Al-Sheikh | Sadeem Fahad Alelayan | Haya Almalaq
Nasser Alqahtani | Hadeel Alkofide | Rahaf Almesned
Lujain K. Alnoghaimshi | Maryam Badah | Noura Altulahri (Saudi Arabia)

242 – Are Drug Safety Measures Harmonized? A Real-World Data from Three Regulatory Authorities [1287]
Sadeem Fahad Alelayan | Leena A. Al-Sheikh
Rana Almutawa | Hadeel Alkofide | Thamir M. Alshammari (Saudi Arabia)

243 – Evaluation of Remifentanil’s Safety Profile: A Multicenter Post Marketing Surveillance in Indonesia [1288]
Jonathan Hasian Haposan | Jarir At Thobari
Lukman Ade Chandra | Nastia Hidayati
Rianiasa Karunia Dewi | Rita Purnamasari
Dyah Juliana Pudjiati (Indonesia)

244 – Flaxseed Interaction with Warfarin and Clopidogrel and The Potential Risk of Bleeding [1289]
Waad Alghamdi | Nouf Alfadel | Fawaz F Alharbi
(Saudi Arabia)

245 – Benefits of Telepharmacy Services for Improving Medication Safety in Cardiovascular Diseases [1290]
Merlin Erhan Esad | Mihaela Popova | Evelina Gavazova
Radiana Staynova | Daniela Grekova-Kafalova (Bulgaria)
**VACCINES**

246 – Experiences and Barriers of Community Pharmacists Towards Participation in COVID-19 Vaccination Campaigns [1291]
Hristina Ivanova Stoynova | Radiana Staynova
Evelina Gavazova | Daniela Grekova-Kafalova (Bulgaria)

247 – Background Incidence Rates of Adverse Events of Special Interest for SARS-CoV-2 Vaccines Safety Monitoring in the US [1292]
Sonja Banga | Laurence Serradell | Irisdaly Estevez
Samantha Schlisky | Anne-Laure Chabanon
Hannah Kreisberg | Alena Khromava (Canada)

248 – Prospective Monitoring of COVID-19 Vaccine Safety in the Republic of Croatia [1293]
Barbara Kovacic | Nikica Mirošević Skvrce | Morana Pavičić
Sandra Dujmović Blažok | Ivana Ljubičić
Siniša Tomic (Croatia)

249 – Exploring The Impact of Mental Health Conditions on Vaccine Uptake in High-Income Countries [1294]
Anne M Suffel | Oyinkansola Ojo-Aromokudu
Helena Carreira | Sandra Mounier-Jack | David Osborn
Charlotte Warren-Gash | Helen Mcdonald (United Kingdom)

250 – The Coverage of Influenza Vaccination and Predictors of Not Receiving the Influenza Vaccination in Danish Cancer Patients [1295]
Lau Amdisen | Lars Pedersen | Niels Abildgaard
Christine Stabell Benn | Mikael Rørth
Deirdre Cronin-Fenton | Signe Sørup (Denmark)

251 – Methodological Considerations for Matching Algorithms in Cohort Studies of COVID-19 Vaccine Effectiveness [1296]
Wilhelmine Meeraus | Sudhir Venkatesan | Mark Joy
Kathryn S. Taylor | Mario Ouvens | Trung N Tran
John Dennis | Debasis Kar | Anna Forbes | Sneha Anand
Anke Stuurman | Sylvia Taylor | F. D. Richard Hobbs
Simon De Lusignan (United Kingdom)

253 – Combining COVID-19 Vaccine Data from Claims with Data from Immunization Information Systems (ILS) to Address Exposure Misclassification: An Approach within the FDA Biologics Effectiveness and Safety (BEST) Initiative [1298]
Elizabeth Bell | Cindy Zhou | Karen L. Schneider
Patricia Lloyd | Taina Clarke | Grace Yang
Michael Wilkinson | Kandace Amend | Emily Myers
Steven Anderson | Azadeh Shoaiibi | John Seeger
Hui-Lee Wong (United States)

254 – COVID-19 Vaccine Hesitancy Among Health Care Workers: The Case of Pharmacy Staff of the Korle Bu Teaching Hospital [1299]
Daniel Ankrgh | Daisy Lamprey | Charles Ofei-Palme
Florence Nkansah | Collins Addae | Dorcas Boateng
Frempomaa Nelson | Godfried Adjei | Grace Aboagye
Isaiah Sagoe | Justice Dogbey | Obedia Seanke
Oksana Corquaye | Desmond Osenda | Priscilla Ekpale
Soulisnaia Bruce | Stanley Lagoh | Stephen Corquaye
Anthony Osei | Abreu SomuahSud Abubakari
Nathan Coomps (Ghana)

255 – Factors Associated with COVID-19 Vaccine Hesitancy in the United States [1300]
Sydney Manning | Christy A. Xavier | Rafia Rasu
Usha Sambamoorthi (United States)

256 – Risk of Rhabdomyolysis After Influenza Vaccination: A Case-Centered Analysis [1301]
Che-Yu Chen | Edward Lai | Wan-Ting Huang
Miyuki Hsing-Chun Hsieh (Taiwan)

257 – Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Among Adults in the United States [1302]
Shayan Hobbi | Keran Moll | Bradley Lufkin | Cindy Zhou
Xiangyu Shi | Kathryn R. Fingar | Mao Hu | Minya Sheng
Jeffrey C. Joyce | Timothy Burrell | Yoganand Chillarige
Jeffrey Beers | Patrick Saunders-Hastings | Stella G. Muthuri
Kathryn M. Edwards | Steven Black | Jeffrey Kelman
Christian Reich | Kandace Amend | Daniel Beachler
Rachel Ogilvie | Alex Secora | John Seeger
Patricia Lloyd | Deborah Thompson | Rositsa Dimova
Joyce Obidi | Steve Anderson | Richard A. Forshee
Hui-Lee Wong | Azadeh Shoaiibi | Shanlai Shangguan (United States)
258 – Cognitive and Other Neuropsychiatric Symptoms in COVID-19: Analysis of Person-Generated Health Data from a Community-based Registry [1303]
Joan Largent | Yiqiong Xie | Matthew Reynolds
Kendall B Knuth | Emma Brinkley | Christina Mack
Stephen Toovey | Nancy Dreyer (United States)

259 – Getting Prepared for COVID-19 Vaccines: How European Regulators Anticipated the Need for Real-World Evidence [1304]
Catherine Cohet | Marcia Rueckbei | Kelly Plueschke
Kate Browne | Thomas Goedecke | Robert Flynn
Chantal Quinten | Mathijs Goossens | Gianmario Candore
Peter Arlett | Xavier Kurz (Netherlands)

260 – COVID Brain: The CARE Experience [1305]
Joan Largent | Yiqiong Xie | Matthew Reynolds
Kendall B. Knuth | Emma Brinkley | Christina Mack
Stephen Toovey | Nancy Dreyer (United States)

261 – Real-World Safety of the Pfizer-BioNTech COVID-19 Vaccine in Pregnancy: Data from the Organization of Teratology Information Specialists (OTIS) Pregnancy Registry [1306]
Christina Chambers | Kenneth L Jones | Diana Johnson
Michael Schatz (United States)

262 – Association Between Antibody Titer Levels, Time from COVID-19 Vaccine and Booster Receipt Among an Occupational Cohort of Fully Vaccinated Individuals [1307]
Erin Wasserman | Saamir Pasha | Deverick J. Anderson
Patti Walton | Christopher J Hostler | Damion A. Martins
Emily Myers | Daniel Eichner | Sabrina Smith | Helen Chen
Madeline Lassiter | Hiba Kouser | Navdeep Singh
Allen K. Sills | Christina Mack (United States)

263 – Assessing The Effect of Statin Use on Influenza Vaccine Effectiveness: A Prior Event Rate Ratio Analysis in Primary Care Data [1308]
Adam J Streeter | Sarah J Walker | Lauren Rodgers
Andrea Shelley | Ian Wellaway | Fergus Hamilton
William Hamilton | William Henley (Germany)

264 – Association Between Influenza Vaccination and the Risk of Acute Kidney Injury Among Older People in Korea: Self-Controlled Case Series Analysis [1309]
Haerin Cho | Eunsun Lim | Hee-Jin Kim | Na-Young Jeong Nam-Kyong Choi (South Korea)

265 – Vaccine Adverse Event Reporting System (VAERS): Evaluation of 31 Years of Reports and Pandemics Impact [1310]
Ohoud A. Almadani | Thamir M. Alshammari (Saudi Arabia)

266 – Evaluating The Effectiveness of Interventions to Improve Human Papillomavirus (HPV) Vaccine Uptake in Africa: A Systematic Review [1311]
Omotayo Carolyn Olaoye | Sara Macdonald (United Kingdom)

Matthew Reynolds | Kendall B. Knuth | Yiqiong Xie
Emma Brinkley | Tom Kwon | Christina Mack
Nancy Dreyer (United States)

268 – Increased SARS-CoV-2 Positivity Rates Among Individuals Tested at CVS Health Retail Sites During the Time of Delta and Omicron [1313]
Scott Chavers | Hannah Kaneck (United States)

269 – Self-Reported Demographics of Unvaccinated and Moderna Vaccinated Individuals Who Test Positive for SARS-CoV-2 at CVS Retail Sites [1314]
Scott Chavers | Hannah Kaneck (United States)

Mona A Almaghrabi | Lama J Alhusayni | Nofal Alfadel
Fawaz F. Alharbi (Saudi Arabia)

271 – COVID-19 Booster Protection Against Incident Omicron Infection in a Highly Vaccinated Cohort [1316]
Christina Mack | Caroline Tai | Sarah Connolly
Kendall B. Knuth | Radhika M Samant | John Difiori
Leroy Sims | Eleanor H. Adams | Gabriel Farkas
Deverick Anderson | Michael Merson | David D. Ho
Lisa L. Maragakis | Yonatan Grad (United States)

272 – Diabetics Report Fewer Side Effects from COVID-19 Vaccination Than Non-Diabetics in the US [1317]
Christina Mack | Kendall B Knuth | Matthew Reynolds
Emma Brinkley | Yiqiong Xie | Tom Kwon | Nancy Dreyer (United States)
Poster Session C

273 – A Nationwide Survey of mRNA COVID-19 Vaccinee's Experiences on Adverse Events and Its Associated Factors [1318]
Dongwon Yoon | Ha-Lim Jeon | Yunha Noh
(Republic of Korea)

274 – Risk of Stroke Following Influenza Vaccination in Elderly: A National-based Self-Controlled Case Series Study in Korea [1319]
Hee-Jin Kim | Joongyub Lee | Eunsun Lim | Haerin Cho
Heehyun Won | Nam-Kyong Choi
(Republic of Korea)

275 – Influenza Vaccine and Risk of Myocardial Infarction in The Korean Elderly [1320]
Eunsun Lim | Hee-Jin Kim | Haerin Cho | Na-Young Jeong
Joongyub Lee | Yejee Kim | Nam-Kyong Choi
(Republic of Korea)

276 – Pneumococcal Serotype Distribution: Data in Pediatric Populations Under 5 Years Around the World, 2011–2021 [1321]
Nicole Cossrow | Rennie Joshi | Henok Ayele
Danielle Badgley | Hanane Khoury | Patricia Saddier
(United States)

277 – Pneumococcal Serotype Distribution in Adults 65 Years and Older Around the World, 2011–2021 [1322]
Nicole Cossrow | Rennie Joshi | Henok Ayele
Danielle Badgley | Hanane Khoury | Patricia Saddier
(United States)

278 – The Acceptability of Mixing Different Generic Types of COVID-19 Vaccine Among the General Population; A Cross Sectional Study in Saudi Arabia [1323]
Hassan Hasan Alwafi | Faisal Minshawi
(Saudi Arabia)

279 – Should We Worry About Flare-ups Following Vaccination in Systemic Lupus Patients? A Nationwide Case-Crossover Study Using the French Healthcare Database [1324]
Lamiae Grimaldi | Philippe Attias | Tom Duchemin
Yann Hamon | Jacques Benichou | Lucien Abenhaim
Yola Moride
(France)

Alicia W. Gilsenan | Alison Tse Kawai | Candace C. Fuller
Cynthia De Luise | J. Bradley Layton | Catherine B. Johannes
Jeffrey Brown, | Richard Platt
(United States)

281 – Adverse Events Following COVID-19 Immunization: Active Vaccine Safety Study from a South Indian City [1326]
Juny Sebastian | Juny Sebastian | Merrin Mathew
(India)

282 – Immunization: Are We Confident or Hesitant? [1327]
Juny Sebastian | Reshma Bobby | Devyani Josh
Mohamed B. Moosa | Besty Biju
(India)

283 – An Assessment of the Risk of Anaphylaxis Following Influenza Vaccination in the Korean Elderly: Implementing Near-Real Time Vaccine Safety Surveillance Methods [1328]
Na-Young Jeong | Hee-Jin Kim | Eunsun Lim
Byung-Joo Park | Nam-Kyong Choi
(Republic of Korea)

284 – The Effectiveness of Single and Two-dose Pfizer-BioNTech Vaccine: A Real-World Evidence from Saudi Arabia [1329]
Yasser Albogami | Abdalaziz Alalwan | Mohammed A. Batais
Khaled Alabdulkareem | Abdullah Abdulaziz Alalwan
(Saudi Arabia)

Candace C Fuller | Alison Tse Kawai | Kevin Haynes
Kevin Coughlin | Juliane Reynolds | Rebecca Hawrusik
Casie Horgan | Brian Calingaert | Catherine B. Johannes
J. Bradley Layton | Aliza Peterson | Nicolas Praet
Corinne Willame | Emily Yost | Carla Brannan
Cheryl N. Mcmahill-Walraven | Maria Guzman
Aziza Jamal-Allial | Vinit Nair | Ryan Seals
Florence Wang | Mano Selvan | Qianli Ma | Richard Platt | Alicia W Gilsenan
Jeffrey Brown
(United States)

286 – SARS-CoV-2 Breakthrough Infections Among the Healthcare Workers Post-Vaccination with ChAdOx1 nCoV-19 Vaccine in The South Indian State of Kerala [1331]
Jose J Kochuparambil | Aleena Issac
Jais Vayalikunnel
(India)

287 – Knowledge About SARS-CoV-19 Booster Vaccines Among the General Public in India – A Web-based Cross-sectional Study [1332]
Jose J Kochuparambil | Aleena Issac
Jais Vayalikunnel
(India)
288 – Risk of SARS-CoV-2 Infection Following Initial COVID-19 Vaccination by Location [1333]
Mina Tadrous | Cherry Chu | Tonya Campbell
Dave Juurlink | Jeff Kwong | Michael Paterson
Tara Gomes (Canada)

Nancy Dreyer | Yiqiong Xie | Matthew Reynolds
Kendall B. Knuth | Emma Brinkley | Tom Kwon
Christina Mack (United States)

290 – Myocarditis and Pericarditis in Immunocompromised Individuals Following COVID-19 mRNA Vaccination: A Living Review of Spontaneous Reports [1335]
Samantha Lane | Alison Yeomans | Saad Shakir
(United Kingdom)

291 – Knowledge Build-Up on The Safety of EMA Approved COVID-19 Vaccines: An Overview [1336]
Florence Van Hunsel | Armin Armiri | Agnes Kant
(Netherlands)

292 – Tree-based Data-Mining for COVID-19 Vaccine Safety Assessment [1337]
Judith Maro | Katherine Yih | David L Mcclure
Jennifer Nelson | Gabriela Vazquez-Benitez
Joshua Williams | Stanley Xu | Martin Kulldorff
(United States)

293 – Side Effects of Vaccines Against COVID-19 in Valencia Region. Results of The ProVaVac Survey Study with 13,837 People in Spain [1338]
Gabriel Sanfelix-Gimeno | Francisco Sanchez-Saez
Salvador Peiró | Anibal García-Sempere | Isabel Hurtado
Clara Rodriguez-Bernal (Spain)

294 – Reduction in Data Lag Using Optum Pre-adjudicated Health Insurance Claims [1339]
Rachel Ogilvie | Jennifer Song | Cindy Zhou
Patricia Lloyd | Hui-Lee Wong | Tainya Clarke
Azadeh Shoabi | Kandace Amend | John Seeger
(United States)

295 – COVID-19 Epidemiology, Prophylaxis and Treatment in The Africa Region [1340]
Maribel Salas | Ilse Truter
Johanna Catharina Catharina Meyer | Johanita Burger
Joseph O. Fadare | Laura Novelli Horne (United States)

296 – Study of Myocarditis and Pericarditis Following Vaccination with COMIRNATY in Persons Under 21 Years of Age [1341]
Cynthia De Luise | Stephan Lanes | Julia Coleman
Bing Cai | Brian Harty | Julie E. Miller | Devon Payne
Katie Kendrick | Gail Pearson | Dongngan Truong
Jane Newburger (United States)

297 – Distinguishing Patterns of Serious Adverse Events with mRNA COVID-19 Vaccines Using Vigibase: A Latent Class Analysis [1342]
Min Taek Lee | Seung-Hun You | Ju Won Lee | Sewon Park
Jeong-Yeon Kim | Dal Nam | Sun-Young Jung
(Republic of Korea)

298 – The Social Patterning of COVID-19 Vaccine Uptake in Older Adults: A Register-based Study in Sweden Within the SCIFI-PEARL Project [1343]
Fredrik Nyberg | Malin Spetz | Lisa Lundberg
Chioma Nwaru | Huqi Li | Ailiana Santos
Susannah Leach | Magnus Gisslén | Niklas Hammar
Maria Rosvall (Sweden)

299 – Monitoring of Adverse Events Following COVID-19 Vaccines in Department of Veterans Affairs [1344]
Kwan Hur | Francesca Cunningham | Jennifer Martin
Lucy Pandey | Bharat Thakkar | Rongping Zhang
Cedric Salone (United States)

300 – Risk of Myocarditis/Pericarditis After mRNA COVID-19 Vaccination in Commercial Insurance Claims [1344]
Alex Secora | Michael Goodman | Christian Reich
(United States)

301 – VAC4EU Active Safety Surveillance Study of the BNT162b2 COVID-19 Vaccine in Five European Countries: Study Design and First Results [1345]
Daniel Weibel | Miriam Sturkenboom | Rene Eijkemans
Rutger Van Den Bor | Roel Elbers | Estel Plana
Xabier Garcia De Albeniz | Rachel Weinrib
Natasha Yefimenko | Beatriz Poblador-Plou | Elisa Bianchini
Luca Stona | Karin Swart | Claudia C Bartolini
Giulia Hyeraci | Debabrata Roy | Angela Lupattelli
Felipe Villalobos | Elisa Barbieri | Renu Garg
Heather Rubino | Cynthia De Luise | Alejandro Arana
(Netherlands)
OUR SERVICES

Systematic Literature Reviews
Consultancy Epi/Stat-IT/MW Qualitative Research
Epidemiological Studies: Primary Data Collection/ HER Studies
Pharmacovigilance and Pharmaco-Epidemiology Support

+32 016 23 50 13
What science can do

Generating Impactful Evidence
We ensure the right evidence is delivered at the right time, to the right stakeholders.

At AstraZeneca, we have an ambitious Global Evidence team, aspiring to be trusted leaders in practice-changing evidence, to positively impact people’s lives.

We shape the Evidence strategy and deliver high-quality studies across the globe in partnership with colleagues, from clinical development through launch and beyond.

Find out more about opportunities in our expanding Evidence teams by following the QR.
MARK YOUR CALENDAR

ACPE 2022
October 21 - 23, 2022
Tainan, Taiwan

ISPE 2023 Mid-Year Meeting
April 23 - 25, 2023
Reykjavik, Iceland

ICPE 2023
August 23 - 27, 2023
Halifax, Nova Scotia, Canada